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Abstract 
 
Background - In the late 1950s/early 1960s Thalidomide was given to thousands of 
pregnant women across the world to relieve morning sickness. The drug caused severe 
birth defects including missing/short limbs and sensory impairments, collectively referred 
to as Thalidomide Embryopathy (TE). However, Thalidomide is not just a historical 
tragedy, it is a contemporary disability issue. Across the world more than 5000 
Thalidomide survivors are still living with TE.  
Aim and Objectives - We know relatively little about the long-term effects of Thalidomide 
damage nor about the survivors’ present day experiences. The aim of this study was to 
address this knowledge gap by exploring the changing nature of health and independence 
amongst UK Thalidomide survivors as they age.  
Methods - A mixed methods grounded theory study, comprised of four stages: a scoping 
literature review; primary content analysis of semi-structured interviews with a sample of 
38 Thalidomide survivors; a cross-sectional survey of all UK Thalidomide survivors (to 
which 375/75% responded); and secondary grounded theory analysis of the semi-
structured interviews. 
Findings - Whilst TE is regarded as a non-progressive condition, it is not static. As they 
age Thalidomide survivors are experiencing new Thalidomide-related health problems and 
deterioration in their original impairments alongside the accumulated disabling 
consequences of a life lived with a rare condition. Shifting impairment was leading to 
efforts to preserve function and the need to rethink independence, which in turn had 
implications for mental wellbeing. 
Discussion - Thalidomide survivors are at a stage in their lives where disability and 
ageing are beginning to intersect.  They are ageing differently to their peers in the general 
population but there are both differences and similarities to other people with early 
acquired disabilities. Importantly, what is happening to Thalidomide survivors, needs to be 
seen in the particular historical, social and economic context of their lives. 
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Chapter 1 Introduction 
Thalidomide has become synonymous with ‘medical’ disasters and is frequently used as 
an example of how, in the past, the unchecked greed and arrogance of pharmaceutical 
companies led to tragic consequences (Ferber 2013). However, Thalidomide is not just a 
historical tragedy, it is a contemporary disability issue (Abrams 2014). Across the world, 
more than 5000 Thalidomide survivors (Johnson et al 2018) and their families, are still 
living with the consequences of the drug. Many have received little or no financial 
compensation. What is more, as they age, they are experiencing new Thalidomide-related 
health problems and deterioration in their original impairments, in addition to the 
accumulated disabling consequences of having a long term condition. However, we know 
relatively little about the long term effects of Thalidomide damage nor about the survivors’ 
present day experiences. The aim of my research was to address this gap in our 
knowledge, by exploring the changing nature of the health and independence of UK 
Thalidomide survivors as they grow older.  
In this chapter and by way of context, I begin by briefly describing: the distribution of the 
drug; it’s consequences, both in terms of the number pregnancies affected and the birth 
defects it caused (collectively referred to as Thalidomide Embryopathy or TE); and its 
current uses. I then go on to provide an overview of the key issues in relation to ageing 
with TE. In the two subsequent sections I set the conceptual context by briefly discussing 
impairment, health and disability in relation to TE, and more broadly, ageing and the life 
course. I go on to define the study and provide an overview of how I conducted the 
research, before outlining why the study matters. I close the chapter with a note about 
terminology, and a description of the structure of the thesis.   
1.1 The Impact of Thalidomide  
Between April 1958 and December 1961 the drug Thalidomide was given to thousands of 
pregnant women in the UK to relieve morning sickness. At the time the drug’s teratogenic 
properties were not fully understood. However, evidence suggests that despite Chemie 
Grünenthal, the makers of Thalidomide, having early indications of its toxicity, they failed 
to take steps to assess the drug’s teratogenic effects (Knightly et al 1979). Many babies 
born to the women who took the drug were still born or died soon after birth, and many 
others died in early childhood (Sjostrom and Nilsson 1972). However, around 520 
‘Thalidomide babies’ survived to adulthood in the UK.  
Globally there are no accurate estimates of the number of babies affected by Thalidomide, 
although a figure of over 10,000, across 46 countries is often quoted, based on the work 
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of Lenz and colleagues (Miller and Strömland 1999; Lenz 1988). However, more recent 
work by Johnson et al (2018) has attempted to estimate not only the number of survivors 
(i.e. those who lived long enough to be registered under compensation schemes or would 
have been registered if schemes existed in their countries), and the number of 
Thalidomide-affected babies born, but also the number of pregnancies affected. To 
provide a sense of the scale of the ‘tragedy’, their estimates suggest that worldwide as 
many as 25,000 Thalidomide babies were born (c2000 in the UK), and in total between 
87,600 and 275,000 pregnancies may have been affected. I discuss this topic in more 
detail in Chapter 2. 
Thalidomide survivors were born with a range of impairments. Most commonly they have 
missing, or short and/or deformed limbs (Dysmelia), including unusually shaped joints.  
This has become the most symbolic and normative representation of ‘thalidomide’. The 
most severely affected have damage to all four limbs, others to arms and hands or legs 
and feet.  Other consequences, although significant, are less recognised in public 
discourse. These include damage to eyes and ears/hearing and facial disfigurement and, 
in rare cases, brain damage.  Thalidomide damage can also be unseen and includes 
damaged or missing internal organs (e.g. heart defects, bowel deformities, small or 
missing kidneys, and damage to reproductive organs). Chapter 2 provides a brief history 
of Thalidomide. It also describes more fully the effects of TE and outlines the legal 
settlement and compensation arrangements for UK Thalidomide survivors.  As we shall 
see, changes over the life course can further complicate the consequences of original 
impairments, adding to the person’s sense of disability.  
Given the scale of the Thalidomide ‘tragedy’ one might assume that Thalidomide is no 
longer licenced or has ceased to be used.  It has, however, remained in regular use, albeit 
for the treatment of different conditions.  Since 1965, it has been marketed in several 
countries (particularly in South America) for the treatment of erythema nodosum leprosum 
(ENL), a painful skin condition which is a complication of Hansen’s Disease (leprosy). 
From the 1990s Thalidomide has also been prescribed in a number of countries for ‘off-
label’ uses (e.g. the treatment of oral aphthous mouth ulcers in patients with HIV). More 
recently it has been approved for the treatment of a range of other conditions including 
certain cancers (e.g. multiple myeloma, prostate cancer and melanoma). Its use for other 
conditions (e.g. gastrointestinal and autoimmune diseases) is currently being explored 
(Vargesson 2015a). The continued use of the drug has created a new generation of 
Thalidomide survivors, particularly in poorer communities with limited access to 
healthcare. For example Castilla et al. (1996) reports that 33 thalidomide-affected children 
were born after 1965 in endemic areas for leprosy in Brazil.  
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1.2 Ageing with Thalidomide Embryopathy  
The first generation of Thalidomide survivors have now been living with the consequences 
of the drug’s damage for over 50 years. They have had to use their bodies in unusual 
ways in order to compensate for their original impairment (i.e. ‘postural adaptation’). They 
have overused ‘good’ limbs or use their feet and teeth for tasks for which others would 
use their hands. As a result, they are increasingly experiencing secondary conditions 
(particularly musculoskeletal problems), linked to their original impairments (Newbronner 
et al 2012; Peters et al 2015; Hinoshita et al 2019). Some Thalidomide survivors in the UK 
and elsewhere (Newbronner et al 2012; Jankelowitz et al 2013) also report experiencing 
new, previously undiagnosed neuropathic symptoms (e.g. tingling, numbness, heat/cold 
and extreme fatigue). Other health problems which may be related to peoples’ original 
damage or are affected by it, include cardiovascular, bowel and digestive problems, sight, 
hearing and dental problems and difficulties with weight management. Furthermore, these 
Thalidomide-related health problems and increased impairment, often make it more 
difficult for people to manage unrelated health problems such as diabetes and asthma. 
Many Thalidomide survivors also report worsening mental health which may be connected 
to declining physical health, increasing impairment and a growing sense of disability. 
These late on-set consequences and symptoms are important because they can have 
profound implications for peoples’ independence and quality of life, but also because no 
account was taken of them in the original compensation settlements. The nature and 
extent of the health problems Thalidomide survivors in the UK and elsewhere are 
experiencing is discussed in much greater depth in Chapters 4, 5 and 6. 
Whilst the effect of these health problems on individuals is clearly linked to the severity of 
their original Thalidomide impairments, many other factors are influencing peoples’ 
response to their changing health and impairment, and their capacity to maintain their 
independence and quality of life. In understanding these processes a number of concepts 
are relevant. These are briefly discussed below and are explored and developed 
throughout this thesis, in particular in Chapters 7 and 8.  
1.3 Impairment, Health and Disability in Relation to TE 
It is useful to begin by thinking about how impairment, health and disability might be 
defined and understood in relation to ageing with TE. The drug caused a range of birth 
defects which constitute peoples’ original impairments. As part of the process of obtaining 
compensation, these impairments were classified. However, there is a tension between 
the classification of impairment and the lived experience of impairment over the life course 
(and consequent experience of disability). Thalidomide survivors in the UK are in an 
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unusual, almost unique position in relation to this. The legal settlement which established 
the compensation arrangements for Thalidomide survivors involved them being given 
‘points’ according to the severity of their impairments. Based on these points, they were 
also placed into one of five impairment bands, with people in Band 5 having the most 
severe impairments (see Chapter 2, section 2.7.7).  
However, this classification has in no sense been a predictor of the boundaries of peoples’ 
lives and it does not reflect the lived experience of their impairments and how these can 
have disabling consequences. Furthermore, this lived experience has changed over their 
life course. The International Classification of Functioning, Disability and Health (WHO 
2001) or ICF as it is often referred to, draws a distinction between two constituent 
elements of impairment, body functions and body structures: “Body functions are the 
physiological functions of body systems (including psychological functions)…Body 
structures are anatomical parts of the body such as organs, limbs and their components”. 
In effect chronic long standing conditions are a category or form of impairment. By this 
definition, Thalidomide survivors have two ‘types’ of impairment caused by the drug: the 
way in which it altered their body structure and the secondary health problems they are 
dealing with which are linked to it (e.g. arthritis and chronic pain). Kemp and Mosqueda 
(2004) suggest that people ageing with disability, experience three groups of ‘health’ 
problems (which could result in impairments related to body functions, and in turn can 
lead to disabling consequences): 
 Secondary conditions which are a direct result of their original impairments. The 
authors use the example of people with spinal cord injuries being more likely to 
develop pressure sores. An example for Thalidomide survivors might be osteoarthritis 
in hip and shoulder joints resulting from the way people have had to use their bodies to 
cope with missing or short arms (Peters et al 2015). 
 Associated conditions are those which are common in people with certain 
impairments. The authors give the example of the link between spina bifida and latex 
allergies. Similarly, hypertension appears to be far more prevalent amongst 
Thalidomide survivors than the general population, although the reasons for this are 
not fully understood (Schulte-Hillen 2017).  
 Comorbid conditions which are unrelated to peoples’ original impairments but might be 
more difficult to manage because of those impairments. Furthermore, people ageing 
with disability may be at greater risk of some ‘lifestyle’ related conditions (e.g. 
diabetes) because of the disabling barriers they face to healthy living (e.g. keeping 
active, eating well).  
18 
 
Thalidomide survivors have a range of secondary conditions, which are in turn changing 
their impairment (Newbronner et al 2012; Kruse et al 2013; Peters et al 2015). They also 
appear to have a number of associated conditions but often the evidence for the link 
between TE and the associated condition is limited or even contested. For this reason, 
throughout this thesis I largely used the terms ‘secondary condition’ or ‘secondary health 
problems, and only refer to ‘associated conditions’ in specific circumstances. The other 
important point to note here is that Thalidomide survivors themselves often perceive that 
many of their ‘health’ problems are related to their Thalidomide damage. As such the 
boundary between impairment and health is blurred, and the relationship between 
impairment, health and disability is complex, contested and fluid. 
Much has been written about what constitutes ‘disability’ (Thomas 2004). The United 
Nations Convention on Rights of Persons with Disabilities (CRPD 2006) – an international 
agreement intended to promote the rights of disabled people, provides a widely used 
definition: “Persons with disabilities include those who have long-term physical, mental, 
intellectual or sensory impairments which in interaction with various barriers may hinder 
their full and effective participation in society on an equal basis with others”. However, 
there are several ‘models’ of disability which seek to explain and operationalise definitions 
of disability. Berghs et al (2016) describe four broad models of disability (see p46). The 
one most closely aligned to the above definition is the Human Rights Model which 
focusses on the fundamental human rights of people with disabilities. In discussing the 
influential Social Models of disability, the authors note that these models draw a clear 
distinction between impairments and disability, seeing disability as the experience of 
social oppression. Critical Disability Studies models overlap with social models but a 
central concern is questioning the dualism between impairment and disability, while also 
acknowledging the potential of intersectionality. They also describe the Medical Model of 
disability which essentially views impairment as an individual problem, indicative of an 
‘abnormality’ or ‘deviation’.  
It is not possible or appropriate to discuss these models in detail here. However, it is 
interesting to briefly consider how one of the key debates in the field - how the social 
model of disability might be ‘reimagined’ to more fully acknowledge the place of 
impairment in disability (Thomas 2004) - could inform our understanding of the 
experiences of Thalidomide survivors. In criticising the social model of disability for 
separating impairment from disability, and the notion that disability is entirely socially 
imposed, Shakespeare and Watson (2001) argue that impairment clearly plays a role in 
causing disability. They suggest that impairment and disability are on a continuum, and 
that disability, when see as restricted activity, is the result of biopsychosocial factors. 
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Thomas (2004), in discussing their ideas, suggests that such non-socially imposed 
restrictions might best be conceptualised as ‘impairment effects’, which in later writing she 
defines as:  
The direct and unavoidable impacts that ‘impairments’ (physical, sensory, 
intellectual, emotional) have on individuals’ embodied functioning in the social 
world. Impairments and impairment effects are always bio-social and culturally 
constructed in character, and may occur at any stage in the life course. (Thomas, 
2010, p. 37) 
This conceptualisation seems particularly helpful in relation to Thalidomide survivors. 
Shakespeare (2006) also make the point that the diverse nature of impairments is 
important - they can be static or episodic, degenerative and even terminal. He contends 
that the social model can only explain so much before the experiential realities of 
impairment have to be confronted. For Thalidomide survivors, particularly those with the 
most profound damage (i.e. short or missing arms and/or legs) it is illogical to argue that 
impairment plays no part in their disability but by the same token, the extent to which they 
have experienced disablement has been heavily influenced by psychological, cultural and 
socio-political factors. Moreover, the concept of ‘impairment effects’ is useful when 
thinking about the diverse and changing nature of the impairments Thalidomide survivors 
are living with. In particular, it enables a contextual approach to understanding the 
disabling consequences of impairment, which are not fixed in time, but can occur at 
different points across the life course. 
More recently, in thinking about how models of disability might evolve, disability activists 
and academics have begun to think about a social model of human rights (Berghs et al 
2019). They suggest that such a model might facilitate greater understanding of the 
intersection of identities across the life course. I return to the question of how the impaired 
body might be thought about in the context of ageing with disability and TE in particular, 
and the intersection of disability and ageing identities, in Chapter 8.   
1.4 Ageing and the Life Course 
In informal conversations about their early lives, Thalidomide survivors have often told me 
that when they were young, there was an assumption they would not have a long life and 
would certainly not reach old age. Sadly, a significant number of Thalidomide survivors did 
die in childhood but those who reached adulthood are now expected to have a near 
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normal life expectancy1. The assumptions made about the life expectancy of Thalidomide 
survivors were in part a reflection of the lack of knowledge about TE, a completely new 
‘condition’. However, they also mirrored both general assumptions about disabled 
peoples’ lives, and the demographic realities of the post-war period. It is really only in the 
last 30 years or so that researchers and demographers have recognised that there are 
now generations of people with various kind of early acquired disabilities, who will live into 
old age. In one of the first texts to explore ageing with disability, Treischmann (1987) sets 
out very clearly why the experience of ageing with from-birth disability, or disability 
acquired in childhood or early adulthood, is both similar and different, and why this 
difference matters: 
…all of us are ageing, all of us experience decline in energy and altered physical 
function over time. For some, however, this very natural process is superimposed 
on other impairments that have imposed a physical, emotional, and financial 
penalty on daily life. Unfortunately for these people with major physical disabilities, 
the process of aging seems to increase the amount of penalty. (p5) 
Despite the demographic imperative, we still have a limited understanding of experience 
of ageing with disabilities and the consequences of coping with impairment over many 
years (Hilberink et al 2017; Freedman 2014; Jeppsson Grassman et al 2012). Jeppsson 
Grassman et al (2012) contend that one reason for the lack of development in this field is 
the incorrect assumption that early acquired impairments are static and that once people 
have learned to cope with these impairments and have maximised their functional ability 
through rehabilitation, “there is no need to worry about additional consequences” (p96). 
There is, however, growing evidence that even in conditions which are regarded as ‘static’ 
(e.g. Cerebral Palsy), peoples’ functional limitations can change across the life course, 
creating further potential for disability (Molton and Yorkston 2017). TE has also been 
regarded as a static condition, and similarly, many Thalidomide survivors have tried from 
a young age to maximise their functioning. Now after a lifetime of living with their 
impairments, maintaining this level of functioning is becoming increasingly difficult. As the 
research presented in this thesis will show, the combination of increasing impairment and 
secondary conditions has profound implications for both their physical and mental health. 
Within disability research, relatively little attention has been paid to concepts of ageing 
and the life course but a few authors (Jeppsson Grassman and Whitaker 2013; Naidoo et 
al 2012; Priestley 2003; Zarb and Oliver 1993) have proposed that a life course approach 
                                               
1 There is no published information about the life expectancy of Thalidomide survivors but in 
informal correspondence the Thalidomide Trust have advised me that their working assumption is 
that most beneficiaries will have a near normal life expectancy. 
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might provide a productive and more holistic framework for thinking about how disability 
affects people at different points in their lives, including ageing with disability. Naidoo et al 
(2012) points out that “age and disability are not defining traits of an individual but 
overlapping phenomena that occur throughout the span of the life course” (p3). This 
echoes Berghs et al’s (2019) call, discussed above, for a better understanding of the 
intersection of identities across the life course. In Chapter 8, I draw on the life course 
perspective to inform our understanding of how Thalidomide survivors are ageing 
differently.  
1.5 Origins and Objectives of the Study 
The genesis of this study lies in my experience of working with Thalidomide survivors over 
a number of years, in particular the evaluation of the pilot Health Grant awarded to them 
by the UK government in 2010 (Newbronner et al 2012). I observed that the health and 
functioning of Thalidomide survivors was changing as they reached late middle age but 
there was limited evidence about the nature of these changes or the prevalence of 
different health problems. The research evidence that did exist appeared to be largely 
biomedical in focus and rarely explored the interaction between these health problems, 
the original impairment and the psychosocial and disabling aspects of the ageing process, 
nor the wider implications for Thalidomide survivors’ daily lives. Furthermore, whilst the 
combination of impairments experienced by Thalidomide survivors is rare, and the 
historical, social and legal context of their lives is unique, they are an identifiable group 
who are ageing together. I felt their experiences might offer new insights into ageing with 
early acquired disability more generally.  
The overall aim of the study was to explore the changing nature and perceptions of health 
and independence amongst UK Thalidomide survivors as they age. To achieve this, the 
following thesis objectives were defined and addressed as the study progressed: 
 To identify the health problems Thalidomide survivors are experiencing as they grow 
older, in particular Thalidomide-related secondary health problems 
 To examine the perceived interaction between original impairment, secondary health 
problems and the ageing process 
 To understand the implications of this interaction for Thalidomide survivors’ lives, 
including their health-related quality of life and independence 
 To highlight any lessons that can be learned from Thalidomide survivors about the 
experience of ageing with early acquired disability  
Alongside these objectives, I wanted to ensure that the research would benefit 
Thalidomide survivors in the UK and worldwide by:  
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 Increasing awareness of the secondary health problems and loss of function 
Thalidomide survivors are experiencing and the implications of them for peoples’ 
independence and quality of life 
 Providing organisations and health professionals working with Thalidomide survivors 
with information which can be used to improve support and care, and inform treatment 
decisions 
 Influencing how policy makers in health and social care might better respond to the 
needs of the growing number of people with early acquired disability who are reaching 
later life, and in particular how they might be supported to ‘age well’. 
1.6 Conducting the Research 
Before moving on to the substantive chapters of this thesis, it is important to briefly 
describe my methodological approach (Chapter 3 provides a detailed account of my 
methods). To address the aim and objectives of the study, I felt that more than one 
method of inquiry would be needed. I therefore decided to use a mixed methods grounded 
theory approach. This comprised four stages: a scoping literature review; primary content 
analysis of semi-structured interviews; a cross-sectional survey; and secondary grounded 
theory analysis of the semi-structured interviews. Working though these stages I was able 
to: bring together and draw on existing research evidence; more fully understand the 
nature and extent of Thalidomide survivors’ health problems and deteriorating impairment; 
and to do justice to the complexity of their experiences, particularly in relation to their 
independence and quality of life. Figure 1 provides an overview of my study design.  
Figure 1 Mixed methods study design 
 
 
 
 
 
 
 
 
23 
 
From my previous work I was aware of a small number of studies from other countries, 
which had explored different aspects of the health of Thalidomide survivors as adults. 
However, there were no published literature reviews which brought this research and grey 
literature together. I decided to conduct a scoping literature review to map what was 
already known about ageing with Thalidomide damage. Chapter 4 describes the nature of 
the review and how I drew on grounded theory methods to collate and summarise the 
evidence. I used the findings from the review to inform the other stages of the study, in 
particular the content of the cross-sectional survey.  
Around the time I was starting to think about my doctoral research, I was asked by the 
Thalidomide Trust (the body which distributes compensation funds to Thalidomide 
survivors in the UK) to support them in monitoring the new ten year Health Grant. In 2010 
the four UK Departments of Health made a Health Grant to Thalidomide-impaired people 
(see section 2.7.8). The Grant was the culmination of years of campaigning by 
Thalidomide survivors and many see it as reparation for the UK government licensing of 
Thalidomide back in the late 1950’s. Officially it is intended to help them address the 
health-related needs they are experiencing as they grow older. The initial three year pilot 
Health Grant was renewed for ten years in 2013. The monitoring project was essentially a 
descriptive study designed to examine how the health and health-related needs of 
Thalidomide survivors were changing over the lifetime of the Grant, and to understand 
how Thalidomide survivors were using their Health Grants to address these needs. The 
Trust intended to use the findings from the study to inform their work and to help build the 
case for the continuation of the Health Grant. The final plan for the first three years of the 
monitoring project included two main elements: semi-structured telephone interviews with 
a representative group of Thalidomide survivors; and a health and wellbeing survey of all 
UK born Thalidomide survivors.  
The Health Grant monitoring project provided me with an ideal opportunity to gather much 
of the data I needed for my doctoral study, and so avoid placing an additional research 
burden on Thalidomide survivors. However, importantly, I was able to take a much more 
sophisticated analytical approach, and contextualise my findings in broader empirical and 
theoretical debates. Following discussions with the Director of the Thalidomide Trust and 
a formal application to the Trust’s Research Committee, I was given permission to use the 
material gathered in the interviews (subject to participants consent) and the data from the 
survey, for my doctoral research. I discuss the interconnection with the Health Grant 
Monitoring project, and the benefits and challenges it created for my doctoral research 
more fully in Chapters 3 and 8. For clarity, I set out below in Box 1, a simple timeline of 
24 
 
the activities associated with my doctoral research and if/how they relate to the Health 
Grant Monitoring project: 
Box 1 Timeline for Doctoral Research and Health Grant Monitoring Project 
December 2013 Health Grant Monitoring Project commissioned by 
the Thalidomide Trust 
January 2014 Doctoral studies commenced 
May 2014 to December 2019 On-going work on scoping literature review (from 
initial exploratory searches to final updating) for 
doctoral research independent of the Trust 
June to August 2014 Conducted semi-structured interviews for use in the 
Health Grant Monitoring Project and doctoral 
research 
September to December 2014 Content analysis of semi-structured interview data:  
 Descriptive summary report for the Trust 
 More detailed textual analysis for first draft of 
thesis chapter 
January to July 2015 Development of Health and Wellbeing Survey based 
on specification of the Trust 
August to October 2015 Conducted Health and Wellbeing Survey 
November 2015 to May 2016 Initial analysis of survey data: 
 Descriptive report for the Trust 
 Presented initial results to PhD supervisors and 
discussed plans for further, more in-depth 
analysis for doctoral research 
November 2016 Thalidomide Trust Health Grant Monitoring Project 
completed 
November 2016 to May 2018 Further statistical analysis of survey data (including 
analysis of health related quality of life) for doctoral 
research and preparation of thesis chapter 
April 2017 to December 2018 On-going research and writing-up of the historical 
and contemporary context material for doctoral 
research 
August 2018 to January 2019 Secondary Grounded Theory analysis of the semi-
structured interview data for doctoral studies  
January 2019 to February 2020 Final writing-up of thesis 
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At this stage I envisaged that following the semi-structured interviews and the health and 
wellbeing survey, a further round of data collection (possibly in depth-case study 
interviews), would be required to properly explore some of the topics of interest to me. 
However, in undertaking the primary content analysis of semi-structured interviews, it 
became apparent to me that, in the majority of the interviews, there was sufficient depth of 
material for a more detailed interpretive analysis, consistent with the objectives of the 
thesis. Following discussion with my supervisors I therefore decided to undertake a 
secondary grounded theory analysis of the interviews. I discuss this decision more fully in 
Chapter 3.  
To conclude this section, it is perhaps helpful to add a brief personal reflection. When I 
embarked on my doctorate, I saw my research as being firmly located in the discipline of 
health sciences. As such I envisaged it being quite practical and somewhat atheoretical in 
nature. However, as my research progressed I began to see that if I was to really 
understand the experiences of Thalidomide survivors I needed to draw on other 
disciplines, in particular disability studies and medical sociology. In truth, at the outset my 
knowledge of the debates and ideas in these disciplines was limited. Venturing into these 
fields certainly influenced how my research developed, and throughout the thesis I have 
tried to reflect on this process of evolution. It was also a learning journey for me, the 
culmination of which I hope is reflected in my Discussion. 
1.7 Why this Study is Important 
This study matters for a number of reasons. In the UK, the legal settlement which led to 
the establishment of the Thalidomide Trust, took place in 1974. At that point two very 
significant assumptions were made – first that the most severely affected Thalidomide 
survivors would have low life expectancy (some people were told that they would not live 
beyond their 30s), and second that the impairments on which the compensation 
settlements were based would be largely ‘static’. Neither of these assumptions have 
proved correct. Most Thalidomide survivors will live into older age but as they grow older it 
has become apparent that their impairments are not static, and they are developing 
secondary (physical and mental) health problems. Thalidomide survivors need 
information, advice and support in dealing with the changes in their health and 
impairment, and the potentially disabling consequences of these. This needs to be based 
on a sound understanding of the contemporary experiences of Thalidomide survivors.  
Diageo (previously Distillers, the parent company of Distillers Company (Biochemicals) 
Limited, the distributors of Thalidomide in the UK) have supplemented the Trust Fund on a 
number of occasions over the years, in part in recognition of the longer life expectancy 
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and increasing needs of Thalidomide survivors. However, it is important to understand 
more fully the secondary health problems that people are experiencing, so that this can be 
taken into account in future uplifts of the Trust Fund. Furthermore, although the pilot 
Health Grant made to Thalidomide survivors in 2010 was renewed for 10 years in 2013, 
there is concern within the UK Thalidomide community that the financial support people 
have to enable them to manage and live with their health problems and disabilities will not 
keep pace with their rate of deterioration. 
Globally the compensation arrangements for Thalidomide survivors vary considerably in 
their nature and scale. In some countries people have received no compensation. 
Currently, Thalidomide survivors internationally but particularly across Europe are 
campaigning for proper compensation from the drug’s original manufacturer, Chemie 
Grünenthal. Whilst clearly the campaign is very much about reparation and social justice, 
it is important that it is informed by a full understanding not only of the original damage 
people experienced but also the related and resulting problems they are experiencing in 
later life. 
Finally, because of inadequate control of the prescribing and management of Thalidomide 
in low and middle income countries, people continue to be born with Thalidomide damage. 
In the decades to come, as they age they too are likely to experience increasing 
Thalidomide related health problems. By better understanding the experiences of the ‘first 
generation’ of Thalidomide-impaired people, there might be a greater chance of later 
generations receiving the treatment and support they need. 
1.8 Terminology 
As part of this introduction it is important to say a few words about the terminology used 
throughout the thesis. People damaged by the drug Thalidomide use a number of terms to 
describe themselves, the most common being Thalidomide survivor, Thalidomide victim, 
and Thalidomider. Thalidomide survivors in the UK advised me that this is the term they 
prefer and therefore this is what I use throughout.  
When referring to people who have from-birth disabilities or acquired disabilities as 
children or young adults, I use the phrase ‘people with early acquired disabilities’2. In 
using this phrase I am primarily concerned with people with physical impairments, rather 
than intellectual impairments (or both). This is because only a small minority of 
                                               
2 Strictly, ‘early acquired impairments’ would be more accurate but ‘early acquired disability’ is the 
phrase commonly used in disability literature. 
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Thalidomide survivors have intellectual disabilities, and so people with early acquired 
physical disabilities provide the most appropriate comparisons.  
1.9 Structure of the Thesis 
This introductory chapter has set the scene for the thesis as a whole. In Chapter 2 I set 
out the historical and contemporary context of Thalidomide in much greater depth, 
including the origins of the drug, the chronology and extent of the Thalidomide ‘tragedy’ 
and the nature of TE. This historical account says much about the present. The chapter 
also provides essential background information about the financial compensation paid to 
UK Thalidomide survivors and the role of the Thalidomide Trust, which is an important 
aspect of understanding current circumstances. Chapter 3 describes the process of 
conducting the research: I explain the rational for my overall research design and the 
methods I have used; I describe how I carried out each stage of the research; and I reflect 
on the challenges I encountered. The methods and findings from my scoping literature are 
presented in Chapter 4. In Chapter 5 I set out the finding from the content analysis of the 
semi-structured interviews and explain how they informed the development of the Health 
and Wellbeing survey. Chapter 6 presents the survey results. Where appropriate I 
contextualise the results with the findings from the literature review (i.e. from studies with 
Thalidomide survivors in other countries), and/or by comparisons with either the general 
population or other groups with early acquired disabilities. In Chapter 7 I return to the 
semi-structured interviews to discuss the findings from the grounded theory secondary 
analysis. Finally, in Chapter 8, I discuss and summarise the findings from the whole study, 
present my emergent theory Ageing Differently, and discuss the implications for policy, 
practice and research.  
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Chapter 2 Historical and Contemporary Context  
Chapter one provided a brief overview of the history of the Thalidomide ‘tragedy’ and the 
contemporary issues facing Thalidomide survivors. However, to fully understand the 
current situation for Thalidomide survivors (physically, emotionally and socially) it is 
necessary to look in more depth at the history of the drug, the damage it caused, and the 
nature and level of compensation received by those affected. This chapter begins by 
outlining the development of the drug and its early marketing, and then describes how 
evidence about the terrible effects of the drug emerged. It goes on to detail what is meant 
by the term ‘Thalidomide embryopathy’, and briefly describes how the health and social 
care system responded to the ‘Thalidomide children’. It then considers the action of the 
drug and its contemporary uses. The second half of the chapter focuses on the legal 
action to obtain compensation from the drug’s manufacturers and distributors, and more 
specifically on the financial and other support available to UK Thalidomide survivors. It 
closes by briefly discussing the wider impact of Thalidomide, in particular on drug testing 
and regulation, and on wider societal concerns such as freedom of the press.   
Sarah Ferber (2013) describes the history of Thalidomide as “emblematic of the advance 
then shocked reversal of the optimism of the ‘pharmaceutical revolution’ of the mid 
twentieth century, a long and painful process followed by the negotiated return of the 
drug” (p133). She uses Thalidomide as a case study to consider the bioethics of the 
pharmaceutical industry from a historical perspective, and importantly suggests that 
historical research, particularly when undertaken in “reflective mode… can help us to 
understand how attitudes to the past affect perceptions of the present”. This has 
resonance for Thalidomide survivors because across the world, pharmaceutical 
companies are once again making substantial profits from Thalidomide and its analogues. 
The popular historical narrative, and one fostered by the company which originally 
manufactured the drug, focuses on the ‘Thalidomide children’ but Thalidomide survivors 
are still living with the damage the drug caused, some with little or no compensation. 
Furthermore, contemporary use of the drug is being extended to a growing number of 
conditions, and despite the existence of safety systems, many commentators 
(Timmermans and Leiter 2000) fear that it is only a matter of time before TE reappears.  
2.2 Development and Marketing of the Drug 
Thalidomide was developed by the West German pharmaceutical company, Chemie 
Grünenthal in the early 1950’s. The company was trying to find an inexpensive method for 
manufacturing antibiotics. In the course of their experiments they produced a new 
molecule, α-phthalimidoglutarmide, which they called Thalidomide (Brynner and Stephens 
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2001). There has been speculation for some years that a form of the drug was initially 
developed during Second World War in National Socialist (‘Nazi’) Germany. In their recent 
book The Thalidomide Catastrophe, Johnson et al (2018) explore the origins of the drug 
and the backgrounds of its creators. Their research shows that a number of Chemie 
Grünenthal’s senior scientists had connections to the National Socialist regime: Dr 
Heinrich Muckter, a doctor and pharmacologist who was the director of the company’s 
scientific department, had been a medical scientist for the Wehrmacht, and was Medical 
Officer to the Superior Command of the German Occupation Forces in Poland; and Otto 
Ambros, a research director at the company, was a chemist at IG Farben, which 
manufactured Zyklon B pesticide for the gas chambers and was one of Farben’s 
managers at its Auschwitz plant. However, they state that they found no proof that 
Thalidomide originated in National Socialist Germany. In their view, what was important 
were “the patterns of behaviour established during the Nazi period which continued into 
the post-war period” (p17) and which led to the corporate irresponsibility and corruption 
that allowed the Thalidomide ‘catastrophe’ to happen. 
The patent application for the drug was made in early 1954 and in April of that year they 
began testing it on animals and humans. Even by the standards of the time, the animal 
tests were limited and lacked scientific rigour. The ‘tests’ in humans essentially involved 
Grünenthal distributing the drug to a number of doctors, some of whom were paid a 
retainer by the company, for them to use on their patients and note the results. Whilst the 
expectations of drug testing in the 1950s were very different from what they are today 
(both in terms of the science and ethics), the ‘tests’ conducted did not match the practices 
of other (reputable) pharmaceutical companies, and were very far from what we would 
recognise as a clinical trial (Knightley et al 1979). There was no use of control groups and 
no blinding, and many of the doctors involved had vested interests. 
The drug was initially tested for its anticonvulsant, spasmolytic and local anaesthetic 
effects. Whilst early results showed that that it was unsuitable for these uses, trials of the 
drug found that it induced sleep, and crucially (given concerns about deaths from 
barbiturates at the time), overdose simply caused prolonged sleep, not death (Smithells 
and Newman 1992). Chemie Grünenthal went on to ‘test’ the drug on patients with a wide 
variety of conditions including tuberculosis, hypertension, hyperthyroidism, 
atherosclerosis, liver disease, gastric complaints, and influenza. There appears to have 
been little scientific basis for testing the drug on such a wide range of conditions, the 
company was simply attempting to find a use for it. Brynner and Stephens (2001) have 
described Thalidomide as “a drug in search of a disease” (p8). However, they go on to 
point out that whilst this may seem an unusual approach to developing a new drug, it is 
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not altogether uncommon. They cite the example of azidothymidine (AZT), which was 
originally developed as an anti-cancer drug in the early 1960’s. It proved to be of no use 
for this purpose but in 1987 Burroughs Wellcome Co. found it was effective in treating 
patients with AIDS.  
The idea that the drug might be used as a hypnotic or tranquilizer came from Herbert 
Keller, Grünenthal’s pharmacologist, who thought that it was a structural analogue of 
barbiturates (Knightley et al 1979). In fact Thalidomide does not fit into any of the 
structural classes of sedatives but the idea was attractive, as a tranquilizer without toxicity 
would have had huge market value (Brynner and Stephens 2001). It was influenza that led 
to the drug (combined with quinine, vitamin C, aspirin and phenacetin) first being 
marketed in 1956 under the name Grippex i.e. suggesting that it could be used to treat 
‘grippe’ or respiratory infections. Again, it is unclear what (if any) evidence there was for 
this use. Information produced by the company at that time listed numerous indications for 
the drug ranging from stage fright and depression to PMT and gallbladder disorders. 
Importantly, however, it claimed that the drug was virtually free from side effects (Lenz 
1988).  
Thalidomide was first marketed as a non-addictive, non-barbiturate sedative in West 
Germany in 1957, under the name Contergan (Vargesson 2013). It was available without 
prescription. Soon after, Chemie Grünenthal began to promote the drug internationally. It 
was eventually made or sold under licence in 46 countries across the world (Sjostron and 
Nilsson 1972). The licensing arrangements and the use of Thalidomide in combination 
preparations meant that it was sold under around 70 different brand names (FfDN 2014). 
In the UK, Australia and New Zealand, the licence was owned by Distillers Company 
(Biochemicals) Limited (DCBL) and Thalidomide was marketed under the name Distaval. 
However, combination preparations were given other trade names, including Valgis and 
Tensival for a tranquilizer and Valgraine for a migraine treatment. The drug also appeared 
under these UK brand names in a number of Commonwealth countries where DCBL 
owned the license. In several countries in Europe (including Ireland, Spain, Portugal, the 
Netherlands, Finland and Switzerland) it was marketed as Softenol; in Canada and the 
USA it was known as Kevadon; in Brazil it was marketed under six different names; and in 
Japan it had ten different brand names. When the dangers of Thalidomide came to light, 
the marketing practice of using multiple brand names made it much harder for both 
patients and doctors to identify who had taken the drug, which in turn had implications for 
compensation claims.  
Even in countries where the drug was not officially licensed, notably the USA, it was 
sometimes made available as samples, whilst in other countries, particularly less 
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developed nations, the drug may have been brought in and sold by individuals. For 
example in Africa the drug was officially available in seven countries - Angola, Ghana, 
Guinea, Mozambique, Somalia, Sudan and ‘West Africa’. However, Klausen and Parle 
(2015) argue that it is almost certain that the drug entered more African countries 
(including the Republic of South Africa) via informal direct importing agents. Furthermore, 
whilst in the UK Thalidomide was a prescription drug, in some countries, notably Germany 
and Japan, it was available over-the-counter, which almost certainly led to it crossing 
borders. 
From the outset, information for doctors and advertising emphasised the safety of the 
drug, as the picture below of a UK advert from the late 1950s illustrates (Figure 2).  
Figure 2 Advertisement for Distaval and Valgraine from the late 1950’s 
 
 
 
 
 
 
 
 
 
 
Sjostron and Nilsson (1972) note that the assertion that Thalidomide was ‘completely 
atoxic’ was “based on the fact that it had been practically impossible to kill experimental 
animals by injecting any amount of the drug in a single dose” (p43). The lack of acute 
toxicity was a valuable attribute as it reduced the risk of accidental poisoning and 
overdose. However, as Sjostron and Nilsson (1972) go on to explain - “…low acute 
toxicity does not guarantee that a drug will be harmless when taken repeatedly in low 
doses over a prolonged period of time i.e. low acute toxicity by no means offers a 
guarantee of a low chronic toxicity” (p43). Even at the time, pharmacologists were very 
much aware of this risk and there were several compounds that were known to have low 
acute toxicity but serious toxic effects (including damage to the foetus) when used over a 
long period (Knightley et al 1979). Furthermore, recent historical research has uncovered 
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documents which suggest that Chemie Grünenthal may have been aware that the drug 
could cause birth defect before such concerns became public (Ferber 2013).  
Relatively soon after Thalidomide was launched, reports of side effects began to emerge. 
In December 1958 a doctor from Frankfurt (Gustave Schmaltz) wrote to Chemie 
Grünenthal to report that Thalidomide had caused giddiness and disturbance of balance in 
his elderly patients. Throughout 1958 and 1959 a number of doctors and pharmacists 
across Germany raised concerns that Contergan was causing peripheral neuropathy in 
patients who had taken the drug for a prolonged period (Knightley et al 1979). In 1960, 
some doctors began to make their concerns public. In West Germany Dr Ralf Voss, a 
nerve specialist presented a paper to a medical conference in Dusseldorf (Knightley et al 
1979), and in the UK Dr Leslie Florence (1960) wrote a letter to the British Medical Journal 
entitled Is Thalidomide to Blame? The letter described the symptoms experienced by four 
patients: marked paraesthesia affecting feet and hands; coldness and pallor in fingers and 
toes; occasional sight ataxia; and night time muscle cramps. Dr Leslie Florence went on to 
say – “It seemed to me to be significant that each patient has been receiving thalidomide 
(“Distaval”) in a dose of 100mg at night, the period during which the drug had been given 
varying from eighteen months to two years”. In 1961 Contergan was placed on 
prescription in three German states and lawsuits for compensation for the peripheral 
neuropathy caused by the drug were prepared. 
The evidence from this time and from research into current uses of the drug (see section 
2.6), clearly shows that prolonged use of Thalidomide can cause peripheral neuropathy, 
and that even when patients stop taking the drug, the damage may not be reversed. This 
issue has contemporary relevance because many Thalidomide survivors report 
experiencing the symptoms of peripheral neuropathy but there is disagreement as to the 
extent to which (if at all) this is caused by the drug.  
The reports of Thalidomide causing peripheral neuropathy was one of the primary reasons 
why Thalidomide was never licenced in the USA. Frances Kelsey, a newly appointed 
Food and Drug Administration (FDA) physician and pharmacologist responsible for 
approving drug licenses, was assigned responsibility for reviewing a new drug application 
for Thalidomide. She had read the reports of peripheral neuropathy in patients taking the 
drug and was concerned about its safety. However, she also had concerns that no 
investigations had been made into the effect of the drug during pregnancy (Vargesson 
2013).  Richardson-Merrell, who owned the licence for Thalidomide (brand name 
Kevadon) in the North America applied to the FDA for a licence in September 1960. 
Kelsey very quickly identified a number of inadequacies in the application: the animal 
studies were not reported in sufficient detail; full details of the clinical studies were not 
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reported; data about chronic toxicity was incomplete; there was limited information about 
the stability of the drug; and its side-effects were not treated seriously (Knightley et al 
1979). Kelsey demanded further information and evidence from animal studies. 
Richardson-Merrell provided additional information in spring 1961 but Kelsey remained 
sceptical, noting later that she felt the company was not being entirely honest with her. 
Despite mounting pressure from Richardson-Merrell on Dr Kelsey and her seniors at the 
FDA throughout 1961, the drug was not licenced. In a fascinating paragraph from their 
book, Knightley et al (1979) speculate on the thinking behind Dr Kelsey’s decision: 
…did she get thalidomide right for the wrong reasons…what emerges from the 
record is that she got it right largely for the right reasons. True she did not predict 
that thalidomide would cause birth deformities, but she did ask the question. She 
was, by chance, especially interested in foetal damage because during the 1940s 
she had worked with her husband on the antimalarial drug quinine, which had 
been found to possess teratogenic activity. But the record clearly shows that this 
was not her main preoccupation. It was even more fundamental. She wanted to 
know – and was clearly never satisfied that she did know – about the way in which 
thalidomide behaved in the body; its stability, its effects on human metabolism, 
even its basic chemistry and pharmacology. (p110) 
The exact action of the drug is still not fully understood and is the subject of on-going 
research (see section 2.6). 
2.3 The Thalidomide ‘Tragedy’ – the Drug and Birth Defects 
It was the claim that Thalidomide was ‘completely safe’ and had no side effects, together 
with its antiemetic properties, that led to the drug being given to pregnant women to 
alleviate morning sickness. Distaval went on sale in the UK on the 14th April 1958. As the 
photographs of the original UK Distaval packaging show (see Figure 3), it was promoted 
as a “safe sedative”, “free from untoward side effects”. Although it was not specifically 
marketed as a ‘morning sickness pill’ as is sometimes believed, information sent to 
doctors in the UK in 1961 did recommend its use in obstetrics and stated “Distaval can be 
given with complete safety to pregnant women and nursing mothers, without adverse 
effects on mother or child…” (Knightley et al 1979). In fact, Chemie Grünenthal had never 
carried out any experimental work to establish whether Thalidomide could have 
teratogenic effects. In a paper in Teratology in 1988, Widukind Lenz, who was 
instrumental in linking Thalidomide to birth defects notes that when Contergan went on 
sale in Germany in 1957, it was already well know that chemical substances with low 
acute toxicity in adults might damage the foetus. He goes on to make the point that: “The 
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assertion that nobody could have foreseen in 1956 a tragedy such as that caused by 
thalidomide does not become true by reiteration” (p203). 
Figure 3 Photographs of original Distaval packaging 
 
 
 
 
 
 
 
 
 
 
 
The first known case of birth defects caused by Thalidomide was a baby girl born in 
Stolberg, West Germany in December 1956. She had no ears. Her father worked for 
Chemie Grünenthal and had been given early samples of the drug for his wife. In the 
following four years there were growing reports of occurrences of severe birth defects, but 
it was not until 1961 that the link with Thalidomide was confirmed by two clinicians 
working on opposite sides of the world: Professor Widukind Lenz in West Germany and Dr 
William McBride in Australia (Vargesson 2015b). Lenz was head of the children’s clinic at 
Hamburg University. In spring 1961 he was approached by a young lawyer from Menden 
near Munster who’s own child and the child of his sister had been born with Dysmelia, just 
a few weeks apart. He agreed to look into the issue further and was startled to find that 
several colleagues working in the field had seen babies born with similar birth defects. He 
began working with an assistant to count the number of cases of such birth defects 
recorded in Hamburg hospitals (Lenz 1962). 
McBride had a large and successful obstetrics practice in Sydney and often delivered 
babies at the Women’s Hospital in Sydney. The hospital was run by a young obstetrician, 
John Newlinds, who had trained under Mc Bride. Distillers Company Biochemicals 
(Australia) Limited began to promote Thalidomide in Australia in 1960 and McBride first 
prescribed it the same year. However, in early 1961 three babies were born at the 
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Women’s Hospital with severe and similar birth defects, including bowel atresia (no bowel 
opening). All of them died soon after birth. Newlinds and McBride were both extremely 
concerned that the congenital malformation rate for the hospital was now three times the 
national average. McBride examined the hospital records of all three mothers and the only 
common factor which emerged was that they had all taken Distaval (Thalidomide) during 
their pregnancy (Magazanik 2015).  
McBride told Newlinds that he thought Thalidomide was responsible for the malformation 
and Newlinds immediately had the drug withdrawn from the hospital pharmacy. However, 
between June and September 1961, 23 women who had been given Thalidomide during 
pregnancy gave birth to healthy babies. This appeared to disprove McBride’s theory. 
Furthermore, in September McBride heard that a paper he had submitted to The Lancet 
earlier in 1961 had been rejected. Then, in September 1961, two more babies were born 
with birth defects typical of Thalidomide. When McBride looked at their records he again 
found that they had taken Thalidomide in early pregnancy. We now know that the main 
risk period for Thalidomide is between the fifth and eighth week of pregnancy but at the 
time McBride could only deduce this from analysis of individual cases i.e. from simple 
descriptive epidemiology. In Suffer the Children (p128), Knightley et al (1979) describe 
McBride writing to The Lancet again in November 1961 – “In view of his earlier rejection, 
he advanced no theories but simply noted what he had observed and sought further 
information” (see Figure 4). The letter was published on 16th December 1961, three weeks 
after the drug was withdrawn from the market in the UK.  
Figure 4 McBride’s letter to the Lancet 
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McBride’s letter drew the medical world’s attention to thalidomide and the extensive 
damage the drug caused to babies when their mother took it during early pregnancy 
(Newbronner et al 2017), whilst in the same year in West Germany, Lenz pressed the 
company and the health authorities to withdraw the drug. The drug was eventually 
withdrawn from the market in West Germany on the 26th November 1961 and a few days 
later DCBL did the same in the UK. 
Lenz (1988) went on to chart the ‘epidemic’ of birth defects caused by Thalidomide and 
linked it to the sales of the drug. He also attempted to estimate the number of babies born 
or affected by Thalidomide. He noted that the occurrence of birth defects caused by 
Thalidomide – “closely followed the monthly sales figures by a distance of 7-8 month, as 
expected if the sensitive period is considered” (p204-205). Eight to nine months after the 
withdrawal of the drug, there was a marked fall in the number of cases. However, in 
several countries the drug was not withdrawn until 1962 (e.g. Ireland, Italy, Canada and 
Brazil) and in Japan not until 1963. Furthermore, in a few countries such as Spain (which 
at the time was under the Franco dictatorship) there was a ‘quiet’ withdrawal i.e. the drug 
was no longer licenced but little effort was made to notify doctors and patients about its 
risks (described in the Spanish film 50 Years of Shame).  
There are no accurate figures for the number of babies affected by Thalidomide. There 
are a number of reasons for this. Firstly the neonatal survival rate varied between 
countries; Kida and Lenz (1968) suggest that it was as low as 40% in Japan but closer to 
70% in West Germany. Secondly there are reports of increased miscarriage rates during 
the period Thalidomide was in use (McCredie 2009; Brynner and Stephens 2001), and in 
addition, not all the babies who did survive were recognised as Thalidomide affected.  
A figure of over 10,000 affected babies (worldwide) is often quoted, based on the work of 
Lenz and colleagues (Miller and Strömland 1999; Lenz 1988). However, recent work by 
Johnson et al (2018) presents much more detailed estimates of the number of survivors - 
those who lived long enough to be registered under compensation schemes or would 
have been registered if schemes existed in those countries (e.g. Spain); the number of 
Thalidomide-affected babies born; and the number of pregnancies affected. They note 
that there are just over 5000 verified survivors worldwide. In the UK, by 2010 the total 
number beneficiaries registered by the UK Thalidomide Trust had reached 520. The 
Federal Republic of Germany (i.e. West Germany prior to unification) had the highest 
number of Thalidomide affected babies, at around 3000 but significant numbers were born 
in other countries e.g. Japan c300; Sweden c147; Canada c122; Brazil c98; Italy c80; and 
Taiwan c36 (Lenz 1988). However, Johnson et al (2018) estimate that the true worldwide 
figure is probably more than 6200. This is based on the fact that where good data is 
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available, the ratio between a country’s population and the number of survivors is 
remarkably consistent (e.g. the UK population in 1960 was approximately 50 million and 
520 survivors had been registered by 2010; similarly Ireland had a population of 3.5 
million and had 35 survivors).  
They go on to explain that the personal accounts of Thalidomide survivors, their families 
and healthcare practitioners, strongly suggest that many more Thalidomide affected 
babies were born. Some died in infancy or early childhood of natural causes (and before 
they could be registered for compensation), but in several countries doctors and midwives 
have described how babies with very severe damage were sometimes left to die. Drawing 
on the work of Professor Richard Smithells, one of the doctors most closely involved in 
documenting the impact of Thalidomide in the UK, Johnson et al (2018) estimate that 
around 2000 Thalidomide babies were born in the UK, with three quarters dying before 
their teens. Based on this ratio they suggest that worldwide the figure must be in excess 
of 25,000 babies. Furthermore, they point to evidence from the UK and West Germany 
that estimates that live births represent only a proportion (between 10% and 40%) of the 
pregnancies affected. Taking these estimates together they suggest that the total number 
of pregnancies, babies and survivors affected worldwide could range from around 87,600 
to 275,000. In short, the 5000 survivors still with us are the tip of the Thalidomide iceberg. 
2.4 Thalidomide Embryopathy 
Thalidomide is now known to be a very powerful human teratogen and the birth defects it 
causes are severe. However, because it can affect almost any tissue/organ in the forming 
body (Vargesson 2013), it can cause a wide variety of birth defects, none of which are 
unique to Thalidomide (Smithells and Newman 1992). For this reason, the combination of 
birth defects caused by exposure to the drug are usually collectively referred to as 
‘Thalidomide Embryopathy’ or sometimes ‘Thalidomide Syndrome’. The time sensitive 
window or ‘critical period’ in which Thalidomide causes damage to the foetus is relatively 
short – between 20 and 36 days after fertilisation or 34 to 50 days after the last menstrual 
period (Smithells and Newman 1992; Miller and Strömland 1999). However, before the 
critical period the drug can induce miscarriage and within it, even a small dose (e.g. a 
50mg tablet) appears to cause birth defects in 50% of pregnancies (Vargesson 2013). 
Different parts of the body are affected at different points in the time sensitive window. 
Figure 5 provides a detailed picture of this. 
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Figure 5 Time sensitive periods for different areas of damage (adapted from Peters 
et al 2015) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vargesson (2015b) notes that the hallmarks or consistent features of TE were established 
by examining the children most severely affected by the drug. These diagnostic criteria 
are still in use today, although they have been up-dated and broadened following a WHO 
sponsored meeting of experts held in 2014. More recently, a diagnostic algorithm has 
been developed for TE by a team at St Georges Hospital, London, supported by the 
Thalidomide Trust (Sahar et al 2019), and is due to be made available worldwide in 2020.  
2.4.1 Limb and joint damage 
Dysmelia (missing, short and/or deformed limbs) is the most common feature of TE and, 
in the public mind, the one most strongly associated with the drug. Phocomelia is the most 
extreme form of Dysmelia. In their worldwide descriptive epidemiological study of 
phocomelia, Bermejo-Sánchez et al (2011) define phocomelia as: 
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…a rare congenital anomaly in which the proximal part of the limb (humerus or 
femur, radius or tibia, ulna or fibula) is absent or markedly hypoplastic, with normal 
or nearly normal hand or foot. True phocomelia is characterized by the total 
absence of the intermediate segments of the limb, with the hand or foot directly 
attached to the trunk. Etymologically, the term phocomelia comes from the Greek: 
φώκη— fóke—“seal,” plus µέλoς—melos— “limb,” and it refers to the similarity of 
the patient’s limb shape to the flipper on a seal. (p305) 
Amongst Thalidomide survivors, Dysmelia ranges in severity from slightly shortened limbs 
and/or damage to hands and feet (e.g. missing or extra digits and/or triphalangeal 
thumbs), to the complete absence of the long bones, with the hands or feet articulating 
directly from the body (Smithells and Newman 1992; Newman 1985). The majority of 
Thalidomide survivors have some limb damage, most often shortened limbs, and this is 
usually symmetrical. Symmetrical limb defects are one of main diagnostic indicators of TE, 
although there is some recognition that there can be differences in severity between one 
side of the body and the other (Vargesson 2015b).  
The majority of Thalidomide survivors with upper limb damage have normal lower limbs 
but a minority have all four limbs affected. Lower limb damage alone is rare (Smithells and 
Newman 1992). According to data held by the Trust, around 1.5% of their beneficiaries 
have lower but not upper limb damage and a study in Germany found a similar proportion 
(Kruse et al 2013). Vargesson (2015b) notes that it is still unclear why upper limbs are 
more likely to be affected than lower limbs. However, he does note that: 
…the lower limbs form slightly after the upper limbs, and we know that 
Thalidomide has a short half-life of activity, thus it is possible a single dose in the 
early stages of pregnancy could affect the upper limbs, whereas multiple doses 
over a few days may be required to affect the later forming lower limbs. (p143) 
Many Thalidomide survivors also have damage to their joints. Shoulder joints are often 
misshapen, hip joints can be hypoplastic or even missing, and knees and ankles can be 
unstable. Changes to the vertebral column is also a feature of Thalidomide damage, 
particularly block vertebrae, and kyphosis (Smithells and Newman 1992; Ghassemi 
Jahani et al 2016a). The consequences of joint and spinal damage are increasing as 
Thalidomide survivors age, with early onset arthritis leading to the need for early joint 
replacement. This issue is discussed more fully in Chapters 4 and 6. 
2.4.2 Sensory impairment and facial damage 
The second most common group of impairments caused by the drug are to the eyes, ears 
and face (Smithells and Newman 1992). This is because the eyes and ears develop in the 
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embryo around the same time as the limbs. This group includes a wide range of damage, 
which can occur in different combinations but the most common are: facial disfigurement 
(e.g. irregular features, small jaw, small nose), facial palsy and cleft palate; missing or 
small eyes, damage to the iris and/or retina and the inability to form tears; and missing or 
small outer ears and narrow ear canal (ear defects are usually symmetrical).  
2.4.3 Damage to internal organs 
Vargesson (2013; 2015b) notes that all of the internal organs can be affected by 
Thalidomide but damage mostly commonly occurs to the heart, kidneys, genitals and 
bowels. Some of these problems were not apparent at birth and have only come to light in 
later life, so there are no accurate estimates of incidence (and they are less fully 
discussed in early writing about ‘Thalidomide defects’). However, it has been suggested 
that severe damage to internal organs, particularly the heart and bowel, may have caused 
many intrauterine and postnatal deaths (Vargesson 2013) 
2.4.4 Nerve damage  
There is some evidence that Thalidomide survivors are more likely to have facial palsies 
(Sjogreen and Kiliaridis 2012) and cranial nerve abnormalities leading to conditions such 
as Duane’s Syndrome, an eye movement disorder characterized by limited horizontal eye 
movement (Miller and Strömland 2011). It has also been suggested that autism and 
epilepsy may be more common amongst Thalidomide survivors but the evidence for this 
mixed (Strömland et al 1994; Imai et al 2014).  
One of the conundrums of Thalidomide is the variability of Thalidomide induced damage 
between individuals. The drug is now known to be a very potent teratogen and yet it is 
estimated that the risk of birth defects from in utero exposure is 50% (Newman 1985 & 
1986). Furthermore, the severity of damage caused by similar levels of exposure at similar 
points in the time sensitive window, can also vary. Vargesson (2013) suggests that this 
variability might be explained by the fact that individuals have different metabolic rates 
and react differently to drugs, which when combined with time of exposure to the drug, 
could lead to different consequences. There are a few congenital conditions which cause 
impairments similar to Thalidomide, notably Okihiro Syndrome and Holt-Oram Syndrome 
which both cause limb reduction, and Roberts Syndrom (also known as 
pseudothalidomide syndrome) which causes phocomelia in all four limbs, facial 
disfigurement and damage to internal organs (Bates 2001). Although all these conditions 
are rare, in cases where there is no confirmation of the mother taking Thalidomide during 
pregnancy, and without genetic testing, their existence can make diagnosing TE more 
difficult.  
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2.5 Response of Health and Social Care Services 
As children, Thalidomide survivors were subjected to repeated medical examinations, 
tests and X-rays. Many had numerous surgical procedures, some of which were essential 
but many were cosmetic, such as attempts to create ‘ears’ for those children born without 
them, even though they remained deaf. Perhaps one of the saddest aspects of these early 
medical interventions was the number of amputations. Doctors often failed to see that 
even residual limbs and digits would be valuable later in life, as people found their own 
ways to use their bodies for everyday tasks. Conversely, for those Thalidomide survivors 
born without thumbs or with triphalangeal thumbs (i.e. a thumb that is like a finger) one of 
the most valuable operations performed was the creation of a thumb from a finger, as this 
gave people a grip function. Many Thalidomide survivors were also forced to use 
prosthetic limbs, and some even had the remnants of limbs they were born with 
amputated so that prosthetics could be fitted. These prosthetic limbs were heavy, 
cumbersome and often largely useless, as the photographs in Figure 6 suggest.  
Figure 6 Examples of prosthetic limbs designed for Thalidomide children 
 
 
 
 
 
 
 
 
 
 
 
 
The Thalidomide Society and the Wellcome Library have examples of these prosthetics, 
as well as photographs and film of Thalidomide survivors attempting to use them. From 
this archive it is not hard to see why many rejected them in preference for their own 
strategies for daily living. Rosaleen Moriarty-Simmonds, a four limb affected Thalidomide 
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survivor from Cardiff recounts the experience of being ‘fitted’ with artificial limbs in her 
book Four Fingers and Thirteen Toes (2009): 
…the determined efforts of the medical profession to equip me with all sorts of 
mechanical paraphernalia in the misguided impression that it would improve my 
life. Sad to say it did not, and the process of wiring, bolting and screwing of all 
these contrivances on to my body was both unpleasant and painful. (p51) 
Most Thalidomide survivors were brought up by one or both of their parents but some 
were placed in institutional care from an early age. A number went to Chailey Heritage 
Craft School and Hospital in West Sussex, an institution for children with severe 
disabilities. Despite the fact that the vast majority of Thalidomide survivors have no 
intellectual impairment, unfounded and negative assumptions were sometimes made 
about their academic ability, and some were sent to what were then referred to as 
‘schools for the educationally subnormal’. In many respect these attitudes reflected 
thinking and policy at the time but as the accounts of Thalidomide survivors and their 
parents show (see for example the Thalidomide Oral History project held by the Wellcome 
Library), most health and social care professionals had never encountered such profound 
impairments before and so did not know how best to support the children and their 
families. These childhood experiences have left many Thalidomide survivors mistrustful of 
the medical profession and reluctant to engage with the social care system, which in turn 
has implications for their willingness to seek help as adults. 
2.6 Action of the Drug and Contemporary Uses 
Thalidomide is a highly unusual drug. Most of its mechanisms of action, both in the adult 
system and in embryo development, are not fully understood. The following extract from 
Brynner and Stephens (2001) provides a very helpful explanation of why this is the case: 
First, it does not readily dissolve in the body, a major problem for researchers 
(drugs that can’t be put in solution are far more difficult to test). Second, when 
thalidomide is metabolised by the liver enzymes, it produces well over 100 
breakdown products, making it difficult to determine which ones cause 
thalidomide’s various actions. Third, the possible mechanisms of action of the drug 
in various tissues and various conditions are either completely unknown or are just 
now beginning to yield to investigation. (p164) 
Over 30 separate models/theories have been proposed to explain the mechanisms of 
action underlying TE (Vargesson 2015b) and the teratogenic process of the drug remains 
a complex and controversial topic, well beyond the scope of this thesis. However, it is 
useful to very briefly note current theories, as they help to explain some of the 
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contemporary uses of Thalidomide. Currently the most commonly accepted theories focus 
on the drug’s ability to inhibit the formation of new blood vessels (angiogenesis) and 
induce cell death, as well as its capacity to bind to molecular targets such as cereblon, a 
protein that alters the function of other molecules to regulate signalling in cells (Vargesson 
2015a). In adults, Thalidomide has the ability to selectively inhibit the production of Tumor 
Necrosis Factor-alpha or TNF-α, a characteristic valuable in treating inflammatory and 
autoimmune conditions. In particular, it is the drug’s ability (in adults), to inhibit the body’s 
inflammatory response as well as prevent blood vessel formation that has led to its 
contemporary use to treat a number of conditions, including certain types of cancer and, 
more recently, ulcerative conditions such as Crohn’s disease (Vargesson 2013).  
Thalidomide has been used to treat ENL, which causes painful and inflamed skin lesions, 
since 1965, following a chance discovery by an Israeli doctor (Jacob Sheskin). It has been 
widely used in Brazil for this purpose. Sadly the areas of the country where leprosy is 
prevalent often have poor access to health services and medicine sharing is not 
uncommon. As a consequence there have been at least 36 cases of TE in Brazil since 
1965 (Schuler-Faccini et al 2007), with some babies being born as recently as the 2006. 
However, this number is likely to be an underestimate as in poor and remote communities 
the birth of babies with Thalidomide damage will very likely not be registered through any 
national birth defects surveillance systems. Furthermore, since the early 2000s there has 
been an on-going debate amongst clinicians and with the WHO as to whether 
Thalidomide is still an appropriate treatment for ENL in Hanson’s Disease. Some 
clinicians have argued that ENL is no longer a significant complication of Hanson’s 
Disease and where it does occur other treatments are available, even preferable. They 
have also pointed out that in relatively poor or under regulated countries, safety and 
monitoring systems designed to prevent women of child baring age being given the drug 
may be weak or patchy. However, the WHO continues to recognise the use of 
Thalidomide for ENL (Ferber 2013).  
In the 1980s, few drugs were available for the treatment of AIDS and HIV. People began 
to experiment with Thalidomide, and found that it had some effect on aphthous ulcers and 
AIDS-related wasting disease. At the time, it was licenced for manufacture in Brazil and 
Mexico (and in small quantities and for restricted use by one company in the USA) for the 
treatment of ENL, and so in the USA and Europe it was only available on the black market 
(Ferber 2013). In the USA, ‘buyers clubs’ smuggled thalidomide and other drugs over the 
border from Mexico and then distributed them through an unofficial national network. By 
the early 1990, there was a huge ‘unofficial’ demand for Thalidomide. The USA Food and 
Drug Administration (FDA) were very concerned about its unregulated use and began to 
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crack down on the buyer’s clubs. However, in 1994, as a result of a chance meeting 
between Gilla Kaplan, an immunologist working on Thalidomide and David Kessler the 
Commissioner of the FDA, and growing pressure from the AIDS/HIV community, the 
process of approving Thalidomide began (Brynner and Stephens 2001). Thalidomide was 
out of patent and so it was Celgene, a then small pharmaceutical company based in New 
Jersey that approached the FDA about approval. In 1998, after a long process, including 
extensive consultation, which eventually included Thalidomide survivors, the drug was 
approved for the treatment of ENL. However, in the USA, drug regulations permit ‘off 
label’ use of FDA approved drugs. Effectively this means that once a drug had been 
approved for one use, doctors can legally prescribe it for the treatment of other conditions. 
Doctors treating AIDS and HIV patients could therefore use it legally but problems with the 
drug had already begun to emerge. Many patients with AIDS-related wasting disease 
could not tolerate the sedative effects of Thalidomide and new and more effective 
medicines had been developed (Johnson et al 2018).  
As the demand for Thalidomide to treat AIDS and HIV declined, interest in the drug’s 
potential to treat certain types of cancer and autoimmune diseases grew. In fact, in 2000 
(just two years after its approval by the FDA) over 140 clinical trials were being conducted 
to assess its efficacy for these conditions (Ferber 2011). For some conditions, such as 
multiple myeloma, it has become a well-accepted and important treatment. Multiple 
myeloma is a cancer of white blood cells. Even with chemotherapy and stem cell 
replacement, survival rates are poor, but Thalidomide can prolong the lives of patients by 
up to 18 months. Two structurally-related analogues of Thalidomide – Lenalidomide and 
Pomalidomide – are currently being marketed for this use (Vargesson 2015a). 
Thalidomide has also been prescribed for a number of autoimmune and inflammatory 
diseases, as well as rare skin conditions. It has been used to treat rare conditions such as 
Behcet’s disease (an immune system induced vascular condition where vessels are 
destroyed causing bleeding and tissue damage), as well as graft versus host disorders 
(which occur for example in bone marrow transplants) but also for more common 
conditions such as Lupus, multiple sclerosis and Crohn’s Disease (Vargesson 2013). It is 
these latter conditions, which can occur in a younger population (i.e. of child bearing age) 
that the biggest concerns about safety and prevention of pregnancy exist.  
In 1997 when the FDA was considering whether to licence Thalidomide, a central concern 
was how to minimise the risk of birth defects. Celgene devised STEPS (System for 
Thalidomide Education and Prescribing Safety), now known as REMS (Risk Evaluation 
and Mitigation Strategy) (Celgene 2020). It requires doctors and pharmacists providing the 
drug to register and be trained in the programme, and for all patients who take 
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Thalidomide to be registered, to be educated about the effects of the drug, to agree to use 
two forms of contraception, and to sign a consent form stating that they know the risk 
associated with the drug. Specifically, the consent form states they will not share their 
medication and will return all unused tablets at the end of their treatment. American and 
Canadian Thalidomide survivors were actively involved in the development of STEPS and 
they feature in the patient education materials. 
In a number of countries, including the UK, scientists are searching for a form of the drug 
that retains the clinical benefits without the side-effect of damage to the embryo 
(Newbronner 2017). 
2.7 Legal Action and Compensation 
The legal process to obtain compensation for Thalidomide survivors varied substantially 
from country to country. In part this was because of differences in the law between 
countries but it was also because in many countries Thalidomide had been sold under 
licence and the pharmaceutical companies who owned the licences responded differently. 
There are a number of accounts of the legal battles fought by the families of Thalidomide 
children and they make for fascinating, if disturbing, reading. More recently the film 50 
Años de Vergüenza (50 Years of Shame) has documented the fight by Spanish 
Thalidomide survivors for compensation. However, for this thesis, what is important is the 
level and format of the compensation awarded, and the implications this has had for 
Thalidomide survivors’ ability to live with their impairments and manage their health. Three 
countries – Germany, Canada, and Sweden - show the different ways in which the law 
treated Thalidomide survivors and provide a comparison with the UK legal settlement. 
Importantly, in none of these cases, nor in the UK, did the idea of ageing with disability or 
the long term effects of the drug, inform discussions about the provision of compensation.  
2.7.1 Germany 
In 1961 the public prosecutor’s office in North Rhine Westphalia started an investigation to 
establish whether there was a case for legal action against Grünenthal. There was no 
precedent for such an action in West German law and so the implications for the liability of 
German pharmaceutical companies were huge. Partly because of the significance of the 
case but also because of obstruction from Grünenthal, it took four years (to 1965) for the 
prosecutor to draw up the indictment charging Grünenthal’s executives with intent to 
commit bodily harm and manslaughter (Sjostrom and Nilsson 1972). The trial began in 
1968 but was suspended in 1970 when an out of court settlement was accepted by the 
parents of West German Thalidomide children. Grünenthal agreed to pay DM 114 million 
(about $31 million) and the West German Government paid an additional DM 50 to 100 
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million (about $13.5-$27 million). Whilst the settlement meant that West German 
Thalidomide survivors received some financial assistance sooner than they might have 
done had the trial continued, especially if it had gone to appeal, it failed to provide a clear 
legal precedent because Grünenthal had neither been found guilty nor acquitted 
(Knightley et al 1979).  
For many years, German Thalidomide survivors have argued that the monthly pension 
they receive from the compensation fund was inadequate and that Grünenthal have never 
been properly held to account for the damage they caused. In 2009, after a long 
campaign, Grünenthal paid an additional €50m in to the fund and in 2013 the German 
government agreed to substantially increase pension payments. A government controlled 
body, the Contergan Foundation, also has a €30m annual ‘special needs’ fund, which 
Thalidomide survivors can apply to for help to cover specific expenses such as 
wheelchairs, adaptations to homes and high cost health treatments. However, many 
Thalidomide survivors regard the Contergan Foundation as bureaucratic and obstructive, 
for example requiring people to provide proof that costs cannot be met by their health 
insurance providers. Furthermore the fund will not pay for assistance services such as 
cleaning and personal care. As a consequence, many Thalidomide survivors are deterred 
from applying to the fund and in 2014, just €2m was used out of the annual pot of €30m 
(The Guardian, 2015). In 2015, a new chair of the Foundation’s Board of Trustees was 
appointed and since then some changes have been made in the way the organisation 
operates.  
2.7.2 Canada 
In Canada Richardson Merrell had the licence to distribute Thalidomide and in fact 
continued to market it until March 1962, three months after it had been withdrawn in the 
UK (Vermette and Benegabi 2013). The legal action against the company occurred in two 
stages. In 1968 Richardson Merrell agreed a legal settlement with ten families in Ontario. 
The law firm Spangenberg Traci negotiated $2 million to be divided amongst the families 
but two conditions were imposed – the amount of money received by each family was to 
remain secret and the law firm had to agree not to represent any more Canadian 
Thalidomide children. The company’s aim was to delay any more claims until the statute 
of limitations expired and this was exactly what happened to 26 Thalidomide survivors 
born in Quebec (Brynner and Stephens 2001).  
However, as Brynner and Stephens (2001) explain, the families were introduced to Arthur 
Raynes who had represented the first US Thalidomide survivors. He proposed suing 
Richardson Merrell in New Jersey where they had a wholly owned subsidiary and which 
was one of only two states in the USA to have a doctrine of government interest. Raynes 
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argued that what happened in Canada was of interest to the state government of New 
Jersey and so the case could be tried there. Although Raynes won the case initially he 
lost on appeal in 1975. However, the threat of further legal action persuaded Richardson 
Merrell to settle out of court, and they agreed to pay $15 million to the 26 families. The 
secrecy the company imposed in Canada makes it hard to know exactly how much 
compensation Thalidomide survivors there received and importantly, as the Thalidomide 
Victims Association of Canada explain, - “resulted in wide disparity in the compensation 
amounts, with settlements for individuals with the same levels of disability varying by 
hundreds of thousands of dollars”. In 1991, the Ministry of National Health and Welfare 
(now Health Canada), made small lump sum assistance payments to Canadian-born 
Thalidomide survivors but many continue to experience severe financial hardship 
(Vermette and Benegabi 2013).  
2.7.3 Sweden 
The first civil court case in Sweden was brought in 1965 by the parents of Thalidomide 
survivors from city of Sodertalje. The case was against Astra, the largest pharmaceutical 
company in Scandinavia, who owned the licence to distribute Thalidomide there. The 
prosecution faced a number of major problems. Firstly the Swedish Medical Board 
announced that the tragedy was ‘unavoidable’ and Astra was not to blame (Knightley et al 
1979). Secondly, they had difficulty finding expert witnesses to testify against Astra, such 
was the company’s influence, and the German prosecutors did not want their witnesses to 
give evidence in Sweden before it was heard in the German criminal trial. Eventually, in 
1969, Astra agreed an out of court settlement with the Association for the Parents of 
Thalidomide Children, of 70m Kroner ($14m), which was more than could have been 
received under the law from a trial (Sjostrom and Nilsson 1972).  
The compensation fund is administered by the Swedish Thalidomide Society (Föreningen 
för de Neurosedynskadade or FfDN), and Thalidomide survivors receive a twice yearly tax 
exempt payment. In 2005 the Swedish government made a lump sum payment to 
Thalidomide survivors amounting to €55,000 per survivor. In 2009, AstraZeneca also 
made a lump sum payment - the average payment was €120,000, with the most severely 
affected individuals receiving up to €380,000. Then in 2010, they put additional funding 
into the compensation scheme, which increased the annual payments by about 30%.  
2.7.4 Other countries 
In some European countries where there were smaller numbers of Thalidomide survivors, 
many obtained compensation via one of the bigger settlements, based on where their 
mothers had been prescribed or bought the drug. For example Thalidomide survivors in 
the Netherlands and Austria fall under the German scheme, whilst those in Finland and 
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Norway were part of the Swedish settlement. However, in Spain, which was under the 
dictatorship of General Franco in the 1960s, Thalidomide survivors have never received 
any compensation. The drug continued to be sold there under various brand names 
throughout the 1960 and 70s, and so the age range of Thalidomide survivors in Spain is 
much wider. Until 2008 the Spanish government denied ever importing Thalidomide but in 
2011, after a long campaign by Avite (the Spanish Thalidomide group) they did pay limited 
compensation to 23 survivors (Sunday Times, 2015). In 2013 Avite won a civil case 
against Grünenthal but a year later the judgment was overturned on the grounds that too 
much time had elapsed. Like their peers in Spain, many Thalidomide survivors in the 
lower and middle income countries where the drug was distributed have received little or 
no compensation.  
2.7.5 UK legal settlement 
In the UK, the fight to get compensation for Thalidomide survivors was as much a moral 
battle as a legal one. Comparing the legal process in the UK to that in other countries, 
Brynner and Stephens (2001) offer this observation: 
“It was a sprawling ordeal that had almost nothing in common with the cases in 
other countries. The issues it raised were fundamental assumptions about human 
society and British culture in particular, free enterprise and responsible capitalism, 
governance, politics, and most of all the law. But at its core the case was always 
about moral justice and the absence of it”. (p79) 
A definitive account of the legal case in the UK and the events surrounding was published 
by The Sunday Times Insight Team in 1979 (Knightly et al 1979). Led by Harold Evans, 
then editor of the Sunday Times, the team were instrumental in making the case for 
compensation for Thalidomide survivors. In November 1962, the parents of 68 
Thalidomide children filed a lawsuit against Distillers. They faced several major obstacles. 
They were reliant on public funding to pay their legal expenses and this was controlled by 
the Law Society, which from the outset had a negative view of the case. The solicitors and 
barrister who were funded changed and often served the families poorly. Then, as in the 
Swedish case, they found it difficult to obtain experts to testify, either because they were 
reluctant to speak against powerful interests in the pharmaceutical industry or because 
they were committed to the German trial. However, perhaps the biggest obstacle was that, 
as Knightly et al (1979) put it: “the moment the writs were issues, the whole affair was 
sealed by the laws of contempt of court into a legal cocoon from which it did not emerge 
until 1977” (p190). In effect this prevented the public (and therefore public opinion) 
knowing about the Thalidomide case but it also meant that the families of other UK 
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Thalidomide children were unaware of the class-action suit and so many of them did not 
come forward until years later. 
In late 1967, just a few month before the case was due to go to court, the families had no 
expert witnesses willing to speak for them, and their lawyer, Desmond Ackner, advised 
them that they would probably lose the case and so should settle out of court. The 
settlement was decided by the High Court in 1969, based on two representative cases but 
it was not until 1971 that actual figures were agreed. Despite attempts to put forward 
actuarial evidence about loss of income and the impact of inflation on lump sum awards 
(Knightly et al 1979), the families were awarded just 40% of the maximum they could have 
received through a trial. However, perhaps equally cruel was the stipulation by Distillers 
that all the families had to accept the offer and if just one refused, they would withdraw it 
(Moriarty Simmonds 2009). Six families refused to settle, although for different reasons. 
The legal team representing the Thalidomide families tried to coerce the six families to 
agree by taking them to the High Court to have them removed as the legal guardians of 
their children and in March 1972 the court agreed to this. However, one parent, David 
Mason, had the money to meet the cost of an appeal and a month later the earlier 
judgement was overturned. As all the families had not agreed to the settlement, the whole 
case ground to a halt.  
Despite the effective press embargo created by the laws of contempt of court, behind the 
scenes The Sunday Times had continued to investigate. The paper had obtained (through 
various routes) thousands of internal documents from Distillers and Grünenthal but if they 
had used them they would have given Distillers grounds to prevent publication. So they 
took a different tack and in 1972 published an article entitled “Our Thalidomide Children: a 
National Shame” which focused on the circumstances of the Thalidomide children and the 
minimal compensation they had received (Knightley et al 1979). A second article followed, 
other papers began to pick up the story and there was support from a small group of MPs 
but Distillers obtained an injunction to prevent a third article being published. However, by 
this time public outrage about the ‘Thalidomide scandal’ was growing and Distillers were 
facing a public boycott. In a forerunner of today’s social media campaigns, posters began 
to appear which mimicked adverts for Distillers products but instead of Johnny Walker or 
Gordons Gin the labels on the bottles read ‘Thalidomide’. This was followed by pressure 
from Distillers shareholders to provide a more generous settlement. Eventually in 1973, 
with their share value plummeting, Distillers agreed to pay £20 million in compensation, 
over ten years, into a charitable trust for the original 62 families and another 367 
Thalidomide children who had been identified by that point. In 1974 the British 
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government donated a further £5 million, which was an offset of tax on the original £20 
million paid in by Distillers.  
For nearly three decades UK Thalidomide survivors received compensation payments 
from the original trust fund, for the birth defects caused by the drug (but not the long term 
consequences of them). However, the annual amounts paid were not substantial and 
payments were subject to tax. In 1996 the British government, without offering any 
particular reason, donated a further £7 million, and then in 2000, after a long campaign, 
they agree to tax exempt the compensation payments (Johnson et al 2018). In 2005, 
Diageo (the company which now owns Distillers) agreed a complex new multi-year 
financial settlement (estimated to cost in the order of £153 million) as additional 
compensation for Thalidomide survivors. The additional funding provided for covenant 
payments to be increased and for the payments to be extended from 2022 to 2037. This 
was calculated on the basis of the money required to double beneficiary annual payments 
from 2004 levels by 20223.  As a result of these changes, over the past two decades, the 
financial position of UK Thalidomide survivors has much improved.  
2.7.6 Creation of Thalidomide Trust 
In 1973 the Thalidomide Trust (or the Thalidomide Children’s Trust as it was originally 
known) was set up to administer payments made by Distillers. The Trust is a discretionary 
trust and a registered charity. With discretionary trusts, a class of beneficiaries is named 
in the trust deed and the trustees have discretion as to how, when, and for whose benefit 
to use some or all of the capital and income of the trust fund. Importantly, the payments 
made by the trust are disregarded in calculating means tested benefits. The aim of the 
Trust is to provide “relief and assistance to people who have disabilities caused by their 
mothers taking Thalidomide”. Since 1973, the Trust has accepted 540 people as 
beneficiaries, though sadly 78 of them have since died4.  
The Trust is responsible for administering two funds – the annual compensation payments 
from the Distillers (now Diageo) trust fund, and the Health Grants funded by the four UK 
Health Departments (see 2.7.8). As the Trust website states: 
“In addition, the Trust provides information, advocacy and advice on health and 
broader wellbeing issues to support beneficiaries in maximising their health, 
independence and quality of life.  An important role of the Trust is to support 
beneficiaries who lack the capacity to make decisions, to ensure that their needs 
are being appropriately met”. 
                                               
3 Information provided by the Thalidomide Trust.  
4 Information provided by the Thalidomide Trust 
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The Trust has ten Trustees. Three of them, including the Chair of Trustees, are external 
appointments made by the Lord Chief Justice of England, the President of the Royal 
College of Surgeons of Edinburgh and the President of the Institute of Chartered 
Accountants in England and Wales. The remaining Trustees are appointed through a 
structured recruitment process which directly involves beneficiaries of the Trust. The Trust 
also has National Advisory Council (NAC) which is made up of 12 beneficiaries, elected 
by all UK Thalidomide survivors. 
2.7.7 Distribution of the compensation 
In 1973, the Thalidomide survivors included in the original settlement were assessed by 
doctors to establish the damage caused by the drug. They were given ‘points’ according 
to the severity of their impairments, with total points ranging from 3.5 to 75 (most severe). 
The total number of points is referred to as their ‘6(iv) b figure’, which refers to the section 
in the legal document which established the Trust. The size of the annual compensation 
payment each beneficiary receives is determined by the number of points they have. In 
2018, annual compensation payments ranged from £3800 to just over £82,000. 
Beneficiaries can take their compensation in a variety of ways. Most choose to receive it 
as an annual payment but the Trust can hold funds for beneficiaries (e.g. for the few who 
lack capacity) and make smaller more regular payments.  
2.7.8 UK Health Grant 
In March 2010 the English Department of Health confirmed it was to make a pilot Health 
Grant of £20 million to Thalidomide survivors in England. This sum was matched 
proportionately by the Scottish, Welsh and Northern Ireland administrations, creating a UK 
wide grant of £26.4 million. The grant was intended to help Thalidomide survivors address 
the “exceptional health and health-related needs they are experiencing as they grew 
older” (extract from the Department of Health letter to the Thalidomide Trust confirming 
the grant). It was distributed by the Trust over three years from April 2010, in the form of 
an annual Health Grant to individual Thalidomide survivors. When they confirmed the 
grant, the Departments of Health set down a number of conditions: 
 It must only be used to meet health-related needs 
 It must not be used to meet needs that were already being met through NHS funding 
 The Trust must account to the Departments of Health for how the money was used 
 The impact of the pilot scheme must be evaluated 
The agreement to make a ‘Health Grant’ to Thalidomide survivors in the UK was the 
culmination of a number of years campaigning by a small group of Thalidomide survivors, 
supported by the Trust. They saw the grant very clearly as reparation for the UK 
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government licensing Thalidomide back in the late 1950s and early 1960s without 
adequate checks and controls. However, there was also an acceptance by many of those 
involved that it was politically expedient to refer to the payment made as a ‘grant’, and that 
referring to it as a ‘Health Grant’ went some way to recognising the health problems 
Thalidomide survivors are experiencing as they age.  
It was important to the campaigners that individuals would not be expected to account to 
the Departments of Health for their expenditure and would be free to spend it as they 
wished in order to meet their health-related needs. As a result, the agreement reached 
with the Departments of Health simply set out seven categories of ‘health-related needs’ 
which Thalidomide survivors should use to ‘guide their expenditure’ (Newbronner et al 
2011). The categories were set out in a guidance note sent to all UK Thalidomide 
survivors: 
Independent mobility - (vehicles, vehicle adaptations, wheelchairs, etc.) ensuring 
that you can lead an independent life without subjecting yourself to unnecessary 
stress and strain, and reducing your vulnerability to harm. 
Home adaptations - to ensure you can lead a safe and independent life in your 
own home as far as possible, also without subjecting yourself to unnecessary 
stress and strain or doing things that could be harmful. 
Communications technology - systems relevant to your disability, again aimed 
at protecting your body (including sensory organs) from harm, and also reducing 
your vulnerability in general terms - or providing information to enable the Trust 
and others to support your health needs effectively. 
Medical treatment costs - other than those already covered by the NHS.   This 
could include various therapies found to be helpful of types not funded for you by 
the NHS. 
Respite - therapeutic “breaks” for either yourself or your carer(s), intended to 
relieve such things as musculoskeletal pain, or the general stress experienced by 
people in unremitting care situations. 
Personal assistance - including care in the general sense, but also the range of 
tasks needed at home or work that would otherwise involve putting your body at 
risk of further damage.   Many of you will already receive personal assistance 
funded by your local authority or the Independent Living Fund; the Health Grant 
can be used to purchase additional personal assistance with activities not covered 
by existing funding. 
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Social activities - activities that help you get out, reduce isolation and improve 
your mental and physical well-being. 
The use and impact of the Health Grant was evaluated and the results of the study were 
used by the Thalidomide campaigners and the Trust to make the case for the Health 
Grant to be continued. A new, and slightly increased ten year Health Grant was agreed in 
2013. The Health Grant money is allocated on the same basis as the annual 
compensation payments (i.e. based on impairment ‘points’) and is around 75% of the 
annual compensation payment. In 2018, Health Grants ranged from £2500 to £53,700.  
2.8 Wider Legacy of Thalidomide 
Although the focus of this thesis is on the contemporary issues facing UK Thalidomide 
survivors, it is relevant to briefly reflect on the wider legacy of the ‘Thalidomide tragedy’, 
as the medical/clinical, legal and social changes it brought about are the backdrop against 
which Thalidomide survivors have lived their lives. One of the most significant and positive 
changes brought about by Thalidomide was the establishment of standards for clinical 
research, which were set out by the World Medical Association in the Helsinki Declaration 
in 1964. In Europe and North America there were also major changes in the procedures 
for approving and regulating medicines (Moro and Invernizzi 2017). However, in the UK in 
particular, Thalidomide and the campaign for compensation also led to major reforms in 
the law. In 1975 the Sunday Times decided to challenge English contempt of court law 
under the European Commission’s Convention for the Protection of Human Rights. In 
1977 the Commission found that the reporters had been denied their right to free speech, 
which ultimately resulted in changes to definitions of contempt in civil law cases (Brynner 
and Stephens 2001). In the field of social policy, prior to Thalidomide there had been little 
public interest in the difficulties faced by families of disabled children, and no pressure for 
policy change (Bradshaw 1980). However, in 1973, as a result of the public campaign 
about Thalidomide, the Government established the Family Fund to help families of 
disabled children, both those affected by Thalidomide and others. The Family Fund still 
exists and is now the largest charity providing grants for families raising disabled or 
seriously ill children and young people in the UK.  
2.9 Summary 
This chapter sets the scene for the thesis as a whole. I began by describing the history of 
the drug: its development in West Germany by Chemie Grünenthal; the company’s 
unscrupulous marketing of Thalidomide worldwide; and the magnitude of the Thalidomide 
‘tragedy’. I have described the birth defects caused by the drug, which include short, 
missing or deformed limbs (Dysmelia), sensory impairment and facial disfigurement, and 
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damage to internal organs. The combination and severity of these birth defects varies with 
each individual, but collectively they are referred to a ‘Thalidomide embryopathy’. 
Throughout their childhoods Thalidomide survivors were often subjected to repeated 
medical examinations, testes and procedure, some of which were of questionable benefit. 
This has left many with a distrust of doctors and reluctance to take part in research.  
I have explained how, in different countries, Thalidomide survivors and their families 
sought to obtain compensation from Chemie Grünenthal and the distributors of the drug. It 
is particularly important to appreciate the legal and institutional obstacles UK Thalidomide 
survivors faced, and the nature of the legal settlement. The trust fund established in 1973 
(and administered by the Thalidomide Trust) provided compensation for the damage 
caused by the drug, but annual payment were not substantial and did not take account of 
the long term consequences of the drug. The financial position of UK Thalidomide 
survivors has improved in the last two decades with uplifts in annual compensation 
payments, and (in 2010) the awarding of a Health Grant to Thalidomide survivors by the 
four UK Departments of Health. Understanding these past events and experiences 
provides some explanation of Thalidomide survivors’ current situation. In Chapter 8 I 
discuss in more depth how the historical and social context of Thalidomide survivors’ lives 
has influenced their experience of disability over the life course, and the implications of 
this for ageing with TE.  The next chapter will outline the methods adopted to address the 
objectives of the study.  
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Chapter 3 Methods 
Chapters one and two have set the scene in terms of the drug Thalidomide – its history, 
its use, the damage it caused to the unborn child, and the on-going consequences for the 
health and lives of Thalidomide survivors. Chapter 4 provides further context by mapping 
existing research about the health of the Thalidomide survivors as they age. In Chapter 1 I 
also described the genesis of this thesis and the objectives of the study, which were to: 
 Identify the health problems Thalidomide survivors are experiencing as they grow 
older, in particular Thalidomide-related secondary health problems 
 Examine the perceived interaction between original impairment, secondary health 
problems and the ageing process 
 Understand the implications of this interaction for Thalidomide survivors’ lives, 
including their health-related quality of life and independence 
 Highlight any lessons that can be learned from Thalidomide survivors about the 
experience of ageing with early acquired disability   
This chapter describes how I addressed these objectives through a mixed methods 
grounded theory approach (MM-GT). It begins by setting out the rationale for using a MM-
GT approach, which is still relatively novel (Guetterman et al 2017). I then discuss the 
ethical considerations relevant to this study. This includes outlining my initial thought 
processes and explaining why I took the decisions I did. I go on to discuss the detailed 
methods used in the three phases of the study; the semi-structured telephone interviews 
and the initial content analysis of them; the cross-sectional self-report postal/online 
survey; and the secondary grounded theory analysis of the semi-structured telephone 
interviews. The methodology for the literature review is contained in Chapter 4. 
Throughout the chapter I reflect on the methods, including practical and theoretical 
challenges. I consider the overall strengths and the limitations of the study further in 
Chapter 8.  
3.1 Rationale for a Mixed Methods Approach 
In developing my research design I felt that more than one method of inquiry would be 
needed to fully understand the health problems of Thalidomide survivors and to do justice 
to the complexity of their experiences. I therefore decided to use a mixed methods 
approach. However, mixed methods research (MMR) also appealed to me philosophically. 
Early definitions of mixed methods research (e.g. Green et al 1989) simply describe the 
mixing of qualitative and quantitative methods but later definitions focus on combining all 
phases of the research process, characterising mixed methods research as a separate 
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methodological orientation (Tashakkori and Teddlie 2003). Other writers have also 
emphasised that mixed methods research is about more than just ‘methods’ (Johnson and 
Onwuegbuzie 2004), seeing it as a ‘research paradigm’. Creswell and Plano Clark (2017) 
prefer the term ‘worldview’. They suggest that there are four worldviews in mixed methods 
research; post positivist; constructivist; transformative; and pragmatist. It is this last 
worldview that had resonance for me because, as Creswell and Plano Clark (2017) 
explain, it focuses “on the consequences of the research, on the primary importance of 
the question asked rather than the methods, and on the use of multiple methods of data 
collection to inform the problem under study” (p37). Ultimately, this pragmatic paradigm 
underpinned my whole study and so I chose a practical definition of MMR, put forward by 
Guetterman et al (2017) drawing on Plano Clark and Ivankova (2016): 
The process of integrating qualitative and quantitative data collection and analysis 
to best address the purpose of a research study (Plano Clarke & Ivankova, 2016). 
Drawing on the strengths of both approaches MMR provides a more complete 
understanding than either approach standing alone, through incorporating the 
depth of participants’ lived experiences with broader, generalizable quantitative 
results. (p2) 
The pragmatist worldview of MMR gives researchers the freedom to use whatever 
methods are necessary to address their research question (independent of the 
philosophies that underpin them). This perspective was the start point for designing my 
study, because the objectives of the study (as set out above) genuinely demanded a mix 
of methods. First I had to identify the types of health problems, particularly Thalidomide-
related secondary health problems, that Thalidomide survivors were experiencing 
(qualitative). I then needed to establish a clearer picture of the prevalence of these health 
problems and with that, a sense of the consequences of them for Thalidomide survivors, 
including the impact on their health-related quality of life (quantitative). However, I also 
wanted to examine the interaction between original impairment, secondary health 
problems and the ageing process, and understand the implications of this interaction for 
Thalidomide survivors’ lives (qualitative).  
I adopted a three stage design which used two methods of data collection (semi-
structured telephone interviews and an online/postal survey) and three approaches to 
data analysis (content analysis and secondary grounded theory analysis of the interviews 
and statistical analysis of the survey). Figure 7 illustrates this approach. I also conducted 
a literature review to map what was already known about ageing with TE. From my 
previous work and an initial scoping search of the literature, I was aware of a small 
number of studies from other countries, which had explored different aspects of the health 
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of Thalidomide survivors in late middle age. I also knew of several reports produced by or 
for organisations representing Thalidomide survivors, or by statutory organisation, which 
had examined health and quality of life more broadly. However, there were no published 
literature reviews which brought this research and grey literature together. The findings 
from the literature did inform the content analysis of the interviews but were primarily used 
to develop the health and wellbeing survey. 
Figure 7 Mixed methods study design 
 
 
 
 
 
 
 
As mixed methods research has evolved, a number of authors have developed typologies 
of mixed methods designs (Doyle et al 2009). It is not possible or appropriate to discuss 
these typologies in detail here but it is useful to locate my study design in one of the most 
commonly used typologies, originally developed by Creswell and colleagues in 2003. 
Based on the latest iteration of this typology (Creswell and Plano Clark 2017), my study 
would be classified as an exploratory sequential design. In this design qualitative data is 
collected and analysed first, and the findings are then used to inform subsequent 
quantitative data collection. This form of ‘integration’ or linking of methods of data 
collection and analysis is usually referred to as ‘building’ (Fetters et al 2013). However, my 
design is slightly complicated by the inclusion of a second stage of data analysis i.e. the 
secondary grounded theory analysis of the semi-structured interviews, and so could 
arguably be described as a multistage mixed methods design.   
The grounded theory approach taken within the thesis is also part of the research design. 
Over the past decade, a few authors have begun to use the term ‘mixed method-grounded 
theory’ or MM-GT (Johnson et al 2010; Babchuk 2015) to describe studies which use 
grounded theory in the context of mixed methods research. In their systematic review of 
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the application of MM-GT, Guetterman et al (2017) conclude that MM-GT sits well with the 
grounded theory ‘family of methods’ (Charmaz 2014) but that in adapting grounded theory 
for use in larger studies, researchers often forgo some of the major features of grounded 
theory, in particular theoretical sampling. To some extent this was the case in my study. 
As I explain in section 3.6.2, secondary grounded theory analysis of the semi-structured 
interviews meant that it was not possible to theoretically sample in a conventional sense 
but I did find ways to partially overcome this limitation. Guetterman et al (2017) also 
recommend that in MM-GT studies “Researchers should also clearly articulate their 
rationale for selecting MM-GT and their specific design decisions” (p13). My decision to 
undertake a secondary grounded theory analysis came after I had collected my interview 
data and so in this respect I didn’t select MM-GT at the outset but rather it emerged from a 
heuristic process. My rationale for using MM-GT nevertheless holds good. 
This heuristic process was influenced by the interconnection with the Health Grant 
Monitoring project, which provided both huge opportunities but also methodological 
challenges. As I explain in Chapter 1, around the time I started thinking about my doctoral 
research, I was asked by the UK Thalidomide Trust to support them in monitoring the new 
ten year Health Grant, made to UK Thalidomide survivors in 2013. The objective of the 
monitoring project was to examine how the health and health-related needs of 
Thalidomide survivors were changing over the lifetime of the Grant, and to understand 
how Thalidomide survivors were using their Health Grants to address these needs. The 
plan for the first three years of the monitoring project did change over that time (mainly 
because of the changing requirements of the Trust and changes in the senior 
management of the organisation) but it eventually included two main elements – semi-
structured telephone interviews with a diverse group of Thalidomide survivors and a 
health and wellbeing survey of all UK born Thalidomide survivors. As I describe in section 
3.2, the Trust gave me permission to use the material gathered in the interviews and the 
data from the survey, for my doctoral research. 
The Health Grant monitoring project provided me with an ideal opportunity to gather much 
of the data I needed for my doctoral study, whilst at the same time reducing the research 
burden on Thalidomide survivors. Working with the Trust also made it much easier to 
recruit Thalidomide survivors for the semi-structured interviews and engage them in the 
survey. On the other hand, linking my doctoral research to the Health Grant monitoring 
project did introduce constraints and involved some compromises. In particular, the 
timescales for the project meant that the semi-structured interviews had to be conducted 
and analysed relatively quickly, in order to inform the development of the survey. I also 
had to ensure that both the interviews and the survey addressed the Trust’s core 
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requirements, as well as my own. I discuss the benefits and challenges of linking my 
doctoral research to the Health Grant monitoring project further in Chapter 8. 
The two methods of data collection, shown in Figure 7 were therefore determined by the 
Health Grant monitoring project, as was the overall timetable for conducting the data 
collection. However, I had some latitude in terms of the topics addressed in the interviews, 
and the content of the survey, and I was largely able to determine my approach to the 
data analysis. I decided to use content analysis for the initial analysis of the interviews 
because it is a relatively simple, descriptive approach which allowed me to look across the 
interview data horizontally, and quite quickly draw out the themes and issues that were 
likely to be relevant to the development of the health and wellbeing survey. For the 
analysis of the survey data, I initially used descriptive statistics. To address my second 
and third research objectives, I then conducted additional analysis (using inferential 
statistics) to explore the relationship between health-related quality of life and other 
factors which the semi-structured telephone interviews and narrative responses in the 
survey had suggested might be important.  
At the start of my doctoral research I had envisaged that following the semi-structured 
telephone interviews and the health and wellbeing survey, a further stage of qualitative 
data collection (possible in-depth case study interviews), which was not part of the Health 
Grant monitoring project, would be required to properly explore some of the topics of 
interest to me. However, as I worked with my interview transcripts for the content analysis, 
it became clear to me that there was the potential to learn much more from them by using 
a more interpretive approach. Once the survey was concluded, I therefore decided to 
undertake a secondary grounded theory analysis of the interviews. I describe my reasons 
for this decision and my approach to this secondary analysis in section 3.6.  
3.2 Ethical Considerations  
Many Thalidomide survivors were the subjects of research, particularly medical research, 
during childhood. Some feel that this research was intrusive and inappropriate, even 
unethical. As a result, there is sensitivity within the Thalidomide community about 
participating in research, and rightly most Thalidomide survivors will only support research 
which either has a direct benefit for Thalidomide survivors or others with similar 
impairments. For this reason, it was important to obtain support from the Trust and the 
National Advisory Council5 (NAC) for my doctoral study.  
                                               
5 The National Advisory Council is comprised of 12 elected beneficiaries. It acts as an advisory 
body for the Trust and is the principal means by which the beneficiaries are able to influence the 
Trust’s policies. 
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Within the Trust, the Research Committee (which has three NAC representatives) is the 
body responsible for giving approval to and overseeing all research (internal and external) 
that involves the Trust’s beneficiaries. The Trust’s Research Committee initially approved 
the Health Grant Monitoring Project, and was actively involved in agreeing key aspects of 
the work such as recruitment processes, research instruments, and approving reports for 
the Trust. In May 2014, I submitted a paper to the Research Committee requesting 
permission to use the data from the Health Grant Monitoring Project for my doctoral study. 
They agreed, on the understanding that individual consent would be obtained from the 
beneficiaries taking part in the interviews for their interview transcripts to be used in my 
thesis.  
Written consent was obtained from all the Thalidomide survivors who volunteered to take 
part in a telephone interview for the Health Grant Monitoring project (the initial consent 
form is shown in Appendix 1). However, because the recruitment process for the project 
began before I commenced my doctoral research, the consent form did not include explicit 
consent for the data to be used for that purpose. To overcome this, I took two steps. First, 
when I contacted volunteers to confirm that they were still willing to take part in a 
telephone interview I explained that the Trust had given me overall permission to use the 
data from the Health Grant Monitoring Project for my doctoral study but that I needed 
specific consent to include their interview transcript in my analysis. The revised consent 
form is shown in Appendix 2. I made it clear that if they declined consent for my doctoral 
research (which two did), they could still take part in the project. Second, when I came to 
conduct the interviews, I verbally reconfirmed consent for both the project and my doctoral 
research, and this was recorded both digitally and in my interview notes.   
In May 2014, I also applied for ethical approval from the University of York Health 
Sciences Research Governance Committee. The decision letter dated the 23rd May 2014 
gave approval for the study. The letter (see Appendix 3) included six minor points of 
feedback, which they suggested I should discuss with my supervisor. Whilst approval was 
not contingent on addressing these points, I did respond to the Chair of the committee in 
June 2014 (see Appendix 3), following a discussion with my supervisor, and I revised the 
consent form. At the time approval for my doctoral study was given, the Trust was 
planning to use annual interviews to monitor the Health grant and had not taken the 
decision to undertake the Health and Wellbeing survey.  In September 2015, once the 
Trust decided to go ahead with the survey, I submitted a substantial amendment to my 
original ethics application (see Appendix 4). This was approved the same month.  
In addition to formal ethical approval there were a number of wider ethical issues to 
consider. I had worked with people in the Thalidomide community for several years and 
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had come to know a number of Thalidomide survivors personally. This had enabled me to 
build up a degree of trust within the community but it also brought with it the danger of 
over familiarity and bias. I discuss this further in Chapter 8 in relation to the strengths and 
limitations of the study. More specifically, I was very aware of the sensitivity within the 
Thalidomide community about participating in research. The Health Grant monitoring 
project was clearly of direct benefit to Thalidomide survivors in that the findings from it 
would potentially be used to support the arguments for the continuation of the Health 
Grant. However, this was not the case for my doctoral research and so I was especially 
careful to explain to the interview participants how their information would be used and 
why it would be of benefits to the Thalidomide community.  
As far as possible I tried to make the interviews a positive experience. The interviews 
were arranged in advance at a time of the interviewees choosing. At the beginning of the 
interview I reminded them of the broad topics I hoped to cover but emphasised that they 
could tell me as much or as little as they wanted. I also explained that they could take a 
break at any time or stop the interview completely if they wished. None of the participants 
became distressed during the interviews but it was clear that some participants were 
dealing with difficult issues. In some cases I did encourage people to contact the Trust to 
see if they could provide support or advice.  
I was also concerned about the potential research burden on Thalidomide survivors. The 
Health and Wellbeing survey was quite long, with 52 questions spread over 12 pages (see 
Appendix 5), although many of the questions were multiple choice. Based on the piloting I 
was able to reassure people that it would only take around 20 minutes to complete, and 
the online version had a ‘save and continue later’ facility which meant that people could 
complete it in stages. Perhaps more importantly, around the time of my data collection 
phases the Trust was supporting two other pieces of research – one about peripheral 
neuropathy and one about loss of earnings. In the light of this, being able to conduct 
secondary analysis of the telephone interviews, rather than a third stage of data collection, 
was an important step in reducing the research burden.  
3.3 Involvement of Thalidomide Survivors  
From my previous work I was very much aware of the sensitivity in the Thalidomide 
community about research. I knew that Thalidomide survivors would only be willing to 
participate in my research if it was seen as relevant and valuable to them. For this reason 
I felt it was essential to involve them in all stages of the study. However, Thalidomide 
survivors are also ‘experts by experience’ - they have lived with a rare condition and its 
consequences for over five decades. Many, but especially those who have been actively 
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involved in the Thalidomide Trust and Thalidomide Society, have developed a wider 
knowledge of Thalidomide Embryopathy and its medical and social consequences. It was 
very important to me that my research was informed by this knowledge and expertise. 
Below I briefly summarise the key ‘PPI’ or Patient and Public Involvement type activities 
within the study, both formal and informal. I also detail the involvement of Thalidomide 
survivors in the different stage of the study, in the relevant sections of this chapter.  
Prior to embarking on my doctoral studies, I had informal conversations with three 
Thalidomide survivors I had come to know quite well, in order to gauge the likely 
acceptability and importance of my research proposals. They agreed that the topic was 
important and their personal reflections on ageing with TE were helpful in terms of setting 
out the rational for the research. As I explain in the previous section, the first formal step 
was obtaining approval from the Trust’s Research Committee for me to use data from the 
Health Grant Monitoring Project for my doctoral research. The Committee membership 
included three Thalidomide survivors who are nominated by the National Advisory Council 
(NAC). This Committee was also actively involved in shaping the research, in particular 
how the data collection was conducted, including:  
 Approving all the letters, forms and information sent to participants 
 Advised on the content of the topic guide for the interviews, which was then tested 
with a two Thalidomide survivors from outside the Committee 
 Helping to shape the content and format of the survey questionnaire, including piloting 
the final draft (along with seven Thalidomide survivors who were not members of the 
Committee) 
 Commenting on the data analysis and presentation of findings 
Even after the Health Grant Monitoring Project was concluded, the Committee and NAC 
maintained their interest in my doctoral research. I presented the findings from my 
literature review to the Committee and as a result they asked me to produce an accessible 
summary for the Trust’s website. At the analysis stages I again had informal 
conversations with current and former NAC members to ‘sense check’ what was 
emerging. I also presented initial findings from the survey and the secondary grounded 
theory analysis of the interviews to NAC Annual Conferences (which are attended by 
around 150 Thalidomide survivors). The feedback received at these events was 
particularly helpful in identifying implications for policy and practice. 
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3.4 Semi-structured Telephone Interviews 
The semi-structured telephone interviews were the first step in gathering information 
about the health problems Thalidomide survivors were experiencing but also in exploring 
how they made sense of their changing health, and how these problems (and associated 
loss of function and increasing impairment) were affecting their lives (and disabling 
experience). In this section I discuss the rationale for using semi-structured interviews and 
for conducting them by telephone. I describe how the interview participants were recruited 
and the process of conducting the interviews.  It is followed by section 3.4 in which I 
discuss my approach to the content analysis. The secondary grounded theory analysis is 
described in section 3.6, after the Health and Wellbeing Survey. 
3.4.1 Rationale for using semi-structured telephone interviews 
There are many different ways of generating data in qualitative research but one to one 
interviews are perhaps the most commonly used method (Barbour 2008). I chose to use 
interviews because I wanted to capture individual narratives in some depth. Thalidomide 
survivors are a heterogeneous group. From my previous work, I was aware that the nature 
of their impairments and their personal history and circumstances (e.g. home situation, job 
etc.) might influence the type of health problems they were experiencing and their 
response to them. I used semi-structured interviews rather than a completely open 
approach because the interviews were being undertaken as part of the Health Grant 
Monitoring project and as such I had to ensure that I covered the core topics of interest to 
the Trust. However, the semi-structured format still gave me flexibility to take account of 
the priority the interviewees placed on each topic, and enabled me to explore topics that 
were more closely aligned to my doctoral research. In fact, as I describe below, the semi-
structured format elicited very full and reflective responses from many participants. 
I decided to conduct the interviews by telephone rather than face to face for practical 
reasons. Thalidomide survivors are spread across the whole of the UK but the budget for 
the research was limited and did not allow for the time and travel costs involved in face to 
face interviews in peoples’ own homes. Furthermore, I had used telephone interviews 
previously with Thalidomide survivors and found they were both acceptable and worked 
well. Aside from the practical and cost issues, telephone interviews have other 
advantages. They can be more convenient and less intrusive for the participant, and there 
is some evidence that telephone interviews generate data of similar quality and depth to 
face to face interviews (Bryman 2015). However, they also have disadvantages, in 
particular being unable to see the participant means that the interviewer cannot respond 
to body language or facial expressions and is reliant on non-visual cues such as tone of 
voice (Taylor and Francis 2013). In the case of my study the major disadvantage was that 
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they effectively precluded Thalidomide survivors who were totally deaf from taking part. A 
number of interviewees did have a hearing impairment and used hearing aids and other 
technology to take part in the interviews but none of the interviewees were completely 
deaf. With hindsight, I should have explored other ways (e.g. a face-to-face interview with 
a sign language interpreter) to enable those with no hearing to be involved. The Trust now 
uses a new service (Sign Live) which enables a hearing person to have a telephone 
conversation with a deaf person, using a sign language interpreter and either a smart 
phone, tablet or computer, but this was not available at the time I conducted the 
interviews. As a consequence, the experiences of deaf Thalidomide survivors are under-
represented.  
3.4.2 Recruiting and selecting the interview sample 
Previous studies (Newbronner et al 2012; Peters et al 2015) suggested that the nature 
and severity of Thalidomide survivors’ damage is one of main factors influencing the type 
of secondary damage they experience. It was therefore important that the interview 
sample included participants with a range of impairments. The original plan (for the Health 
Grant monitoring project) was to recruit a purposive sample of around 25 Thalidomide 
survivors, i.e. five in each of the five impairment severity bands, with roughly equal 
numbers of men and women (reflecting the gender balance of all UK Thalidomide 
survivors).  
Three main approaches were used to recruit participants. All those Thalidomide survivors 
who took part in two earlier studies - the Health Grant Evaluation and a cost of disability 
study Securing Our Futures (NAC 2012), were asked if they would like to be involved in 
monitoring the Health Grant. In total 123 took part in the two studies, but some people 
(number unknown) took part in both studies. These Thalidomide survivors were already 
familiar with the Health Grant work to date and had some understanding of what would be 
required of them. A letter from me (Appendix 6) about the Health Grant monitoring project, 
and the initial consent form (Appendix 1) was sent to them by the Trust. The letter 
contained information about the overall project, what taking part in the interviews would 
involve and how the information would be used. The consent forms were returned directly 
to me in a freepost envelope.  
Initially the Trust wanted to use this single approach to recruit participants but I was 
concerned that it might skew recruitment towards those who were more confident about 
taking part in research, and/or those with more knowledge about the Health Grant. I 
therefore agreed with the Trust that two further approaches would be used. Firstly, 
information about the study was distributed through the Trust’s regular communications 
with its beneficiaries (e.g. the Directors quarterly newsletter). Second, the project was 
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promoted at the 2013 annual conference of the National Advisory Council. Those 
interested in being involved were invited to either return a consent form or to contact me 
directly by email or phone. It is impossible to know how many participants were recruited 
through each approach as some people may have received information about the project 
via all three routes.  
Fifty-three beneficiaries indicated that they would be interested in taking part in the study 
– more than double the planned number. At this stage one option would have been to 
purposefully select 25 participants as originally planned. However, in discussion with the 
Trust it was decided that all the beneficiaries who had expressed in interest should be 
given the opportunity to take part. This was partly because the Trust wished to be 
inclusive. Historically, there has been some distrust of research within the Thalidomide 
community, and certainly researchers in other countries have experienced difficulties 
recruiting Thalidomide survivors to take part in research. For example, personal 
correspondence with a colleague working with Thalidomide survivors in Sweden revealed 
that she had encountered difficulties in getting the Swedish Thalidomide Society (FfDN) to 
support her research and this led to problems with recruitment. For this reason the Trust 
did not want to turn away willing volunteers at this early stage.  
In addition, my experience of the Health Grant Evaluation, which also used semi-
structured interviews, suggested that not all those who volunteered would ultimately take 
part. In fact, when I eventually contacted those who had expressed an interest in the 
study, to confirm that they still wished to be involved and to re-consent them, five people 
immediately withdrew for personal reasons such as ill health or family difficulties. When I 
came to contact people to make arrangements for the interviews, a further seven either 
did not respond or it proved impossible to arrange a date and time for their interview. In 
addition, one participant was clearly experiencing severe mental health problems at the 
time of the interview and so I terminated the interview and agreed with him that I would 
ask the Trust to contact him to provide advice and support. Forty Thalidomide survivors 
were eventually interviewed by telephone (and one responded in writing). Of these, two 
declined consent for their interview transcripts to be used as part of my doctoral research, 
and so the analysis of the interviews is based on 38 participants.  
The make-up of the sample did have the diversity I wanted to achieve from the purposive 
sampling, in that the participants were drawn from all four UK nations, in very similar 
proportion to all UK Thalidomide survivors, and were spread across the Trust’s 
impairment bands, although Thalidomide survivors in Band 2 are under-represented and 
those in band 5 over-represented. A comparison, by band, with all UK Thalidomide 
survivors is shown in Table 1. There was, however, an imbalance in the sample in relation 
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to gender.  Whilst just over half the Thalidomide survivors in the UK are women, the 
interview group was made up of 68% (26) women and 32% (12) men. 
Table 1 Proportion of interview sample in each impairment band compared to all UK 
Thalidomide survivors 
 Band 1 Band 2 Band 3 Band 4 Band 5 Total 
Number 5 6 12 7 8 38 
Interview 
Sample  
13% 16% 32% 18% 21%  
UK Overall 11% 26% 35% 15% 13%  
 
I did not collect data about age or ethnicity because the vast majority of UK Thalidomide 
were born between 1959 and 1962 (with just a handful born in the following three years) 
and the Trust estimates that only 15 of its 467 beneficiaries are from BME communities. In 
terms of home circumstances, seven lived alone, 26 lived with their partner (or their 
partner and children), and five lived with their children. No structured information was 
collected about social class but the group did include people from a range of occupational 
backgrounds, including a few who had never worked due to their disability, manual and 
semi-skilled workers, and those in managerial and professionals roles. At the time of the 
interviews, 26 participants were not working: sixteen said they were unable to work 
because of their health problems/disability; eight had given up work for a combination of 
health and personal reasons (e.g. family commitments, lifestyle); and two said they had 
decided not to work entirely for personal seasons. Ten were working part-time, and of 
these half said they no longer felt able to work full time because of their health 
problems/disability, and half said they had reduced their working hours for a mix of health 
and personal reasons. Two were working full-time. With hindsight I should have included a 
question about social class and ethnicity in the interview, although the Trust does not hold 
information about the social class or ethnicity of its beneficiaries and so it would not have 
possible to make a comparison with all UK Thalidomide survivors.  
3.4.3 Conducting the interviews 
In this section I describe the development of the topic guide for the telephone interviews 
and the practical process of conducting them. The Trust asked me to address four main 
topics in the interviews: 
 Current and recent health problems 
 Use of the 2013/14 Health Grant  
 Social Care Support 
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 Future Needs  
Although the core topics were fixed, I had flexibility to explore them as I felt best. I 
developed a first draft of the topic guide which was reviewed by the Trust’s Research 
Committee (which includes three Thalidomide survivors). After incorporating their 
comments, I piloted the topic guide with two Thalidomide survivors who had assisted with 
previous research but who were not involved in the Health Grant monitoring project. The 
final version of the topic guide (which is shown in Appendix 7) had 10 main question in 
four short sections. Section 1 Current and Recent Health Problems asked about: the 
nature of any Thalidomide-related health problems; how these health problems were 
affecting people both practically and emotionally; and whether they had sought or 
received any treatment for their health problems. Section 2 Social Care Support simply 
asked if the interviewee had social care support and if they did, whether they had 
experienced any problems with the level of support provided. Section 3 Use of the Health 
Grant explored how people had used their 2013/14 Health Grant; the main reasons for 
choices/decision; and any impact on their health and wellbeing. Finally Section 4 The 
Future asked interviewees about anticipated future health-related needs, and any plans 
for the use of their Health Grants in the longer term. 
 
The semi-structured format worked well, ensuring that the core topics were covered. In 
addition, to ensure the interviews provided sufficient data for my doctoral study, alongside 
the ten main questions I identified a number of related topics or sub themes which I also 
explored. For example question 2 asked: How have these health problems affected you? 
My ‘prompt’ then read: Explore: Physical and emotionally affects as well as practical 
affects (e.g. lifestyle/quality of life; impact on family; impact on employment). Many 
interviewees gave very full answers to the questions and naturally addressed a number of 
the sub-themes without me having to ask about them. However, for more reticent 
interviewees I used these ‘prompts’ to elicit fuller responses.  
The interviews were conducted by telephone during June, July and August 2014 and 
lasted between 40 and 90 minutes. All except two were digitally recorded, with the 
Thalidomide survivors’ consent, using an Olympus VN-5200PC Digital Voice Recorder. 
Two participants did not wish their interviews to be recorded, and so in these interviews I 
took detailed hand written notes. All recordings were transcribed (intelligent verbatim)6 in 
full using Microsoft Word. Twenty four were transcribed by me and 14 were transcribed by 
two different transcribers and then checked by me. 
                                               
6 Intelligent verbatim transcription is a style of transcription that converts recorded speech into text 
while editing out the fillers (e.g. ah, um) and repetitions.  
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3.5 Content Analysis of the Interviews  
Content analysis is a widely used method for analysing qualitative data in health research 
(Hsieh and Shannon 2005). However, even a limited examination of the literature reveals 
that definitions vary and there are different understandings of the characteristics of the 
approach. There is also confusion or blurring of the boundaries between content analysis 
and other approaches to qualitative data analysis, notably thematic analysis (Vaismoradi 
et al 2013), with some authors (e.g. Green and Thorogood 2009) conflating them into 
‘thematic content analysis'.  Generally, content analysis is split into two classifications. 
The first is quantitative content analysis, which Silverman (2013) suggests “involves the 
establishing categories and then counting the number of instances when those categories 
are used in a particular text” (p64). The second is qualitative content analysis which also 
focuses on the systematic examination of texts, using coding and categorising (Pope et al 
2006) but which does not necessarily involve counts or frequencies. However, Hsieh and 
Shannon (2005) suggest that qualitative content analysis can include a summative 
approach, which begins with the researcher “identifying and quantifying certain words or 
content in text with the purpose of understanding the contextual use of the words or 
content. This quantification is an attempt not to infer meaning but, rather, to explore 
usage” (p1283). They go on to explain that if the researcher stopped at this point, the 
analysis would be quantitative, and so a summative approach to qualitative content 
analysis should go beyond counts to include interpretation of content. It is this description 
that best fits my approach to the qualitative content analysis of my interviews, although I 
began with interpretation and then moved on to counts. 
The content analysis of the interviews had two main purposes: to prepare a report for the 
Trust from the first stage of the Health Grant monitoring project, structured around the four 
topics they were interested in; and to inform the development of the Health and Wellbeing 
survey. I began by up-loading the interview transcripts in to QSR International's NVivo 
11 qualitative data analysis software. My analysis was then both deductive and inductive. I 
used the high level categories from the interview topic guide to provide an outline 
structure for the analysis i.e. they became my nodes (deductive). Within this structure I 
identified the key themes and issues to emerge from the interview transcripts as I read 
them, and then created sub-nodes for each of these (inductive). Table 2 provides an 
overview of the categories and themes.  
The headline findings from this analysis were incorporated into the report for the Trust 
(Newbronner 2015). To address the first two objectives of my thesis (i.e. identifying the 
health problems Thalidomide survivors are experiencing and examining the interaction 
between original impairment, secondary health problems and the ageing process) I then 
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focused on the material relating to current and recent health problems. It is this part of the 
analysis that I report in Chapter 5.  
The initial interpretive phase of the content analysis enabled me to identify the main health 
problems respondents were experiencing, and begin to understand: the language people 
used to describe their health problems; how they linked different problems; and any 
connections they made to their original Thalidomide damage. To gauge the relative 
importance or ‘prevalence’ of them, I counted the number of interviewees who reported 
experiencing different health problems. The findings from my literature review helped me 
think about how to group them but I was primarily guided by the data. 
Table 2 Content analysis - categories from the topic guide and themes emerging 
from the analysis 
High Level Categories Themes 
Background Information Home circumstances; implications of changing family 
circumstances; giving up work or changes in employment; 
working and health problems 
Current or recent health 
problems  
Health Problems: Joint problems; Shoulders, arms and 
hands; Hips, knees and feet; Back and neck; Pain; 
Neuropathy symptoms; Mental and emotional health; Long 
term conditions/other health problems; Weight 
management; Sight and hearing problems 
Dental health 
Use of health services: access and availability; staff 
attitudes and service quality; knowledge and 
understanding of TE; effectiveness of treatments; and role 
of GP 
Growing older with disability 
Social Care Support Level of service; quality and flexibility; attitudes and 
seeking help 
Use of Health Grant Use of HG in 2013/14; rationale of using HG in this way; 
adequacy of HG; perceived impact of HG on health and 
wellbeing  
The Future Main health-related needs in near future; thoughts about 
using HG to address these needs 
 
Initially I had eight main groups of health problems with just one for musculoskeletal 
(MSK) problems. However, it soon became apparent that the coding of these types of 
problems needed to be more fine-grained if I was to reflect the detail of what respondents 
were describing. I decided to cluster MSK problems by the areas of the body affected. 
There were three main reasons for this. Firstly, because so many of the interviewees were 
reporting MSK problems, having all the references under one heading became unwieldy. 
By splitting them into several groups the data became more manageable. Secondly, MSK 
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problems appeared to be in part related to the nature and severity of interviewees’ limb 
difference, and this was potentially an important connection to be explored further in the 
Health and Wellbeing survey. Thirdly, the Trust was in the process of establishing a 
network of orthopaedic specialists who could diagnose and treat Thalidomide survivors, 
and so it was helpful for them to know what interviewees said about MSK problems in 
different areas of the body.  
I eventually settled on four main groups for MSK problems but retained a separate group 
for ‘pain’ because this was so often a feature of respondents’ experience. This gave me 
eleven groups of health problems: 
 MSK problems - Joints 
 MSK problems - Shoulders, arms and hands 
 MSK problems - Hips, knees and feet 
 MSK problems - Back and neck 
 Pain  
 Neuropathy symptoms 
 Mental and emotional health 
 Long term conditions/other health problems 
 Weight management 
 Sight and hearing problems 
 Dental health 
There is some overlap between the themes, especially between ‘MSK problems – joints’ 
and the other MSK groups, and between MSK groups and ‘Pain’ as often people 
described a range of problems and the pain they were experiencing as a result of them, 
together, in one segment of the interview. Table 3 provides an example of this and of how 
I moved from my raw data to the health problem ‘groups’ used for the count of health 
problems.  
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Table 3 Example of content analysis coding 
Interview Text Coding 
I’m quite fit and still quite mobile but I’ve got one leg longer 
than the other slightly, although it’s not something that’s ever 
been addressed, because it’s so slight.  But the last few years, 
I’ve been limping more because my foot turns over to 
compensate, so I get through loads of pairs of shoes – they 
wear down – and it does give me knee and hip pain – I think 
my hips aren’t made properly either.  I have had a lot of hip 
pain and more knee pain recently over the last couple of 
years.   
 
The other thing I get is shoulder and neck pain where I’m 
reaching for things and bending and sort of my back.  I’ve 
noticed that more and more as I’m driving.  I’ve never really 
had trouble driving but I feel when I drive now, my shoulders 
hurt more and more, and I think that’s probably wear and tear 
because we tend to put so much weight behind our shoulders 
because we don’t have the strength in our arms. 
 
 
 
 
MSK problems – hips, 
knees and feet 
MSK problems - joint 
Pain 
 
 
MSK problems – 
shoulders arms and 
hands 
 
The qualitative content analysis also helped me to understand the language people used 
to describe their health problems and to explore what people perceived were the root 
causes of their Thalidomide related health problems. I anticipated that both these things 
would be important in shaping the Health and Wellbeing survey and this was the case. I 
discuss this further in Chapter 5.  
3.6 Self-Completion Health and Wellbeing Survey 
The content analysis provided a broad picture of the health problems Thalidomide 
survivors were experiencing but the analysis was based on the experiences of a limited 
sample of 38 Thalidomide survivors. To address the first aim of my doctoral research I 
needed to gain a much more detailed understanding of the prevalence of these health 
problems and with that, a sense of the consequences of them for Thalidomide survivors, 
including the impact on their health-related quality of life (the third objective of my 
research). For a number of reasons the Trust also wanted to gather information about 
health and wellbeing of its beneficiaries: to influence negotiations with Diageo about 
investment in the Trust Fund; to inform a new five-year strategy; to help shape their 
support services; and to provide baseline information for the monitoring of the Health 
Grant. In particular, they wanted information to be collected directly from Thalidomide 
survivors themselves, and they wanted quantitative data. Together we decided that a 
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cross sectional survey of all UK born Thalidomide survivors, administered online and by 
post would be the best way to gather this information.  
3.6.1 Survey design 
Bryman (2015) explains that survey research: 
“comprises a cross-sectional design in relation to which data are collected 
predominantly by questionnaire or structured interview on a sample of cases 
drawn from a wider population and at a single point in time in order to collect a 
body of quantitative or quantifiable data in connection with a number of variables 
(usually many more than two), which are then examined to detect patterns of 
association.” (p54)  
Given this definition, survey research enabled me to address the objectives of my doctoral 
research (and meet the needs of the Trust) in a number of important ways. I wanted to 
collect data from as many UK born Thalidomide survivors as possible. At the time there 
were 467 and so the most practical and affordable way to reach them was via a survey. 
Although the Trust may repeat the survey (or a version of it) in the future, at the time it 
was seen as a ‘snapshot’ (i.e. the data were being collected at a single time point).  
Furthermore, I wanted to collect quantitative or quantifiable data on a number of variables, 
with much of these data only being available from Thalidomide survivors themselves. 
Specifically I wanted to include both self-report questions (e.g. about the health problems 
people were experiencing) and self-report measures which would provide respondents 
subjective assessments of their health-related quality of life and mental wellbeing (Bowling 
2005). There are risks in using self-report questions, in particular the accuracy of 
respondents’ recollections (Bowling and Ebrahim 2005), but there was no other practical 
way in which to collect the data needed. The Trust holds up to date postal addressed for 
all its beneficiaries and around two third had also indicated that they were happy for the 
Trust to contact them by email and so with the aim of increasing the response rate, I 
agreed with the Trust that we would give people the option to complete the survey by post 
or online. This is discussed further in section 3.6.4. 
Overall then, collecting data I required through a postal and online survey made sense 
both from a study design and a practical point of view. However, online/postal surveys do 
have disadvantages (Fowler 2009). By their nature, self-completion questionnaires do not 
lend themselves to more than a few open questions, because respondents are usually 
reluctant to write a lot. Their usefulness can also limited by poor response rates and/or 
poor response rates from certain groups, making them unrepresentative of the ‘population’ 
of interest. In this case, Thalidomide survivors had a strong incentive to complete the 
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survey, including open questions, as the findings from it could influence their future 
financial support and services. Ultimately I did include a small number of text boxes where 
respondents could add information and included a half-page comments box at the end of 
the survey, which yielded surprisingly rich data. Self-completion surveys can also 
experience problems with missing data if respondents choose not to answer a question, 
and inaccurate or contradictory data, if respondents misunderstand a question. This was 
certainly an issue in the Health and Wellbeing survey, despite (at the design stage) 
incorporating skip-logic into the online version and piloting both the online and postal 
versions. It was also possible to take some steps at the data analysis stage to help 
address this and I discuss this further in 3.6.5. 
One particularly helpful aspect of this survey was that unlike much survey research, no 
sampling was required because the Trust wanted the survey to be sent to all UK born 
Thalidomide survivors and they had the administrative systems in place to do so. It was 
therefore easy and appropriate to include all of them in the survey. A small number of 
Thalidomide survivors lack capacity and have a family member or solicitor who acts on 
their behalf. However, we decided that this group should still be included in the survey as 
their guardians might be able to provide some useful information about their health and 
wellbeing. Four partially completed ‘proxy’ returns were received.  
3.6.2 Development of the survey 
PPI or the active involvement of Thalidomide survivors was central to the development 
and piloting of the survey. It was initially developed in conjunction with the Trust’s Health 
and Wellbeing and Research Committees, which are made up of officers, trustees and 
Thalidomide survivors (nominated by the NAC). We began by agreeing the overall aims of 
the survey which were to: 
 Quantify the different health problems Thalidomide survivors were experiencing  
 Examine the mental and emotional wellbeing of Thalidomide survivors compared to 
the general population 
 Explore if/how Thalidomide survivors health and wellbeing were related to the nature 
or severity of their Thalidomide damage or their personal circumstances 
 Gather supporting socio-demographic information about the circumstances of 
Thalidomide survivors (e.g. housing and employment situations) 
I then prepared a paper for the Health and Wellbeing Committee, which outlined the 
proposed broad content and format of the survey. The paper drew on the content analysis 
of the telephone interviews and evidence from my literature review, including the reports 
from the Health Grant Evaluation. These sources highlighted many of the topics that 
would need to be explored in the survey. For example, the content analysis pointed to the 
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importance of gathering background information about home and family circumstances, 
and employment, as many Thalidomide survivors were experiencing changes in these 
areas of their lives. They also flagged up many of the secondary health problems 
Thalidomide survivors were beginning to experience, and the related treatment choices. 
This informed the sections of the survey covering health problems and the use of health 
services. Lastly, the literature provided a number of potential comparisons, which could 
help set the experience of UK Thalidomide survivors in an international context.  
Comments on the paper from the Health and Wellbeing Committee informed the 
development of the first draft of the survey. For some topics, they wanted to add questions 
to explore specific issues e.g. the reasons people felt they might need to move house in 
the next five years, and how well their GP understood their Thalidomide damage. Some 
new topics and questions were added e.g. a question about pension provision and 
another about future need for local authority social care support. The other important 
discussion was around which validated instruments to use to measure mental wellbeing, 
the impact of ill health/loss of function and/or health-related quality of life. We eventually 
agreed that two would be used: the short form of the Warwick and Edinburgh Mental Well-
being Scale (WEMWBS) (Warwick Medical School 2018) to provide a baseline measure 
of mental wellbeing; and SF12 (Rand Health Care – no year given) to assess health 
related quality of life. I discuss the reasons for choosing these instruments in section 
3.6.3.  
The first full draft of the survey was circulated to the Research Committee and their 
comments were taken into account in a revised draft. This second draft was then piloted 
with ten Thalidomide survivors – five (one from each impairment band) selected from the 
40 who took part in the Health Grant monitoring interviews, four who were members of the 
Health and Wellbeing and Research Committees, and an additional ‘volunteer’ who had 
held a senior role in a social research organisation and had particular expertise in 
questionnaire design. Two of them completed the survey on paper and the others 
completed the online version. As they completed the questionnaire, they were asked to 
note: 
 How long it took them to complete the whole questionnaire 
 Any questions they felt were unclear or any wording that could be improved 
 Any instructions that they found confusing or unclear 
 Overall how easy or difficult the questionnaire was to complete  
 The overall look/format of the questionnaire and any ideas for improvement 
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They provided feedback in a variety of ways – through telephone discussions, via email 
and by annotating the paper and online versions with comments. This feedback was 
invaluable and greatly improved the questionnaire. The nature and extent of the 
comments provided varied hugely from four pages of detailed comments, from the 
Thalidomide survivor who had been a social researcher, to much briefer comments about 
the time it took to complete the survey and its general user friendliness. The quotations 
below illustrate the range of comments received: 
“Question 24. ‘In the past 5 years, have you experienced any problems obtaining 
or receiving the health treatment/care you needed?’ I originally answered ‘no’ to 
this, but when I looked at the answer list on the follow-up question 25 (which I 
should have ignored if I’d followed the filtering instructions) I realised that I 
probably should answer ‘yes’ because nobody’s ever been able to give me a 
proper blood pressure reading (i.e. they don’t know how to interpret the figures for 
most people who have the pressure taken on the leg). In other words, I haven’t 
had a problem in the past five years because I’ve stopped asking for it, since I 
know they can’t do it!” (Pilot 8) 
I only know that there is such a thing as a 6(iv) b figure7 but am not sure I have 
ever been told what it is. Are we supposed to know? (Pilot 10) 
I completed it easily in 16 minutes including using the Save & Continue facility and 
the Print Response Facility, both of which worked well. I completed part of it on a 
tablet, part on a smart phone and part on a laptop and it worked well on all these 
devices. (Pilot 4) 
The comments led me to remove some questions (e.g. asking respondents for their 6(iv) b 
impairments figure), and refine the wording of others. Whilst overall they reassured me 
that the survey was relatively easy and quick to complete, the very detailed comments 
from the Thalidomide survivor who had expertise in questionnaire design, really helped 
me improve the instructions on the paper version and the ‘skip logic’ in the online version. 
Following piloting, a final draft of the questionnaire was prepared and again circulated to 
the Research Committee. After a few further minor changes, the final version was agreed.  
                                               
7 The ‘6(iv) b figure’ refers to the number of impairment ‘points’ Thalidomide survivors were given 
when they were originally assessed as beneficiaries of the Trust. 
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3.6.3 Content of the survey 
A copy of the paper version of the survey is shown in Appendix 5. However, for ease of 
reference Table 4 below summarises the content of the survey. In the right hand column I 
indicate which variables I did and didn’t use in my doctoral study. 
Table 4 Summary of the survey sections and topics 
Section Topics Included in 
Doctoral 
Study? 
About You 
Gender 
Highest educational level 
Yes 
Yes 
Family and Housing 
Home circumstances 
Housing situation 
Planned adaptation 
Need to moving home 
Yes 
Yes 
No 
No 
Work and Pensions 
Work situation  
Change in work situation 
Pension cover 
Yes 
Yes 
No 
Original Thalidomide 
Impairments 
Limb damage 
Other damage 
Yes 
Yes 
Mobility and Equipment 
Use of wheelchairs and mobility scooters 
Hearing aids/implants 
Adapted Vehicles 
No 
No 
No 
Health Problems 
Current and recent health problems 
Steps to improve health or wellbeing 
Yes 
No 
Use of Health Services 
Treatments in past 10 years 
Experience of GP services 
Problems with healthcare services 
Yes 
Yes 
Yes 
Social Care Support 
Use of local authority social care 
Use of personal assistants 
Future needs for social care 
Yes 
Yes 
Yes 
Mental Wellbeing  
Warwick Edinburgh Mental Wellbeing Scale 
Emotional wellbeing 
Social life 
Yes 
No 
No 
Health-related Q of L Short Form 12 Health Survey Yes 
Future Concerns Area of life of most concern for the future Yes 
Additional Comments 
Box for anything respondents wanted to 
add 
Yes 
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Before discussing the content of the survey, it is important to explain that ideally I wanted 
Thalidomide survivors to give their names on their survey forms, so that I could obtain 
(with their consent) three items of background information about them held by the Trust. 
These were gender, country of residence, and 6(iv) b (impairment) figure. This information 
was used to assess how representative the survey respondents were of the whole UK 
Thalidomide community, and for conducting additional analysis of the data. However, 
some of the questions were quite sensitive in nature. For example, the question about 
original Thalidomide impairment asked about damage to reproductive organs and the list 
of health problems included alcohol/drug misuse. I was concerned that if people felt they 
had to give their name, they would either skip questions or not return the survey at all. So, 
from both an ethical and practical standpoint it was important to give people the option to 
complete the survey anonymously.  For those respondents who did not give their name I 
knew I would not be able to obtain information from the Trust, and so some background 
information was collected in the survey, notably gender and details of respondents’ 
original Thalidomide impairments. As the quotation in the previous section illustrates, the 
Thalidomide survivors involved in developing the survey advised against asking 
respondents to provide their 6(iv) b figure, as an indicator of severity of impairment, 
because many do not know their figure or even what ‘6(iv)b figure’ refers to. 
Inevitably, some trade-offs had to be made between the data the Trust and I wanted to 
collect and the need to avoid making the survey too onerous to complete. The final survey 
had ten sections. The order of the sections was designed so that what might be seen as 
‘easy’ biographical question came first. The questions about current or recent health 
problems came next, with the questions about use of health services and social care 
support naturally following on. I placed the two sections which used validated standard 
measures (about mental wellbeing and health-related quality of life) at the end of the 
survey, mainly because I thought that respondents might find these sets of questions the 
least ‘user friendly’. However, there is evidence that preceding questions set the context 
for the questions which follow and this can effect survey results (Lavrakas 2008). I felt that 
asking people about their personal circumstances, and their health and support first, might 
help them judge their responses to the mental wellbeing and quality of life questions. It is 
impossible to say whether this created any positive or negative bias in the results.  
Below I briefly describe the content of each section, the reasons for the choice of 
questions and the limitations/problems that emerged in relation to them when the survey 
went ‘live’. Lastly, it is important to note that because the survey was primarily to meet the 
needs of the Trust, not all the data collected were relevant to my doctoral research (see 
Table 4). The data from a few question also had limitations from an academic perspective 
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and so I excluded these from my analysis. These issues are discussed in the relevant 
sections below.  
About You 
This section simply asked the respondent for their gender and the highest level of 
educational qualification they had obtained. I was interested in educational level for two 
reasons. Firstly, to facilitate comparisons with the general population – there is some 
evidence from Germany (Peters et al 2015) that, as a group, Thalidomide survivors there 
achieved a higher level of education attainment than their peers in the general population. 
Secondly, to examine whether educational level had any bearing on responses to other 
questions in the survey. Schneider (2011) notes that in the UK there is no standard way of 
measuring educational attainment but asking for the highest educational qualification 
(academic or vocational) achieved is a common approach. In this survey, respondents 
could tick one of eight categories, which are widely used in health research. However, at 
the analysis stage I had to merge some categories in order to facilitate comparison with 
Office of National Statistics data from the 2010 census. This involved me making 
judgements about what groups of qualifications to put together, creating the danger of 
different understandings and interpretations. It may therefore have been better to use 
fewer categories from the outset. 
Family and Housing 
There were six questions in this section. The semi-structured interviews suggested that 
Thalidomide survivors’ home circumstances (e.g. whether they live alone, with a partner 
etc.) and housing situation (e.g. living in rented accommodation) might have an influence 
on their general wellbeing. There is evidence that in the general population these are risk 
factors for feelings of loneliness, which is in turn has a strong relationship with poorer 
wellbeing (ONS 2015). So, the first two questions asked about home circumstances and 
housing situation. The remaining questions focused on housing adaptations and the 
possible need to move home. These were issues of operational interest to the Trust and 
are not discussed in this thesis. 
Work and Pensions 
There is evidence that the work situation of Thalidomide survivors has changed quite 
considerably in the last 10 to 15 years (Newbronner 2015; Vermette and Benegabi 2013; 
Kruse et al 2013), with proportionately fewer of them working than their peers in the 
general population. The content analysis suggested that this trend was accelerating as 
Thalidomide survivors approach their late 50’s, and that being unable to work might be 
associated with poorer mental wellbeing. So, in this section I asked about respondents’ 
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current work situation. The question had 10 answer choices which not only allowed 
respondents to indicate whether they were working full time, part time or not working but 
also why they were working part time or were not working (e.g. I work part time:  because 
of my disability or health problems; to preserve my health/functioning; for family or 
personal reasons). This distinction was important because an employment survey of 
conducted for the Trust (Newbronner 2015) had indicated that the wellbeing of 
Thalidomide survivors might be affected by whether they choose not to work or to work 
part time, as opposed to feeling unable to work or only able to work part time because of 
their disability or health problems. 
I also asked how their work situation had changed since 2000. That year was chosen 
partly because of research evidence about the onset of secondary health problems 
(Kennelly et al 2002; Newbronner et al 2011) but also because in the last 15 years there 
have been some important changes to UK Thalidomide survivors’ financial support, in 
particular:  
 In 2000 Annual Grants received by Thalidomide survivors as a result of the legal 
settlement with Distillers (now Diageo), were exempted from taxation 
 In 2001 there was an uplift in Annual Grants (because of additional investment in the 
Trust Fund by Diageo)  
 In 2010 the pilot Health Grant was introduced and then renewed for ten years in 2013  
The evaluation of the Health Grant (Newbronner et al 2013) suggested that for some 
beneficiaries whose deteriorating health was affecting their ability to work and others who 
felt that working was having a detrimental effect on their health, the improvement in their 
financial position enabled them to change their work situation.  
At the time of the survey, the Trust was establishing a working group to explore loss of 
earnings and pension provision amongst UK Thalidomide survivors and it was intended 
that data from this section of the survey would inform their work. The Trust wished to 
include a question about pension provision, but devising meaningful and reliable 
questions was difficult. I decided to include just one simple question which asked, ‘If you 
have paid into an employers’/company or private pension (in addition to your state 
pension), approximately how many years of contributions do you have?’. However, the 
question proved problematic, because where respondents left the answer box blank, it 
could either mean they didn’t have an additional pension or they couldn’t remember the 
number of years contributions they had. For this reason I have not used the data from this 
question in my thesis.  
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Finally, at the end of the work and pensions section there was a free text box where 
respondents could provide additional information. Ninety-one respondents chose to do 
this and their comments were very helpful in bringing to life the decisions and dilemmas 
they had faced.  
Original Thalidomide Impairments 
As was noted above, I anticipated that a proportion of respondents would choose to 
complete the survey anonymously. If this was the case, I would be unable to obtain any 
information about the severity of their original Thalidomide impairments. Furthermore, 
even for those respondents for whom I could obtain their 6(iv) b figure, I would only know 
the severity of their impairments, not the nature of them (e.g. upper and/or lower limb 
damage, sensory impairments etc.). The content analysis of the semi-structured 
interviews suggested that the nature of Thalidomide survivors’ original impairments was a 
potentially important factor in their current health and wellbeing. I provide a more detailed 
explanation of this in Chapter 5 but for example, Thalidomide survivors with very short or 
no arms often use their feet for everyday tasks and this has implications for wear and tear 
of hip and knee joints. Research in Germany by Kruse et al (2013) also found that 
secondary musculoskeletal problems such as osteoarthritis, muscle weakness and 
muscle tension in upper limbs was clearly associated with severity of impairment. A 
number of studies discussed in my literature review appear to give only limited 
consideration to how the severity and nature of participants’ original impairments might 
affect their health in later life, which to me seemed a significant omission.  
However, developing the categories of impairments/damage to be used in the survey was 
difficult. Most UK Thalidomide survivors were assessed in the early 1970’s as part of the 
compensation settlement, although over the years since, around 80 people have been 
assessed by the Trust to establish whether their impairments were caused by 
Thalidomide, and then accepted as beneficiaries. However, whilst the Trust holds detailed 
information in individual records, at the time of the survey it did not have an agreed 
standard classification of impairments/damage nor did it have readily available aggregate 
data about the number of its beneficiaries with different types of impairment.  
In developing the categories for the survey, I used three approaches: I looked at the 
categories used in studies from other countries (see Vermette and Benegabi 2013 and 
Peters et al 2015); I drew on a draft classification being developed by the Trust’s Medical 
advisor (and held discussions with her); and I tested draft categories with Thalidomide 
survivors. This final approach was partly to test peoples’ understanding or interpretation of 
descriptions (e.g. minimal or no arm, damage to face and/or outer ear), but also to ensure 
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that the language I used was acceptable to Thalidomide survivors. For example, they 
preferred the word ‘misshapen’ to terms like ‘deformed’ or ‘abnormality’ which have been 
used in past studies (see O’Carroll 2011 and Bent 2007). 
In relation to the International Classification of Functioning, Disability and Health or ICF 
(WHO 2001), gathering information about the nature and severity of respondents original 
damage provided an understanding of one element of their impairment i.e. body 
structures. However, it did not address the second element of the ICF – body function nor 
impairment effects (Thomas 2010) which is why it is important to set the information about 
respondents’ Thalidomide damage in the context of the whole survey. 
Overall, the final set of categories worked well, although a few respondents gave 
potentially contradictory answers (see section 3.6.5 for how I dealt with these). However, 
by the time I came to prepare the final report from the survey, the Trust had developed its 
classification and was able to produce aggregate data. Unfortunately, the Trust’s 
categories did not fully match those used in the survey, so some adjustment had to be 
made to compare the impairments reported by survey respondents with those of all 
beneficiaries of the Trust. There were some discrepancies (see Tables 13 and 14) which it 
is important to acknowledge but none were so great as to invalidate the survey data.  
Mobility and Equipment 
For operational reasons the Trust was interested in gathering some brief information 
about mobility and equipment and so four questions were included, seeking information 
about the use of manual and electric wheelchairs, mobility scooters, and prosthetic limbs, 
hearing aids and hearing implants, and adapted cars. The Trust planned to use these data 
to inform the development of their support services. Whilst it was important for their work, 
it did not really add anything to my analysis and so I have not included it in results 
presented in Chapter 6. 
Health Problems 
The survey not only provided an opportunity to assess prevalence of secondary health 
problems identified in the content analysis, it also enabled me to explore co-morbidities, 
and other general health problems, the management of which might be affected by 
peoples’ Thalidomide impairments. It also made it possible to examine whether there were 
differences between groups of Thalidomide survivors with particular impairments or 
characteristics. To simplify data collection and analysis I developed a list of health 
problems or groups of health problems, and respondents were then asked – Are you 
currently experiencing or have you recently had any of the following health problems 
(please tick all that apply to you)? There was also a free text box where respondents 
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could describe other health problems or add comments about their health. The list of 
health problems was discussed with the Research Committee, tested with Thalidomide 
survivors and was subject to several iterations. Overall, it worked well and generated 
valuable data. However, the question proved to have two important weaknesses. 
First, the content analysis suggested that most people described their health problems 
using lay language. As this was a self-completion questionnaire, as far as possible I 
wanted to use this lay language rather than medical language when asking people to list 
their health problems. Whilst this worked well in terms of respondents understanding of 
the question, some of the descriptions used were inevitably a little imprecise (e.g. kidney 
problems). Later, when I came to compare Thalidomide survivors with the general 
population of a similar age, it was sometimes difficult to find suitable comparative data. 
With hindsight, I should have worked with the Trust to specify in more detail the areas 
where they wanted to make such comparisons, and as far as possible, found the 
comparator data I intended to use before finalising the survey. Secondly, the question 
used the phrase ‘Are you currently experiencing or have you recently had…’ rather than 
specifying a time-period, such as ‘in the last year’. The reason for this was to give 
respondents some flexibility in reporting their experiences and to allow for people not 
being able to remember exactly when a problem had occurred. However, inevitably 
respondents will have interpreted the word ‘recently’ slightly differently, and so without a 
fixed time-period (Gerstman 1998) the results can only provide an indication of 
prevalence. This also made comparisons with the general population and studies about 
the health of Thalidomide survivors in other countries more difficult. For example, Peters 
et al (2015) used both point prevalence and lifetime prevalence but their data were 
collected face to face in clinical interviews, which would have allowed for clarification.  
Use of Health Services 
This section had two parts to it. The first question asked respondents about the health 
treatments they had had in the past 10 years. I chose to use the term ‘health treatments’ 
because I wanted to identify the interventions (or broad groups of interventions) 
respondents had experienced but I did not want to use academic or technical language. 
Eighteen health treatments were listed and respondents could tick all that applied to them. 
The list of health treatments was informed by the findings from the Health Grant 
evaluation and as with the list of health problems, it was discussed with the Research 
Committee and tested with Thalidomide survivors. There was also a free text box for 
respondents to list other health treatments or add comments. In developing the question, I 
had several discussions with colleagues at the Trust about the most appropriate time-
period to use. We chose ten years because the evidence suggested that the secondary 
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health problems experienced by Thalidomide survivors (and possibly their related need for 
treatments) have increased over this period. Whilst the accuracy of peoples’ recollections 
of service utilisation is likely to decline with time this question was simply asking if they 
had used a treatment or not, and so we judged this was unlikely to create major problems 
with data accuracy.  
The second group of questions was essentially concerned with the quality and 
appropriateness (in the broadest sense) and availability of health services. As part of its 
strategy, the Trust was working to raise awareness amongst health professionals of 
Thalidomide-related health problems, and the challenges that Thalidomide impairments 
can create when providing routine diagnostics and treatments (e.g. blood pressure 
measurement, diabetes management). They therefore wanted to use the survey to gather 
information about any problems Thalidomide survivors had experienced with health 
professionals and/or health services. This question listed ten ‘problems’ which 
Thalidomide survivors had reported in the Health Grant evaluation and respondents were 
ask to tick those that they had experienced. The Trust was also interested in perceptions 
of GPs understanding of Thalidomide damage and their willingness to refer Thalidomide 
survivors to a specialist with knowledge of Thalidomide damage. Ultimately, I excluded 
this last question from my analysis as I felt the responses were likely to be subject to too 
much conjecture.  
Social Care Support 
Within the Thalidomide community there had been discussions about the 
adequacy/flexibility of local authority social care support, and the Heath Grant evaluation 
revealed that many Thalidomide survivors purchase personal and domestic support 
privately. For these reasons the Trust wanted to know what proportion of its beneficiaries 
were in receipt of local authority social care. They also wanted to gain a better 
understanding of Thalidomide survivors’ use of both local authority and private social care 
support, now and in the future, to inform their support and information work with 
beneficiaries. This topic was also of interest to me as there is some evidence from 
research in Germany (Kruse et al 2013) that the ability to access and pay for appropriate 
social care support has an impact on Thalidomide survivor’s mental wellbeing.  
Mental Wellbeing 
The Trust’s National Advisory Council, which is entirely comprised of Thalidomide 
survivors, had a particular interest in mental wellbeing and one of the aims of the survey 
was to examine this issue in more depth. There is also evidence that people with 
disabilities are at greater risk of depression and/or anxiety (Meltzer et al 2012), and that 
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the mental wellbeing of people with early aquired disabilities may become more 
vulnerable as they age (Kemp and Mosqueda 2004). In discussion with the Trust and 
NAC members we agreed that this section should include a validated measure of 
wellbeing so that: the mental wellbeing of Thalidomide survivors could be compared to 
people in the general population of a similar age; and we had a baseline measure of the 
wellbeing at the start of the 10 year Health Grant, which could be used to assess changes 
in the mental wellbeing of Thalidomide survivors if the survey was repeated at a future 
date. 
I suggested using the (short) Warwick and Edinburgh Mental Well-being Scale 
(WEMWBS), which was developed by Warwick and Edinburgh Universities in 2007 
(Warwick Medical School 2018) and is validated for use in the UK. It has been used in the 
Health Survey for England since 2011 (NHS Digital 2011), so comparator data for the 
general population was available. The seven questions are positively worded, with just 
five response categories, making it easy to complete, and it is free to use. WEMWBS did 
enable me to compare the mental wellbeing of Thalidomide survivors with the general 
population, and it does provide a baseline from which to assess changes.  
The Trust also wanted to include two bespoke questions about emotional wellbeing and 
social isolation, and an additional question (at the end of the WEMWBS) about how 
honest respondents felt they could be about how they were feeling/coping. I was 
concerned that these questions were too open to interpretation and could not be 
contextualised by comparison with the general population, and so I excluded them from 
my analysis. 
Health-Related Quality of Life 
Bowling (2005) notes that “Health-related quality of life is one dimension of wider quality of 
life” and that both are “multi-level and amorphous concepts” (p7). She goes on to suggest 
that, amongst researchers, there is no commonly accepted definition. Nevertheless, 
measures of health-related quality of life are frequently used in research studies and 
evaluations. There are many validated standard measures of health status and health-
related quality of life. Bowling argues that “Scales of broader health status are more 
stable, and have better reliability and validity than single item questions” (p45). There is 
also a strong case for using general rather than specific indicators of health status in 
population surveys (Bowling 2005) and this made sense for my survey, as I was not 
looking at a particular illness or disease. 
Including a well-tested and widely used measure of health-related quality of life within a 
broader survey can be very useful. It facilitates comparisons with the general population 
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and/or groups of people with similar conditions, and so helps to contextualising findings. If 
the measure is used internationally, inter-country comparison is also possible. However, 
selecting the most appropriate measure can be difficult because there are so many 
measures available; all have advantages and disadvantages; and some may work better 
with certain groups or in certain contexts. Two of the mostly widely used measures of 
health-related quality of life are the Short Form-36 Health Questionnaire (Rand Health 
Care – no year given) and the 12 item version of SF-36, SF12 (Jenkinson 1997). SF36 
had been used in other studies of the health of Thalidomide survivors in Australia, 
Germany, and Sweden (Chorlton 2013; Peters et al 2015; Ghassemi Jahani 2016b), and I 
successfully used SF12 with UK Thalidomide survivors as part of the Health Grant 
evaluation (Newbronner et al 2012).  
The Short Form 12 Health Survey is a 12-item version of the Short Form-36 Health 
Survey Questionnaire, which was originally developed by the Rand Corporation in the late 
1980s (Rand Health Care – no year given). SF36 is now one of the most frequently used 
measure of generic health status in the world. SF12 consists of eight scaled sections 
(General Health; Pain; Physical Functioning; Role Limitation Physical; Mental Health; Role 
Limitation Emotional; Social Functioning; Vitality), which can be ‘aggregated’ into two 
domains – mental health-related quality of life and physical health-related quality of life. I 
chose to use SF12 because it has the advantage of being easier and quicker for people to 
complete. However, because it has fewer items, the scores are less precise (Jenkinson 
1997). Nevertheless, the data from SF12 can be compared with that gathered using SF36. 
I therefore decided to use SF12 for a number of reasons:  
 It would make possible valuable comparisons - with Thalidomide survivors in other 
countries, with the general population 
 It would enable me to look at associations between both physical and mental health-
related quality of life and other important characteristics 
 Individually, the components of SF12 might yield some interesting data, for example 
about the impact of pain on peoples’ quality of life  
Closing Questions 
The final page of the survey asked respondents to indicate (from a list of 10) which areas 
of their lives were of most concern to them when they thought about the future. This 
question was really intended to help guide the Trust’s priorities for further work. There was 
also a free text box for respondents to add any further information about their health and 
wellbeing or highlight any concerns or issues. Ninety-eight respondents provided 
additional comments, many of which brought to life their responses to other questions. I 
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analysed these comments thematically. Some comments were linked to specific issues 
explored in the survey e.g. changes in employment status, and in Chapter 6 I use these in 
the relevant sections to illustrate the issues emerging from the quantitative data. Others 
reflected respondents’ thoughts about the future, and so I have brought these together to 
conclude Chapter 6 and help set the scene for the analysis in Chapter 7. However, they 
do need to be treated with some cautions, because some groups of respondents may be 
more likely to add comments than others, and so they may not be representative of 
respondents as whole. 
3.6.4 Survey distribution and response rate 
The final version of the survey was printed as a 12 page A4 booklet and was sent by post, 
by the Trust to all beneficiaries (467 at the time of the survey) on the 11th August 2015. 
Enclosed with it was a brief information sheet (see Appendix 8), a covering letter from the 
Trust’s Director and the Chair of the NAC Health and Wellbeing Committee (see Appendix 
9) and a Freepost reply envelope addressed to me. Those beneficiaries who had 
previously informed the Trust that they were happy to be contacted by email were also 
sent an email, which included a live link to the online survey. The online survey on was set 
up on Smart Survey and the first page contained the same information as the information 
sheet sent out with paper version. Both the information sheet and the covering letter also 
offered beneficiaries a further option to complete the survey on the telephone with me. 
The survey was publicised in a variety of other ways, including through the UK 
Thalidomide survivors Facebook page, at NAC meetings, ‘word of mouth’ by NAC 
members, in the Trust’s newsletter, and by Trust staff encouraging individuals who rang 
the Trust’s offices to complete the survey.  
By the 7th September 300 beneficiaries had completed the survey. To improve the 
response rate further, after four weeks (10th September 2015) a reminder letter and email 
were sent by the Trust to all beneficiaries for whom no response was recorded (either 
because they had not responded or they had chosen not to give their name). The survey 
officially closed at the end of September 2015, although seven late responses that came 
in during October, were included. Figure 8 shows the response rate each week. The 
majority of responses were received in the first four weeks but the reminder did boost the 
response rate, taking it from 64% at the end of week four to the final figure of just over 
75%. Bryman (2015) citing Mangione (1995: 60-1) suggests that a response rate of 70 to 
85% for a postal survey can be regarded as ‘very good’. 
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Figure 8 Number of survey responses received each week 
 
 
 
 
 
 
 
 
 
 
 
 
 
In total, 351 responses were received – 232 on paper, 118 online and three completed on 
the telephone with support. These three included one respondent with multiple and 
extremely complex health problems, another with poor literacy and the other simply 
preferred to complete the survey on the phone. Four survey forms were filled in by a 
family member or guardian because the respondents were unable to complete it 
themselves. All of these were incomplete but it was possible to include the responses to 
the questions that were answered. Forty-nine respondents (13%) chose to complete the 
survey anonymously. 
3.6.5 Data entry and analysis 
The survey responses received by post or completed on the telephone were entered into 
an Excel spreadsheet. The responses received electronically were downloaded from 
Smart Survey as a CSV file and then initially transferred to an Excel spreadsheet. Once 
the survey had closed, the two spreadsheets were merged. Excel was used initially 
because, as part of the Health Grant Monitoring project, the Trust wanted access to some 
anonymised data from the survey and they asked that this be provided in Excel. Also a 
colleague, who assisted me with the data collection and data entry aspects of the survey, 
was familiar with and had easy access to Excel and so it was practically much easier to 
use this programme.  
For those beneficiaries who had provided their name, I was able to obtain their 6(iv) b 
figure/impairment band and country of residence from the Trust (the latter being of interest 
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to the Trust). This data was then added to the main spreadsheet. Six questions had free 
text boxes where respondents could add further information or comments. These were 
also entered into the Excel spreadsheet and then transferred to a word document for 
thematic analysis.  
To ‘quality check’ the data entry process my colleague and I took a random sample of 15 
respondents and crosschecked the answers on the spreadsheet against their original 
paper submission. We did not find any errors. However, across the whole dataset, there 
was inevitably some missing data (e.g. questions not answered or not answered in full) 
and I note this where relevant in the results in Chapter 6. In addition, 27 respondents gave 
contradictory answers to the questions about original Thalidomide impairments (e.g. 
ticking ‘arm shorter than elbow’ and ‘arm normal length’ for the same limb). For this 
problem, where respondents had given their name, it was possible to clarify some of these 
responses by checking the answers given against the information held in the Trust’s 
records. This was done in 19 cases. For the other eight cases I used the most severe 
impairment option.  
The first stage of analysis was conducted in Excel, and included counts and descriptive 
statistics. My original intention had been to stop at this stage but the high response rate 
and representativeness of the respondents meant that further statistical analysis was 
appropriate. Following discussion with my supervisors, I transferred the data to SPSS 
(version 24) in preparation for a limited second stage of analysis using inferential 
statistics. The initial analysis helped me think about where to focus further analysis but I 
also examined the narrative comments which respondents added at the end of their 
survey forms, and briefly reviewed the findings from the content analysis and literature 
review, to identify any relationships or factors that it might be particularly relevant to 
explore, especially in relation to health-related quality of life (the third objective of my 
thesis). I began the analysis by simply looking at the relationship between key 
characteristics e.g. severity of impairment and musculoskeletal problems.  I then 
examined the association between respondents’ health-related quality of life and original 
impairment using Pearson Correlation. However, the narrative responses to the questions 
in the survey (and the content analysis and literature review) suggested that other factors, 
such as gender, living circumstances and employment status might be important in 
explaining variance in both physical and mental health-related quality of life. To explore 
the influence of these other factors (and with advice from a colleague) I used Hierarchical 
Regression, using three sets of variables: original impairment level (as indicated by the 
number of impairment points) (step 1); being unable/able to work and qualifications (step 
2); and gender and living alone/living with others (step 3). Multicollinearity checks were 
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run on all predictor variables included in the models. Whilst this second stage of analysis 
was limited, it did provide new and valuable results. These are discussed in Chapter 6.  
3.7 Secondary Grounded Theory Analysis of the Interviews 
When I started my doctoral research, my original plan was to conduct a further round of 
qualitative data collection, (possible in-depth case study interviews), after the semi-
structured telephone interviews and the health and wellbeing survey. However, as I was 
conducting (and transcribing) the semi-structured telephone interviews, my sense was 
that they were generating a great deal of rich material. This was further confirmed as I 
worked with the transcripts for the content analysis. I felt that I could learn much more 
from them than the content analysis had allowed, and that there was the potential to 
achieve the objectives of my study without the third round of data collection that I had 
initially envisaged. Following discussions with my supervisors, and after completing the 
Health and Wellbeing survey, I therefore decided to conduct a secondary analysis of the 
existing transcripts. Before setting out my rationale for the use of Grounded Theory in my 
secondary analysis, it is important to briefly discuss what is meant by secondary analysis 
and explain why I have used this term to describe what I have done.  
Secondary analysis of quantitative data is a widely used and well accepted form of inquiry 
but over the last two decades there has been growing interest in secondary analysis of 
qualitative data. Perhaps because the field is still developing, definitions appear to vary 
significantly. Many authors (e.g. Bryman 2015; Boslaugh 2007) have suggested that 
secondary analysis is when data collected by one person is analysed by another. Under 
this definition my approach could not be described as secondary analysis. However, 
Heaton (1998) adopts a broader definition: 
Secondary analysis involves the use of existing data, collected for the purposes of 
a prior study, in order to pursue a research interest which is distinct from that of 
the original work; this may be a new research question or an alternative 
perspective on the original question. (p1) 
This definition allows for the possibility of the researcher who collected the data also 
undertaking the secondary analysis. She goes on to suggest that one form of secondary 
analysis (of qualitative data) involves additional in-depth analysis of a dataset with “a more 
intensive focus on a particular finding or aspect than was undertaken as part of the 
primary work” (p2). Szabo and Strang (1997) go further, suggesting that secondary 
analysis can involve exploring the same research questions using different methods of 
analysis. This was the case in my study. Both rounds of qualitative data analysis were 
exploring my overarching research questions but each brought a different perspective: the 
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initial content analysis enabled me to look across the data set to identify the main health 
problems respondents were experiencing, how they linked problems and how they 
described them, which informed the development of the survey; the secondary grounded 
theory analysis facilitated me looking deeper in to the data to understand how people 
experienced and made sense of their health problems, and how they affected them 
physically, mentally and practically, adding an explanatory element to my overall mixed 
methods design.  
The context of my secondary analysis meant that some of the disadvantages commonly 
cited (Heaton 1998) did not arise or were not a major concern. There were no ethical 
issues because consent had been obtained for the interview transcripts to be used in the 
study. Data quality was also not a concern as I had largely had control over the data 
collection process. However, Whiteside et al (2012) highlights two other potential 
problems. The first is data fit i.e. the fit between the purpose of the secondary analysis 
and the nature of the original data. Overall the data fit was good but a more open 
interview topic guide would have probably generated slightly richer data, especially in 
relation to certain topics such as the emotional impact of health problems. The second is 
the relationship of the secondary analyst to the data. She suggests that “Where the 
researcher is close to the primary dataset, there are benefits in regard to knowing the 
context of the study” (p507) but there is also a risk that they might have preconceived or 
fixed ideas about the phenomena in the dataset. This was clearly a danger for me but as I 
explain in 3.7.2, the process of line by line (initial) coding pushed me to look at the data 
with fresh eyes. In 3.7.2 I also consider the specific challenges of secondary grounded 
theory analysis.  
3.7.1 Rational for use of grounded theory 
Sandelowski and Barroso (2003) suggest that research findings can be placed in a 
continuum from description to interpretation, based on the degree of transformation of the 
data during the data analysis process. Content analysis sits at the descriptive end of that 
continuum. In order to address my research questions, in particular examining the 
interaction between original impairment, secondary health problems and the ageing 
process, and the implications of this interaction for Thalidomide survivors’ lives, I felt I 
needed to adopt a far more interpretive approach for my secondary analysis. After some 
further reading about different methods and discussion with my supervisors, I decided to 
use grounded theory for my secondary analysis. Reflecting the pragmatic approach to my 
study, this was in part an analytical choice. Grounded theory is a strongly interpretive 
approach but it is also a very structured approach to qualitative inquiry. The methods 
employed in grounded theory, particularly initial (line by line) coding, facilitated me going 
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deeper into my data and helped me to take a different perspective on it. Moreover, it 
brought back the individual voices, which had been partially lost in the content analysis. 
In the fifty years since the publication of The Discovery of Grounded Theory (Glaser and 
Strauss 1967), grounded theory has become one of the most popular research designs in 
the world (Birks and Mills 2015). However, as Oliver (2012) notes “there are significant 
differences in how grounded theory has evolved under different epistemological 
paradigms” (p376) and the grounded theory tradition is now diverse (Sbaraini et al 2011). 
In recent years, much has been written about constructivist grounded theory (Mills et al 
2006) and many researchers new to grounded theory, including myself, draw on the work 
of Kathy Charmaz, in part because her writing is so engaging and well written. However, I 
have never felt able to embrace her constructivist philosophy, which Birks and Mills (2015) 
define as “a research paradigm that recognises that reality is constructed by those who 
experience it and thus research is a process of constructing that reality” (p177). I find 
myself more in tune with critical realist ontology, which assumes that there is an objective 
reality (i.e. fixed structures and objects), although this may sit alongside the individual’s 
ability to construct their own reality and influence change (Birks and Mills 2015). So whilst 
I have greatly benefitted from reading her work, I retained my own ‘worldview’ in this stage 
of my study. Importantly, regardless of the researchers philosophical position, all 
approaches to grounded theory share common characteristics: Charmaz (2014) has 
described grounded theory as a “constellation of methods”; and Babchuck (2011) talks 
about the grounded theory “family of methods”. As such one of the attractions of grounded 
theory is that it offers a helpful set of strategies for collecting, managing and analysing 
qualitative data (Charmaz 2014).  
3.7.2 Conducting the secondary grounded theory analysis  
There are differing views about what constitutes a true grounded theory study. Charmaz 
(2014) suggests that what makes a grounded theory study is the actions of the researcher 
and she lists nine actions, the first five of which she sees as:  
…evidence of a grounded theory study…: 
1. Conduct data collection and analysis simultaneously in an iterative process 
2. Analyze actions and processes rather than themes and structures 
3. Use comparative methods 
4. Draw on data (e.g. narratives and descriptions) in service of developing new 
conceptual categories 
5. Develop inductive abstract analytic categories through systematic data analysis 
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6. Emphasize theory construction rather than description or application of current 
theories 
7. Engage in theoretical sampling  
8. Search for variation in the studied categories or process 
9. Pursue developing a category rather than covering a specific empirical topic (p15) 
Birks and Mills (2015) highlight the following as “essential grounded theory methods: initial 
coding and categorisation of data; concurrent data generation or collection and analysis; 
writing memos; theoretical sampling; constant comparative analysis; theoretical sensitivity; 
intermediate coding; identifying a core category; and advanced coding and theoretical 
integration” (p10). Guetterman et al (2017) draw on Birks and Mills (2015) but refer to the 
“founding principles of grounded theory” (p3) within which they include: simultaneous data 
collection and analysis; memo writing; constant comparison; theoretical sampling (as a 
form of purposive sampling); development of concepts and categories; theoretical 
saturation; and theory construction and development. In short, there is no single definition 
of a grounded theory study but there are some core features which most grounded 
theorist would acknowledge. For clarity, I have listed below seven grounded theory 
methods which I have used either fully or partially. I then describe (with examples where 
appropriate) how I have used them, including discussing the limitations the secondary 
analysis imposed: 
 Memo writing 
 Theoretical sampling/concurrent data collection and analysis 
 Initial and intermediate coding of the data 
 Development of concepts and categories 
 Constant comparison 
 Theoretical saturation 
 Theory construction 
I did write memos at various points whilst planning and conducting my research. Although 
the memos varied in level of detail and coherence, it was very helpful to look back on 
them when I came to write-up certain sections of my thesis. However, with hindsight I 
should have used them more extensively to document my thinking. 
As the preceding paragraphs illustrate, theoretical sampling and concurrent data collection 
and analysis, are regarded as a core features of grounded theory. Unfortunately, as Birks 
and Mills (2015) explain, the biggest challenge “when using data from secondary sources 
in the inherent limitation this has for theoretical sampling” (p82). Theoretical sampling 
involves the researcher simultaneously carrying out targeted data collection and analysis 
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but when using secondary data, this can only be done within the confines of a pre-existing 
dataset (Whiteside 2012). This means that if initial analysis reveals gaps in the data or 
unanswered questions, there is no scope to collect further data to address these i.e. a 
conventional approach to concurrent data collection and analysis is not possible. 
Whiteside (2012) goes on to note that: “As a consequence of both these issues, data 
saturation of categories may not be possible and gaps may exist in the final theoretical 
construction” (p507). However, it is possible to partially offset these issues by working with 
a dataset that is of sufficient size to allow for a degree of theoretical sampling (Szabo and 
Strang 1997).  
With 38 interview transcripts my dataset was large and so a form of theoretical sampling 
was possible. I began by taking five interviews which I knew were quite rich and detailed. I 
then created a word document for each interview with a column each for the raw data, the 
initial codes and the intermediate codes. First I line-by-line coded them and then having 
completed the set, I returned to each interview to explore the intermediate codes. Once I 
felt reasonably confident that this approach to coding was working, I took a further 
purposive sub-sample of 14 interviews and analysed them. Together these 19 interviews 
(half my dataset) were broadly representative of the whole dataset in terms of gender and 
impairment level. At the end of this process I reviewed the codes to see if any potential 
conceptual categories were emerging. From this first sub-sample of interviews I identified 
11 possible conceptual categories. I then purposively selected and analysed another ten 
interviews (to include participants in different impairment bands), to see if these categories 
held good or needed modifying, and to explore further the conditions or properties of the 
categories and the relationships between them. This left nine interviews which I had not 
analysed. I could have stopped at this point because I felt reasonably confident that the 
conceptual categories were sound and it was unlikely that new codes relevant to them 
would emerge from the remaining data i.e. I had reached theoretical saturation. However, 
Hennink et al (2019) describe theoretical saturation as being about the sample having 
sufficient conceptual depth and richness to support theory development. So, I decided to 
continue and analyse the remaining interviews, partly for completeness and partly 
because I felt they might add further depth to the categories, which they did to a limited 
extent.  
In her seminal paper ‘Discovering’ chronic illness; using grounded theory (1990) Charmaz 
discusses the process of coding and categorising data. She emphasised that codes and 
categories should not simply describe topics but rather reveal emerging ideas. She goes 
on to explain that:  
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The codes and categories then help the researcher to begin to take the data apart 
and frame analytic questions about it. In that way, the codes and categories help 
the researcher to build an analysis of the data rather than remain at a level of 
ethnographic description. (p1167).  
At first I found the task of initial coding hard, partly because at times it did seem difficult to 
move beyond the descriptive. More importantly, because I had already worked with the 
data for the content analysis, I struggled to set aside preconceived ideas and assumptions 
about it. Gradually, however, the process of line by line coding pushed me to look at my 
interview data from a fresh perspective. I also adopted Charmaz’s suggestions to code for 
processes, actions and consequences rather than for topics, and to code with gerunds 
(i.e. a type of verb that ends in "-ing") (Charmaz 1990; 2014).  
In relation to intermediate coding, Birks and Mills (2015) describe a number of different 
definitions put forward by different grounded theorists but in essence they all involve 
elevating or building on existing codes that have particular significance, and identifying 
patterns and relationships between codes. I began by looking for the intermediate codes 
in each of my interview transcripts but quite quickly I could see potential categories 
emerging and so as my analysis progressed, the process of intermediate coding and the 
development of categories and sub-categories became more intertwined, especially as I 
analysed the second half of my dataset. One of the most important analytic processes in 
developing conceptual categories is constant comparison between data (in my case the 
coded interview transcripts) but also between categories and sub-categories (Charmaz 
1990) and so this ‘mixing’ felt appropriate. Table 5 provides an example of how I moved 
from the raw data, to initial and intermediate codes and the conceptual category. 
Table 5 Example of coding process from interview with Alison 
Raw Data Initial Codes Intermediate 
Code 
Conceptual 
Category 
“I think back in October, when I’d hurt 
my shoulder in the May, and I didn’t 
feel like it was getting any better, 
even though I’d been attending 
physio – and they simply gave up on 
me – they didn’t know what else to do 
– and I think by September, I thought 
enough is enough – I’ve got to take 
control of the situation myself. So I 
Lacking 
confidence in 
NHS physio  
 
Feeling that HCPs 
had given up on 
her 
 
 
 
Absence of 
diagnoses or 
explanations of 
problems 
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Raw Data Initial Codes Intermediate 
Code 
Conceptual 
Category 
booked the holiday and found myself 
an osteopath – and I did go back to 
the GP and said ‘Look, I’m in so 
much pain’.  But the GP was really 
horrible, really horrible – very sharp, 
very unsympathetic. He didn’t seem 
to appreciate that having an injured 
shoulder had a massive knock-on 
effect to my ability – that things were 
difficult anyway, so that hurting 
myself made life even more difficult.  I 
didn’t feel he appreciated that at all 
but he was the one that gave me the 
Tramadol, which did help a lot with 
the pain.” 
Deciding to take 
control of the 
situation 
Choosing own 
treatments 
 
GP not 
understanding 
implications of 
shoulder problems 
Daily life 
becoming more 
difficult and 
painful 
 
Lack of 
confidence in 
HCP  
 
 
Using 
complementary 
therapies 
 
 
 
 
Taking 
Control of 
Own 
Health 
 
The analysis of the sub-sample of 19 interviews had generated eleven potential 
conceptual categories. However, some of them overlapped or could possibly be seen as 
sub-categories. I discussed this in some depth with my supervisors which helped to clarify 
my thoughts. By the end of analysing the second sub-sample of interviews I was focusing 
on just seven conceptual categories and I had renamed some of the retained categories. 
Table 6 show how the conceptual categories changed between the first and second 
phases of analysis.  
Table 6 Development of conceptual categories 
First round of conceptual categories Second round of conceptual categories 
Shifting Impairment Shifting Impairment 
Trying to Preserve Function Preserving Function 
Daily Living Getting Harder 
Rethinking Independence 
Striving to Keep Independence 
Life Becoming More Limited 
Vulnerable Mental Wellbeing  
Mental Wellbeing Increasingly 
Vulnerable 
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First round of conceptual categories Second round of conceptual categories 
Taking Control of Own Health Taking Control of Own Health 
Ageing Prematurely  
Ageing Differently 
Fearing Growing Old with Thalidomide 
Money Making a Difference Money Matters 
Embracing Thalidomide Identity Integrated in to other categories 
 
At this stage I decided to write a description of each of the seven conceptual categories, 
using quotations to illustrate them. However, before I started I moved the coded 
transcripts into NVivo, partly to help me see the sub-categories more clearly but also 
manage my use of quotations and extracts. I felt the process of writing about them would 
crystallise my ideas but also help me begin to set out the properties of each category. 
Birks and Mills (2015) explain that categories and sub-categories “have properties that 
need to be identified in the data and explained in full in order to develop conceptual depth 
and breadth” (p95). Properties can include things like the conditions under which they 
operate, or the range of variance within the category or the relationship to other 
categories. At the end of the initial writing up process, which was indeed very helpful, I 
decided to reflect on what was emerging.  
In terms of next steps in the Grounded Theory ‘process’, I found there were differing views 
about the necessity of identifying a ‘core category’. In the early seminal text identifying a 
‘core category’ around which all the other categories are integrated (Strauss and Corbin 
1990) was a key step. However, in later texts (Clarke 2005; Charmaz 2014) selecting a 
core category appears to be less important, with more focus placed on how categories 
and sub-categories fit together to form the grounded theory. Glaser (1978) described a 
core category as, generalizable, having ‘grab’, and suggests that a category will always 
emerge and ‘core out’. At this point I reviewed my conceptual categories alongside the 
findings from the literature review and the survey. In GT language this step would be 
described as theoretical sensitivity i.e. the ability to recognise and extract from the data 
elements that have relevance for the emerging theory (Birks and Mills 2015). I began to 
feel that Ageing Differently was a common thread. Charmaz (2014) suggests that part of 
the GT process is thinking about how your own theory relates to fundamental concerns 
and contested ideas in your field of study. For me Ageing Differently did this in relation to 
currently thinking about ageing with early acquired disability.  
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3.8 Summary 
In this chapter I have described how I used a mixed methods grounded theory approach 
to address the objectives of my thesis. I began by explaining my rational for choosing this 
approach; notably that more than one method of inquiry was needed to fully understand 
the health problems of Thalidomide survivors and to do justice to the complexity of their 
experiences. I have discussed in detailed each element of my three stage design (see 
figure 7): the content analysis of the semi-structured telephone interviews with 38 
Thalidomide survivors; the cross-sectional health and wellbeing survey; and secondary 
grounded theory analysis of the semi-structured telephone interviews. The semi-
structured telephone interviews provided a practical method for capturing individual 
narratives. The initial content analysis of them enabled me to identify the main health 
problems Thalidomide survivors were experiencing, and informed the development of the 
self-completion survey.  
I have described how the survey was developed, and in particular the active involvement 
of Thalidomide survivors in both designing and testing it. I have also discussed how 
conducting the survey for the Thalidomide Trust brought both constrains and advantages. 
In particular it helped me to achieve a very high response rate (75%), and ensured that 
the survey respondents were highly representative of the UK Thalidomide population as a 
whole. This chapter also describes the planned analysis of the survey data. The findings 
from the analysis, including comparisons with the general population, are presented in 
Chapter 6.  
In the final section of the chapter I discuss my decision to undertake secondary analysis of 
the semi-structured telephone interviews, in particular the scope to learn much more from 
the data, without placing a further research burden on Thalidomide survivors. I also 
explain how using grounded theory enabled me to look at the data from a fresh 
perspective and adopt a far more interpretive approach to the analysis. This analysis 
generated seven conceptual categories, which I describe in detail in Chapter 7. I also 
drew on grounded theory methods in analysing the evidence in my literature review. 
Whilst the two processes were separate, using grounded theory in these two aspects of 
the study contributed to the overall consistency of my approach. 
In my Discussion in Chapter 8, I bring the findings from all the elements of my study 
together in three integrative explanatory categories. Together these provide the 
framework or ‘storyline’ for my emergent theory – Ageing Differently - which explores the 
extent to which Thalidomide survivors experience of ageing at this point in the life course 
is different or similar to their peers in the general population and to other people with early 
acquired disabilities.  
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Chapter 4 Ageing with Thalidomide Embryopathy – 
A Review of the Literature 
Chapter 2 set out the historical and contemporary context of the drug Thalidomide and the 
individual and societal consequences of its use. In this chapter, I review the literature 
about ageing with TE. However, it is interesting to begin by briefly describing the ‘history’ 
or evolution of the literature, as in part this mirrors the wider historical context of the drug. 
I then go on to describe the nature of the review, and the rationale for undertaking a 
scoping review. In particular, I explain why and how I drew on grounded theory methods in 
analysing the evidence. I go on to describe the literature searches, screening, study 
selection and results. To collate and summarise the evidence I have used two 
approaches, a numerical summary, describing the characteristics of the included studies 
and a descriptive thematic analysis. I then present a limited synthesis of the evidence in 
the form of ‘intermediate codes’.  Finally, I close the chapter with my overall reflections on 
the literature, including what is missing from the current body of evidence. 
4.1 Evolution of the Literature 
In the 1960’s and 1970’s a great deal was written, especially in the medical press, about 
the drug Thalidomide, its teratogenic effects, and the nature of the damage it caused 
(McBride 1961; Lenz 1962; Millen 1962). In this same period in the UK, a number of 
reports, books and papers about the health and circumstances of Thalidomide children 
were published alongside coverage in the mainstream press, in particular by the Sunday 
Times (Knightly et al 1979). During the 1980 and 1990s there were a small number of 
studies involving Thalidomide survivors but these tended to examine narrow topics. For 
example, the ophthalmic damage caused by Thalidomide (Strömland and Miller 1993); a 
review of prosthetics services for Thalidomide survivors (Mustapha 1990); and 
Thalidomide, pregnancy and renal failure (Brown 1990).  It was only in the 2000’s, when 
Thalidomide approached its 50th ‘anniversary’ and Thalidomide survivors entered middle 
age, that research specifically about the health and quality of life of Thalidomide survivors 
as adults began to appear in academic journals and online. Over the past 20 years, 
several reports and papers have been published. Some focus on specific late onset health 
problems, others look more broadly at health and quality of life.  
With the benefit of this historical perspective it is clear that these ‘phases’ in the evolution 
of the literature about Thalidomide reflect the changing medical, academic and public 
interest in the drug and its consequences. These began with identifying the link between 
the drug and birth defects, then moved to practical concerns about the needs of 
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Thalidomide children, and finally on to the health of Thalidomide survivors as adults. 
However, even in this final phase, the contours of the debate have remained relatively 
narrow, often focusing on specific health problems, with only limited exploration of the 
social consequences for Thalidomide survivors.    
4.2. Nature of the Review 
A number of the studies about ageing with TE begin with some examination of the 
literature but often this is restricted to the area of clinical interest. As a result, they present 
only a limited picture and fail to reflect the complexity of the health problems many 
Thalidomide survivors face, nor their implications for health-related quality of life across 
the life course. Until this review (see Appendix 10: Disability and Health Paper), there 
were no published reviews of the literature about the health of Thalidomide survivors as 
they age. As part of my thesis, I wished to address this gap in the knowledge base. More 
specifically, I used the findings from my review to inform and set in context my primary 
research, and to help me address my research objectives (in particular the first and third): 
 Identify the health problems Thalidomide survivors are experiencing as they grow 
older, in particular Thalidomide-related secondary health problems 
 Examine the perceived interaction between original impairment, secondary health 
problems and the ageing process 
 Understand the implications of this interaction for Thalidomide survivors’ lives, 
including their health-related quality of life and independence 
I therefore decided to conduct a scoping review. There is no single accepted definition of 
a scoping review (or scoping study). Levac et al (2010) suggest that they generally involve 
‘mapping’ or summarising the evidence. Arksey and O’Malley (2005) note that whilst 
mapping implies breadth of coverage, the depth or amount of information extracted will 
vary depending on the purpose of the scoping review. I chose this form of review because 
it enabled me to: identify the nature and extent of the research evidence about the 
Thalidomide-related health problems experienced by Thalidomide survivors as they age; 
summarise these research findings (to inform my thesis and for dissemination); and 
highlight the gaps in the literature. In addition, compared to systematic reviews, scoping 
reviews: lend themselves to broader research questions; can more easily accommodate a 
range of study designs and published and grey literature (Levac et al 2010); and are 
consistent with the use of grounded theory methods. Furthermore they are more feasible 
where time and resource constraints are an issue, which applied in my case. 
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4.3. Literature Searches and Study Selection 
Although my review was not a systematic review, I developed a review protocol based on 
widely accepted guidance produced by the Centre for Reviews and Dissemination (CRD 
2009). I used this to guide the search and selection process, and to demonstrate 
transparency. In the sections below, I describe in more detail my search strategy, and my 
study selection and data extraction processes. 
4.3.1 Search strategy 
I carried out an initial exploratory search of MEDLINE to gain a better understanding of the 
nature of the literature and to inform the development of the search terms to be used in 
the electronic searches. I then searched the following seven electronic databases for 
eligible studies: 
 MEDLINE (1946 Onwards) (OvidSP)  
 EMBASE (OvidSP) 
 CINAHL Plus (EBSCO) 
 PsychINFO (OvidSP) 
 ASSIA (ProQuest) 
 Social Policy and Practice 
 Index to Theses (www.theses.com/) 
The search strategies for each database used both subject headings and key words in the 
title and abstract. The search strategy used for MEDLINE is shown below in Table 7 as an 
example.  
Table 7 Search strategy used for MEDLINE 
 Search Terms 
#1 
thalidomide OR distaval OR tensival OR asmaval OR valgis OR valgraine OR 
sedoval OR celgene OR contergan 
#2 Pregnan$ OR during adj3 pregnancy or in adj3 pregnancy 
#3 #1 AND #2 
#4 
Impair$ OR damage$ OR disable$ OR disabilit$ OR handicap$ OR deformit$ OR 
deform$ OR affect$ or consequen$ of 
#5 #3 AND #4 
#6 health OR health problem$ OR physical health OR mental health OR illness$ 
#7 #5 AND #6 
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I began in search #1 by simply using the name of the drug, Thalidomide, and the most 
common names under which it was marketed in the 1950’s and 1960s. As expected, this 
produced a huge number of records. Most were either concerned with the more recent 
use of Thalidomide to treat a range of conditions (e.g. multiple myeloma), or with the wider 
topic of pharmaceutical regulation. I used search #2 to focus on the use of the drug during 
pregnancy. Whilst this reduced the number of records substantially, it left in a large 
number that were primarily concerned with the teratogenic action of the drug and/or the 
clinical or ethical issues around drug administration during pregnancy. I combined these 
searches (search #3) with search #4, to narrow the results down further to the 
impairments or damage caused by exposure to the drug in the womb (search 5#). I then 
combined searches 5# and #6 to try and capture records that were specifically concerned 
with health problems.  
The searches were run in May 2015 and again in November 2016. Ageing with TE is a 
specialist area with a very limited number of peer reviewed papers each year. The 
researchers working in the field keep in regular contact and normally notify each other of 
newly published papers. For this reason I did not re-run the electronic searches but 
continually tracked the literature through liaison with colleagues and experts in the field. I 
up-dated the results in December 2019. 
The focus of this thesis is UK Thalidomide survivors and so I was primarily interested in 
studies involving the ‘first wave’ of Thalidomide survivors (i.e. people born in the late 
1950’s and early 1960’s), and in studies focusing on their health and quality of life in 
middle to late life. However, at the search and screening stage I decided not to use any 
date restrictions. I thought that some earlier studies might identify authors who had 
conducted more recent, relevant research and/or provide useful background information 
for the historical context sections of my thesis. I also decided not to exclude the small 
number of studies which include Thalidomide survivors born in South America between 
the 1970s and the 2000s, as I felt they may contain useful contextual information and/or 
relevant citations. I did restrict the review to English language sources, as I did not have 
the resources to pay for translations. However, I was fortunate in that the Trust had paid 
for three very relevant publications (two from Germany and one from Japan) to be 
translated into English and I was able to obtain copies of the English language versions.  
Whilst searching the electronic databases listed above was essential, the exploratory 
search suggested that the records found through this route were likely to be limited in 
number and nature (e.g. a bias toward clinical studies). Furthermore, from my own 
previous work and discussions with others working I the field, I was aware of several 
relevant studies that were in the public domain in the form of reports but did not appear in 
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peer-reviewed journals. If I had restricted my searches to published academic literature, I 
would have missed a number of important studies and lost data that ultimately proved 
very valuable. For this reason, it was necessary to search via a number of other sources, 
and I chose four: 
Websites of Thalidomide Organisations - In most of the countries where significant 
numbers of people were born with Thalidomide damage, there are societies and 
associations that represent them. Whilst they vary in size and purpose, a number have 
commissioned or carried out work that was relevant to the review. I began by looking for 
potentially useful websites and identified two that had links to relevant studies: 
 The Swedish Thalidomide Society (FfDN) website is available in an English language 
version and lists a number of reports and publications from several different countries 
 Thalidomide Victims Association of Canada have made their own reports freely 
available via their website 
The Federal Association of Contergan Victims in Germany also has a website that was 
potentially useful but there was no English translation. However, I was aware of relevant 
research taking place in Germany and was able to obtain English language versions of 
the reports from these studies via the Trust. 
Contacting experts in the field - Internationally there is a small, informal network of 
clinicians and researchers with an interest in TE. Through my previous work with the Trust 
I was in contact with clinicians/researchers in Germany, Japan, Sweden and Australia and 
obtained copies of their reports and/or was directed to their publications (most but not all 
of which had been identified through searching the electronic databases). Contacting 
experts in a field to increase the likelihood of identifying all or most of the studies relevant 
to a review is now accepted practice (McManus et al 1998). It can be particularly helpful 
where the lack of sensitivity of electronic databases is a problem. From my exploratory 
search, I felt this was likely to be an issue in relation to my searches. I maintained these 
contacts throughout my doctoral studies and through them identified six papers published 
after the main searches.  
‘Hand’ searching reference lists and journals – the reference lists did yield a few 
records that I had not identified through other sources but searches of three key journals – 
Disability and Society, Disability Studies Quarterly, and Journal of Disability Policy Studies 
only produced one potentially relevant paper. 
Google Searches – because much of what has been written about Thalidomide in recent 
years has not appeared in peer-reviewed journals, I also made several Google searches, 
using a number of different words and phrases (e.g. Thalidomide survivor, Thalidomide 
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Embryopathy, Thalidomide damage). Whilst much of the material I found took the form of 
newspaper articles, website content and blogs, I did find two relevant reports via this 
route.  
4.3.2 Criteria for screening the records 
Given that the focus of my thesis is on the health of Thalidomide survivors (i.e. people 
with TE), not the health of people who have taken Thalidomide or its derivatives for other 
conditions, I wanted a clear way of screening out studies that looked at more recent uses 
of the drug. I developed two broad criteria for the initial screening of the records found in 
the searches: 
 Type of exposure – only studies which are concerned with exposure to the drug 
Thalidomide (at any dosage and over any period) whilst in the womb were included 
 Types of participants – only studies that focus on people born with physical and/or 
mental impairments that resulted from their mothers taking the drug Thalidomide 
during pregnancy were included.  
For reasons I explain in 4.3.1 above, at the search and screening stage I did not impose 
any date restriction. In relation to the types of studies, the searches revealed that there 
was considerable variation in the size of the studies, study designs, contexts and the 
quality of the studies. In addition to the studies reporting primary research, there were a 
number of case series and reports from organisation representing Thalidomide survivors, 
which contained potentially relevant material. For this reason, I did not place any 
restriction on the type of study to be included.  
4.3.3 Study selection 
I assessed the titles and abstracts of the identified records to evaluate their potential 
eligibility and those that were clearly irrelevant were discarded at this stage. Where 
possible, I retrieved the full text of all the potentially relevant papers and assessed them 
using four questions:  
 Is the study population Thalidomide survivors born in the late 1950 or early 1960’s? 
 Does the study report on the health and/or impairment of Thalidomide survivors? 
 Does the study report on the quality of life of Thalidomide survivors? 
 Does the study focus on the health/quality of life of Thalidomide survivors in middle 
age? 
If the answer to the first question and at least one of the following questions was ‘yes’ I 
included the study. I developed a study selection form (shown in Appendix 11) to 
document my decisions. The study selection forms for the final list of included papers 
were audited by my main supervisor.  
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4.4 Data Extraction 
In scoping reviews, the data extraction stage is often referred to as ‘charting the data’ 
(Arksey and O’Malley 2005). To ensure consistency in the type and depth of data 
extracted from the included studies, I used a data extraction form. An example of a 
completed form is shown in Appendix 12). I looked at a number of forms and templates 
(see for example Egan et al 2003; Noyes and Lewin 2011) and drawing on these 
developed my own form. This approach worked well for the journal articles and created 
helpful overviews for the longer reports. However, four key reports – one from the UK, one 
from Canada and two from Germany – were too long and detailed to summarise 
meaningfully in this way and so I annotated the reports, to make it easier to revisit key 
themes and findings later. My approach was relatively simple. I began by reading the 
reports in full and marking (with sticky bookmarks), the main topics or themes covered. As 
the headings for my descriptive analysis emerged (from all the literature), I re-read the 
reports and re-named my bookmarks to align them with these headings. At this stage, I 
also made additional notes on the hard copies or electronically, which flagged specific 
topics or data which I intended to include in the write up of the descriptive analysis.  
4.4.1 Quality appraisal 
Typically, scoping reviews, unlike systematic reviews, do not include any quality 
assessment of the included studies (Grant and Booth 2009). However, at the data 
extraction stage I felt it would be valuable to undertake a limited appraisal of the quality of 
the studies. The issue of how to assess and document the quality of the studies presented 
some difficulties: there were several different types of studies; some were highly clinical in 
nature; and the records included publicly available but unpublished literature. Due to the 
very diverse character of the studies, I did not use any standard quality assessment tools 
(e.g. Cochrane Risk of Bias or COREQ) but I did make notes on the quality of the studies 
and recorded these on the data extraction form. These notes did influence the weight I 
placed on the findings from some studies, especially where they were not supported by 
data from other studies. In this way, they informed the thematic analysis presented in 4.8. 
4.5 Collating and Summarising the Evidence 
Unlike a systematic review, which seeks to ‘synthesise’ the evidence, a scoping review 
simply collates and summarises the evidence (Arksey and O’Malley 2005). Nevertheless, 
in my review I wanted to use an approach that could deal with the heterogeneous nature 
of the literature I had found and if possible, allow some synthesis of the evidence. As my 
reading progressed, it struck me that drawing on some of the methods used in grounded 
theory might offer an interesting approach, which could both ‘handle’ the very mixed group 
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of studies found, and would ‘fit’ methodologically with the mixed methods grounded theory 
approach to my study. 
In their review of possible methods for analysing qualitative and quantitative evidence, 
Dixon-Woods et al (2005) note that there are very few examples of the use of grounded 
theory but suggest that: 
In principle, grounded theory offers a potentially suitable approach to the synthesis 
of primary studies. The constant comparative method, the most widely used 
element of grounded theory, has the most obvious potential for application, in part 
(especially in later formulations) because it offers a set of procedures by which 
data may be analysed. (p47) 
Many methods for the qualitative analysis of evidence draw on the analytical methods 
described by Glaser and Strauss (1967), although the connection may not always be 
explicit (Pope et al 2007; Barnett-Page and Thomas 2009). The paper most often cited in 
relation to the use of grounded theory is Margaret Kearney’s (2001) analysis of women’s 
experiences of domestic violence, which included 15 studies. Importantly, a prerequisite 
for inclusion in Kearney’s analysis was that the studies should have some affinity with 
grounded theory methods, notably that they should have used constant comparative 
techniques for data analysis and that the theories developed should be ‘grounded’ in the 
data. Kearney used constant comparative analysis to analyse the data descriptively and 
theoretically. She then used substantive (or initial) coding to identify and cluster concepts 
that were identified across studies into new categories. Axial (or intermediate) coding was 
used to examine the nature of the categories in more depth and to explore the 
relationships between them. Finally, she used selective (or theoretical) coding to develop 
and test her emergent theory. 
All the studies included in Kearney’s synthesis were qualitative in nature, and as noted 
above had some affinity with grounded theory methods. By contrast, the literature in my 
review was methodologically diverse and only a handful of the studies had any affinity with 
grounded theory methods. Nevertheless, I still felt that grounded theory offered a heuristic 
approach, and indeed Dixon-Woods et al (2005) note that:  
The generation of higher order themes [using GT], as a means of synthesis 
encourages reflexivity on the part of the reviewer while preserving the interpretive 
properties of the underlying data…..The approach could potentially deal with 
quantitative data by converting quantitative data to qualitative form, for example 
through a narrative descriptive process, though there are currently no examples of 
this. (p48) 
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My approach to using grounded theory methods to collate and summarise the evidence 
had three main elements. I used the data extraction process as a form of initial coding and 
constant comparative analysis to analyse the data thematically. The thematic analysis 
was relatively straightforward but it allowed me to identify categories that cut across the 
studies. Constant comparative analysis also worked well and felt quite a ‘natural’ 
approach. It enabled me to: compare data from different types of studies (e.g. surveys and 
focused biomedical studies); move between and bring together findings from studies that 
were very different in scale and scope (e.g. major multifaceted studies involving large 
numbers of participants and small case studies); and to ‘convert’ quantitative data from 
the studies in to narrative description. I then developed intermediate codes that spanned a 
number of studies. However, unlike Kearney, I did not move on to subject the data to 
theoretical coding. To explain my reasons for this it is necessary to go back a step and 
reflect on the place of the literature review in grounded theory, and the purpose of this 
review in my study.  
The debate about the use of literature in grounded theory is long standing (Birks and Mills 
2015) and much of this debate centres on when a formal review of the literature should be 
conducted. In particular, in The discovery of grounded theory, Glaser and Strauss (1967) 
argued that a formal review of the literature should be delayed until data analysis has 
been completed, to avoid the researcher’s thinking being unduly shaped by existing 
knowledge and theories. However, later writers (Urquhart 2007) regard reviewing the 
literature as a way of the researcher orientating themselves to the field of study, and Birks 
and Mills (2015) suggest that the literature can be used at various stages in a grounded 
theory study, including as data during analysis. For me the review did serve these two 
purposes – it developed my understanding of my research topic and provided an 
important source of data. Charmaz (2014) also considers the place of the literature but in 
broader terms, and importantly draws a distinction between the literature review and 
theoretical frameworks. She suggests that the boundary between the two is often blurred 
and that the sharpness of the distinction will depend on the purpose of the study.  
The literature on the health of Thalidomide survivors as they age is almost completely 
devoid of theoretical frameworks and so it was possible and appropriate to draw a clear 
distinction between the literature review and the exploration of relevant theoretical 
frameworks, discussed in Chapter 8. The absence of theoretical frameworks also meant 
that in examining this literature prior to completing my data analysis there was little danger 
of my own theory being unduly influenced by it. I therefore decided to treat the studies 
found in the literature review as another source of data, and use intermediate coding to 
synthesise the evidence. The review provided me with a very valuable picture of the types 
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of health problems being reported (in the UK and internationally), which I used to shape 
the content analysis of the semi-structured telephone interviews, and to inform and 
contextualise the health and wellbeing survey discussed in Chapter 6.  
At this point, it is appropriate to reflect briefly on the use of GT methods for my evidence 
analysis and synthesis. I carried out most of the work on my literature review early in my 
doctoral research. At that stage, the overall ‘shape’ of my study was still evolving and I 
was new to Grounded Theory. As my research progressed, (especially since completing 
the secondary Grounded Theory analysis of the semi-structured telephone interviews), so 
did my understanding of grounded theory methods. When I came to update my literature 
review in December 2019, I was able to reflect on how I describe my methods. In 
particular, when I first wrote up my review, I described the codes presented in Table 10 as 
‘initial codes’. On reflection, I think these are more appropriately described as 
‘intermediate codes’, with the data extraction process being akin to the initial coding. 
However - and given how my study has evolved - I feel that drawing on Grounded Theory 
methods for the evidence analysis and synthesis was appropriate and helpful.  It provided 
an explanatory account, which outlined the scope of the literature along with its content.  
Finally, it is helpful to note that in scoping reviews the analysis of the evidence is generally 
presented in two ways: a numerical summary, describing the characteristics of the 
included studies (e.g. year of publication, country, study design, research methods); and 
descriptive thematic analysis (Arksey and O’Malley 2005; Levac et al 2010). The 
numerical summary is presented in tabular form in 4.7 and the thematic analysis is 
presented as a narrative in 4.8.  
4.6 Results 
The literature searches (conducted in May 2015 and November 2016 and updated in 
December 2019) confirmed that there was very little published research about the health 
and quality of life of Thalidomide survivors, as they grow older. They yielded 575 records 
from electronic databases and 21 from other sources, which once duplicates had been 
removed, left 506 records. I first screened the titles to remove studies that were not 
concerned with exposure to Thalidomide whilst in the womb (a large number of studies 
focused on either the action of the drug or its contemporary uses). I then screened the 
abstracts using the inclusion criteria described in section 4.3.2. Figure 9 below shows the 
number of studies at each stage in the search and selection process. It includes all 32 of 
the records (which came from 28 studies) included in this review, regardless of when they 
were identified. 
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Figure 9 Literature review flow chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.7 Summary of the Evidence 
As noted in the introduction to this chapter, it was only in the 2000’s, when Thalidomide 
approached its 50th ‘anniversary’ and Thalidomide survivors entered middle age, that 
reports and papers specifically about the health and quality of life of Thalidomide survivors 
as adults began to appear. My review focuses on this body of literature. Although I have 
Records identified through 
database searching 
n = 575 
Records remaining after duplicates removed 
n = 506 
Titles screened 
n = 506 
Records excluded  
n = 429 
Abstracts screened 
n = 77 
Full text articles/reports 
excluded 
n = 18 
Articles/reports included in 
the review 
n = 32 (28 studies) 
Additional records identified 
through other sources 
n = 21 
Full-text articles/reports 
assessed for eligibility 
n = 50 
 
Records excluded 
n = 27 
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used the phrase ‘body of literature’, it is in fact quite limited and disparate.  It is also 
largely descriptive and rarely engaged with broader theoretical debates about ageing, 
health and disability. Despite the fact that Thalidomide was distributed in 46 countries, the 
32 records (from 28 studies) come from just eight countries – Australia, Brazil, Canada, 
Germany, Ireland, Japan, Sweden, and the UK. For this reason, in Table 8 I have 
structured the evidence summary by country and then by year. In some countries, more 
than one paper or report has been produced from the same study, with the same group of 
participants. Specifically, all six of the records from Sweden come from one large multi-
disciplinary study. However, they address different aspects of the health of Thalidomide 
survivors and use both cross-sectional and case control designs, and so in this summary I 
have treated them as separate ‘studies’. 
In terms of the types of study, 20 had a cross sectional design, five were case control 
studies, and three were case series. Of the 25 primary research studies, 21 used 
quantitative methods, one used qualitative methods and three multi-methods. The majority 
of the quantitative and multi-methods studies used validated questionnaires and/or clinical 
measures. The number of participants in these studies ranged from 15 to 870 and all 
except Nippert et al (2002), included men and women. All the studies except one 
(Kowalski et al 2015) focused solely on adult Thalidomide survivors who had been born in 
the 1950s or 1960s. The mean age of participants at the time of the studies ranged from 
35 to 55 (excluding Kowalski et al (2015) where participants were aged 19 to 55).  
My assessment of the quality of the studies was very limited (see 4.4.1), consisting of 
notes recorded on the data extraction form. However, it worth noting here that of the 25 
primary research studies, I identified significant quality issues with six studies. A few of the 
studies were well conducted but there were wider issues such as the age of the data 
being used or (in prevalence studies), the lack of comparisons to set findings in context. In 
my thematic analysis of the evidence (4.8), I refer to any specific quality concern as part of 
my discussion of individual studies.  
Table 8 Numerical summary of the evidence from the literature review 
Authors and Year 
(grouped by 
country) 
Type of Study and Study Sample Overview of Methods / 
Measures Used  
Australia (2 records) 
Chorlton M 
2013  
 
Cross-sectional survey of health-
related quality of life  
 
15 Thalidomide survivors across 
Australia and New Zealand 
Self-completion SF36 health 
questionnaire distributed by post  
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Authors and Year 
(grouped by 
country) 
Type of Study and Study Sample Overview of Methods / 
Measures Used  
Jankelowitz et al  
2013 
 
Cross-sectional study into late 
onset neurological symptoms  
 
16 Thalidomide survivor with limb 
difference 
 
Detailed medical history 
Clinical neurological 
examination 
Neurophysiological testing 
Brazil (1 record) 
Kowalski et al 
2015 
Cross-sectional study of health 
and social circumstances 
 
23 adult Thalidomide survivors  
Note: The study included 
Thalidomide survivors aged 19 to 
55 
Face to face administration of a 
questionnaire 
Clinical examinations 
Canada (1 record) 
Vermette and 
Benegabi  
2013 
Cross-sectional survey of health 
and social circumstances 
 
65 Thalidomide survivors  
Self-completion questionnaire 
distributed by post 
Ireland (1 record) 
O'Carroll et al 
2011 
 
Cross-sectional study of health 
and social circumstances 
 
26 Thalidomide survivors  
Self-completion questionnaire 
distributed by post 
Japan (6 records) 
Oshima et al 
2006 
 
Case series  
 
Three Thalidomide survivor with 
radial dysplasia who were 
experiencing Carpal Tunnel 
Syndrome 
 Examination, diagnostic 
tests and surgical 
procedures including: 
 Clinical examination 
 Electrophysiological tests 
 Carpal canal pressure 
measurement (pre/post 
operatively) 
 Treatment was the Okutsu 
endoscopic carpal tunnel 
release 
Kayamori 
2013 
 
Cross-sectional survey 
 
201 Thalidomide survivors 
Methods section implies that the 
researchers went to peoples’ 
home and completed the survey 
with them but this is not clear, 
partly due to poor translation. 
Imai et al  
2014  
 
Case-control study into the 
presence/absence of mental 
health problems and the 
existence of epilepsy and autism.  
 
Individual interview followed by: 
Measurement of electrical brain 
activity 
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Authors and Year 
(grouped by 
country) 
Type of Study and Study Sample Overview of Methods / 
Measures Used  
22 Thalidomide survivors who 
were admitted to a hospital for 
medical examination during the 
period from September 2011 to 
February 2012 
Results compared to ‘healthy 
controls’ but details unclear 
Wechsler Adult Intelligence 
Scale-III (WAIS-III; Japanese 
Version) intelligence test  
Autism-Spectrum Quotient  
General Health Questionnaire-
28  
MINI short structured psychiatric 
diagnostic interview instrument  
Shiga et al 
2015 
 
Cross-sectional study 
investigating the development of 
lifestyle-related diseases and 
identify risk factors for visceral 
disorders 
 
76 Thalidomide survivors 
Medical examination, including a 
wide range of tests and 
investigations, were conducted 
at two centres between 2011 
and 2014.  
Tajima et al 
2016 
 
Cross-sectional study examining 
the prevalence of internal 
anomalies 
 
22 Thalidomide survivors  
Whole-body image screening 
using 
unenhanced whole-body 
computed tomography (CT) and 
head magnetic resonance 
imaging (MRI) 
Hinoshita et al 
2019 
Cross-sectional survey about 
gathering information about 
health and living circumstances 
 
173 Thalidomide survivors  
 
Self-completion questionnaire 
distributed by post 
Sweden (6 records all of which are from one large multi-disciplinary study) 
Ekfeldt and 
Carlsson 
2008 
 
Cross-sectional study into the 
dental conditions and functional 
aspects of the masticatory 
system, with a special focus on 
tooth wear 
 
31 Thalidomide survivors 
Face to face administration of a 
questionnaire 
Clinical examination – WHO 
criteria for DMFT; tooth wear 
recorded; periodontal 
examination 
Radiographic examination  
Sjogreen and 
Kiliaridis  
2012 
 
Case-control study of the 
frequency and characteristics of 
facial palsy in Thalidomide 
survivors. 
 
25 Thalidomide survivors without 
recognized facial impairments 
and 25 healthy adults of a similar 
age. 
Clinical examinations of: 
voluntary facial movements 
using Sunnybrook Facial 
Grading System; lip mobility 
(calculated mouth width, mouth 
width change and asymmetry); 
and lip force 
Ghassemi Jahani  
et al  
2014 
Cross-sectional study into the 
long-term effect of limb 
malformations on the function of 
Orthopaedic and neurological 
examination  
CT Scans 
112 
 
Authors and Year 
(grouped by 
country) 
Type of Study and Study Sample Overview of Methods / 
Measures Used  
 the extremities and the 
development of degenerative 
osteoarthritis (OA) in the lower 
extremities 
 
31 Thalidomide survivors 
Functional assessment using 
Rheumatoid and Arthritis 
Outcome Score and Disabilities 
of the Arm, Shoulder and Hand 
Outcome Measure 
Ghassemi Jahani  
et al 
2016a 
 
Case-control study examining 
degenerative changes in the 
cervical spine 
 
27 Thalidomide survivor and 27 
age matched controls 
Clinical examination by an 
orthopaedic surgeon 
MRI examination of the cervical 
spine 
Ghassemi Jahani  
et al 
2016b  
 
Cross-sectional study 
investigating the effect of limb 
malformations on health-related 
quality of life 
and function of the extremities 
 
31 Thalidomide survivors 
Clinical examination 
A questionnaire including Short 
Form 36 Health Survey and 
EuroQ Five Dimensions was 
completed in a face to face 
interview 
Upper limb function was 
assessed using Rheumatoid 
and Arthritis Outcome Score 
and Disabilities of the Arm, 
Shoulder and Hand Outcome 
Measure 
Ghassemi Jahani  
et al 
2017  
 
Cross-sectional study 
investigating the need for 
orthopaedic surgery and limb 
orthosis in relation to function and 
physical independence 
 
31 Thalidomide survivors 
Self-administered questionnaire 
about: limb surgery; use of 
orthotic devices; work; 
accommodation; disability 
adjustments; personal 
assistants; and time needed for 
activities of daily living 
Physical function measured by a 
modified General Function 
Score 
Germany (6 records, two from the same study) 
Nippert et al 
2002 
 
Case-control study of 104 female 
Thalidomide survivors in North 
Rheine Westphalia and an age 
matched control group of 104 
women from the same region 
Self-completion questionnaire 
distributed by post. WHO QOL-
BREF was incorporated into a 
larger questionnaire which 
gathered data about 
socioeconomic status  
Kruse et al  
2013 
 
Cross-sectional study 
investigating the health, social 
care and living circumstances. 
 
870 Thalidomide survivors 
Self-completion questionnaire 
distributed by post and returned 
by 870 
23 Focus Groups involving 112 
participants 
285 Face to face interviews 
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Authors and Year 
(grouped by 
country) 
Type of Study and Study Sample Overview of Methods / 
Measures Used  
NOTE: It is not clear whether 
the focus group and interview 
participants also completed the 
questionnaire. 
Peters et al  
2015  
 
Cross-sectional study examining: 
socio-economic circumstances; 
physical and mental health; 
experience of pain; use of health 
services; and quality of life. 
 
202 Thalidomide survivors living 
in North Rheine Westphalia 
Face to face structured 
questioning of each participant 
using a questionnaire with a 
number of validated instruments 
(e.g. painDETECT, SF-36, EQ-
5D, SKID-1 & 11 psychological 
disorders questionnaire), 
personal examination by two 
specialist doctors, and 
structured recording of 
psychological disorder 
characteristics. Depending on 
individual symptoms, x-ray 
and/or ultrasound were also 
carried out. 
Niecke et al 
2017 
Journal paper presenting the 
mental health findings from 
Peters et al 2015  
above 
 
Merkle et al 
2016 
 
Case series 
 
Four Thalidomide survivors and 
one other patient with Dysmelia  
Patients were treated with 
shoulder arthroplasty and 
assessed clinically and 
radiographically before and after 
surgery.  
Weinrich et al 
2018 
 
Cross-sectional study assessing 
the prevalence of congenital 
vascular and organ anomalies 
 
78 Thalidomide survivors  
Clinical examination using non-
contrast Magnetic Resonance 
Angiography 
UK (8 records, three from same study) 
Newman 
1999 
 
Case series of shoulder joint 
replacement surgery in one upper 
limb affected Thalidomide 
survivor 
Description of patients condition 
before and after joint 
replacement 
Kennelly et al 
2002 
 
Cross-sectional study 
11 Thalidomide survivors 
participated in Focus Groups; 34 
took part in interviews; and 209 
responded to the telephone 
survey.  
 
421 people from the general 
population of a similar age 
Focus groups  
In depth interviews 
Structured telephone survey of 
Thalidomide survivors 
Structured telephone survey of a 
sample of the general 
population of a similar age 
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Authors and Year 
(grouped by 
country) 
Type of Study and Study Sample Overview of Methods / 
Measures Used  
responded to the telephone 
survey 
Bent et al 
2007 
 
Cross-sectional mixed methods 
study exploring health status, 
impairment, activity limitation; 
participation and quality of life 
quality of life 
28 Thalidomide survivors took 
part in interviews and 41 
responded to the survey. 
Qualitative face to face 
unstructured interviews 
Postal Questionnaire using 
standardized measures 
(Rosenberg Self-Esteem Scale; 
Perceived Stress Scale; General 
Perceived Self-Efficacy Scale; 
Bodily Pain and Vitality and 
Physical Function Scale of the 
SF36; Barthel Index and; 
London Handicap Scale; 
EuroQoL General Well-Being 
Index 
Newbronner et al  
2011, 2012 and 
2013 
 
Cross-sectional evaluation of the 
pilot Health Grant 
 
A representative sample of 
Thalidomide survivors - 53 took 
part in 2011, reducing to 49 in 
2012 and 41 in 2013 
Semi-structure telephone 
interviews conducted annually 
over three years. 
Newbronner 2015 Cross-sectional study about 
employment and health-related 
quality of life 
 
245 Thalidomide survivors 
Self-completion questionnaire 
distributed by post  
SF12 used to assess health-
related quality of life 
Nicotra et al 
2016 
 
Case-control study investigating 
peripheral neve dysfunction 
 
17 Thalidomide survivors with 
upper limb anomalies and 
neuropathic symptoms and 17 
healthy controls 
Clinical examination and 
standard neurophysiological 
testing 
 
4.8 Thematic Analysis 
In this section, I draw together the thematic analysis of the data from the literature. I have 
grouped the analysis under eight main headings, which are somewhat biomedical in 
nature. This structure may seem at odds with the contemporary theoretical understanding 
of disability. It is important to explain that the headings do not imply support for the 
medical model of disability but rather reflect the predominantly biomedical, a-theoretical 
and/or quantitative nature of most of the studies. Using a grounded theory approach 
enabled me to move beyond these descriptive themes and develop intermediate codes, 
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which begin to draw out the implications and meaning of these biomedical groupings for 
Thalidomide survivors.  
4.8.1 Musculoskeletal problems 
Thirteen studies discussed the musculoskeletal problems that Thalidomide survivors are 
experiencing, as they grow older. However, these discussions range from accounts of the 
problems being reported by Thalidomide survivors in qualitative interviews and broad 
health surveys to biomedical studies focusing on very specific musculoskeletal problems. 
In this section therefore, I begin by describing the findings from the qualitative studies and 
bringing together the relevant material from the survey-based studies. I then consider the 
findings from the biomedical papers. 
In the focus group discussions and qualitative interviews conducted by Kennelly et al in 
their 2002 study, when Thalidomide survivors were entering their 40s, they were already 
beginning to report musculoskeletal problems, including arthritis, joint pain, muscular pain, 
and stiffness. The results of the survey conducted as part of the same study also reported 
on the musculoskeletal problems respondents described, but because of the construction 
of the survey questions it is difficult to extract robust figures for different ‘types’ of 
problems. Nevertheless, some broad findings are evident. Around 20% of the survey 
respondents said they had ‘arthritis’ and similar proportion reported ‘increased joint pain’. 
Roughly a quarter said they were experiencing ‘increased muscular pain’, and a few 
reported specific issues such as scoliosis and back problems. 
Almost a decade later, the evaluation of the Government Health Grant made to UK 
Thalidomide survivors found that over three quarters of the study participants were 
experiencing deterioration in one or more joints, and joint, back and/or neck pain 
(Newbronner et al 2011). Some participants described this pain as ‘arthritic’ but they did 
not necessarily have a formal diagnosis. In the second year of the evaluation, around a 
fifth of participants (Newbronner et al 2012), reported problems with muscle strain, 
especially in the back and neck, and/or muscle weakness, particularly in their arms and 
hands. For many participants, the musculoskeletal problems they were experiencing were 
associated with over-use of ‘good’ limbs or more generally the way they had to use their 
bodies to compensate for their impairments. In Kennelly et al’s 2002 study, some UK 
Thalidomide survivors were already beginning to feel that their health and particularly their 
musculoskeletal health, was not as good as their peers in the general population. 
However, this theme emerged much more clearly in the later Health Grant evaluation 
(Newbronner 2011), with some participants explicitly stating that they felt older than their 
chronological age - “I feel like I have the body of a 70 year old” (p21). 
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Six studies reporting on surveys of the health and quality of life of Thalidomide survivors 
also present some findings about musculoskeletal problems. The study by Nippert et al 
(2002) of the health-related quality of life of 104 female Thalidomide survivors (described 
in more depth in section 4.8.7) found that 41.6% of the survey respondents had 
experienced deterioration in their health in the preceding twelve months, and of this group 
83% reported increased musculoskeletal problems. Bent et al (2007) found that almost 
half the 41 survey respondents reported having arthritis in their shoulders and just over a 
third reported hip pain. Thalidomide survivors with more severe impairments reported 
significantly more musculoskeletal problems. O’Carroll et al (2011) also note that 
respondents in their survey reported deterioration in their ‘original condition’…due to hand 
arm overuse, injuries and musculoskeletal problems affecting the feet, knees and back’ 
(p476). Lastly, the TVAC survey of Canadian Thalidomide survivors (Vermette and 
Benegabi 2013) found that 80% reported increasing muscular pain and 71% reported 
increasing joint pain.  
A Japanese study of the health of 201 Thalidomide survivors (Kayamori 2013), described 
the musculoskeletal problems they were experiencing as ‘overuse syndrome’. Based on 
this self-report survey, the author then identified five main problems: hip joint deterioration; 
shoulder pain (with a number of causes); poor posture, leading to scoliosis and thoracic 
kyphosis (dorsal hump); tendonitis, especially in the arms and hands; and back pain, 
sometimes caused by over-use, and/or lumbarization8 and other congenital deformities of 
the spine. The paper also includes some limited data about prevalence. Around a third of 
participants reported joint pain, and a similar proportion reported shoulder stiffness. In a 
more recent survey (Hinoshita et al 2019), Japanese Thalidomide survivors reported a 
range of musculoskeletal problems, the most common being “stiff shoulder (22.5%), 
followed by lumbago or low back pain (21.4%)…arthropathy9 (15.0%)” (p3). 
In the first of the two large German studies Kruse et al (2013) describe the ‘secondary 
damages’ reported by the 870 Thalidomide survivors who responded to their survey. They 
define ‘secondary damages’ as: “physical impairments that develop in thalidomide victims 
during the course of their lives in areas of the body not damaged prenatally” (p14), and 
suggest that they are caused by “some movement patterns practiced early on to 
compensate for missing functions”. They distinguish these ‘secondary damages’ from 
                                               
8 Lumbarization is a congenital anomaly, in which the first and second segments of the sacrum do 
not fuse, and consequently the lumbar spine appears to have six vertebrae or segments, not five, 
while the sacrum appears to have only four. 
9 Arthropathy is a disease of a joint. 
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‘long term sequelae’, which they describe as damage that “occurred prenatally but were 
only detected at a later point in time” (p14).  
The survey questionnaire asked respondents to indicate the severity of four 
musculoskeletal problems – pain, osteoarthritis, muscle weakness and muscle tension – 
using a simple four point scale, where 1=slight, 2=moderate, 3=considerable and 
4=extreme. The mean values for each problem or ‘item’ were then calculated for three 
areas of the body – ‘upper extremities’, ‘lower extremities’ and ‘vertebral column/pelvis’. 
The results from this survey are compared to data from five years ago. Unfortunately, no 
information about where this earlier data comes from is provided in the report. The study 
found that musculoskeletal problems in the ‘upper extremities’ were significantly worse 
than five years ago with the mean value for each problem shifting from between 1.4 and 
1.9, to between 2.3 and 3. There was also deterioration in the ‘lower extremities’ and 
‘vertebral column/pelvis’. Severity of pain, osteoarthritis, muscle weakness and muscle 
tension in the ‘upper extremities’ was clearly associated with the severity of original 
Thalidomide damage but for the ‘lower extremities’ and ‘vertebral column/pelvis’, the 
picture was less clear. The linked survey of participants’ physicians found that 90% of the 
problems presented during consultations “related to the musculoskeletal system” (p42).  
Kruse et al (2013) also discuss the pain associated with musculoskeletal problems. They 
found that 84.3% of their survey respondents experienced pain. Of this group, 50% 
experienced pain ‘every day’ and 39% had ‘persistent’ pain. The proportion of 
respondents reporting pain increased with the number of ‘damage areas’ they had. The 
authors suggest that:  
The reason for pain is both wear and tear or destruction of damaged joints, as well 
as tension in muscle attachments and tendon insertions. Pain is also the result of 
secondary damages that have developed in area not affected prenatally. In 
practice, it is quite difficult to separate the two causes of pain and functional 
impairment. The current situation defines the everyday life of the victims and 
represents the situation that has shaped itself in the amalgamation and 
development of prenatal damages and secondary damages over the course of 50 
years. (p16) 
In the second German study (Peters et al 2015), two doctors examined each participant 
and then completed a questionnaire, which recorded both ‘primary impairment’ (i.e. 
original Thalidomide damage) and ‘subsequent impairment’ or ‘consequential damage’ 
(both terms are used). In relation to consequential damage, data was collected about loss 
of movement and musculoskeletal pain in joints/areas of the body (the study also included 
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a more in-depth assessment of the nature and severity of participants’ pain, and this is 
described in section 4.8.2). Pain was most frequently reported in the neck, back and 
shoulders, closely followed by knees and hips. Movement restrictions were most common 
in the hand, shoulder and elbow, and around two thirds of participants had painful, 
hypertonic10 muscles in one or more area of the body. In addition, the self-completion 
questionnaire asked about “accompanying illnesses diagnosed by a doctor” and 27.7% of 
respondents listed diseases of the musculoskeletal system and connective tissue.  
A Brazilian study (Kowalski et al 2015), which involved 28 Thalidomide survivors aged 
from 3 to 53 years (21 born between 1959 and 1964), aimed to assess the extent to which 
their current health problems were a direct result of in utero exposure to Thalidomide or 
consequential damage associate with posture and lifestyles. They found a high frequency 
of musculoskeletal disease (30%) amongst the study participants, with arthrosis being the 
most commonly reported condition. However, as in the two major German studies, they 
conclude that these problems were “probably caused by compensatory postures and 
difficulties in executing normal daily tasks due to limb anomalies” (p801).  
Five studies examined specific musculoskeletal problems. An early case study by 
Newman (1999) describe a shoulder joint replacement procedure for a then 35-year-old 
Thalidomide survivor with end-stage osteoarthritis. Although this is a single case study, 
the author speculates on three important issues: the likelihood of Thalidomide survivors 
developing degenerative joint disease, which will compound existing impairments; the 
need to recognise ‘overuse symptoms’; and the potential benefits of shoulder 
replacement. A more recent paper by Merkle et al (2016) presents a case series 
describing five shoulder replacements in four patients with Dysmelia, including three 
Thalidomide survivors. The mean age of the patients at the time of surgery was 50.4. All 
had been experiencing increasing shoulder pain and restricted range of movement due to 
osteoarthritis for a number of years and conservative therapy options had been 
exhausted. The authors suggest that overuse of upper limbs in patients with Thalidomide 
induced phocomelia results in premature wear and tear of the shoulder joint. Following 
resurfacing arthroplasty, all the patients in this study had almost complete remission of 
pain and significant improved range of movement. The authors argue that, for the type of 
shoulder dysplasia often seen in Thalidomide survivors with Dysmelia (i.e. glenohumeral 
joint dysplasia), resurfacing arthroplasty is preferable to arthroplasty with stemmed or 
reverse shoulder prosthesis because: it is less invasive; has shorter operation time; 
                                               
10 Abnormally high muscle tone. 
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carries lower risk of facture; and so does not involve loss of humerus length, all issues 
which are likely to be of significant concern to Thalidomide survivors.  
A Swedish study (Ghassemi Jahani et al 2014), examined the development of 
osteoarthritis in the ‘lower extremities’ of 26 Thalidomide survivors using computed 
tomography (CT) scans and the Rheumatoid and Arthritis Outcome Score (RAOS). Five 
participants with major deformities of the lower limbs were excluded from this part of the 
study as the nature of their impairments might affect the development of osteoarthritis. 
The authors found that nearly 40% of the participants had osteoarthritis in the hip and 
60% in the knee. They note that comparisons of prevalence rates of osteoarthritis of these 
joints in the general population of a similar age are problematic because estimates vary 
but they do cite estimates for both knee and hip osteoarthritis of 10% in Australian study 
and 15% in a Swedish study. They conclude that the rates found in Thalidomide survivors 
are much higher but suggest that these degenerative changes “were mostly mild and had 
little clinical significance”. 
A second paper by the same lead author (Ghassemi Jahani et al 2016a) examined 
degenerative changes in the cervical spine in a group of 27 Swedish Thalidomide 
survivors, and compared them to 27 age and gender matched controls. They found that 
Thalidomide survivors had a significantly higher degree of disc degeneration, alongside 
other changes, notably foraminal narrowing11 - the passageway through which all spinal 
nerve roots pass. They concluded that Thalidomide survivors have a higher frequency of 
degenerative changes in the cervical spine and suggest that this may be caused by an 
altered load on the cervical spine. A third paper (Ghassemi Jahani et al 2017) based on 
research with the same group of participants, examined the number of surgical 
procedures they had undergone. The participants had undergone relatively few surgical 
procedures on their limbs until middle age, with carpal tunnel release being the most 
frequent procedure. The authors raise the question of whether carpal tunnel syndrome “is 
caused by the limb malformations and the resulting overuse or changed use of the wrists, 
or is a consequence of the embryonic damage caused by the drug or a combination of 
these is however unclear”. It is worth noting that whilst these three papers led by 
Ghassemi Jahani (and the 2017 paper discussed in 4.8.7 below) were published relatively 
recently and are from a well conducted study, the data was collected some years 
previously, when the mean age of participants was 46 years. They are also based on data 
from the same group of 31 Thalidomide survivors. 
                                               
11 The foramen is the bony archway created by the pedicles of the adjacent vertebrae that provides 
the passageway through which the spinal nerve roots pass.  
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4.8.2 Pain and neuropathic symptoms 
As the previous section shows, muscle and joint pain associated with musculoskeletal 
problems is common amongst Thalidomide survivors. However, one of the qualitative 
studies (Newbronner et al 2012) and two of those drawing on qualitative and/or survey 
data (Vermette and Benegabi 2013; Kruse et al 2013) also found that some Thalidomide 
survivors report generalised, possibly neuropathic12, pain and neuropathic symptoms such 
as numbness, tingling, loss of sensitivity/dexterity and partial paralysis. None of these 
studies makes comparisons with pain prevalence in the general population of a similar 
age but Peters et al (2015) do and their findings are discussed below.  
Only one study (Peters et al 2015) has specifically examined the issue of neuropathic 
pain. They used the painDETECT questionnaire – a standardised instrument that was 
completed by participants (171 out of 202 provided usable questionnaires). The 
questionnaire asks about the characteristic clinical symptoms of neuropathic pain and a 
score of 19 or more (maximum 38) indicates that a participant is likely to have a 
neuropathic component to their pain. The results showed that around 20% of participants 
probably had a neuropathic component to their pain, which the authors note compared to 
an estimate of 8% in the general population in Germany aged 45-54. Interestingly, 
participants without Dysmelia were most likely to have a neuropathic pain component, 
followed by those with quadruple damage and finally those with double damage. 
Two studies have looked at late-onset neurological symptoms in Thalidomide survivors. 
The first study (Jankelowitz et al 2012) involved 16 Thalidomide survivors from Australia 
and New Zealand who had all presented with new neurological symptoms. The aim of the 
study was to “determine whether there was ongoing nerve damage/loss in this population 
as a ‘late effect’ of thalidomide exposure or whether the effects were due to exacerbation 
of the normal ageing process as a result of lack of the normal ‘redundancy’ within the 
nervous system” (p509). The study involved taking detailed medical histories, clinical 
neurological examinations and neurophysiological testing. The study found no evidence of 
clinically or neuro-physiologically of late-onset generalized neuropathy and concluded that 
the neurological symptoms experienced by their participants were largely due to 
compressive neuropathies. Lower limb musculoskeletal symptoms were more common 
                                               
12 The website Patient states: “Neuropathic pain is defined by the International Association for the 
Study of Pain (IASP) as pain arising as a direct consequence of a lesion or disease affecting the 
somatosensory system”. It notes that the pain is usually chronic in nature and has a number of 
possible features such as: patients experiencing a burning sensation, or sharp, shooting pain;  
allodynia - seemingly harmless stimuli, such as light touch, provoking pain; hyperpathia - a short 
episode of discomfort causing prolonged severe pain; and hyperalgesia - discomfort, which would 
otherwise be mild, being felt as severe pain. 
http://patient.info/doctor/neuropathic-pain-and-its-management - accessed 20 March 2016. 
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amongst participants with more severe impairments, and the authors suggest that these 
may be due to postural abnormality. 
The second study (Nicotra 2016 et al) was funded by the UK Thalidomide Trust in 
response to anecdotal reports of an increase in the number of UK Thalidomide survivors 
experiencing neurological symptoms, and/or the growing severity of these neurological 
symptoms. This small pilot study aimed to determine whether Thalidomide survivors have 
problems (e.g. numbness, tingling pain or weakness) with their peripheral nerves, i.e. the 
nerves that connect the skin and muscles to the spinal cord. The 17 Thalidomide survivors 
involved all reported sensory symptoms in their upper limbs and a few in their feet. They 
took part in a range of motor and sensory examinations and their results were compared 
to 17 healthy volunteers. The authors found that the majority of the Thalidomide survivors 
in the study (15 out of 17) had nerve compression, most commonly around the wrist but 
also of the nerve roots in the lower back and of the spinal cord in the neck. The findings 
for generalised neuropathy were less clear. They suggest that some symptoms could be 
due to abnormal peripheral nerve development or (in the lower limbs) early peripheral 
nerve dysfunction but that more research is needed.  
Jankelowitz et al (2012) also noted that the chance of developing median nerve 
compression at the wrist is probably greater in Thalidomide survivors because overuse of 
the hand to compensate for other limb deformities coupled with musculoskeletal 
deformities may lead to narrowing of the carpal tunnel. A small study (Oshima et al 2006) 
of three Japanese Thalidomide survivors with Carpal Tunnel Syndrome and radial 
dysplasia13 supports this finding, as do the findings from Kayamori’s 2013 study.  
4.8.3 Dental problems/facial damage 
Just one study looked specifically at the dental health of Thalidomide survivors (although 
five other studies do touch in the topic). Ekfeldt and Carlsson (2008) examined the dental 
status and oral function of 31 Swedish Thalidomide survivors. They found that dental 
caries was similar to general population but the number of decayed, missing or filled teeth 
(DMFT) was slightly higher. They suggest that this might be explained by fact that 
Thalidomide survivors find tooth brushing more difficult. They also found that tooth wear 
was on average more extensive than the comparable age group in the general population. 
The authors think this is due to dental erosion associated with high prevalence of 
regurgitation (although it is not clear if regurgitation is caused by Thalidomide damage) 
and to a lesser extent by using teeth as tools.  
                                               
13 Radial dysplasia a condition where the radius bone of the forearm is underdeveloped or absent. 
It is often associated with hand deformities such as small or missing thumb and is common 
amongst Thalidomide survivors. 
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Kowalski et al (2015) report that 17% of their study participants had loose or weak teeth, 
which is very similar to Hinoshita et al 2019 who found that 17.9% of their survey 
respondents had dental problems. These findings, together with those from Newbronner 
et al (2012) qualitative study, and those of Kruse et al (2013), support Ekfeldt and 
Carlsson’s (2008) findings. Upper limb affected participants frequently used their teeth to 
help them with everyday tasks such as getting dressed, opening bottles, holding keys etc. 
and some felt that this was causing damage to their teeth. These participants also 
described having difficulty cleaning their teeth properly, which could lead to higher rates of 
tooth decay. Peters et al (2015) also found that a third of their participants reported tooth 
wear, and this was significantly more common amongst participants with Dysmelia.  
A connected study to Ekfeldt and Carlsson (2008), which involved 25 of the same 
participants, surveyed the frequency and characteristics of facial palsy in Thalidomide 
survivors (Sjogreen and Kiliaridis 2012). They used a range of approaches to test 
voluntary facial movements, lip mobility and lip force and compared the results for the 
Thalidomide survivors with those for 25 ‘healthy’ adults of a similar age. They found that 
three Thalidomide survivors (10%) had acquired facial palsy - more than would occur by 
chance, and suggest this may indicate that the facial nerve in Thalidomide survivors is 
more vulnerable. They also noted that Thalidomide survivors in the study without 
recognized facial impairments had poorer lip force and mobility, suggesting mild facial 
muscle weakness that had not been previously clinically identified. 
4.8.4 Deteriorating sight and/or hearing 
In the UK around a quarter of Thalidomide survivors were born with damage to their eyes 
and almost a third have a hearing impairment (data provided by the Thalidomide Trust). 
The first study to highlight concerns about further deterioration was Nippert’s (2002) study 
of the health-related quality of life of 104 female Thalidomide survivors found that 13% of 
survey respondents reported ear and eye problems. However, no further details were 
reported. In 2011 Newbronner et al noted that the Thalidomide survivors in their study 
group who were partially sighted and/or partially deaf were reporting deterioration in their 
sight and/or hearing, and a small number of other participants reported more recently 
acquired sight or hearing problems. Again no further details are given. The Thalidomide 
Victims Association of Canada survey (Vermette and Benegabi 2013) found that around 
22% of respondents reported ‘deterioration in eyesight’ and around 15% ‘deterioration in 
hearing’. However, it is not clear what proportion of these respondents are Thalidomide 
survivors who had original damage to their sight or hearing, and no comparison with the 
general population of a similar age in Canada is made. Similarly Hinoshita et al (2019) 
report that 19.1% of their survey respondents had “ocular diseases”. Neither of the two 
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large German studies (Kruse et al 2013; Peters et al 2015), discuss the deteriorating sight 
or hearing among Thalidomide survivors.  
4.8.5 General health and ‘lifestyle diseases’ 
Three studies, two from Japan and one from Brazil, gathered information about general 
health and ‘lifestyle diseases’. The first Japanese study (Shiga et al 2015) looked 
specifically at lifestyle-related disease and found the most common disease was 
hypertension, which affected nearly half the 76 participants, followed by (central) obesity, 
which affected nearly a quarter of participants. The paper makes few direct comparisons 
with the general population of a similar age but it does highlight gender differences, noting 
that male Thalidomide survivors were at higher risk of developing lifestyle related 
diseases. Perhaps the most interesting aspect of this paper for me was the authors’ 
reflections on the problem of accurately measuring blood pressure and body mass index, 
when people have missing or short limbs. These are two of the most commonly used 
indicators of risk of lifestyle diseases, and yet Thalidomide survivors may be less able to 
benefit from them because of the unreliability of the measurements produced. The most 
recent survey of Japanese Thalidomide survivors (Hinoshita et al 2019) also asked about 
general ‘health conditions’. The three most commonly reported problems were 
hypertension (15.6%), dyslipidaemia (13.9%) and diabetes mellitus (12.7%). 
The Brazilian study (Kowalski et al 2015) found that 40% of their sample (aged over 40) 
had hypertension, which they reported is only marginally higher (with no statistical 
difference) than the general prevalence of the disease in Brazil (35%). For heart disease, 
they found that prevalence for study participants aged 50 was very similar to that of the 
general population of a similar age. However, the rate was much higher than the 
population norm for younger participants (14.2% compared to 3.7%). They conclude that 
there is a tendency for early onset of cardiovascular disease amongst Thalidomide 
survivors. Importantly, Kowalski et al (2015) also found that 65% (n=15) of their sample 
had at least one chronic disease (including long-term mental health problems), compared 
to 31.8% of the general population aged 15 to 59. 
Three other studies looked very broadly at general health but the data presented in them 
is of limited use. Kennelly et al (2002) report that approaching half the Thalidomide 
survivors in their study felt their health was worse that people of the same age unaffected 
by Thalidomide. They also state (very imprecisely) that - “participants have experienced 
an increase in diagnosed medical conditions or health problems over the last 5-10 years” 
(page 34). The TVAC survey (Vermette and Benegabi 2013) also asked about “general 
health status and wellbeing”. Over three quarters of their respondents said their overall 
health and wellbeing had worsened in the past 5 years and a similar proportion said they 
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had “a persistent health problem” (often a musculoskeletal problem).  However, the report 
does not discuss the prevalence of lifestyle related diseases or risk factors such as weight 
gain. The second report from the evaluation of the Health Grant (Newbronner et al 2012) 
does briefly describe the concerns of some participants about weight gain, difficulties 
exercising and the complications of managing lifestyle related conditions such as diabetes 
and hypertension.  
Finally, two recent studies have looked at the extent and implications of the damage to 
internal organs and systems caused by Thalidomide. A Japanese study (Tajima 2016) 
examined the prevalence of “internal anomalies in Thalidomide embryopathy”, using MRI 
and CT imaging. Twenty-two Thalidomide survivors were “selected” to take part in the 
study. They each underwent a medical examination and then had both a whole body CT 
scan and an MRI of the head. The study found a high prevalence of abnormalities of the 
auditory organ, the vascular system and the gallbladder, and block vertebrae were seen in 
around a quarter of the group. The paper concludes by noting the value of using MRI and 
CT imaging to identify internal abnormalities but says nothing about the implications of 
these abnormalities for the health of Thalidomide survivors.  
A team of researchers in Germany (Weinrich et al 2018) used non-contrast magnetic 
resonance angiography to determine the type and frequency of congenital vascular and 
organ anomalies, and to assess the effect of observed malformations on renal function in 
Thalidomide survivors. The study had 78 participants (50 female and 28 male) with a 
mean age of 55. Participants were split into three groups based on the extent of their 
upper limb Dysmelia. Information about ear, eye and face anomalies was retrieved from 
medical records. The main findings from the study were that nearly three quarters (74%) 
of participants had vascular anomalies, with two thirds of these related to arteries and 
one-third to veins. Most of the vascular anomalies were within reported frequencies for the 
general population. However, the study did find that “supernumerary renal arteries, left 
vertebral artery originating from aortic arch and a retroaortic left renal vein occurred more 
often in subjects with TE than previously reported” (p2369). The most common abdominal 
organ anomalies involved the renal system (i.e. missing or duplicated kidneys, and 
malpositioned and/or malrotated kidneys).  
Although there was no evidence that the vascular or organ anomalies observed were 
affecting renal function, the authors point out that “knowledge about possible 
malformations is important for subjects with TE in case of future abdominal surgical or 
vascular treatment” (p2369). Importantly, the authors recommend that for Thalidomide 
survivors requiring abdominal surgery, preoperative imaging (preferably non-contrast 
MRA) of the abdominal organs and vessels should be conducted and used to inform a 
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plan for the operation. Lastly, they note that this study only included Thalidomide survivors 
with upper limb damage, and it is possible that vascular and organ abnormalities are more 
common and more severe in Thalidomide survivors with lower limb damage. 
4.8.6 Mental health 
Seven studies have explored the mental health or mental wellbeing of Thalidomide 
survivors. Of these, just two have specifically set out to assess the prevalence of mental 
disorders. Imai et al (2014) examined the psychological and mental health problems of 22 
Japanese Thalidomide survivors and compared them to a ‘healthy’ control group. He also 
considered the prevalence of autism and epilepsy, as previous studies (Strömland et al 
1994; Kanno 1987) had suggested that these conditions are more common in people with 
TE. I have not included the findings from this part of the study here as they concern the 
prevalence of original impairments caused by Thalidomide rather than the implications of 
living with these impairments in later life. The participants in this study (nine men and 
thirteen women) had all been admitted to hospital for general medical examinations. 
Whilst their original Thalidomide impairment are briefly described, no information is 
provided about how representative they are of the population of Thalidomide survivors in 
Japan as a whole.  
The General Health Questionnaire-28 (GHQ-28), a self-administered screening 
instrument, was used to measure psychological distress and minor psychiatric disorders. 
The maximum score for an individual is 12. No formal threshold exists for identifying 
probable mental ill health, but based on a cut-off point of 5 and above, the authors 
suggest that 59% (13 out of 22) of the group had some kind of mental health problem. The 
average GHQ score for the Thalidomide survivors was 7.36 (SD 5.34) which was 
significantly higher than the ‘healthy’ subjects group (2.76; SD2.31; P 0.01). Imai et al 
(2104) also found that participants who were single or divorced had higher depression 
scores, and higher scores for impaired social activity than married participants. However, 
the study does not comment on how this compares to the ‘healthy’ subjects. MINI, a short 
structured psychiatric diagnostic interview instrument, was used to make diagnoses of 
psychiatric disorders. The study found that 40.9% of participants had one or more 
psychiatric disorders. The author states that “This is a percentage that it comparatively 
high” but no comparison with the general population in Japan is made.  
Niecke et al (2017) examined the nature and prevalence of mental disorders (according to 
the International Classification of Diseases) amongst 193 Thalidomide survivors 
participating in the wider study reported by Peters et al (2015). To do this they used a 
structured clinical interview for DSM-IV disorders (SCID-I and SCID-II). Their results 
showed that: 
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 Ninety-one participants (47.7%) had at least one mental disorder in the four weeks 
preceding the examination, compared to a 12 month prevalence in the German 
general population aged 50 to 64 of 27.1% 
 Male Thalidomide survivors were more likely to experience mental disorder (based on 
4-week and lifetime prevalence) than their female peers, which is in contrast to the 
general German population where 12 month prevalence is higher for women by a 
factor of 1.5 
 Unipolar depression was the most common mental health diagnosis and it affected 
men and women equally. The lifetime prevalence of 33.2% was much higher than the 
general population of a similar age (18% lifetime prevalence). The prevalence for 
Thalidomide survivors rose to 39.4% when dysthymic or persistent depressive disorder 
and minor depressive syndromes were included 
The full report from this study (Peters et al 2015) also reported that: 
 For the two most frequently diagnosed disorders (depressive and somatoform14), 
prevalence was higher amongst participants with no Dysmelia compared to the two 
groups with Dysmelia – for depressive disorders 38.1% compared to just over 22% for 
the double and quadruple damage groups, and for somatoform disorders 23.8% 
compared to 17.5% and 16.7% respectively. However, it is important to note that 
almost two thirds of the no Dysmelia group were deaf or had a severe hearing 
impairment and many also had facial damage 
 Of those participants with a mental disorder, 51.1% had two or more disorders 
compared to 44.4% for the general German population 
Interestingly, Nieke et al (2017) found a high degree of mental comorbidity amongst the 
Thalidomide survivors in their study but a low use of “psychosocial treatment services”. 
They identified 73 participants who were in need of immediate mental health treatment 
and yet by contrast, just 32 participants (16.6%) had accessed some form of professional 
help in the preceding 12 months. Finally the authors speculate that the high prevalence of 
mental disorders in Thalidomide survivors: “may be explained by biological factors (i.e. 
neurotoxicity) as well as by psychological factors (i.e. stress arising from restrictions of 
physical function and restricted social participation), social mortification and the specific 
historic context (i.e. stigmatization, ‘thalidomide scandal’)” (p173). 
                                               
14 The somatoform disorders are a group of psychological disorders in which a patient experiences 
physical symptoms that are inconsistent with or cannot be fully explained by any underlying general 
medical or neurologic condition. 
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In their survey of 870 German Thalidomide survivors, Kruse et al (2013) looked 
specifically at the prevalence of depressive disorders. In the publicly available report, the 
methods used to do this are not described in detail but the authors appear to have used 
the Major Depression Inventory (MDI), a self-report mood questionnaire developed by the 
World Health Organisation15. They estimate that 11.7% of their survey respondents were 
suffering from a depressive disorder, compared to 8.1% of the general German population 
aged 50 to 65. Like Peters et al (2015) they also found that in contrast to the general 
population, there was no substantial difference in prevalence between male and female 
Thalidomide survivors. They did however, identify a number of factors that appeared to 
increase the risk of Thalidomide survivors experiencing depression. These included: 
 A poor social network – those respondents who said that they did not have anyone to 
help them when they were in difficulties were more likely to have experienced 
depression  
 Unemployment – participants who were unemployed were three times more likely to 
report symptoms of depression than those in full time work (12.9% compared to 3.7%) 
 Recent experience of severe pain – 18.4% of participants who reported ‘severe to 
extremely severe pain in the last 2 weeks’ reported symptoms of depression 
 The need for long term care and assistance – those participants who required on-
going care were almost twice as likely to report symptoms of depression than those 
who did not, and the proportion was even higher for those who said they did not have 
adequate insurance to cover their needs  
 The severity or extent of Thalidomide-impairments – the more areas of ‘Thalidomide-
induced damage’ (i.e. the number of limbs affected; sensory impairments; internal 
organs damaged etc.) participants had, the higher the risk of them developing 
symptoms of depression. The authors also suggest that depression is more common, 
and/or more severe, amongst deaf Thalidomide survivors but the data presented is 
unclear  
Kowalski et al (2015) found that 52% of their participants aged 18 or over had some kind 
of “chronic psychological disturbance” which compares to 25-30% in the adult population 
in Brazil. Anxiety and depression were the most commonly reported problems (26% and 
17% respectively). However, the authors note that participants also reported sporadic 
episodes of anxiety and depression, which are not included in their analysis.  
                                               
15 The MDI is able to generate an ICD-10 or DSM-IV diagnosis of clinical depression in addition to 
an estimate of symptom severity. 
128 
 
In addition to the three studies described above, the TVAC survey (Vermette and 
Benegabi 2013) asked Thalidomide survivors about the ‘recurrent or persistent health 
problems’ they had experienced in the past five years, and 23% (15 out of 65 
respondents) said that they had had depression. No further analysis appears to have 
been undertaken and the authors do not provide any information about the prevalence of 
other mental health problems. In Hinoshita et al (2019) 9.8% of respondents reported 
having ‘depression and/or other mental disease’. 
Two studies explored mental wellbeing using qualitative approaches. In their 2002 mixed 
methods study of the quality of life of UK Thalidomide survivors, Kennelly et al state that - 
“A number of participants have become more aware of the mental health effects of their 
physical impairments, reporting increasing experiences of depression…” (p34). They 
found that one in ten participants had consulted either a psychologist or counsellor at least 
once in the last five years and “a number” of participants reported being depressed or 
having experienced periods of depression. However, in response to the survey question – 
‘What medical conditions or health problems do you have now that you didn’t have or 
weren’t aware of 5 or 10 years ago?’ just 7 participants (3%) reported having 
‘depression/mental health problems’. A further 5 (2%) reported depression when asked 
‘Do you have any other health problems not already mentioned, including any long 
standing problems?’. 
As part of the evaluation of the Health Grant to UK Thalidomide survivors (Newbronner et 
al 2012), 49 Thalidomide survivors were asked, through telephone interviews, about their 
current or recent health problems, including their mental wellbeing. A minority of the group 
reported experiencing depression or anxiety but many more described feeling ‘down’ or 
experiencing a decline in their emotional wellbeing in recent years. They often linked this 
to physical problems related to their Thalidomide impairments, such as pain or loss of 
function. 
4.8.7 Health-related quality of life/quality of life 
Although several studies included in this review make general reference to ‘quality of life’ 
or ‘health and quality of life’, in fact just six studies actually assessed quality of life or 
health-related quality of life using standardised instruments. Only these studies are 
considered in this section. The first study (Nippert et al 2002) looked specifically at the 
health-related quality of life of female Thalidomide survivors in North Rhine Westphalia, 
Germany, and compared them to a control group matched for age (mean age 38), gender 
and area of residence. The study used the WHO QOL-BREF, a self-completion instrument 
designed to assess quality of life in health and health care. It has 26 items grouped in to 
four domains (physical health, psychological wellbeing, social relationships and 
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environment), and produces a global quality of life score, with 100 being the highest 
possible score. The WHO QOL-BREF was incorporated in to a larger postal 
questionnaire, which included questions about socio-economic status, personal 
circumstances and, for the Thalidomide survivors only, their Thalidomide impairments. 
The survey was sent to all the female Thalidomide survivors know to the Contergan 
interest group in North Rhine Westphalia, and 104 (63%) returned completed 
questionnaires.  
The study found that quality of life in health and health care was significantly poorer for 
women Thalidomide survivors than women of the same age from the general population. 
They had significantly lower global WHO QOL scores (63.0) and physical health scores 
(67.9) than the control group (global score 70.7 and physical health score 77.8). However, 
they had slightly higher psychological scores compared to the control group (71.7 vs. 
68.5), and were more likely to be satisfied with four important areas of their lives: safety in 
daily life; their physical environment; their living conditions; and the support they get from 
their friends. 
Bent et al (2007) gathered data on the quality of life of 41 Thalidomide survivors via a 
postal questionnaire, which used a mix of instruments to explore health status and quality 
of life. Overall health status was measured using the EuroQoL (EQ5D), and subjective 
quality of life was assessed by the General Well-Being Index (GWBI). The authors also 
used five of the eight components from the SF36 Health-Related Quality of Life survey – 
Physical Function, Role Limitation Physical, Pain, Vitality and Role Limitation Emotional. 
However, they report these individually rather than as overall scores for physical or mental 
health domains. All the results (except Physical Function) are presented as median rather 
than mean scores and so no comparison with the findings from other more recent studies 
is possible. 
The authors state that: “the median EuroQol score of 0.59 suggests poor health status but 
despite this…59% reported their health to be good and 70% reported their QoL was good 
or better than good” (p154). The results of all instruments used are tabulated in the paper, 
and show that the mean GWBI score was 80, but there is no explanation of this score or 
its implications in the discussion. In relation to the SF36 Physical Function scale, 
participants in this study had a mean score of 69.7, which the authors suggest is “well 
below the population norms for this age” (p154), but no comparative data is presented. 
They go on to suggest that despite a significant relationship between SF36 Physical 
Function score and severity of impairment (based the Trust’s impairment bands) there are 
‘outliers’ or individuals that have poorer physical health-related quality of life than 
expected for their impairment band. 
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The study evaluating the Health Grant made to UK Thalidomide survivors (Newbronner et 
al 2012), used the SF12 survey (a 12 question form of SF36) to examine the health-
related quality of life of 49 Thalidomide survivors. Overall the study found that in the 
physical domain the Thalidomide survivors had lower average aggregate scores than 
people of a similar age (45-54) in the general population, indicating that their physical 
health-related quality of life is significantly poorer than their peers. Furthermore, 70% of 
the Thalidomide survivors had a physical domain score of below 30 i.e. the same or worse 
than the 2% of the general population with the poorest physical health-related quality of 
life. Only two Thalidomide survivors had a score above the average for the general 
population. In the mental health domain, the Thalidomide survivors’ average aggregate 
scores were only marginally worse than the general population of a similar age. However, 
a small group of Thalidomide survivors (n=7/14%) had a score below 30 i.e. the same or 
worse than the 2% of the general population with the poorest mental health-related quality 
of life.  
A slightly later study (Newbronner 2015), also conducted for the Thalidomide Trust, 
focused on employment and health-related quality of life. It used SF12 as part of a larger 
survey exploring changes in employment. SF12 data was available for 234 respondents 
and the results were broadly similar to those reported by Newbronner et al in 2012. It also 
found that in the physical domain the Thalidomide survivors had lower average aggregate 
scores than people of a similar age (45-54) in the general population (23.7 compared to 
50), indicating that their physical health-related quality of life is significantly poorer than 
their peers. Furthermore, 68.4% of the Thalidomide survivors had a physical domain score 
of below 30 i.e. the same or worse than the 2% of the general population with the poorest 
physical health-related quality of life. Fifteen Thalidomide survivors had a score above the 
average for the general population. In the mental health domain, the Thalidomide 
survivors’ average aggregate scores were only marginally worse than the general 
population of a similar age (43.2 compared to 50). However, a small group of Thalidomide 
survivors (n=38/16%) had a score below 30 i.e. the same or worse than the 2% of the 
general population with the poorest mental health-related quality of life. Detailed results 
for this study and Newbronner et al (2012) are shown in Table 9. 
In 2013, Dr Mark Chorlton conducted a small, unpublished16 study of the health-related 
quality of life of 15 Thalidomide survivors from Australia and New Zealand using SF36. 
Again, detailed results are shown in Table 9. Although the number of participants was 
small, and other than gender (8 women and 7 men) there is no information about the 
                                               
16 The short report from this study was given to me by Mark Chorlton following personal 
correspondence. 
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representativeness of the group, it does provide useful comparative data. Like their 
contemporaries in the UK, Australian and New Zealand Thalidomide survivors had 
significantly lower physical health-related quality of life than Australians in the general 
population of a similar age (55-64). However, their mental health-related quality of life was 
much closer to the general population. Further statistical analysis showed that these 
differences were statistically significant. 
The Swedish researchers who undertook the orthopaedic studies described in section 
4.8.1 also examined the health-related quality of life of their 31 study participants 
(Ghassemi Jahani et al 2016b). They used four validated questionnaires. Function of the 
limbs was evaluated using DASH (Disorder in Arm Shoulder and Hand) and RAOS 
(Rheumatoid Arthritis Outcome Score). Health-related quality of life was measured using 
SF-36 and EQ5D. Comparisons were made with the general population in the same age 
group and they examined differences between four sub-groups: those with and without 
‘major malformations of the extremities’ and those with and without PFFD17 (proximal focal 
femoral deficiency). They found that the physical health-related quality of life of 
Thalidomide survivors was significantly lower than the national reference population but 
mental health-related quality of life was similar (SF-36 mean physical composite score 
was 40.6, 95% CI 35.4-45.8 / MH composite score was 51.5, 95% CI 47.1-56.0). Poorer 
physical health-related quality of life correlated with severity of limb malformations, and 
participants with PFFD had lowest scores. 
For EQ5D all dimensions involving physical activities revealed a lower level of health-
related quality of life for Thalidomide survivors compared to general population, while the 
mental aspect (anxiety/depression) was unaffected i.e. similar to the results found for the 
SF-36. The authors speculate that mental health-related quality of life may not be affected 
by TE either because “children who are born with congenital malformations do not know 
anything but the situation they have and have therefore adapted to it” (p12). However, 
they also acknowledge that it could be in part because Thalidomide survivors in Sweden 
receive a good level of financial compensation and/or because the sample was 
unrepresentative, i.e. those who volunteered for the study had better mental health-related 
quality of life. Although this is a good quality study, the data presented is quite old. The 
authors do not state when the questionnaires were administered but the mean age of the 
participants was 46 suggesting that the data was gathered around 2007 i.e. ten years 
before publication. The literature described earlier in this chapter suggests that there has 
                                               
17 There are different grades of PFFD ranging from a slightly shorter femur to the complete 
absence of the femur and associated deformity of the hip. 
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been a marked change in the health and possibly health-related quality of life of 
Thalidomide survivors as they reached their mid-50s.  
The final study in this group (Peters et al) also used SF36 and as Table 9 shows, their 
results are very similar to the other three studies which used SF36/SF12. The physical 
health-related quality of life score for the 186 German Thalidomide survivors who 
complete the survey was significantly lower (p = .000) than the German population in the 
same age group – 29.6 compared to 49.2. Their mental health sum score was also 
significantly lower (p = .014) but the difference was much less marked – 47.8 compared to 
50.2. Peters also examined the SF36 results for their three sub-groups – no Dysmelia, 
dual limb damage and quadruple limb damage. For all three sub-groups, physical health-
related quality of life was significantly worse than the general population. However, whilst 
the mental health-related quality of life of participants without Dysmelia and with dual limb 
damage was also worse than the general population, the group with quadruple limb 
damage showed no significant difference. However, the authors note that statistical 
significance could be affected by the small number in the group (n=20). 
Table 9 Comparison of SF36/SF12 results from the five health related quality of life 
studies 
 
Component 
Study 
Newbronner 
et al 2012 
(n=49) 
Chorlton M 
2013 (n=15) 
Peter et al  
2015 
(n=186) 
Newbronner  
et al 2015 
(n=234) 
Ghassemi 
Jahani et al 
2016 (n=31) 
Physical: 
Overall Score 
24.6 30.52 29.6 23.7 40.6 
Physical 
Function 
19 40.56 50 15.40 65.3 
Role Limitation 
Physical 
33.5 12.50 38 33.90 54.6 
Pain 28.6 35.97 39 31.20 59.2 
General health 33.4 33.00 42 31.80 60.9 
      
Mental Health:  
Overall Score 
43.8 49.72 47.8 43.20 51.5 
Vitality 41 42.22 46 38.00 59.2 
Role Limitation 
Emotional 
41.3 44.44 64 41.00 80.2 
Social 
Function 
29.5 44.44 63 29.9 90.2 
Mental Health 36.9 67.78 64 36.20 29.5 
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The sum scores for physical and mental health quality of life are similar for all five studies. 
Looking across the studies at the individual component scores, there are some marked 
differences. Role Limitation Physical is markedly lower in the Australian study, and in the 
UK studies Physical Function is much lower than the other studies. However, comparing 
the studies is difficult because data collection methods varied, there are significant 
differences in the number of participants, and the findings from the smaller studies may be 
less robust.  
4.9 Intermediate Coding and Conclusions 
The descriptive analysis of the literature was inevitably quite ‘factual’, as many (but not all) 
of the studies contained little contextual information. At first I found it quite difficult to 
conceptualise how the ‘intermediate codes’ might move beyond this towards synthesis. I 
looked at examples of initial coding from a number of other grounded theory studies (see 
Sbaraini et al 2011), and whilst the majority of these were coding qualitative data, it was 
helpful in clarifying my thinking. I decided to group my intermediate codes alongside the 
themes from the descriptive analysis, so that the ‘link’ with the data from the primary 
studies was maintained. I present this in tabular form below. My aim in doing this was to 
facilitate the integration of the findings from the literature review, with those emerging from 
the analysis of my other primary data, notably the semi-structured interviews and the 
health and wellbeing survey.  
Table 10 Intermediate codes from the literature review 
Thematic 
Analysis Heading 
Intermediate Coding 
Musculoskeletal 
Problems 
 Musculoskeletal problems are the most common health issue 
amongst Thalidomide survivors as they age 
 The prevalence and severity of musculoskeletal problems 
appears to increase with the severity of Thalidomide survivors 
impairments but this relationship is not simple or linear 
 Secondary damage to joints and muscles is primarily caused by 
‘overuse’ and postural adaptations 
 The pain and movement restriction caused by secondary damage 
is compounding existing impairments 
Pain and 
Neuropathic 
Symptoms 
 Neuropathic pain and symptoms are more common amongst 
Thalidomide survivors (including those with no Dysmelia) than the 
general population 
 The causes of neuropathic pain and symptoms are disputed and 
often unclear 
 Thalidomide survivors are more vulnerable to compressive 
neuropathies but these are hard to diagnose and treat 
Dental 
Problems/Facial 
Damage 
 Thalidomide survivors have higher levels of decayed, missing and 
filled teeth, and tooth wear than the general population 
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Thematic 
Analysis Heading 
Intermediate Coding 
 The causes of poorer dental health are multiple, including 
difficulties with dental hygiene, using teeth as tools and 
regurgitation 
 The dental and facial health of Thalidomide survivors is vulnerable 
Deteriorating 
Sight and/or 
Hearing 
 Thalidomide survivors are reporting deteriorating sight and 
hearing  
 It is unclear whether this deteriorating in sight and hearing is 
Thalidomide related or due to general aging 
 There is very little evidence about the extent and nature of 
deteriorating sight and hearing, and the impact on Thalidomiders 
quality of life 
General Health   It is difficult to accurately measure blood pressure and body mass 
index when people have missing or short limbs and this can make 
affective treatment/prevention difficult 
 Some Thalidomide survivors are aware that they are at risk of 
lifestyle related diseases but find their Thalidomide impairment 
make it difficult manage their weight or exercise 
 Hypertension may be more common amongst Thalidomide 
survivors but more evidence is needed 
Mental Health  Mental health problems are significantly more prevalent amongst 
Thalidomide survivors than the general population 
 Depressive disorders are the most frequently diagnosed or 
reported mental health problem,  
 The relationship between mental health and severity of 
impairment is unclear but Thalidomide survivors with severe 
hearing impairment and facial damage appeared to be at greater 
risk of developing depression 
 The consequences of physical impairment (i.e. stress of daily 
functioning, restricted social participation and stigmatization),  
appear to be contributing to poor mental health  
 Other risk factors for poor mental health are similar to the general 
population and include poor social networks; living alone; 
unemployment; the need for on-going assistance; and recent 
experience of pain 
Health-related 
Quality of Life 
 Thalidomide survivors have a much poorer physical health-related 
quality of life that their peers in the general population 
 The mental health-related quality of life of Thalidomide survivors 
is also lower than the general population of a similar age but the 
difference is less marked 
 Poor physical health-related quality of life is clearly related to 
severity of impairment but mental health-related quality of life is 
not 
 The mean scores for both physical and mental related quality of 
life mask ‘outliers’ i.e. people with very poor quality of life 
 
In developing the codes I have tried to ‘get underneath’ the descriptive analysis and draw 
out what the literature tells us not only about the health problems of Thalidomide survivors 
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but how these differ from people in the general population at similar points in their lives, 
and the implications they have for quality of life. I also wanted to reflect on what the 
causes of these health problems might be and how they might relate to or interact with 
original Thalidomide damage. Importantly, intermediate coding provided a means to 
identify and cluster concepts that spanned a number of studies. 
4.10 Summary 
I began this chapter by explaining the rationale for undertaking a scoping review. I then 
described the literature searches, screening, study selection and results. After the 
numerical summary of included studies shown in Table 9, I present the descriptive 
thematic analysis, in which I drew on Grounded Theory methods. Table 10 links the 
themes from the descriptive analysis to the GT intermediate codes. 
The review has shown that the literature about the health and quality of life of Thalidomide 
survivors as they grow older comes from just eight countries. It is limited in scope and 
disparate in nature. As the descriptive analysis highlights, most of the quantitative 
biomedical studies, perhaps by their nature, tend to address quite narrow clinical topics. 
The focus is mostly on diagnosing and examining the clinical problem being experienced, 
although some studies do make comparisons with prevalence in the general population 
and occasionally with other groups with early on-set disability. However, there is relatively 
little discussion of the functional and practical implications of these problems for 
Thalidomide survivors’ daily lives, and none of these studies discuss early onset health 
problems in the context of the life course. 
A small number of studies looked more broadly at the health and quality of life of 
Thalidomide survivors. This group of studies mostly use mixed methods, and some 
include clinical assessments. They all, in some way, discuss the implications of early 
onset health problems for Thalidomide survivors quality of life and future health and 
functioning, and a number reflect the experiences of Thalidomide survivors themselves, 
through quotations and case studies. However, because of the different topics covered, 
the range of methods adopted, and the different measures of quality of life and/or health-
related quality of life used, they do not provide a coherent body of evidence. Furthermore, 
none of them discuss theoretical perspectives in relation to disability and ageing.  
In the subsequent chapters of this thesis I aim to address this ‘gap’ in the knowledge 
base. In the next chapter, I begin by exploring the type and range of health problems UK 
Thalidomide survivors are experiencing. 
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Chapter 5 Changing Health: Content Analysis of 
the Interviews 
This short chapter brings together the findings from the content analysis of the semi-
structured telephone interviews. In doing so sets the scene for the health and wellbeing 
survey reported in Chapter 6 and the secondary grounded theory analysis of the 
interviews (Chapter 7). As I explain in Chapter 3, the main purpose of the content analysis 
was to inform the development of the Health and Wellbeing survey, although I also used it 
to prepare a short report for the Trust as part of the Health Grant Monitoring. To address 
this aim, I began the analysis with an initial interpretive phase which enabled me to 
identify the main health problems participants were experiencing, and begin to 
understand: the language people used to describe their health problems; how they linked 
different problems; and any connections they made to their original Thalidomide damage. 
To gauge the relative importance or ‘prevalence’ of these health problems, I counted the 
number of participants who reported experiencing different health problems. The findings 
from my literature review helped me think about how to group them but I was primarily 
guided by the data. 
I begin this chapter by describing the type and range of health problems discussed in the 
interviews. I then present a simple ‘count’ of the number of participants who discussed 
them and the number of times they were referred to. In 5.2 I go on to discuss three 
overarching findings to emerge from the interpretive phase of the content analysis, which 
were important for the design of the survey. The first relates to language, the second to 
the connection between health problems and treatments, and the third to perceived 
causes. Throughout the chapter I use quotations from participants to illustrate or bring to 
life the points being made. The names shown are pseudonyms.  
Before moving to the substance of the chapter it is perhaps helpful to reintroduce the 
interview participants. Of the 38 interviewees, 26 were women and 12 were men. As I 
note in Chapter 3, I did not collect data about age, as the overwhelming majority of UK 
Thalidomide survivors were born between 1959 and 1962 (i.e. aged 52 to 55 at the time of 
the interviews). The interview group came from across the UK and included Thalidomide 
survivors in all five impairment bands, although those with more severe impairments were 
slightly over-represented. At the time of the interviews, 26 participants were not working, 
10 were working part-time and two were working full-time. Of those who were not working, 
sixteen said they were unable to work because of their health problems/disability, eight 
had given up work for a combination of health and personal reasons (e.g. family 
commitments, lifestyle), and two said they had decided not to work entirely for personal 
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seasons. In the group working part-time, half said they no longer felt able to work full time 
because of their health problems/disability, and half said they had reduced their working 
hours for a mix of health and personal reasons. In terms of home circumstances, seven 
lived alone, 26 lived with their partner (or their partner and children), and five lived with 
their children.  Appendix 13 lists the interview participants’ characteristics and their 
pseudonyms. 
5.1 Type and Range of Health Problems 
Initially, I had eight main themes or groups of health problems with just one for 
musculoskeletal (MSK) problems. However, it soon became apparent that the coding of 
these types of problems needed to be more fine-grained if I was to establish a sufficiently 
detailed picture of this group of problems. I therefore decided to cluster MSK problems by 
the areas of the body affected. There were three main reasons for this. First, because so 
many of the participants were reporting MSK problems, having all the references under 
one heading became unwieldy. By splitting them into several themes the data became 
more manageable. Secondly, MSK problems appeared to be in part related to the nature 
and severity of participants’ limb difference, and this was potentially an important 
connection to be explored further in the Health and Wellbeing survey. Thirdly, the Trust 
was in the process of establishing a network of orthopaedic specialists who could 
diagnose and treat Thalidomide survivors, and so it was helpful for them to know what 
participants said about MSK problems in different areas of the body. I eventually settled 
on four main themes for MSK problems and a separate theme of ‘pain’. Although pain was 
often closely associated with MSK problems, the interviews suggested that some 
Thalidomide survivors experience more generalised pain, which may not have a clear 
cause.  
The table below shows all the eleven descriptive themes that emerged, the number of 
people who discussed them and the number of times they were referred to. There is some 
overlap between the themes, especially between ‘MSK problems – joints’ and the other 
MSK themes, and between MSK themes and ‘Pain’ as often people described a range of 
problems and the pain they were experiencing as a result of them, together, in one 
segment of the interview. 
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Table 11 Health problems/themes identified in the content analysis 
Health Problem/Theme 
Number of 
Participants 
Number of 
References 
MSK problems – Joints 28 40 
MSK problems - Shoulders, arms and hands 16 21 
MSK problems - Hips, knees and feet 14 20 
MSK problems - Back and neck 11 15 
Pain  14 20 
Neuropathy symptoms 14 15 
Mental and emotional health 11 16 
Long term conditions/other health problems 9 13 
Weight management 9 11 
Sight and hearing problems 7 10 
Dental health 5 9 
 
Table 11 provides a useful overview but it is also important to understand what is 
encompassed by each of the themes. By this I mean both descriptively, in terms of the 
types of the health problems included and how participants themselves described them, 
but also experientially i.e. how participants perceived and made sense of their health 
problems. Delineating these themes was very helpful for the Trust and for the 
development of the survey but in some ways the neatness of them belies the 
interconnected nature of the health problems people were experiencing. Not only did 
people talk about more than one problem in the same segment of the interview, there was 
often a physical connection between them e.g. MSK problems were frequently 
accompanied by pain; pain and loss function led to depression or low mood; and loss of 
function and depression sometime contributed to reduced activity and weight gain. Below I 
describe the eleven themes in more depth and use quotations to illustrate these two 
dimensions.  
5.1.1 Musculoskeletal problems  
Many Thalidomide survivors were born with deformed, misaligned or dislocated hip, 
shoulder and knee joints, and so it was not surprising the ‘MSK problems – joints’ 
emerged as a theme. People ‘grouped’ their MSK problems in different ways. These 
groupings appeared to be related to either the parts of their body where they were 
experiencing pain or loss of movement, and/or their original Thalidomide damage. For 
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example Rowena who has one short arm explained that she gets pain in her shoulder: “It 
is because I’ve got one short arm – my forearm’s shorter on the more affected side. I’m 
always compensating with the arm that’s full length and I think that’s probably why I get a 
lot of these shoulder pains”. The information gained from the interviews helped me think 
about the best way to categorise or group MSK problems in the survey. There were 
eventually ten MSK options included in the multiple choice questions about health 
problems in the survey.  
The problems people were experiencing in their shoulders, arms and hands appeared to 
be strongly related to either overuse of a ‘good’ hand or arm, or progressive deterioration 
in already damaged limbs and digits. These problems seemed to be equally significant for 
participants with mild and more severe upper limb damage. The quotation below is from a 
Thalidomide survivor with less severe impairments: 
 “About 10 years ago, my hand just seized up…the biggest deformity is in my right 
hand but actually now, I suffer most – because I put so much pressure on my left 
hand, not realising that that was also deformed, and that’s where I get the most 
pain…I thought it was just a strained ligament or something and I left it for several 
months.  Actually then it didn’t go away, so I went to the doctor, he sent me for an 
X-ray and I was called in when it showed all the deterioration”. Jenny 
However, some participants who had no upper limb damage also reported problems with 
their shoulders or arms. One person who covered several miles a day in a manual 
wheelchair explained – “I’ve carpal tunnel – not last year the year before – from the 
wheelchair because I’m very active”. Carol 
The pain or loss of function people were experiencing in their lower limbs fell into two 
distinct categories. Participants with no arms or very short arms, who used their feet for 
everyday tasks, appeared most likely to report problems with their hips and feet, as the 
quotation below illustrates: 
“Now we’re in our 50s, the rheumatism, arthritis etc. have started to kick in 
because we’re using our legs for things they weren’t designed for…[the pain] is 
worse in my feet because everything you would do with your hands, I do with my 
feet basically.  Over the years what I can do has dwindled”. Fiona 
Those who were lower or four limb affected described different and more varied problems, 
including dealing with the long term consequences of amputations and prosthetic limbs. 
One participant who uses a below the knee prosthetic on his left leg, described the 
problems he was now having in his right leg: 
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“I had a sudden, I suppose you’d call it a malfunction in my right leg.  I got up one 
morning and I couldn’t actually put my foot down…Basically, what it is - my ankle 
is twisted and it’s twisted so that it bends inwards.  So the outer bone through my 
knee and my foot is out of line with my femur and my patella.  That causes the 
problem within the knee joint…but also the bones in my foot are completely flat on 
the ground – I’ve got no arch – so that’s going to cause problems.  They did say 
there’s a possibility of completely reconstructing the bones within it – but I think 
that’s too risky because if that goes wrong, it could bugger me up completely.  I’d 
rather live with what I’ve got at the moment”. Ben 
Carol, the participant who had carpal tunnel syndrome, explained that she had both legs 
amputated below the knee as a child. She talked about the pain and infections she had 
experienced in recent years: 
“I used artificial legs up to 10 years ago and then I had to give them up because 
they were causing me so much pain. Getting infections in my stump ends – 
cellulitis – which was quite bad. I’m now in a wheelchair all the time…Then I had a 
knee infection this year. February, my knee got infected because I was moving 
around on my stump ends and stuff and getting infections and that”. Carol 
Lastly, a participant who is four limb affected explained that compensating for an in-
balance in the length of her legs had led to problems in her ‘good’ leg: 
“I’ve had a couple of bouts - I think one was in the last year – of bursitis in my left 
hip. That is probably caused by my disability because from what I understand 
about bursitis you get it in one joint that’s used more than the other and I have one 
leg longer than the other, so that’s in my longer leg”. Meg 
The final MSK theme was back and neck problems. These were reported by over a 
quarter of the participants but this one theme included a wide range of conditions and 
causes, which were not necessarily related to the severity of peoples’ original impairment. 
One participant, who described herself as “one of the luckier ones”, explained that she 
has one short arm. She has been very active and sporty all her life but feels that constant 
over-bending and overstretching has led to premature wear and tear in her spine: 
“About 10-15 years ago I started having trouble with my back and I went to the 
clinic up in [town], which is where I used to live, and had an X-ray and they said 
my spine was wearing away.  The actual spine was becoming serrated and 
wearing away but at that time, all the discs and everything were OK.  Then about 
2½ years ago I started having trouble walking and pain in my left leg and not being 
able to stand on my foot…They sent me for an MRI scan and they found then that 
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I had a trapped nerve at the 4th and 5th vertebrae and 3rd vertebrae, where the 
discs had totally collapsed and where the actual spine is virtually sitting on bone 
and there are no spongy discs between.  So that is my problem at the moment”. 
Ann 
Several other participants talked about deterioration in their spines, ranging from disc 
problems and arthritis to curvature. Often this ‘structural’ deterioration was accompanied 
by muscular spasms and muscular pain. Upper limb affected participants generally felt 
that their problems were caused by over-using one side of their body and/or using their 
teeth (and hence their neck) for tasks that other people would do with their hand. One 
participant who talked about pain in her neck explained – “I use my neck a lot cos I take 
clothes on and off with my mouth and things like that, so my neck is constantly in use” 
(Tessa). However, some lower limb affected people also had back problems as the 
quotation below illustrates: 
“I have arthritis in the spine and damage to the soft tissue coming from the spine 
and obviously that’s creating a lot more pain and the physiotherapist has 
tentatively suggested that it’s the way I am pushing myself in the wheelchair”. Alan 
Whilst deterioration was a common theme, the interviews also suggested that as people 
aged, previously unknown damage had come to light or joint problems that they had 
coped with all their lives were now causing difficulties: 
“I think it’s the shin bone is completely missing, so I’ve got a slightly twisted leg 
and I know when I saw the surgeon years ago he said the knee wasn’t great and 
probably I would get arthritis in my knee”. Nicola 
“I hurt my left shoulder quite badly.  I couldn’t bear weight on my arm – it was my 
good arm that I do my transferring with – and it took about 8 months to repair.  I 
tore the rotating cuff in my shoulder blade and had some X-rays, and they said my 
shoulder socket wasn’t normal.  I am able to bear weight on it…but I lost the 
strength in it, which is what I need to lift myself”. Alison 
Often participants were experiencing more than one MSK problem, and this was reflected 
in the way they spoke about them. People ‘listed’ several problems and explained or 
speculated on how they felt they were interrelated. The quotation below illustrates this 
point: 
“I’ve got problems in my neck, part of my back and down might right side. I’ve also 
got numbness in my right arm. I’ve got arthritis in my neck due to an injury 
sustained by using my head incorrectly. My teeth are chipping so I’m trying not to 
use them any more [for holding things etc.]. My right side [problem] is due to 
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overuse, standing on my right leg and doing things with my left leg and using my 
feet to do stuff. The left arm….I’m not quite sure what that is. I think it’s coming 
from my neck”. Amanda 
5.1.2 Pain and neuropathic symptoms 
As the quotations above about MSK problems show, many participants were living with 
pain to some degree, and again the connection with people’s original thalidomide damage 
was evident. Most people described chromic pain, which had almost become part of 
everyday life - “it just means sort of a constant nagging pain in my neck that I suppose in 
some ways I’m just used to” (Meg). However, sometimes the pain was related to an acute 
problem. Karen, who has very short arms and relies heavily on her abdominal core 
muscles for movement, developed an acute condition that normally affects young 
sportsmen. The treatment involved several weeks of bed rest and strong painkillers:  
“It started in January and lasted three months – I hate talking about it really! I had 
this horrendous pain in my rib cage and obviously my torso is what I move with, I 
do everything from my stomach. Whatever I do comes from there, the abdomen 
and I couldn’t do anything. I thought what the hell is this? Anyway, I went to the 
doctor and he diagnosed something which is quite rare…It’s something called 
Tietzes and it’s like all you muscles in your rib cage are in spasm”. Karen 
When people talked about the pain they experienced, their descriptions were often 
intertwined with explanations of the dilemmas they felt about the use of pain medication or 
pain treatments. Ann explained her situation in some detail and the extract from her 
interview below vividly illustrates the difficulties they faced: 
“I’ve had a cortisone injection.  I’ve had a nerve epidural…I’m having acupuncture.  
I’m having massage.  I’m on massive painkillers… I’m on an anti-
inflammatory…I’m on high doses of codeine and paracetamol four times a day.  
Then I’ve got this other drug, duloxetine…It’s like a nerve relaxant and also an 
anti-depressant, so I’ve been taking all sorts.  I hate taking pills…After the 
injection, the nerve injection, it seems to do something and after the acupuncture, 
that seems to do something.  So I started to try to reduce the medication to see 
what I could get away with but I’m at the point now where the pain is coming back, 
so I’m having to up it again.  I was at a point where I thought ‘Oh, I can walk, oh, I 
can stand, oh, I can do things’.  I’d cut down on the medication but now I’m having 
to put it back up again…[the injection] only works up to about 6 months.  I had it in 
March, so at some stage it’ll wear off and they won’t give it to you until you’re at 
the point of excruciating pain again”. Ann 
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The interviews also revealed clear interconnections between MSK problems, pain and 
neuropathic symptoms. Furthermore, although people used lay language, their 
descriptions reflected the mixed evidence from existing literature about the causes of 
these symptoms (i.e. compressive neuropathies resulting from Thalidomide survivors’ 
unusual impairments and/or generalised neuropathy due to peripheral nerve damage 
caused by the drug). Either way, within the Thalidomide community there is a perception 
that neuropathic symptoms are a common feature of ageing with Thalidomide damage 
and more than a quarter of the participants spoke about them. Some had received a 
diagnosis and treatment (e.g. to relieve trapped nerves) but others were simply living with 
or trying to manage the symptoms. As I described above, Rowena had shoulder pain, 
probably linked to overuse of her ‘good’ arm. However, she was also experiencing tingling 
in her arms and hands and she speculated on the causes: 
“Of course, you do things you probably shouldn’t do.  You should wait to get help 
but you carry on and I really notice it, more than I would have done, and the 
tingling’s always there – in my fingers, my arms, my hands…I think a lot of the 
tingling is from trapped nerves and things like that and they [physiotherapist] could 
never release them, like they could in somebody else.  But that probably suggests 
that there’s a degenerative thing going on as well”. Rowena 
Tingling or ‘pins and needles’ appeared to be most commonly reported in peoples’ upper 
limbs but some participants experienced strange sensations, including numbness and 
extreme heat or cold, in their lower limbs. Jo described what happened to her – “I got up 
one morning and the front of my left leg was numb and I’ve never experienced it before”, 
whilst Gwen also suggested possible causes for what was happening to her: 
“I have pins and needles all the time in my feet. My feet burn. They feel like they’re 
really hot and again it’s all to do with just the way things are worn out really and it’s 
probably nerve damage and stuff just from the way I’ve used them”. Gwen 
5.1.3 Sight, hearing and other physical health problems 
Gwen’s situation starkly illustrates how many Thalidomide survivors are coping with 
multiple impairments and health problems. She has no arms and uses her feet for 
everyday tasks. Alongside the neuropathy symptoms described above, she has 
spondylosis (wear and tear of the spinal column) and arthritis in her hips. However, the 
most dramatic change in recent years was the decision to have her eyes removed. She 
had lost her sight some years ago but because her eyes had not formed properly she had 
repeated cysts and infections in them which made her feel very ill. Having her eyes 
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removed made her feel better physically but it brought with it practical and emotional 
issues. She explained:  
 “I now have two artificial eyes.  It’s made me have to depend on....because I have 
no arms, I can’t clean the eyes and I have to get my PA to do that, so for me that’s 
the first thing I’ve got that I can’t actually deal with [myself]… For me, it was 
something I never wanted to have to do. One of my eyes never formed properly 
and never worked, and it was always on the cards that it would have to come out.  
It was something I always held out against because I didn’t want to. I actually 
believed for quite a long time about them being the window to your soul.  It was 
quite an emotional thing and even though I couldn’t see, I wondered if it was going 
to plunge me into a different blackness to what I already had.  It was a very difficult 
period of time”. Gwen 
Other participants reported changes to their vision or hearing that are associated with 
‘normal’ ageing but might be complicated by their Thalidomide damage. Jenny who only 
had damage to her hands described the changes in her sight – “Up to my 40th, I had 
20:20 vision and then my short-sightedness started to deteriorate quite rapidly… it takes 
rather an adjustment”. Her optician was so concerned about how quickly her sight was 
deteriorating, (especially as there was no family history), that she sent her for further tests. 
When these came back negative she speculated on whether there might be a link to 
Thalidomide.  
With hearing impairment there is a known, and sometimes very obvious connection to 
Thalidomide damage. Around a third of UK Thalidomide survivors have damage to their 
inner and/or outer ear and many of this group are deaf or severely hearing impaired. 
However, the interviews suggest that some Thalidomide survivors have more minor 
damage which can exacerbate the normal decline in hearing associated with ageing: 
“I have narrow ear canals and I suffer with having my ears cleaned… But I know 
that’s probably part of my disability as well…You know when somebody’s 
speaking, I have to make sure I’m looking at them so I can see what they’re 
saying, as well as hearing”. Tessa  
Just five participants spoke about dental health but their descriptions of the problems they 
were experiencing were consistent with the research evidence about the higher rate of 
decayed, missing or filled teeth amongst Thalidomide survivors. For some it had led to the 
need for major dental work: 
“I’ve been under treatment at the Dental Hospital for the last four years and that’s 
coming to a climax again because I’m having implants because my teeth are worn 
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out. I’m not even thinking about that as my health but that it absolutely related to 
my disability. I use my teeth for picking things up and all sorts. It’s another hand, 
another gripping thing. I’ve got 5 dental implants…[its] not so much wearing down 
as fallen out. Because also I’ve had problems with my gums which is related to 
how well I can and can’t clean my teeth”. Martin 
Like many people in their 50’s, several participants reported struggling to manage their 
weight, although some noted that this was a long standing issue for them, in part related 
to the nature of their impairments and the associated barriers to maintaining a healthy 
lifestyle: 
“I think it’s like weight loss is something that I’ve struggled with since I was 9 and 
it’s been a massive realisation that I can’t eat the same calories as my peers 
because I don’t move as much and my body is not as big”. Meg 
A number of people felt that weight gain was making their MSK problems more difficult to 
cope with, reducing their flexibility/mobility and linked to this, contributing to increased 
levels of pain. A few had specific health problems, which were exacerbated by being 
overweight. Gwen, who as we saw earlier is already dealing with a number of health 
problems explained: 
“I have a battle like quite a lot of us do with the weight…Also I’ve got high blood 
pressure so to put on the weight is quite an important issue and obviously 
because, taking blood pressure on me, you can’t get an accurate reading, that 
makes life a little bit hard”. Gwen 
Amongst those participants with long term conditions such as high blood pressure and 
diabetes, a common theme was the complication of managing these conditions with a 
physical impairment. The quotation from Gwen (above) illustrates this. 
5.1.4 Mental health problems 
I have left mental health to the end of this section, not because it is any less important 
than physical health, but rather because the physical health problems people were 
experiencing, were in many instances directly contributing to poor mental health. My 
literature review suggested that common mental health problems, such as depression and 
anxiety, are significantly more prevalent amongst Thalidomide survivors than in the 
general population, with some studies estimating that around half of all Thalidomide 
survivors have experienced mental health difficulties. In relation to mental health, the 
interview participants in my study may not be fully representative of the UK Thalidomide 
community, as those Thalidomide survivors with mental health problems may be less 
likely to volunteer to take part in research. Nevertheless around a quarter of the 
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participants described periods of low mood, depression and anxiety. Importantly, a 
number discussed what they perceived might have led to these problems. Their 
reflections shed light on how Thalidomide survivors themselves made sense of these 
difficulties. 
Some participants felt that their mental health problems were linked to the experience of 
living with disability and particularly rare impairments. They described a sense of being 
‘different’ and the effort it had taken to ‘fit in’. However, loss of function was at the heart of 
many participants’ emotional and mental health problems. Often this loss was progressive 
but sometimes is was related to an injury. Nevertheless the impact was similar, as the two 
extracts below illustrate: 
“It makes me cross. I’m more irritable than I was. I become frustrated, so yes. I 
mean it does affect you psychologically. You know I find myself being more 
irritable. I always think of myself as being of a sunny disposition but I’ve become a 
miserable git! It’s like everything’s going swimmingly well and everything in the 
garden is rosy and then suddenly it turns and you think fuck! It’s like it completely 
takes your day away because there’s something you can’t do. Especially if it’s 
something you used to be able to do that you can’t do. That kind of really does 
frustrate me”. Martin 
“I broke my arm a few years ago and it was my right arm which I do everything 
with, so I was completely dependent.  I couldn’t do anything because I do most 
things with my right arm, so I was back to using my feet again which I did when I 
was a child, and that was fine, but I was still very dependent on my husband for 
getting me dressed and washed and all sorts of things, and it was really scary that 
something that wouldn’t affect you so much – if you broke one of your arms, you’d 
still manage.  But I couldn’t even feed myself cos I couldn’t use my fork in my other 
arm cos I have no strength or control in that arm.  So it was that really that made 
me feel very low – to be so dependent – and to be told ‘Well, we don’t know how 
your arm was meant to be before you broke it, so we’re not sure how it’s going to 
heal or if you’ll ever get the same use back’…and I’m a really optimistic person, so 
it really shocked me that I was feeling quite so low about it”. Amy 
A few people felt that their mental health problems were linked to life events, such a 
bereavement, that could affect anyone but that perhaps their disability had made their 
mental wellbeing more fragile. Nicola explained that the death of her mother, who had 
been a huge support throughout her life, had precipitated a period of what she described 
as “mental strain” but also said – “I do wonder if that is a bit linked to my disability – 
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feeling less able to cope sometimes than other people – I don’t know”. Other participants 
talked about how financial worries or relationship breakdowns had contributed to their 
problems and several of the women participants noted that the menopause had been a 
complicating factor.  
5.2 Language, Links to Treatments and Perceived Causes 
The content analysis not only enabled me to describe the type and range of health 
problems discussed in the interviews, it also allowed me to identify three overarching 
findings which were important for the design of the survey. The first relates to language, 
the second to the connection between health problems and treatments, and the third to 
perceived causes.  
When participants talked about their health problems, most described them using broad 
‘lay’ terms. However, a few, especially those who had had a diagnosis and/or treatment, 
did use medical terms. The short quotations below illustrate this: 
“I get pains in my fingers and my arms – in my neck, lower back, hip area – I’ve 
got one dislocated hip [and] a dodgy knee. In that respect, in that way, yes – a lot 
of aches and pains basically”. Tessa 
“I got a diagnosis last year, possibly related to thalidomide damage, I have lot of 
pain in my coccyx and I had a MRI scan and the orthopaedic consultant found 
coccydynia” [an unstable coccyx, which causes chronic inflammation]. Simon 
This was an important observation because it had implications for the phrasing of 
questions about health problems used in the survey. So for example in the survey, within 
a multiple choice question about health problems, the theme ‘neuropathy symptoms’ 
translated in to three options – ‘Tingling/pins and needles’; ‘Numbness/loss of feeling’; and 
‘Sensations of extreme heat or cold’. 
The second overarching issue was the connection between health problems and 
treatments or treatment options. For example a few people talked about how a procedure 
or treatment had helped them (e.g. by reducing pain) but often treatments brought both 
benefits and difficulties, as the quotations below show: 
“Things are quite a lot better since I had the hip replacement.  I can feel pain 
gathering in my other leg – I had the hip replacement in my right hip – and I can 
actually feel... I think eventually there’ll be a need for a hip replacement in the left 
leg”. Isobel 
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“My arms - they’re short and they’re deformed and stuff.  But they’re not as short 
as some of the others.  But I was feeling – a lot of arthritis was setting in about 10 
years ago, and it really was getting – it was painful.  Since then, I’ve had about, 
altogether, I think about 8 operations on my arms…It has taken the pain away but 
there’s things now that I can’t do – a lot of things I can’t do now with my arms”. Jim 
Again this influenced the survey, leading me to include both a detailed multiple choice 
question about the health treatments people had had but also a free text box in which 
people could describe treatments not listed or add comments about outcomes and 
experiences.  
Finally the other important overarching finding to emerge from this initial analysis was that 
people perceived three (often interconnected) root causes of their Thalidomide related 
health problems. The first was that some problems were directly linked to peoples’ original 
Thalidomide damage. For example, one participant who has been blind in her left eye 
since birth, explained that her right eye was now deteriorating, due to a cataract. 
However, the eye is small and deformed, and so her Ophthalmologist had advised that it 
was too dangerous to operate. Another had developed breathing difficulties related to her 
original impairments: 
“I’ve got something called bronchiectasis which I developed about 6 years ago 
which is a chronic lung condition, or breathing condition…My breathing capacity is 
pretty small.  It’s 30%, reduced for somebody my age.  The consultant said that it’s 
not asthma or anything like that.  It’s to do with constriction...particularly on the left 
side, my heart is over to the left, and my ribcage, with my disability.... everything’s 
a bit more constricted”. Penny 
The second and perhaps the most common root cause discussed in the interviews was 
what people perceived as premature wear and tear caused by the ways in which they 
have had to use their bodies to compensate for their impairments (often referred to in the 
literature as ‘postural adaptations’). For example, one participant described what he felt 
were the long term consequences of being a foot user: 
“Basically, I don’t have any arms at all so I use my legs to do everything.  So 
therefore the lower back – the hip area and the lower back – cos you’re constantly 
lifting your knees up – up to a table, whatever it is really, some sort of working 
surface.  So that takes its toll over the years maybe, I don’t know”. Alex  
Secondary damage was frequently highlighted in relation to MSK problems but was also 
touched on when people talked about pain and neuropathy symptoms. It was most 
commonly raised by those people with limb difference and to some extent, as many of the 
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quotations in this section show, it is a thread running through peoples’ lived experience of 
their impairments.  
The third root cause was accidents and injuries. Some participants talked about accidents 
and injuries, which they felt had occurred as a result of their impairments e.g. falls linked 
to mobility, balance or sight problems. Beth described how mobility and balance problems 
had contributed to her falling and breaking her arm – “…because of the way I walk (I have 
no knee joint), I sort of swing from side to side.  So I’m conscious now that my balance is 
not the same”. Another, who only has sight in one eye, explained that deterioration in her 
sight had contributed to a series of falls, one of which has resulted in a cracked kneecap – 
“I had three pretty nasty falls, all in the space of about a month. You start to worry don’t 
you? My eye sight had got really bad and I’d gone into varifocals” (Karen).  
5.3 Summary 
This chapter explains that the primary purpose of the content analysis of the semi-
structured telephone interviews was to inform the development of the Health and 
Wellbeing survey. I describe how the initial interpretive phase of the content analysis 
enabled me to identify the main health problems participants were experiencing. By 
counting the number of participants who reported experiencing different health problems, I 
was then able to gauge the relative importance of them. The chapter shows how the 
content analysis began to shed light on the language people used to describe their health 
problems; how they linked different problems; and what they perceived to be the three 
root causes of their Thalidomide related health problems. Whilst it was not possible to 
directly explore these links in the survey, the findings did reinforce the need to gather 
information in the survey about respondents’ original Thalidomide damage, and I describe 
this in the next chapter. They also highlighted the importance of examining these issues in 
more depth in the secondary grounded theory analysis of the interview data, and in 
particular, exploring the relationship between these perceived root causes and 
Thalidomide survivors experience of ageing. This is discussed in Chapter 7.  
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Chapter 6 Health and Wellbeing Survey 
This chapter presents the findings from the health and wellbeing survey of UK 
Thalidomide survivors. Wherever possible I discuss the findings in relation to other people 
with early acquired disabilities and/or the general population of a similar age. The survey 
was conducted in 2015, as part of the Health Grant Monitoring project I was undertaking 
for the Thalidomide Trust. However, as I explain in Chapter 3, it also enabled me to 
address the objectives of my doctoral research by generating a huge amount of valuable 
data about the health and wellbeing of Thalidomide survivors, and providing an 
understanding of the prevalence of specific health problems. Importantly, the high 
response rate and the representativeness of the respondents, in term of gender and level 
of impairment, mean that the results can be treated with a high degree of confidence. 
The chapter begins by examining how representative the survey respondents are of the 
whole population of UK Thalidomide survivors, in terms of the severity and nature of their 
Thalidomide impairments, and their country of residence. I then describe their socio-
economic circumstances in some detail, including living circumstances, educational 
qualifications and work situation. I have purposefully presented the information in these 
two sections at the start of the chapter, as it contextualises and informs the analysis 
presented later in the chapter. These sections are followed by a detailed examination of 
respondents self-reported health problems, and their self-reported use of health and social 
care services. The survey also explored Thalidomide survivors’ health-related quality of 
life, and mental wellbeing. The overall findings in relation to these topics are discussed, 
followed by further analysis of the relationship between quality of life, mental wellbeing 
and the characteristics of respondents. This is followed by a brief discussion of ‘concerns 
for the future’ that respondents highlighted in a final narrative question at the end of the 
survey. I have presented them here as they bring to life how health problems are affecting 
Thalidomide survivors’ daily lives.  
6.1 Representativeness of the Survey Respondents 
Limb difference, and in particular missing or short arms, is the most commonly recognised 
feature of Thalidomide damage in the public discourse. However, Thalidomide damage 
took many forms and varied considerably in severity. The drug was also no respecter of 
class or culture, and so survivors are in fact a heterogeneous group. It was therefore 
important to assess how representative the survey respondents were of all 467 UK 
Thalidomide survivors. Representativeness is important in quantitative research because 
it allows wider inferences to be made from the sample being studied (Silverman 2013). In 
this case, it had implications for my analysis and the strength of conclusions I could draw 
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from the results. However, in order to establish representativeness, the characteristics of 
the study sample (i.e. the respondents to the survey) needed to be checked against the 
characteristics of the population (i.e. the all UK Thalidomide survivors). The Trust does 
hold some core information about the ‘characteristics’ of its beneficiaries, notably gender, 
severity of impairment and type of impairments. The Trust also knows where people live 
but it does not routinely hold information about socio-economic characteristics (e.g. 
educational qualifications or marital status) or ethnicity. I could therefore only check the 
representativeness of the survey respondents in relation to four characteristics – gender, 
severity and type of impairment, and country of residence. Each of these are examined 
below. 
In terms of gender, 174 respondents were female and 174 were male. This matches the 
gender split of all UK Thalidomide survivors. Three respondents did not give their gender. 
As explained in Chapter 2, as part of the legal settlement all Thalidomide survivors were 
assessed and given ‘points’ according to the severity of their impairment. The total 
number of points is referred to as their 6(iv) b figure. For analysis and reference purposes, 
the Trust also groups its beneficiaries into five ‘impairment bands’. The spread of 6(iv) b 
impairment figures/Bands for the survey respondents almost exactly matched that of all 
UK Thalidomide survivors. There were only minor differences, which can be seen in 
Figure 10.  
Figure 10 Survey respondents and all UK Thalidomide survivors by impairment 
band 
 
 
 
 
 
 
 
 
 
 
NB: The total number of survey respondents in Figure10 is 302. This is because I was only able to 
identify impairment band for those beneficiaries who provided their names 
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The survey asked respondents to describe their original Thalidomide impairments. There 
were 25 categories covering limb damage, sensory impairments and damage to internal 
organs, plus a free text box where respondents could add other damage. As I discuss in 
Chapter 3, there are inevitable limitations and issues of accuracy when self-classification 
is used. However, the aim of gathering this information was not to compile a 
comprehensive clinical classification but rather to help assess the representativeness of 
the respondents and enable me to look at any variations between groups of Thalidomide 
survivors with different types of impairments (e.g. upper limb damage; hearing impaired). 
For analysis purposes, the 25 categories were collapsed into fourteen groupings. To 
check how representative the survey respondents were in terms of their original 
Thalidomide impairments, I compared the self-reported information from the survey with 
data held by the Trust on the number of its beneficiaries with different impairments. This 
data is based on the clinical information captured at the time they were accepted as 
beneficiaries by the Trust, which could be any time from the early 1970s to the present. As 
was noted in section 3.5.3, there are some differences between the survey categories and 
the categories used by the Thalidomide Trust, and so it was not possible to make direct 
comparisons for all categories.  
Tables 12 and 13 show the self-reported information about impairments from the survey 
compared with information held by the Trust. It is important to note that many Thalidomide 
survivors have multiple impairments and so will appear in both tables. For example: 
 73 respondents had both upper limb damage and were deaf or partially deaf 
 27 respondents said they had both sight and hearing impairment 
 All except one of the respondents who had damage to their internal organs also had 
another impairment/s 
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Table 12 Comparison of survey respondents’ self-reported limb damage with Trust 
information 
Impairment 
Survey 
Number 
Survey % 
(351) 
Trust 
Number 
Trust % 
(467) 
Upper & Lower limb mild/moderate 39 11%   
Upper & Lower limb severe 50 14%   
Upper and Lower limb total 89 25% 157 34% 
Upper limb mild 23 7% 55 12% 
Upper limb moderate 69 20% 40 9% 
Upper limb severe 61 17% 85 18% 
Upper limb very severe 52 15% 73 16% 
Upper limb only total 205 58% 253 54% 
Lower limb only 14 4% 7 1.5% 
No limb damage 43 12% 50 11% 
Total respondents/beneficiaries 351  467  
 
Table 13 Comparison of survey respondents’ self-reported non-limb damage with 
Trust information 
Impairment 
Survey 
Number 
Survey % 
(351) 
Trust 
Number 
Trust % 
(467) 
Scoliosis 77 22%   
Spinal damage   151 32% 
Totally Deaf 28 8% 
147 31% 
Partially deaf 96 27% 
Blind/Partially sighted 40 11% 117 25% 
Damage to face and/or outer ear 65 19% 218 47% 
Damage to internal organs 110 31% 102 22% 
Damage to nervous system 52 15%   
Learning needs   27 6% 
Epilepsy   17 4% 
 
There are a number of points to note in comparing the self-reported survey information 
and the clinical information held by the Trust. The proportions of respondents/beneficiaries 
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who have no limb damage and those who have upper limb damage only, are broadly 
similar. Amongst those with limb damage, there is a big difference between the proportion 
of Thalidomide survivors in the survey group who have both upper and lower limb 
damage, and the proportion found in the Trust’s records (25% compared to 34%). The 
number of Thalidomide survivors who have lower limb damage only is small but there is 
also a marked difference between the proportion in the survey and the Trust’s information. 
However, it may be that there are a number of Thalidomide survivors that the Trust’s 
records show as having both upper and lower limb damage, who have not recorded the 
damage to their upper limbs in the survey, possibly because they regard this damage as 
minimal, compared to their peers (e.g. minor damage to hands). 
Whilst the proportion of Thalidomide survivors who are hearing impaired is similar in the 
survey and the Trust’s records, substantially fewer respondents reported that they were 
blind or partially sighted, suggesting that Thalidomide survivors with a visual impairment 
may be under represented in the survey. The number of respondents who self-reported 
damage to their face and/or outer ear was also significantly lower than the Trust’s records 
suggest. This may be because those with ear damage felt they had reported this by 
identifying as partially or completely deaf in the survey, which reflects a weakness in the 
phrasing of the questions used to illicit this information. Lastly, a far greater proportion of 
survey respondents reported that they had damage to their internal organs than the 
Trust’s information would suggest.  However, some of this damage may not have been 
apparent at the time of their original assessment and so may not be documented in the 
Trust’s records. 
Table 14 compares the country of residence of the survey respondents with that of all UK 
beneficiaries, and shows that the pattern is broadly the same. The information was 
important for the Trust, as the funding for the Health Grant comes from the four UK 
Departments of Health (rather than central government) and the Trust reports to each of 
them on the use of the Grant. However, it was also useful for my analysis, as there is 
increasing divergence in health and social care policy across the four nations of the UK, 
and this may have implications for the health and wellbeing of Thalidomide survivors (e.g. 
arising from access to services and support). 
 
 
 
 
155 
 
Table 14 Country of residence for survey respondents and all UK Thalidomide 
survivors 
Country of Residence UK Thalidomide Survivors Survey Respondents 
England 325 (69%) 214 (71%) 
Wales 37 (8%) 16 (5%) 
Scotland 55 (12%) 38 (13%) 
Northern Ireland 19 (4%) 14 (5%) 
Non-UK resident 31 (7%) 20 (7%) 
NB: The total number of survey respondents in Table 15 is 302. This is because I was only able to 
identify country of residence for those beneficiaries who provided their names. 
6.2 Socio-economic Characteristics of the Respondents 
In this section, I describe and discuss the socio-economic characteristics of the survey 
respondents, including their home circumstances and housing situation, educational 
qualifications and work situation. This information is interesting in its own right, as it is the 
first time that such a full picture of the socio-economic circumstances of UK Thalidomide 
survivors has been obtained. However, it also provided a basis for comparisons with the 
general population of a similar age, and enabled me to undertake sub-group analysis. In 
particular, some of the information in this section is cross-tabulated with data presented 
later in the chapter.  
6.2.1 Home circumstances and housing situation 
In the general population, people in their fifties often experience changing family 
circumstances e.g. adult children leaving home, but they may also take on new family 
responsibilities, such as supporting older parents. A briefing note by Carers UK (2014) 
suggests that the peak age for caring is 50-64, with one in five people in that age group 
being carers. Recent NICE guidance (2015) highlights ‘mid-life’ (defined as 40 to 64) as a 
key period of age related changes in health and functioning, which can be made worse by 
social circumstances, like caring responsibilities or reduced income. Just like their peers, 
Thalidomide survivors are experiencing these changes but the implications for them can 
be more profound, especially where they rely on day-to-day help from family members. 
They can also have an emotional impact, with Thalidomide survivors feeling more 
vulnerable or socially isolated, or simply frustrated that they are unable to do more for 
older parents who have supported them all their lives and now need help (Newbronner 
2015). As part of the survey it was therefore important to gather information about home 
circumstances. I also asked respondents about their housing situation, as the health grant 
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evaluation had revealed that housing adaptations and/or the need to move to more 
suitable accommodation was a growing concern for many Thalidomide survivors.  
Almost two thirds of respondents lived with their partner/spouse or with their 
partner/spouse and their children/another family member. Nearly a quarter (76/22%) lived 
alone.  As a comparison, 17% of the general UK population aged 50-64 live alone (ONS 
2014). Just over 10% of respondents lived with another family member/s (e.g. parents or a 
sibling). Nine respondents said they lived at home with full-time paid carers or lived in 
residential care. The majority of respondents (304/87%) owned their own house or flat, 
which is a higher proportion than the general UK population aged 50 to 64 (75%) (ONS 
2013). Twenty-one (6%) lived in a private rented house or flat; 15 (4%) in a housing 
association/local authority house or flat; and just six lived in a residential care home or 
supported housing. Five did not answer this question. Of the 36 respondents who lived in 
rented accommodation, a significantly higher proportion lived alone (43% compared to 
22% for all respondents) and they were also more likely to be unable to work due to their 
disability or health problems. Respondents in band 2 were over-represented in this group 
(31% compared to 23% for all respondents). 
6.2.2 Education  
Table 15 provides a profile of respondents’ educational qualifications. The pattern is 
broadly similar to that of the general population of a similar age (ONS 2011), although 
Thalidomide survivors are less likely to have a degree (20% compared to 27%) and less 
likely to have no formal qualifications (23% compared to 25%). Comparisons with the 
educational profile of people with physical disabilities, of a similar age, are hard to find but 
the ONS Labour Force Survey 2012 (ONS 2012) estimates that 19.2% of people with 
disabilities of working age do not hold any formal qualifications, whilst 14.9% hold a 
degree level qualification. However, these figures encompass people with learning 
disabilities and describe the situation for all working age adults. It is likely that the profile 
for people with physical disabilities and those in the same age group as Thalidomide 
survivors will be different. 
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Table 15 Educational qualifications by impairment band 
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Band 1 34 
10 
[29%] 
2  
[6%] 
4  
[12%] 
6  
[18%] 
2  
6%] 
5  
[15%] 
0 
5  
[15%] 
Band 2 79 
13 
[16%] 
13 
[16%] 
6  
[8%] 
15 
[19%] 
6  
[8%] 
9  
[11%] 
3  
[4%] 
13 
[16%] 
Band 3 99 
20 
[20%] 
3  
[3%] 
9  
[9%] 
18 
[18%] 
10 
[10%] 
13 
[13%] 
1  
[1%] 
24 
[24%] 
Band 4 50 
8  
[16%] 
3  
[6%] 
6  
[12%] 
15 
[30%] 
1  
[2%] 
4  
[8%] 
0 
13 
[26%] 
Band 5 40 
8  
[20%] 
5  
[13%] 
5  
[13%] 
4  
[10%] 
1  
[3%] 
2  
[5%] 
1  
[3%] 
13 
[33%] 
Not 
known 
49 
11 
[22%] 
4  
[8%] 
7  
[14%] 
7  
[14%] 
1 
[2%] 
2  
[4%] 
1  
[2%] 
12 
[24%] 
Overall 351 
70 
[20%] 
30  
[9%] 
37 
[11%] 
65 
[19%] 
21  
[6%] 
35 
[10%] 
6 [2%] 
80 
[23%] 
NB Percentages are of the band. Seven respondents did not answer this question. 
 
These results suggests that, as a group, UK Thalidomide survivors are not substantially 
educationally disadvantaged compared to their peers. Peters et al (2015) also found that 
overall, German Thalidomide survivors had a similar, if not slightly higher educational 
profile that their peers in the general population. However, this masked differences 
between groups of Thalidomide survivors with different impairments. In particular, those 
with a hearing impairment had fewer qualifications. I also compared the education 
qualifications of respondents with different severity and types of impairment. It revealed 
that, as in the German study, respondents with a sensory impairment (with or without limb 
damage), were least likely to have a degree or higher degree and most likely to have no 
formal qualification. In terms of severity of impairment, respondents in band 1 one were 
most likely to have a degree. The proportion without any formal qualifications rose steadily 
with severity of impairment, rising from 15% for respondents in band 1 to 33% for 
respondents in band 5. I also examined whether educational level had any influence on 
employment status and the results of that analysis are presented in section 6.2.3 below.  
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6.2.3 Work situation 
The survey asked respondents to describe their current work situation by ticking one of 
ten statements. Table 16 provides an overview for all respondents and Figure 11 show the 
breakdown of responses for men and women. Overall, 15.4% (54) of respondents were 
working full time. Seventeen percent of all respondents (59) were working part time either 
because of their disability/health problems or because they had chosen to do so to 
preserve their health/functioning, and a few (17/4.9%) had chosen to work part time for 
family or personal reasons. A small number (15/4%) said they were not working at the 
moment but would like to. By far the biggest group were those who were unable to work 
because of their disability or health problems (145/41%).  
Table 16 Work situation – all survey participants 
Work Situation – all respondents Number % 
I’m unable to work because of my disability or health problems 145 41.4% 
I work full-time 54 15.4% 
I have chosen not to work in order to preserve my health/functioning 45 12.9% 
I work part-time because of my disability or health problems 30 8.6% 
I work part time in order to preserve my health/functioning 29 8.3% 
I work part-time for family or personal reasons 17 4.9% 
I’m not working at the moment but would like to 15 4.3% 
I’ve chosen not to work for family or personal reasons 8 2.3% 
Other (e.g. education) 7 2.0% 
 
Figure 11 shows that there were some important differences between men and women. 
Men were nearly three times more likely to be working full-time and women were nearly 
twice as likely to work part-time.  Unlike the general population where women are less 
likely to be working (DWP 2015), the proportion of men and women not working was 
approximately equal. 
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Figure 11 Work situation of men and women 
 
 
 
 
 
 
 
 
 
 
 
 
Table 17 shows the work situation of respondents by impairment band. The proportion of 
respondents who are unable to work increased with severity of impairment, from 35% of 
those in band 1 to 75% for those in band 5.  The proportion in full-time employment goes 
in the opposite direction reducing from 32% to 8%, but the pattern for those respondents 
working part-time is less clear. However, although respondents in the lower impairment 
bands (1 and 2) were more likely to be in full time work, around a third of them said they 
were unable to work because of their disability or health problems. 
Table 17 Work situation by impairment band 
 Impairment Band 
No in 
group 
I work full-
time 
I work part-
time 
I have chosen 
not to work 
I am unable 
to work 
Band 1 34 11 [32%] 6 [18%] 5 [15%] 12 [35%] 
Band 2 79 15 [19%] 22 [28%] 17 [22%] 25 [32%] 
Band 3 99 13 [13%] 24 [24%] 15 [15%] 45 [45%] 
Band 4 50 4 [8%] 8 [16%] 9 [18%] 28 [56%] 
Band 5 40 3 [8%] 5 [13%] 2 [5%] 30 [75%] 
Band not known 49 8 [16%] 12 [24%] 8 [16%] 20 [41%] 
Overall 351 54 [15%] 77 [22%] 56 [16%] 160 [46%] 
 NB: Percentages are of the band 
Other
I’ve chosen not to work for family or 
personal reasons
I’m not working at the moment but would 
like to
I work part-time for family or personal
reasons
I work part time in order to preserve my
health/functioning
I work part-time because of my disability or
health problems
I have chosen not to work in order to
preserve my health/ functioning
I work full-time
I’m unable to work because of my disability 
or health problems
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% of respondents
Male Female
69 
5 
11 
7 
8 
4 
5 
4 
2 
13 
23 
21 
14 
40 
76 
19 
10 
16 
160 
 
Comparisons with the general population, and/or with people with disabilities as a whole 
are difficult, as different sources use different terminology, definitions and age groupings. 
Furthermore, Thalidomide survivors themselves are a diverse group in terms of the 
severity of their impairments. The comparisons I present here should therefore be treated 
with some caution. Data from the Department of Work and Pensions show that in 2015, 
the employment rate for people aged 50 to 54 in the general population was 82% (78% for 
women and 86% for men) (DWP 2015). This suggests that 18% of this age group were 
‘economically inactive’, compared to 63% of the survey respondents. However, data 
collated by the Papworth Trust suggest that disabled people are four times as likely as 
their peers without disabling impairments to be unemployed or involuntarily out of work 
(Papworth Trust 2014). 
As in the general population, there was an association between the level of educational 
qualifications and the proportion who were in work, either full or part-time.  Table 18 
shows that nearly 70% of those with degrees or higher degrees are working, whilst only 
12% of those with no formal qualifications are working.  However, within the qualification 
groups there was a spread of impairment bands and types of impairment (e.g. the 19 
respondents with degrees working full time are in all five bands and all impairment types 
except lower limb only). This suggests that whilst respondents’ ability to work is strongly 
linked to the severity of their impairment, educational qualifications also have an important 
influence.  
Table 18 Work situation by educational qualifications 
  
No in 
group 
I work full-
time 
I work 
part-time 
I have 
chosen not 
to work 
I am 
unable to 
work 
Degree or higher degree [e.g. 
MA, PhD] 
70 19 [28%] 28 [41%] 6 [9%] 16 [23%] 
Diploma or professional 
qualification [e.g. Reg. Nurse] 
30 5 [17%] 8 [27%] 3 [10%] 14 [47%] 
A Levels or Highers 37 4 [11%] 10 [28%] 5 [14%] 17 [47%] 
O Level or GCSE equivalent 
[Grade A-C] 
65 6 [9%] 13 [20%] 13 [20%] 33 [51%] 
O Level or GCSE equivalent 
[Grade D-G] 
21 6 [29%] 3 [14%] 3 [14%] 9 [43%] 
Vocational Plus [e.g. HND] 35 10 [29%] 6 [17%] 7 [20%] 12 [34%] 
Vocational [e.g. OND 6 1 [17%] 0 [0%] 1 [17%] 4 [67%] 
No formal qualifications 80 2 [3%] 7 [9%] 17 [22%] 52 [67%] 
NB: Percentages are of those in the qualification group 
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There is evidence that the work situation of Thalidomide survivors has changed over the 
last 10 to 15 years (Newbronner 2015; Vermette and Benegabi 2013; Kruse et al 2013). In 
the UK context, this trend may be partly related to important changes to Thalidomide 
survivors’ financial support, in particular Annual Grants being exempt from taxation from 
2000, an uplift in the Annual Grants in 2001, and in 2010 the introduction of the Health 
Grant (see section 2.7.7 and 2.7.8). I was therefore interested in exploring how many 
respondents had changed their work situation since 2000. In all, 207 participants had 
made changes since 2000: 128 had stopped working, 62 had reduced their working hours 
and 35 had changed the type of work they did. Fifteen respondents had made more than 
one change (so may appear in more than one category in the table and figure below). Of 
this group, all had reduced their working hours and all bar one had changed the type of 
work they did. Figure 12 clearly illustrates that since 2000 there have been some major 
changes in the work situation of respondents, with the biggest changes taking place in the 
five years from 2010 to 2015, when Thalidomide survivors were entering their 50s.  
Figure 12 Changes in work situation since 2000 
 
 
 
 
 
 
 
 
 
Tables 19 and Figure 13 examine whether there is any association between recent 
employment changes and impairment band. Overall, almost two thirds of respondents had 
changed their work situation. Respondents in bands 1, 2 and 3 were more likely to have 
reduced their working hours or changed the type of work they do. Whilst a greater 
proportion of those in bands 4 and 5 had stopped working, this change was occurring 
across all the bands. Figure 13 compares the proportion of beneficiaries in each band who 
were working before 2000 and the proportion working at the time of the survey. It shows 
that over three quarters of respondents in bands 1 to 4 were working prior to 2000. By 
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2015, less than half of all respondents were working and, moving from band 1 to band 5, 
there is a gradual fall in the proportion working. 
Table 19 Changes in work situation since 2000 by impairment band 
Impairment Band 
No in Band 
working in 2000 
I have reduced 
my working 
hours 
I have changed 
the type of work 
I do 
Those who 
have stopped 
working  
Band 1 27 8 [30%] 6 [22%]  11 [41%]  
Band 2 63 19 [30%] 10 [16%] 27 [43%] 
Band 3 73 18 [25%] 11 [15%] 36 [49%] 
Band 4 38 5 [13%] 2 [5%] 25 [66%] 
Band 5 22 4 [18%] 2 [9%] 13 [59%] 
Not known 36 9 [25%] 5 [14%] 16 [44%] 
Overall 259 63 [24%] 36 [14%] 128 [49%] 
NB: Percentages are of those in the Band who were working in 2000 
Figure 13 Proportion of respondents working pre and post 2000 by impairment 
band 
 
 
 
 
 
 
 
 
 
Furthermore, over three quarters (118) of the respondents who were working full or part-
time thought that their Thalidomide-related disability/health problems would require them 
to change their work situation in the next five years, and of these, 51 thought that they 
might have to stop working. 
Of the respondents whose work situation had changed since 2000, 91 volunteered 
additional comments (in response to the open question at the end of the work and 
0% 20% 40% 60% 80% 100%
Band 1
Band 2
Band 3
Band 4
Band 5
Not known
Overall
Proportion working now Proportion working before 2000
163 
 
pensions section of the survey). Their comments provided a personal perspective on the 
changes reflected in the data, and helped me to understand more fully the nature and 
impact of these work changes on peoples’ wellbeing. I briefly discuss this below, using a 
number of quotations taken from the responses to the open question, to illustrate key 
points. At the end of the section, I bring together the quantitative data about work changes 
and the issues highlighted by the narrative comments. 
The comments showed that for many respondents the change in their work situation was 
incremental, often moving from full to part time employment, or reducing working hours or 
changing jobs, and then giving up work completely.  
“Increasingly from 2002 onwards, at which time I was a Director of a limited 
company working in excess of 50 hours per week. I now struggle to manage 18 
hours per week. I have now reached the point where stopping work altogether is 
imminent.” Survey ID2 
Whilst a few respondents noted that the improvements in the financial support for 
Thalidomide survivors since 2000 had enabled them to change their work situation, others 
still felt under financial pressure to continue working, despite health problems: 
“Injury to hand, equivalent of RSI – my physio told me I needed to retire, cannot 
afford to, but cut down.” Survey ID89 
“I left work for a bit due to ill health but could not survive on benefit money and had 
to go back to full time work.” Survey ID166 
Others had reluctantly given up work, sometimes because their employer could not 
accommodate their needs: 
“2011 I was forced to make a difficult decision to stop working due to continued 
failing health.” Survey ID183 
“In 2009 I had to reduce my hours in line with medical advice.  In 2010 I had 
further problems… and in 2011 I was medically retired (not at my request) as my 
employer had no role for me.” Survey ID276 
Together, the data from all the questions about work show that since 2000, but particularly 
since 2010, many Thalidomide survivors have changed their working situation, often 
(eventually) giving up work altogether. Proportionately, Thalidomide survivors with the 
most severe impairments (i.e. in bands 4 and 5) were the most likely to have stopped 
working since 2000 but from 2013 onwards, a growing number of Thalidomide survivors in 
bands 1, 2 and 3 also ceased working. It was clear from the semi-structured interviews 
discussed in Chapter 5, that the Health Grant provided many Thalidomide survivors with 
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the financial means to reduce their working hours or stop working. However, the 
comments respondents added to the survey suggest that often several interrelated factors 
underpinned this difficult decision.  
For some respondents, changing their work situation was an important means of 
preserving their health. In effect they were self-managing their declining health or 
functioning by taking greater control over how, and how much, they had to use their 
bodies. However, other respondents clearly felt ‘forced’ to stop working. Certainly, 
compared to their peers in the general population, health problems appear more likely to 
affect Thalidomide survivors’ ability to work or to work full time. I was unable to find data 
about employment patterns over the life course, for people with early acquired physical 
disabilities in the UK, and so it is difficult to know whether the changing work pattern of 
Thalidomide survivors is unusual when compared to people with similar impairments. 
However, a report by the Office for National Statistics on disability and employment in the 
UK (ONS 2019) found that in the 55-59 age group just under half (49.9%) of disabled 
people were in employment compared with 83.7% of their peers in the general population.  
There are several reasons why people with disabilities have lower employment rates, 
including lower educational attainment, poor health, employment discrimination or a lack 
of suitable employment (Fevre et al 2016). In certain respects, Thalidomide survivors are 
atypical in that as a group, they appear to have a similar level of educational qualifications 
to the general population in the same age group. The annual (compensation) payments 
and the Health Grant they receive may also mean that economically they are more secure 
than is the case for many people with disabilities, and so they may have more choice 
about whether to work or not. However, as they reach their pre-retirement years, poor 
health, a lack of suitable employment and employment discrimination appear to be 
growing issues for Thalidomide survivors too. 
6.3 Self-Reported Health Problems 
The content analysis of the semi-structured interviews indicated that it is sometimes hard 
for Thalidomide survivors to make a clear distinction between their original Thalidomide 
damage and secondary health problems associated with that damage. This is particularly 
the case in relation to damage/health problems associated with internal organs (e.g. 
bowel and digestive problems). Thalidomide survivors with limb damage (e.g. 
musculoskeletal problem), are often able to chart more recent health problems related to 
this damage through changes such as reduced flexibility and/or mobility and increasing 
pain, although they may not know the ‘medical’ cause of these problems. However, even 
for this group the line between original damage and secondary problems can be a little 
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blurred, for example with damage such as misshapen joints only coming to light when 
secondary problems are investigated. To help respondents make the distinction between 
their original damage and secondary health problems, I used the order in which the 
questions appeared in the survey, purposefully asking them about their original 
Thalidomide damage before asking them about the health problems they had recently 
experienced or were currently experiencing.  
Asking respondents to identify their health problems inevitably created potential for 
tension between social and medical models of disability. It is important to note, therefore 
that the question had a very specific purpose i.e. to enable the Trust to gather information 
about their beneficiaries’ health problems so that they could better plan services to 
support them. For me the data provided a means of examining links between the self-
reported health problems of Thalidomide survivors as they aged and other factors such as 
severity of impairment, and from this to explore how original impairments, secondary 
health problems, and socio-economic circumstance might be intersecting as Thalidomide 
survivors grow older. 
For the purposes of analysis, I grouped the data into a number of categories. This made 
cross tabulation more manageable and the presentation of results clearer.  I also took the 
decision to use categories that are somewhat biomedical in nature, as it facilitated 
comparisons with both the general population and the clinical studies in my literature 
review. The findings are presented below under five main headings: musculoskeletal 
problems; generalised pain, neuropathy, fatigue and balance; mental health; hearing, 
sight and dental problems; and other health problems (including ‘lifestyle’ related 
conditions). At the end of the section, I consider the important issue of comorbidity and the 
implications the impairments caused by Thalidomide have for managing long-term 
conditions. 
6.3.1 Musculoskeletal problems 
A study by Manchester University (Parsons et al 2011) noted that the term 
‘musculoskeletal conditions’ includes over 200 disorders affecting joints, bones, muscles 
and soft tissues. The survey results suggest that overall, 93% of respondents were 
experiencing musculoskeletal problems (defined in the survey as pain and/or loss of 
movement in one or more joint, including their neck and/or back). As Table 20 shows, 
back problems were the most commonly reported musculoskeletal problem, closely 
followed by shoulder pain/loss of movement and problems with hands.  
Whilst comparisons with general population are not straightforward, the General 
Household Survey of 2007 (ONS 2007) does provide some context. It found that 19.5% of 
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adults aged 45-64 reported having a chronic musculoskeletal condition. More specifically, 
a global study of the burden of low back pain (Hoy et al 2014) estimates that in Western 
Europe around 15% of the population is suffering back pain, with slightly more men 
suffering the condition than women, and prevalence increasing with age. The prevalence 
of musculoskeletal problems, and back problems in particular, is therefore much higher 
amongst UK Thalidomide survivors than in the general population. These finding are 
supported by other studies with Thalidomide survivors. A recent Swedish study 
(Ghassemi Jahani et al 2016a) found that degenerative changes in the cervical spine 
were more common and more extensive in Thalidomide survivors than in an age-matched 
control group. The categories/groupings used by Peters et al (2015) in their study of the 
health problems of German Thalidomide survivors are slightly different to those used in 
this survey and so full comparison is not possible. However, the proportion of beneficiaries 
reporting back, shoulder and hip problems was very similar, whilst in the German study 
hand problems were less common and neck problems were more common.  
Table 20 Musculoskeletal problems reported 
Musculoskeletal Problem Number % 
Back problems – prolapsed disc; damage to vertebrae; scoliosis 
and/or muscular pain  
254 72% 
Shoulder – pain, loss of movement or deterioration of the joint 211 60% 
Hands – pain, loss of grip and/or dexterity 210 59% 
Arms and wrists – pain, loss of strength and/or movement 197 56% 
Neck pain and/or loss of movement 195 55% 
Knee – pain or deterioration of the joint 168 48% 
Hip – pain, loss of movement or deterioration of the joint 164 46% 
Ankles, feet and toes – pain and/or loss of movement 100 28% 
 
Importantly, many survey respondents reported multiple musculoskeletal problems, with 
the mean number of problems being 4.5 and over half of all respondents reporting five or 
more problems (see Figure 14 below).  
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Figure 14 Number of musculoskeletal problems reported 
 
 
 
 
 
 
 
 
 
I looked at whether there were any differences between respondents with different 
types/severity of impairment. My analysis suggests that Thalidomide survivors with severe 
or moderate upper limb damage and those with upper and lower limb damage reported 
marginally more problems.  Figure 15 below gives a breakdown of the number of 
problems reported by each impairment group. 
Figure 15 Number of musculoskeletal problems by impairment group 
 
 
 
 
 
 
 
 
 
 
 
6.3.2 Generalised Pain, Neuropathy, Fatigue and Balance 
Thalidomide has long been known to cause peripheral neuropathy in adult patients 
(Fullerton and Kremer 1961) and it is one of the known side effects of its current use for 
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conditions such as multiple myeloma (Nicotra et al 2016). Many Thalidomide survivors 
report experiencing symptoms of neuropathy and/or generalised pain (i.e. pain affecting 
many parts of the body) but the causes are unclear and disputed. Through the survey, it 
was possible to explore the extent of this issue.  
In addition to the very high proportion of respondents reporting joint pain, 49% said they 
had generalised pain; 92 (26%) respondents said this was severe and/or continuous and 
a further 81 (23%) described it as moderate and/or intermittent. As Table 21 shows, 
respondents in bands 5 were the most likely to report experiencing generalised pain and 
those in band 2 least likely to do so.  
Table 21 Experience of generalised pain by impairment band 
 Band 1 Band 2 Band 3 Band 4 Band 5 
Generalised pain - severe 8 (24%) 12 (15%) 30 (30%) 13 (26%) 15 (38%) 
Generalised pain - moderate 9 (26%) 19 (24%) 21 (21%) 13 (26%) 10 (25%) 
Generalised pain - either 17 (50%) 31 (39%) 51 (51%) 26 (52%) 25 (63%) 
NB: Percentages apply to the proportion in the impairment Band 
 
The open comments added by respondents provided some valuable background 
information, in particular suggesting that for some, the cause of their pain was unclear and 
therefore treatment choices were limited or difficult. 
“Chronic neuropathic pain in peroneal nerves - both legs, below knee. 5 years. No 
cause found. Does not respond to treatment/pain management medication.” 
Survey ID298 
“I have been suffering with regular bouts of pain in my side. I have had several 
tests done but I am told there is no conclusive reason for the pain.” Survey ID104 
Overall, 66% (231) of respondents reported experiencing symptoms of neuropathy, with 
tingling/pins and needles being the most common symptom (see Table 22). My review of 
the literature suggests that from a clinical perspective, there are differing views about the 
causes of these symptoms (Jankelowitz et al 2012; Nicotra et al 2016). However, 
Thalidomide survivors report that the impact on their general wellbeing can be significant, 
especially where sleep is affected (Newbronner 2015). 
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Table 22 Symptoms of neuropathy reported 
Symptoms of Neuropathy Number % 
Tingling/pins and needles 182 52 
Numbness/Loss of feeling 130 37 
Sensations of extreme heat or cold 127 36 
 
A significant proportion of respondents also said that they experienced severe tiredness/ 
fatigue (139/40%) and nearly a third of all respondents said they had problems with 
balance/falls. However, as Table 23 shows, whilst the proportion of respondents reporting 
symptoms of neuropathy was consistent across all five impairment bands, fatigue was 
more commonly reported by those in bands 1 and 2. This may be partly because 
respondents in these bands were more likely to be working and therefore less able to rest 
when needed. The survey also suggests that respondents in bands 3 and 4 were more 
likely to experience balance problems but these could have many different and/or multiple 
causes, including deteriorating sight and musculoskeletal problems. 
Table 23 Symptoms of neuropathy, fatigue and problems with balance/falls by 
impairment band 
 Band 1 Band 2 Band 3 Band 4 Band 5 
Band not 
known 
Neuropathy 22 (65%) 50 (63%) 66 (67%) 34 (68%) 28 (70%) 31 (63%) 
Fatigue 15 (44%) 34 (43%) 36 (36%) 21 (30%) 15 (38%) 18 (37%) 
Balance/Falls 5 (15%) 15 (19%) 37 (37%) 24 (48%) 10 (25%) 18 (37%) 
 NB: Percentages apply to the proportion in the impairment Band 
 
6.3.3 Mental health 
Overall, 50% of respondents said that they were currently experiencing or had recently 
experienced depression and/or anxiety, and a further 19% said they had generally poor 
emotional health. Table 24 provides a more detailed breakdown of the problems reported. 
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Table 24 Mental health problems reported 
Mental Health Problems Number % 
Anxiety 145 41% 
Depression 118 34% 
Alcohol or drug misuse 26 7% 
Other mental health problems 25 7% 
 
The Mental Health Foundation (2007) estimates that in the UK, 20% of adults aged 
between 50 and 54 experience a common mental health problem (i.e. depression, anxiety 
or panic) and between 8% and 12% of the population (all ages) experience depression in 
any year. I was unable to find specific data about the prevalence of common mental 
health problems amongst working age adults with physical impairments. However, a study 
by Meltzer et al (2012), which looked at (self-reported) physical ill health, disability, 
dependence and depression in a sample of nearly 7500 adults (including older adults) 
across the UK, found a prevalence rate for depression and mixed depression/anxiety of 
19.5% for people with disabilities compared to 7.2% for people disabling impairments. The 
self-reported prevalence of mental health problems amongst Thalidomide survivors is 
therefore significantly higher than in the same age group in the general population and 
higher than adults (all ages), with physical disabilities. It is however, very similar to the 
prevalence of mental health problems found in the recent German study (Peters et al 
2015). Using face-to-face psychiatric assessment (rather than self-reporting), that study 
found that 47.7% of Thalidomide survivors had experienced a mental health problem in 
the preceding four weeks or were currently experiencing mental health problems. 
6.3.4 Hearing, sight and dental problems 
Deteriorating sight/eye problems were a concern for nearly half of respondents and 38% 
(133) said that they had deteriorating hearing/other ear problems (see Table 25). These 
figures will almost certainly encompass both deterioration in sight/hearing due to general 
ageing and more severe problems directly related to respondents’ Thalidomide damage 
e.g. just 40 respondents reported being blind or partially sighted from birth, compared to 
the 151 who are now reporting deteriorating sight/eye problems. However, it is important 
to note that even ‘normal’ deterioration in sight due to aging can cause additional 
problems for Thalidomide survivors. For example, having very short arms can make 
putting glasses on and off difficult and the use of contact lenses impossible, and for those 
Thalidomide survivors with facial damage (e.g. a missing ear) simply wearing glasses can 
be a challenge.  
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Over a third (120/34%) of respondents reported dental health problems. The unusual and 
varied nature of the original damage to Thalidomide survivors’ hearing, sight and 
teeth/jaws makes comparisons with the general population difficult. However, a Swedish 
study (Ekfeldt and Carlsson 2008) of the dental health of Thalidomide survivors found that 
they had higher levels of tooth wear and decayed, missing or filled teeth than the general 
population of a similar age. The study suggests that these differences may be due to a 
combination of factors including difficulties with tooth brushing, using teeth as tools and 
regurgitation/acid reflux.  
Table 25 Sight, hearing and dental problems reported 
Hearing, Sight and Dental Problems Number % 
Deteriorating sight/eye problems 151 43% 
Deteriorating hearing/other ear problems 133 38% 
Dental Health Problems 120 34% 
 
6.3.5 Other health problems 
The content analysis of the interviews suggested that weight management is a concern for 
many Thalidomide survivors, and the survey confirmed this with 40% (141) identifying this 
as a health problem. The survey did not provide data on the number of Thalidomide 
survivors who are overweight but there is evidence that people with disabilities are more 
likely to be overweight or obese. Public Health England’s (2013) report on obesity and 
disability concluded that adults with disabilities have higher rates of obesity  than  adults 
without disabilities. It went on to say: 
The association between obesity and disability varies by age and sex, and by level 
or type of disability. Physical inactivity and muscle atrophy, as well as secondary 
conditions (such as depression, chronic pain, mobility problems and arthritis) have 
all been found to contribute to the development of obesity among people with 
physical disabilities. (p6) 
Thalidomide survivors are reporting all the secondary health problems highlighted in this 
quotation, which suggests that they may be at greater risk of becoming overweight and/or 
find it harder to lose weight. 
Respondents also reported a range of other health problems and a breakdown of these is 
shown in Table 26 below. In addition, eight people noted in the free text box that they had 
high blood pressure, or were being treated for hypertension.  
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Table 26 Other health problems reported 
Health Problem Number % 
Bowel or digestive problems 98 28% 
Bladder or continence problems 72 20% 
Asthma or breathing problems 54 15% 
Diabetes 32 9% 
Kidney problems 30 9% 
Heart problems 28 8% 
Cancer 17 5% 
Stroke/TIA 5 1.4% 
 
All of these health problems are experienced by people in the general population. For 
some conditions the prevalence rates reported by respondents appeared to be similar or 
lower e.g.:  
 Information collated by Diabetes UK (2015) suggests that in the UK around 19% of 
people aged 50-59 have diabetes (Types 1 and 2) whereas 9% of the respondents in 
the survey reported having diabetes. 
 Five (1.5%) respondents (all men) reported that they had had a stroke/TIA. This 
compares to a prevalence rate of between 0.8 to 2% in the UK population aged 45 to 
54 (with prevalence rates being higher for men) (Townsend et al 2012). 
However, some problems may be more prevalent amongst Thalidomide survivors e.g.: 
 In 2011, the national outcomes strategy for COPD and asthma (DH 2011) estimated 
that 13% of the population aged over 35 had COPD (both diagnosed and 
undiagnosed) and around 6% of the adult population had asthma. This compares to 
15% of survey respondents reporting asthma/breathing problems. 
 NICE (NICE 2014) defines chronic kidney disease as ‘abnormal kidney function and/or 
structure’ and Kerr (2017), suggests that the prevalence of doctor diagnosed chronic 
kidney disease is between 4.3% and 6.5% (all ages). This compares to 9% of 
respondents reporting kidney problems. 
These comparisons need to be treated with caution, as there are differences in definitions, 
prevalence periods and age groups etc. What is clear, however, is that all these health 
problems may be made more difficult to manage, or be exacerbated by Thalidomide 
damage.  For example, a Japanese study (Shiga et al 2015) of ‘lifestyle’ diseases 
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amongst Thalidomide survivors suggested that hypertension is a particular area of 
concern because of the problems many Thalidomide survivors have in exercising and 
controlling their weight and the potential inaccuracy of blood pressure measurement in 
people with limb difference. 
6.3.6 Multimorbidity 
The rise in the number of people living with multiple long-term conditions is a growing 
concern in the UK (Barnett et al. 2012). The NICE guidelines on the clinical assessment 
and management of multimorbidity (NICE 2016) define it as - the presence of 2 or more 
long-term health conditions, which can include: 
 defined physical and mental health conditions such as diabetes or schizophrenia 
 ongoing conditions such as learning disability 
 symptom complexes such as frailty or chronic pain 
 sensory impairment such as sight or hearing loss 
 alcohol and substance misuse. 
The survey showed that a high proportion of Thalidomide survivors were experiencing 
multiple physical and mental health problems (i.e. multimorbidity). I examined the survey 
data to identify how many respondents reported that they were currently or had recently 
experienced two or more of the following health problems – a musculoskeletal problem, 
generalised pain, neuropathic symptoms, a mental health problem, bowel or digestive 
problems, bladder or continence problems, asthma or breathing problems, diabetes, 
kidney problems, heart problems, cancer and stroke/TIA. Figure 16 shows that just 9 
respondents (3%) had no health problems, 85% had two or more health problems, and 
almost three quarters (73%) reported between three and nine health problems.  
Figure 16 Proportion of respondents reporting multiple health problems 
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6.4 Use of Health and Social Care Services 
In research in the UK (Newbronner et al 2012) and Germany (Peters et al 2015), 
Thalidomide survivors report problems getting access to healthcare practitioners who 
understand Thalidomide damage and have the knowledge and skill to diagnose and treat 
them effectively. The semi-structured interviews suggested that even where they can 
access the right services, they may face difficult decisions about treatments. For example 
joint replacement surgery may reduce the pain a person is experiencing but it may also 
reduce their flexibility. This has led to many Thalidomide survivors to pursue, where 
possible, self-management strategies, including the use of complementary therapies, such 
as osteopathy and remedial massage. However, access to appropriate preventative, 
diagnostic and treatment services is vital if Thalidomide survivors are to maintain their 
health. The survey provided an opportunity to gather information about the health 
treatments Thalidomide survivors had used over the past ten years, and to understand 
more about the problems they may have experienced in getting access to appropriate 
services.  
The Trust was also interested in their beneficiaries’ use of local authority social care 
services.  Anecdotal evidence suggested that a relatively low proportion of Thalidomide 
survivors receive support from their local authority, and the Trust felt their beneficiaries 
might need more advice and information around this issue. Again, access to social care 
services could have implications for the wellbeing of Thalidomide survivors and so I have 
included a brief analysis of these data in this chapter. Below I discuss the findings from 
my analysis under three headings – use of health services, access to health services and 
use of social care services. 
6.4.1 Use of health services 
The data collected in the survey about the health treatments Thalidomide survivors have 
used, both NHS treatments and those purchased privately was very useful for my 
research. It shed light on some important issues, including approaches to self-
management, treatment options, and the difficult choices that are sometimes associated 
with them.  
Physiotherapy and Complementary Therapies 
The most commonly used treatments were physiotherapy (NHS or private) and/or 
complementary therapies (especially therapeutic massage), with over two thirds of 
respondents ticking these categories. Table 27 provides a more detailed breakdown.  
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Table 27 Use of physiotherapy and complementary therapies 
Treatment Number % 
Physiotherapy – NHS 105 30% 
Physiotherapy – private 88 25% 
Therapeutic massage  89 25% 
Chiropractic 61 17% 
Acupuncture 53 15% 
Osteopathy 34 10% 
 
Joint and Back Surgery 
Overall, 17% (60) of respondents said they had had joint or back surgery. As Table 28 
shows, hip replacement/hip surgery was the most common procedure. Six percent of 
respondents reported that they had had a hip replacement/hip surgery in the last ten 
years, compared to 1% of the general population aged 50 to 54 (Age UK 2012). Similarly, 
4% of respondents had had knee surgery, compared to just under 1% of the general 
population aged 50 to 54 (Age UK 2012). Similar comparisons with the general population 
for wrist/arm, shoulder and back surgery are less straightforward as these grouping cover 
a wider range of procedures. Furthermore, national data collection is less developed for 
these areas. However, data collected by the National Joint Registry (2012) suggests that 
there are only about 2000-3000 shoulder and elbow procedures performed each year 
(compared to around 85,000 hip replacements), so the proportion of Thalidomide 
survivors who have had these procedures appears high. 
Table 28 Joint and back surgery in the past ten years 
Type of joint/back surgery Number % 
Hip replacement/hip surgery 21 6% 
Wrist/arm surgery 18 5% 
Knee replacement/surgery 14 4% 
Shoulder replacement/surgery 12 3% 
Back surgery 6 2% 
 
The open comments respondents added to their questionnaires revealed that some 
respondents were facing difficult decisions about if, and when, to have surgery. The 
quotations below illustrate this: 
176 
 
“Need a shoulder replacement but surgery is not an option as it can only be done 
once and will wear out within 4-5 years potentially leaving me in a worse situation. 
Managing related pain using meds and will get surgery if/when the issue is no 
longer bearable”. Survey ID43 
“Both knees are in need of replacement. Surgeon reluctant to do this due to 
flexibility after surgery.” Survey ID257 
The figures presented here may not be surprising given the number of respondents 
identifying hip, knee and/or shoulder damage as one of their original Thalidomide 
impairments (158/45%), and the high proportion reporting pain and/or loss of movement in 
one or more of their joints. However, coupled with evidence from the literature on aging 
with TE, they suggest that the management and treatment of MSK problems is a major 
issue for Thalidomide survivors, and an area in which treatment decisions can be difficult. 
Pain Medication and Treatment 
Half of the respondents (174/50%) said that they had either taken prescription pain 
medication and/or had pain-relieving treatment such as injections in the past ten years. 
Nearly half (168/48%) had used prescription pain medication and nearly a quarter 
(79/23%) had had other treatments to relieve pain. The comments respondents added to 
their questionnaires bring to life the issues they are facing, as this quotation illustrates: 
“Recently diagnosed with congenital fusion of two coccygeal segments for which I 
undergo an annual steroid injection into the joint.  This is effective for three to four 
months but can only be repeated annually”. Survey ID3 
Interestingly, the use of pain medication/treatment was marginally more common amongst 
respondents in bands 1 and 2, as Table 29 shows. A higher proportion of respondents in 
these bands were still working (full or part time), which raises the questions of whether 
they are more reliant on pain medication/treatment because they are less able to self-
manage their pain through rest and ‘pacing’ activity.  
Table 29 Use of pain medication/treatment by band 
Band Number % 
Band 1  21 62% 
Band 2 46 58% 
Band 3 42 42% 
Band 4  27 54% 
Band 5 18 45% 
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Not surprisingly, the more MSK problems respondents reported, the more likely they were 
to report that they had had prescription pain medication/treatment (e.g. of the 33 
respondents reporting eight MSK problems, n=25/76% were using pain medication and/or 
treatment). Figure 17 provides a more detailed picture. 
Figure 17 Pain medication/treatment and number of MSK problems 
 
 
 
 
 
 
 
 
 
 
Given that 93% (327) of respondents reported pain or loss of movement in one or more 
joints, these figures suggest that a significant proportion of them were self-managing their 
pain through the use of other treatments, non-prescription medication and/or changes to 
their lifestyle, living or working situations. One respondent described the changes they 
had made in order to manage their pain: 
“[Some] years ago I had real health issues and things got so bad I had to take 
dramatic action…sell [my] business and change lifestyle. So I had to learn to be 
less independent - to actually be dependent…I refused all help but I had to change 
my mind-set. I've gone from excessive painkillers every single day to rarely 
touching one now.” Survey ID94 
Mental Health Care 
With regard to mental health, a quarter of respondents (87) had received treatment for 
anxiety and/or depression and 10% (35) had had counselling for emotional issues (22 
respondents had both). Given that 50% of beneficiaries reported anxiety and/or 
depression, it is likely that a significant proportion of Thalidomide survivors who have 
experienced mental health problems have not had any professional treatment. 
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6.4.2 Access to health services 
In the Health Grant evaluation (Newbronner et al 2012), a number of Thalidomide 
survivors talked about the problems they had experienced with either obtaining access to 
appropriate health services or the perceived quality of care they received. Specifically, 
many of them reported that healthcare professionals often had a poor understanding of 
their particular impairments and/or Thalidomide damage in general. Clearly, access to 
knowledgeable care and appropriate treatment is important for Thalidomide survivors’ 
health and wellbeing. I was able to use the data gathered in the survey to explore this 
issue further, both for health services in general and general practitioner (GP) care in 
particular. 
The survey question listed nine problems with health care services that had emerged from 
the Health Grant evaluation and respondents could tick all that applied to them. There was 
also a ‘no problems’ option and a box where respondents could describe problems not 
listed or add comments. Table 30 shows all the responses. Overall, nearly two-thirds 
(215/61%) of respondents said that (in the last five years) they had experienced one or 
more problems with the quality of and/or access to health services. The main areas of 
concern were a perceived lack of knowledge/understanding of Thalidomide damage in 
general amongst health professionals (170/48%), and a perceived lack of 
knowledge/understanding of respondents’ impairments amongst health professionals 
(127/36%). However, difficulties/delays in seeing a suitably experienced health 
professional/specialist (81/23%) and general delays in getting treatment (82/23%) were 
also a concern.  
Table 30 Problems reported with healthcare services in the last five years 
Question Number % 
Lack of knowledge/understanding of Thalidomide damage in 
general amongst health professionals 
169 48% 
Lack of knowledge/understanding of my impairments amongst 
health professionals 
127 36% 
Not experienced any problems with healthcare services 132 38% 
Difficulties/delays in seeing a suitably experienced health 
professional/specialist 
82 23% 
Delays in getting treatment 81 23% 
Inflexible care or treatment 62 18% 
Lack of involvement/choice in decisions made about my care and 
treatment 
51 15% 
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Question Number % 
Problems with the quality or choice of equipment 50 14% 
Misdiagnosis or delayed diagnosis 48 14% 
Incorrect or inappropriate treatment 47 13% 
 
A number of respondents added open comments about their experiences of healthcare 
services. The quotations below highlight the difficulties two respondents had in getting the 
knowledgeable, skilled care they needed (the most frequently highlighted issue in the 
comments) and the knock-on consequences that poor care can have for mental wellbeing: 
“I have not enjoyed my usual robust general health for three years now. I have 
recently struggled with depression/isolation. I am awaiting the results of blood tests 
as I complete this form. I delayed the tests because of the difficulty in getting a 
needle into me to take blood. An angiogram ordered by a specialist had to be 
abandoned after s/he had tried unsuccessfully three times to insert a drip.” Survey 
ID265 
“Could not get bloods done as nurses could not do it – took 2 years to get doctors 
to do it. Having a nervous breakdown due to stress and worry. It is hard to admit 
all about your illnesses, when it is your bowels and bladder. You feel ashamed 
when it is not your fault. The last thing you want is strangers knowing.” Survey 
ID212 
Importantly, a small number had experienced misdiagnoses or delayed diagnoses 
(48/14%) and a similar number reported being given incorrect or inappropriate treatment 
(47/13%). From the survey data I was unable to determine whether these experiences 
concerned respondents’ Thalidomide related health problems or general health problems. 
However, as the following quotation illustrates, some beneficiaries perceived that the 
misdiagnosis of their problems was related to being a Thalidomide survivor: 
“There is a lack of understanding of depression/psychological issues and 
Thalidomide amongst general health professionals. Living a life of being stared at 
and fighting against barriers and perceptions has taken its toll.  My depression was 
misdiagnosed by general health professionals originally.  Thanks to the Trust's 
assistance I was able to access a specialist.” Survey ID345 
The survey also asked respondents - “How well does your GP/GP surgery understand 
how your Thalidomide damage affects you?”. Over half said that their GP fully understood 
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or partly understood how their Thalidomide damage affected them. Just 20% said their GP 
did not understand and the remainder were not sure (see Table 31). Given the 
‘gatekeeping’ role of GP in relation to referral to specialist services and their role in 
offering coordinated, continuity of care, this is an important issue. 
Table 31 GP/GP surgery level of understanding of Thalidomide damage 
Response Number % 
Fully understands 57 16% 
Partly understands 136 39% 
Doesn’t understand 72 21% 
Not sure/don’t know 81 23% 
 
6.4.3 Use of social care services 
Sixty-six respondents (19%) were receiving local authority funded social care at the time 
of the survey. I looked at this group in more depth and found that respondents who lived 
alone, and therefore may have had less day-to-day help from family members, were more 
likely to be getting social care (25%) than those who lived with a partner or other family 
member (16%). As might be expected, the proportion of respondents receiving local 
authority social care increase with the severity of their impairment (see Figure 18).  
Figure 18 Use of local authority social care by impairment band 
 
 
 
 
 
 
 
 
 
Of those respondents receiving local authority funded social care, just over half (34/52%) 
said that the level of support they were getting was enough to meet their needs. However, 
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of these 14 felt that their package was not enough to meet their needs. In addition, almost 
two thirds of respondents (40/60%) who received local authority funded social care were 
also paying for additional time or services from their own income, and three quarters 
(49/74%) thought they would need more support in the next five years. 
Whilst the majority of respondents (282/81%) were not receiving local authority funded 
social care, almost two thirds of this group (181/64%) were buying support privately (e.g. 
personal assistance, help in the home, gardening, DIY). Nearly 20% (54) thought that they 
would need to apply for local authority funded social care in the next five years. 
6.5 Health-Related Quality of Life 
In the earlier sections of this chapter, I have looked at the socio-economic circumstances 
of Thalidomide survivors, the health problems they are experiencing and their use of 
health and social care services. I now go on to examine in some depth, their health-
related quality of life, and reflect on how socio-economic factors, and secondary health 
problems might affect this.  This includes a comparative analysis, in which the experience 
of Thalidomide survivors is contextualised in relation to broader population norms. 
As I explain in Chapter 3, the SF12 Health Survey is a tool for measuring generic health 
status which is widely used in health research in the UK and internationally. SF12 consists 
of eight scaled sections (General Health; Pain; Physical Functioning; Role Limitation 
Physical; Mental Health; Role Limitation Emotional; Social Functioning; Vitality) which can 
be ‘aggregated’ into two domains – physical health-related quality of life and mental 
health-related quality of life. Here I present the findings for both the physical health and 
mental health domains.  Of the 351 survey respondents, 335 returned SF12 
questionnaires that were useable for the analysis18. Of these 285 gave their name and so 
I was able to link their SF12 scores to their 6(iv) b figures (level of impairment).  
The results for the physical and mental health domains are presented in ‘normalised form’ 
i.e. the scores for the general population group are adjusted such that the mean is 50 and 
the standard deviation (i.e. the spread) is 10. This means that 96% of the population in the 
normalised general population group will have SF12 scores between 30 and 70 (+/- 2 
standard deviations).This is simply a device to facilitate easy comparison between specific 
sub-groups and the general population. I decided to present the results in this way 
because in many respects the SF12 scores for Thalidomide survivors only become 
meaningful when they are set alongside the score for the general population of a similar 
age (45 to 54 years). Figure 19 shows the results for the survey respondents compared to 
                                               
18 Questionnaires which were not been completed in full could not be used in the analysis. 
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the general population aged 45-54, based on responses to the Central England Healthy 
Life Survey (Jenkinson et al 1993). 
Figure 19 Normalised SF-12 physical and mental health scores for survey 
respondents compared to UK population 
 
 
 
 
 
 
 
 
 
 
 
In the physical health domain respondents had a markedly lower average aggregate score 
than the general population (i.e. a mean of 26.7 compared to 50) indicating that their 
physical health-related quality of life is much poorer. 59.7% (n = 200) of the respondents 
had a score below 30 i.e. the same as or worse than the 2% of the general population 
group with the poorest physical health-related quality of life, and only 7.5% (n = 25) of the 
respondents had a score above the average for the general population group. In the 
mental health domain the average aggregate score for respondents was 46.5, slightly 
lower than the general population (score 50). This suggests that on average Thalidomide 
survivors’ mental health-related quality of life is only marginally poorer than their peers in 
the general population; indeed 40.9% of respondents (n = 137) had a score above the 
average for the general population. However, 10.7% (n = 36) had a score below 30 i.e. the 
same as or worse than the 2% of the general population with the poorest mental health-
related quality of life.  
Table 32 shows the component scores that make up the two domains. In the four 
components for the physical domain, perhaps not surprisingly, respondents had the 
lowest scores for Physical Functioning (20.9). Of the four sections that make up the 
mental health domain, respondents had the lowest score for Social Functioning (34.6).  
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Table 32 SF12 component scores for physical and mental health domains 
Component Mean Min Max 
Physical Health Domain 
Physical Functioning (PF) 20.9 1.7 57.6 
Role Limitation Physical (RP)  36.4 21.9 55 
Pain  (BP) 33.6 14.2 59.2 
General Health (GH) 33.7 13.7 63.7 
Mental Health Domain 
Vitality (VT) 40.4 21.3 68.2 
Role Limitation Emotional (RE) 43.5 23.7 55.3 
Social Functioning  (SF) 34.6 2.0 55.5 
Mental Health (MH) 40.7 7.4 64.5 
 
These findings suggest that Thalidomide survivors experience significantly poorer physical 
health-related quality of life compared to the general population but their mental health-
related quality of life was only marginally poorer than their peers in the general population. 
The findings are also consistent with a German study of 186 Thalidomide survivors in 
North Rhine Westphalia, which used SF36. Peters et al (2015) reported that Thalidomide 
survivors had a mean aggregate physical score of 29.6 and a mean aggregate mental 
health score of 47.8. A Swedish study of 31 Thalidomide survivors (Ghassemi Jahani et al 
2016b) also found that their physical health-related quality of life was significantly lower 
than the general population, although their mental health-related quality of life was similar. 
As well as comparing health-related quality of life with the general population norms, I also 
used the SF12 results to examine what might explain the variance in health-related quality 
of life among Thalidomide survivors. First I examined whether there was any relationship 
between health-related quality of life and gender, and then between health-related quality 
of life and level of impairment. Overall men had a higher mean score for physical health 
than women (28.6 compared to 24.7) and this difference was statistically significant (t 
(327) = 2.567, p = 0.01.). Although women had a higher mental health score than men 
(47.8 compared to 45.1), this difference was not significant (t (327) = -1.981, p = 0.05). 
For level of impairment, I found that there was a negative correlation (r = -.276; p = .000) 
between lower SF12 physical health scores and severity of impairment i.e. the more 
severe a respondent’s Thalidomide damage, the poorer their physical health-related 
quality of life was likely to be. In contrast, when I examined the same relationship for 
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mental health-related quality of life, I found that the less severe a respondent’s 
Thalidomide damage, the poorer their mental health-related quality of life was likely to be 
i.e. there was a positive (but weaker) correlation between lower SF12 mental health 
scores and less severe impairment (r = .148; p = .012).  
The content analysis of the semi-structured interviews and the responses to the narrative 
questions in the survey, suggested that other factors, in particular being unable to work 
because of secondary health problems and living alone, could be important in explaining 
variance in both physical and mental health-related quality of life. To examine if this was 
the case I used hierarchical regression, using three sets of variables: original impairment 
level (as indicated by the number of impairment points) (step 1); being unable/ able to 
work and qualifications (step 2); and gender and living alone/living with others (step 3). 
Tables 33 and 34 show the results for SF12 physical and mental health scores. 
The model predicting physical health-related quality of life was significant at: step 1—F (1, 
273) = 24.526, p <.001; step 2 –F (3, 271) = 30.337, p < .001; and step 3 –F (5, 269) = 
19.396 p < .001 (Table 33). These results show that together the five variables explained 
25% of the variance in physical health-related quality of life. However, only three variables 
make a unique statistically significant contribution (i.e. p = .05 or less) to the model – a 
higher level of original impairment, being unable to work, and gender (being male), 
predicted poorer physical health-related quality of life, with being unable to work 
accounting for most of the variance. 
Table 33 Hierarchical regression results for SF12 physical health related quality of 
life 
Variable B SE B B (95% CI) Sig. 
Impairment Level - 0.194 0.063 -0.31, -0.07 0.002 
Unable to Work 11.556 1.572 8.46, 14.65 0.000 
Qualifications - 0.184 0.290 -0.75, 0.38 0.526 
Gender - 3.207 1.471 -6.10, -0.31 0.030 
Live Alone - 0.343 1.755 -3.79, 3.11 0.845 
NB: Step 1 Adj R2 = 0.079; Step 2 Adj R2 = 0.243, ∆ R2 = 0.169; Step 3 Adj R2 = 0.251, ∆ R2 = 0.014 
 
The model predicting mental health-related quality of life was significant at: step 1—F (1, 
273) = 5.348, p = .021; step 2 –F (3, 271) = 7.514, p < .001; and step 3 –F (5, 269) = 
5.080 p < .001 (Table 34). For mental health-related quality of life, the five variables 
explained just 7% of the variance, with only two variables – lower level of original 
impairment and being unable to work, making a unique statistically significant contribution 
to predicting poorer mental health-related quality of life. 
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Table 34 Hierarchical regression results for SF12 mental health related quality of 
life 
Variable B SE B B (95% CI) Sig. 
Impairment Level 0.190 0.060 0.07, 0.30 0.002 
Unable to Work 5.026 1.497 2.07, 7.97 0.001 
Qualifications - 0.355 0.276 -0.89, 0.18 0.200 
Gender 2.077 1.401 -0.68, 4.83 0.140 
Live Alone 0.974 1.671 -2.31, 4.26 0.561 
NB: Step 1 Adj R2 = 0.016; Step 2 Adj R2 = 0.067, ∆ R2 = 0.058; Step 3 Adj R2 = 0.069, ∆ R2 = 0.009 
 
Whilst the more severe a respondent’s original Thalidomide damage, the poorer their 
physical health-related quality of life was likely to be, being unable to work accounted for 
most of the variance in SF12 scores. This suggests that secondary health problems and 
associated loss of function may be a far more important influence on physical health-
related quality of life than original impairment alone. In relation to mental health-related 
quality of life, the narrative responses to the survey suggest that for Thalidomide survivors 
with lover levels of impairment, who have probably been actively employed for most of 
their lives, having to give up work (as opposed to choosing not to work) is having a 
detrimental effect on their mental wellbeing. However, the quantitative analysis showed 
that being unable to work accounted for just under 7% of the variance in SF12 scores, 
which implies that psychosocial factors, not explored in the survey, may be of more 
importance. 
6.6 Mental Wellbeing 
The content analysis of the semi-structured interviews, and anecdotal reports from the 
Thalidomide community suggested that some Thalidomide survivors were experiencing 
declining mental wellbeing. As part of the survey, I wanted to gauge the mental wellbeing 
of Thalidomide survivors, compared to the general population, and explore any 
relationship to severity of impairments and/or personal circumstances. To do this I used 
the Warwick Edinburgh Mental Wellbeing Scale (WEMWBS). WEMWBS was developed 
to capture the broad concept of positive mental wellbeing. It has a long form with 14 
questions and a short form with seven (SWEMWBS), which is the one used in the survey.  
The reasons for choosing this instrument are discussed in Chapter 3. Respondents were 
asked to rate each of seven statements against a five-point scale – ‘None of the time’, 
‘Rarely’, ‘Some of the time’, ‘Often’, ‘All of the time’ – where ‘None of the time’ = 1 and ‘All 
of the time’ = 5. So, for SWEMWBS the minimum score is seven and the maximum score 
is 35. The seven statements are: 
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 I’ve been feeling optimistic about the future 
 I’ve been feeling useful 
 I’ve been feeling relaxed 
 I’ve been dealing with problems well 
 I’ve been thinking clearly 
 I’ve been feeling close to other people 
 I’ve been able to make up my own mind about things. 
To compare SWEMWBS results with WEMWBS data from the Health Survey for England 
2016, the scores have to be ‘transformed’ (i.e. weighted and then doubled).  It is these 
weighted scores I use here. The comparison (for those aged 45 to 54) shows that for both 
men and women Thalidomide survivors have a lower mean scores (43.2 and 44 
respectively) than the national means for England of 49.5 and 48.6 respectively (NHS 
Digital 2016). There was no obvious relationship between mean mental wellbeing score 
and impairment band. There are no hard and fast rules for interpreting WEMWBS, but 
guidance provided by Warwick Medical School (2018) suggests that a score of 40 and 
below corresponded to probable depression and they note that NHS Direct have adopted 
this cut of as indicating low mental wellbeing. Overall, 41.3% (n=140) of the survey 
respondents fell in the low mental wellbeing group. The Health Survey for England 2016 
also showed that in the 45 to 54 age group, 10% of the population (i.e. the 10th centile) 
had a score of 38 or below (NHS Digital 2016). For Thalidomide survivors, 35% had a 
score of 38 or below. Moreover, for those respondents who said that they were unable to 
work, 51% had a score of 38 or below.  
As I note in Chapter 3, the main purpose in using this tool was to provide a baseline for 
future Thalidomide Trust surveys. However, the results, which show some marked 
differences, also help to set the mental wellbeing of Thalidomide survivors in the context 
of the general population.  
6.7 Concerns for the Future 
At the end of the survey, there was a free text box where respondents could make 
comments, or provide more information on any topic. Ninety-eight respondents added 
comments and many of these reflected their concerns for the future. I undertook a very 
simple thematic analysis of these comments. They need to be treated with some caution, 
as in the context of a quantitative survey narrative comments may not be representative of 
respondents as a whole. Nevertheless, I briefly present the results here because they 
vividly illustrate how health problems are affecting both Thalidomide survivors’ daily lives 
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now and their outlook for the future. They also provide an early indication of a number of 
important issues, which I explore much more fully in Chapter 7.  
It is clear that physical health was the major area of concern for the vast majority of 
respondents. This was reflected in the comments, which ranged from concerns about 
deterioration in general health, either now or in the future, to specific health problems: 
“Health-wise, I feel at the moment I am in between feeling quite well and 
potentially deteriorating quite quickly. I could stay at this level of health for the next 
20 years or so but equally all it would take is for a few physical problems to occur 
and my health and way of life both domestically and socially would change 
forever.” Survey ID70 
“As a result of doing everything with my only arm I have multiple RSIs, trapped 
nerves in my neck and shoulder and have lost some dexterity and experience 
numbness in my hand.  I have been told that this won't improve and have had to 
stop doing a lot of everyday general activities about the house.  There is the 
possibility that I will completely lose the use of my arm but there's no way to 
predict when.” Survey ID276 
Many of the health problems beneficiaries mentioned were causing progressive loss of 
function and it was the implications of this for independence and family relationships that 
caused concern: 
“My only normal hand is deteriorating badly. I've had 3 operations on it, they can't 
do anything more. I'm in pain with it nearly all the time. I can't do hardly anything 
for myself now. I'm terrified. I'm only 55 – how much worse is it going to get? 
Having one hand I was never disabled but I am now. Luckily I have fantastic 
children who all automatically do everything for me that's needed. They cut my 
food up, do up my buttons, zips, and laces, and are amazing but I don't want to be 
a burden to them. Losing your independence is soul destroying.” (Survey ID307) 
A number of beneficiaries described wider fears about coping and loss of identity or self-
esteem, if their health declined further: 
“This past few years my health has declined, my anxiety is more and I worry about 
coping. I physically struggle more with daily life. I don't like talking about not being 
able to cope or asking for help. Hate having to rely on people. Simple things I used 
to do I can no longer do. It makes me feel a burden and useless at times.” Survey 
ID126 
188 
 
“From being a fully employed, independent active and optimistic person, I am 
becoming isolated and cut off from work and family. I may have to consider moving 
back to the UK in 5-10 years’ time, which would negatively affect my marriage and 
wider life. Any serious health concerns – diabetes, cancers etc. – will be both 
difficult and painful to manage. Perhaps more than anything I dread the prospect 
of going blind. While I am endeavouring to remain active and positive and have 
received huge support from family, friends and Thalidomiders (social media is 
invaluable) at times, I feel my sense of myself as a person is under siege.” Survey 
ID265 
Deterioration in physical health and loss of independence were, for many respondents, 
intertwined with their emotional health, and their comments highlighted this. For some, 
worries about emotional health resulted from a lifetime of dealing with physical 
impairment, whilst for others it arose from recent problems or events: 
“Everything in life is and always has been a compromise from the type of property I 
live in to what I may prefer in clothes, social activities, holidays, or helping with 
grandchildren.  All aspects of life are a compromise between what I would like and 
what my disability allows.  Emotionally, psychologically, physically this is impacting 
far more as I age. A combination of deteriorating health/ability and [the] realisation 
of the freedom of choice my peers have." Survey ID132 
“In the last few years I have noticed a huge deterioration in my everyday needs 
and emotional wellbeing. This has made me suffer with deep anxiety and panic 
attacks.  I do feel safe and secure when in my own home [but] cannot cope with 
busy environments at all these days… [since] I had a serious fall…which left me 
with very little confidence and scared of falling again.” Survey ID80 
A number of respondents highlighted their growing need for personal assistance and help 
in the home. Some beneficiaries found it hard to come to terms with this in relation to their 
independence and personal privacy.  
“I am very independent…but I find it harder to manage.  The big dilemma is how to 
maintain independence or how to manage help or minimize it because I don't mind 
one-off visits e.g. for garden or handyman jobs but regular cleaning etc. I don't like. 
It feels like an interference and I like my space.” Survey ID192 
Respondents’ comments about personal assistance and help in the home often 
overlapped with comments about support from family members and fears about this 
changing in the future.  
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“Because I live with my partner, I feel relatively secure. This year he had a cancer 
scare and though his results were negative I came face to face with the 
precariousness of my living arrangement. I would be in a disastrous situation if 
anything happened to him. I rely on him 100%.” Survey ID85 
“What happens to me when my parents are no longer alive?” Survey ID133 
Running through many of these comments is a common thread, namely that some 
Thalidomide survivors feel their current way of life was vulnerable, even precarious.  
6.8 Summary 
Given the substantial range and depth of the material presented in this chapter, it is 
perhaps helpful to briefly summarise the main findings. The survey respondents were 
highly representative of all UK Thalidomide survivors in terms of gender, country of 
residence and level of impairment, although there were some differences in relation to the 
nature of respondents’ impairment. In particular, Thalidomide survivors with visual 
impairment were under-represented. The educational qualifications of respondents was 
broadly similar to that of the general population of a similar age, but their work situation 
was radically different with almost half reporting that they were unable to work or had to 
work part-time, because of their disability or health problems.  
Musculoskeletal conditions and mental health problems were the two most frequently self-
reported health problems, but generalised pain and multimorbidity were also common. 
Compared to the general population of a similar age, a higher proportion of respondents 
had undergone joint surgery. Only half of those reporting mental health problems had 
received treatment for these problems. In relation to health-related quality of life (as 
measured by the SF12 Health Survey), respondents had much poorer physical health-
related quality of life than the general population of a similar age but their mental health-
related quality of life was only marginally poorer. Further statistical analysis, which 
showed that poor physical health-related quality of life was associated with severity of 
original impairment and being unable to work, led me to conclude that secondary health 
problems and associated loss of function may be a far more important influence on 
physical health-related quality of life than original impairment alone. Those respondents 
who reported being unable to work were also likely to have poorer mental health-related 
quality of life and low mental wellbeing (as measured by SWEMWBS).  
Lastly, the comments that respondents added in the free text box at the end of the survey, 
remind us that the health problems Thalidomide survivors are experiencing are being 
layered onto a lifetime of living with disability and this has profound and complex 
implications. I explore these issues in greater depth in the next chapter. 
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Chapter 7 Changing Lives: Secondary Analysis of 
the Interviews 
In Chapter 5 Changing Health, I began to scope the type and nature of the health 
problems that Thalidomide survivors are experiencing as they grow older. Descriptive 
analysis enabled me to identify the main ‘groups’ of health problems, whilst content 
analysis helped me gauge the relative importance of the health problems discussed in the 
interviews. This initial analysis informed the development of the health and wellbeing 
survey, which has determined the prevalence of these health problems and provided 
insights into how deteriorating health is affecting the quality of life of Thalidomide 
survivors. This final results chapter presents the findings of the secondary analysis of 
interview data, which were much richer than originally anticipated, with participants talking 
in some depth about the impact that secondary health problems were having on them, 
physically and mentally. This enabled me to understand how their lives were changing in 
response to deteriorating health, and develop conceptual constructs consistent with the 
principles of grounded theory.   
As I describe in Chapter 3, I set the initial content analysis aside, and reanalysed the 
interview transcripts using a grounded theory approach. From the initial and focused 
codes, seven conceptual categories emerged. In this chapter I describe what is 
encompassed by each of these conceptual categories and the relationships between the 
categories. I present them in the order that seemed most logical and informative but in 
reality the categories overlap and intersect. Some categories influence or provide context 
for others and occasionally they throw up contradictions but collectively they show how, in 
their own different ways, Thalidomide survivors are adapting and changing their lives as 
they age. As in Chapter 5, I use quotations from participants to bring the conceptual 
categories to life and illustrate themes within them. The names shown are pseudonyms.  
7.1 Shifting Impairment 
The initial analysis of the interviews highlighted the health problems Thalidomide survivors 
are experiencing as they grow older. The Health and Wellbeing Survey (Chapter 6) 
provided further evidence about the prevalence of these health problems. Together they 
show that whilst TE is non-progressive, the impairments it caused are not static. 
Thalidomide survivors are experiencing shifting impairment. This makes them especially 
conscious of managing future uncertainty, which in turn makes them more aware of the 
importance of independence 
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In the initial analysis of my interviews, I identified three perceived root causes of peoples’ 
Thalidomide related health problems. The first was that some problems were directly 
linked to peoples’ original Thalidomide damage. This encompassed both deterioration of 
known damage (e.g. in eye sight or a heart condition) but also the emergence of newly 
recognised damage (e.g. a missing kidney) or an increased understanding of the extent of 
known damage (e.g. the nature of malformed joints). The second and perhaps the most 
common root cause was secondary damage or premature wear and tear caused by the 
ways in which people have had to use their bodies to compensate for their impairments. 
The third root cause was accidents and injuries, where these had occurred as a result of 
existing impairments (e.g. falls linked to mobility, balance or sight problems). All three of 
these root causes, but particularly the first two, are central to this shifting impairment. 
Below I explore Thalidomide survivors experiences of shifting impairment, including how 
they talked about this change, the implications for their functioning and mobility and, for 
some, the heightened sense of ‘being disabled’ that it engendered.  
A number of people described how deterioration in known damage was affecting their 
health and functioning. Fiona explained that she was born with a hole in her heart and had 
operations as a child to repair a valve. However, in recent years she had required further 
treatment: “In the last 3 years it needed replacing altogether and I had a new valve fitted 
in 2011.  That was major surgery again”. More commonly people talked about 
deteriorating eyesight or hearing resulting from the original damage to their eyes or ears, 
whilst a few people touched on other issues such as long standing bladder and bowel 
problems becoming worse. For example, in talking about his reluctance to take pain 
medication, Gary mentioned that this was linked to concerns about his bowel problems: 
“Such medication will only serve to irritate or exacerbate my existing stomach and 
intestinal abnormalities which are already beginning to cause related bowel issues”. 
Others described how the process of seeking diagnosis and treatment for health problems 
revealed the extent of their Thalidomide damage. Linda, who described herself as “one of 
the least disabled out of all of us” developed severe pain and a lump on her wrist from 
pushing wheelchairs as part of her work. She explained: 
“…they said they thought it was carpal tunnel but they’d never seen anybody’s 
hands like mine, and could they do X-rays.  When it came back, I did find a lot of 
things out and one of the things I found out was there was only one blood supply 
into my hand and everybody has two”. Linda 
Several participants had sought treatment because deterioration in existing impairments 
was causing severe pain and/or loss of function but were often unsure about whether to 
proceed. There was a real fear that addressing one problem might create new and 
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different problems. Amy explained that she has one leg slightly longer than the other, so 
her foot turns over to compensate and she suspects that her hips “aren’t made properly 
either”. In recent years her limp has become more pronounced and she is getting pain in 
her knee and hip.  
“I think I need to go and have some things put into my shoes to stop my left foot 
turning because I think that would help.  I think the difficulty is that I’m quite 
worried that if I redress that balance, and skew everything back, it’s going to put 
everything else out.  Because I’ve been walking like this for so long, because that’s 
the way I reach for things and that’s the way I do things.... but the worry is then 
that if I skew everything back and make it all straight, it’s going to cause more 
problems”. Amy 
The choice was even starker for those being offered surgical treatments. This issue is 
discussed more fully in Section 7.5 Taking Control of Own Health. However, it is useful to 
note here that whilst for some, surgical treatments had relieved the symptoms they were 
experiencing with no permanent loss of function, for others it led to a significant shift in 
their impairment. Jim had been experiencing severe pain in his shoulders and arms for 
about ten years. Diagnostic scans showed major deterioration in his shoulder joints and 
so he decided to have both shoulder joints replaced. However, whilst the operations had 
taken away the pain, his movement had become much more restricted, and the 
procedures also had unexpected and major ‘knock on’ consequences for his health and 
level of impairment, as the extract from his interview reveals: 
“When I had my shoulders and that done, something happened to my back.  What 
it was, I’d been stooping because my shoulders were broke. I was stooping a little 
bit and of course I’d got a humped back.  The thing is, what happened to my back 
– the spine straightened itself and - it took over 2 years – [I was] getting taller and 
taller…But something bad happened.  I was having all these headaches and that 
and I went to the hospital – neurology hospital – in London and they gave me an 
angiogram and they found out that the blood was coming up the spine but it wasn’t 
going to the places it should be going to…they had to do it [an operation] straight 
away and I was on the verge of a haemorrhage….I mean I was lucky…they 
explained to me that, because of the complications, I could die and I could never 
walk again.  But it had to be done to get the blood going to the right places.  And it 
was all good but the only thing that happened was I had a stroke under the 
anaesthetic – yes – my left leg is completely numb.  This is the worst thing that’s 
come out of it. My left leg is completely numb and I’m walking on it but it’s not 
getting any better and it’s dragging a bit, if you see what I mean.  So it’ll get better 
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one day, the nerves might come back but I can’t see it myself.  But I was lucky – I 
was so lucky really if you think about it. But I mean that’s what happens - there are 
other sides to things – but this is all to do with the Thalidomide anyway.  It was my 
fault.  I mean, I wanted to do things in my shoulders and I didn’t think that would 
happen to my back and it did, so it was all down to me, and I’ll never blame 
anybody at all....My own health is all right, it’s my arms – I just can’t use them, and 
my legs”. Jim 
For a few participants the emergence of newly recognised damage, coupled with 
deterioration, was leading to significant changes in the nature of their impairment. Carol 
described how she only discovered that she had a hole in her pelvis, when she broke it 
about 15 years ago. She then went on to talk about her decision to stop using her artificial 
legs: 
“I used artificial legs up to 10 years ago and then I had to give them up because 
they were causing me so much pain. Getting infections in my stump ends – 
cellulitis – which was quite bad. I’m now in a wheelchair all the time.” Carol 
Helen, another lower limb affected Thalidomide survivor had taken a similar decision 
because of the back pain and fatigue caused by using her artificial legs. The change from 
walking with artificial legs to becoming a wheelchair user is a very visible manifestation of 
shifting impairment. It might also be seen as ‘worsening impairment’. However, ultimately 
both Carol and Helen saw this change as positive because they felt better physically and 
were in many ways more mobile: 
“When I was younger, a child, I walked around with nothing – no sticks or crutches 
or anything.  Probably in the early 1990s, I started using crutches because of my 
back, and over a period of time I used the chair more and more, so it would be 
1999 when I completely gave up my limbs and I found I was more mobile without 
them on – without using them.  I just said ‘It’s easier to get round in a wheelchair’.” 
Helen 
The overwhelming majority of Thalidomide survivors perceived their shifting impairment as 
being directly linked to the ways in which they have use their bodies to cope with or 
compensate, for their original impairments. However, they made sense of this change in 
different ways and their response to it also varied. Some people appeared relatively 
sanguine about the problems they were experiencing, and described them in quite matter 
of fact terms: 
“Because I've had problems with me right leg, me left leg's done all the donkey 
work and it's now basically saying ‘I've had enough’ and I've had problems with me 
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left knee, left hip. I've always had problems with basically me spine, just general 
wear and tear.” Tom 
For those with more severe damage in particular, there was a sense that the deterioration 
was inevitable, given the nature of their original impairments. Fiona simply talked about 
“using our legs for things they weren’t designed for”, whilst Alex explained that he has no 
arms and uses his legs to do everything, leading to problems in his lower back and hips. 
Similarly, Alan, a lower limb affected Thalidomide survivor was told that the arthritis in his 
spine was probably the result of the way he was pushing himself in his wheelchair. He 
commented: “There’s no other way I can push myself, other than not pushing myself at all, 
which isn’t really an option”. 
Many participants described in some detail the unusual ways in which they had to use 
their bodies and speculated on the secondary damage this may have caused. Often they 
illustrated this by talking about everyday activities: 
“I would have to say it’s the pain in my joints, especially now I’m finding it in my 
feet as well because I would use my feet for turning on and off plugs instead of 
bending down, and then of course my fingers with typing and you know getting 
dressed…and then my teeth. Obviously you use hands for pegging out clothes, 
well I use my teeth to hold clothes to the pegs. Things like that, or opening a bottle 
or water or juice or something like that because you wouldn’t have the power in 
your hands to do that anymore. So your teeth have taken wear and tear which I 
think people forget about”. Joyce 
“My right foot is my useful foot where I have a lot of dexterity in the toes. It’s the 
one for picking up things, picking things up off the floor and putting them onto 
surfaces, in reach of my hands, and things like that. I use that foot for filling the 
washing machine, and taking the clothes out of the washing machine and things 
like that, so it’s actually now having quite a big effect on me. And because that leg 
is going bad, it’s affecting my balance and walking is not so good”. Moira 
When participants talked about the everyday activities they could no longer manage, or 
could only manage with aids or support, they were, in effect, talking about how their 
impairment had shifted. As such, everyday activities had become the barometer by which 
they measured the changes in their impairment, often comparing what they could do when 
they were younger and what they could do now:  
“I have experienced deterioration in my arms and hands over the last ten fifteen 
years. My fingers are not as flexible and my arms haven’t got as much movement, 
so things that I could have done ten fifteen years ago I can’t do now. I mean from a 
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personal care point of view, like being able to wipe ones bottom and that type of 
thing, I can’t bend anymore. I can’t do that for myself. I have to rely on my Clos-o-
mat toilet or I have a disability aid which is like a tissue holder that I can use. 
Whereas before, I was flexible enough that I could have managed that sort of thing 
myself but I definitely can’t do that now”. Tracy 
For some participants, the ‘unpicking’ of how they used their bodies was perhaps a way of 
understanding or even reconciling themselves to shifting impairment. In trying to make 
sense of the loss of strength in his arms, Malcolm reflected: “I’m trying to over-reach – 
trying to…adapt to the problem.  I think my arm, because it’s not wanting to do that, I think 
my shoulders are trying to compensate for it, so therefore it’s hurting my shoulders and 
my neck”. For others it also appeared to be about developing strategies or taking steps to 
reduce further loss of function (these efforts to preserve function are discussed in greater 
depth in Section 7.2). This latter group were more likely to use quasi medical words and 
phrases such as ‘overuse’, or ‘over compensate’ and ‘right/left side dominance’. For 
example Moira, who in the quotation above described the loss of function in her ‘useful’ 
right foot, went on to say:  
“It is all part of the overuse syndrome, and I think in my case, and I would imagine 
other Thalidomiders like this, I’m very right side dominant in terms of my right arm 
and right leg being the ones I’ve always used to do things. They are wearing out 
quicker than the left side. So I’m having to try and adapt, to train my left foot to 
start doing the kind of work my right foot used to do”. Moira 
Amongst participants whose original impairments were less severe, deterioration in their 
function or mobility often engendered a new or heightened sense of ‘being disabled’.  
Participants like Linda talked about the emotional reaction: 
“I was really worried because I’ve always tried to be the same as everybody else.  
That’s emotionally how it’s affected me because even when you were at school 
when you were younger and things like that, I never wanted to be different, so try 
to over-compensate.  So when something started to go wrong, and you start to 
think ‘Oh, no – I’m not going to be able to do this anymore’”. Linda 
Others talked about the practical implications. For some, relatively minor shifts in 
impairment had led to them feeling more ‘disabled’ by their environment. For example 
Amy explained that she was finding it increasingly difficult to manage things like door 
handles, keys and ticket machine: “I often go places and think actually, I can’t go to the 
toilet here cos its round door handles and if I go in, I’m not going to be able to get out 
again”. Others talked about accepting bureaucratic indicators of ‘disability’. Ann described 
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how loss of earnings (due to sickness absence from work) and mobility problems had led 
her to apply for Disability Living Allowance and a Blue Badge.  
“I finally got a blue badge about a couple of years ago…I never needed it before 
but now with the bad back....Well, a couple of years, I wasn’t able to walk – I 
needed to park near things…so the Blue Badge has been helpful and the Disability 
[Living Allowance] thingy I’ve never had that before”. Ann 
In concluding this section, it is perhaps helpful to touch on two other aspects of shifting 
impairment which had a strong relationship to other conceptual categories. The first is that 
alongside participants actual deterioration in their function or mobility, was a fear of further 
deterioration. This inevitably led participants to think about ways of preserving their 
function, which was in turn linked to attitudes to independence and access to financial 
resources. The other is the ‘life course’ aspect to shifting impairment, which was clearly 
linked to Thalidomide survivors’ broader experience of ageing. A few participants didn’t 
really perceive that their impairments had shifted but rather their ability to cope with them 
had changed, as they aged. More commonly people struggled to disentangle the 
deterioration they were experiencing from ‘normal’ age related changes. This reflects the 
fact that shifting impairment really assumes meaning when set in the context of the life 
course and normative assumptions about ageing. 
7.2 Preserving Function 
Coming to terms with the loss of function caused by shifting impairment was often hard 
and involved both psychological and physical adjustments. Not surprisingly, it had a major 
impact on some participants’ mental wellbeing and I discuss this further in Section 7.5. 
However, many participants also talked about the practical steps they were taking to try 
and preserve the function they still had. For some this process began with a change in 
their mindset, which was in part driven by the fear of what further deterioration would 
mean for their daily lives: 
“When you’ve always done it, and you suddenly can’t do it, it’s very frustrating.  I’ll 
be honest, it’s one of the things – it took me a while to be able to say ‘Well, you 
can’t do it, so you’d better just stop messing around and just get on and let 
somebody else do it.  You cannot do this’.  It did take a while to let that sink in…it’s 
stupid because you’re just going to deteriorate.  If you don’t do something about it 
now, what are you going to be like in 10 years’ time?” Linda 
Like Linda, many participants acknowledged that it had taken time for them to recognise 
that they needed to change aspects of their lives, both big and small, in order to preserve 
their bodies. A few, especially those with lower levels of damage who tended to be less 
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connected to the Thalidomide community, almost had to begin by acknowledging their 
disability, so that they could then seek advice about what to do.  
“I just need to know where to go – obvious I think for the future…I think 
adaptations is what I need to do, but I really don’t know what would be appropriate, 
or what would help, or where to go…I really need information and also to try things 
out.  I don’t move in the world of disability – I know that sounds really weird but I 
don’t move in that world.  I don’t know much about it, so I try and function just the 
same as everybody else and probably need to step into a new way of thinking 
really.” Jenny 
A few participants were particularly proactive in their efforts to preserve their function, 
perhaps in a more explicit attempt to gain some control over what was happening to them. 
Interestingly they were sometimes critical of other Thalidomide survivors who they felt 
were not making the effort to help themselves – a view that perhaps mirrors some of the 
argument in public health around the role of the individual in promoting or preserving their 
own health: “We really need to keep our bodies functioning…but some people are just not 
interested. They’ll lie on their couch and stuff themselves with cream cakes and worry 
about tomorrow when they can’t get off the couch” (Amanda. However, the majority of 
participants were trying to preserve their functioning in a variety of ways. The approach 
they chose was in part determined by the nature of their impairments and associated 
physical needs but family circumstances, the acceptability of different strategies (e.g. aids 
and adaptations versus personal assistance) and resources also played a part.  
Although many Thalidomide survivors, especially those with severe damage, have always 
had help with daily living, often some or all of this help was provided by family members. 
Changing family circumstances sometimes meant that in order to preserve their function 
(and maintain their independence) a number were now having to buy in help, as Beth 
explained: “I’ve had to give in and get a gardener in, because we have a garden, and I 
can’t cope with it.  It’s not fair asking my sister and brother-in-law to do it.  Their health’s 
not 100% either.” Others were putting more support in place in anticipation of adult 
children leaving home or ageing parents no longer being able to help them:  
“I’m paying for a lot more help, an awful lot more help. I do not do things that are 
going to put a strain on me…when you’ve been in so much pain and you can have 
a quality of life …it’s a bitter pill but I’m very fortunate that my eldest daughter is 
still at home at nearly thirty. She will have to go. I’m almost going to have to push 
her away. But of course she’s my main help in the house but things will change.” 
Karen 
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Many simply saw accepting more help from family and friends or buying in help with 
domestic tasks as one of the most practical ways of reducing the strain on their bodies. 
Rowena, who described herself as “fiercely independent” when she was young, reflected 
that she was now accepting more help around the house from her husband and son in an 
effort to avoid further deterioration in her arms and hands. As the quotation from Karen 
above implies, preserving function was also intertwined with avoiding or reducing pain, in 
part because pain was often seen as a ‘marker’ of deterioration. For example Alan, who is 
a wheelchair user explained that because of arthritis in his spine and pain in his hands, he 
has accepted his PA pushing his wheelchair when he is away from home for long periods. 
Tom put it very clearly: 
“Truthfully, I think there's a lot of us who are, are starting to turn round and have 
the attitude it's easier if somebody helps, it's easier if somebody does it; to a 
certain extent, it could possibly make you look a bit lazy, but being a bit lazy and 
pain free is, is a lot easier than being in pain.” Tom 
However, others were reluctant to accept help, or at least help from outside the family. 
Carol, who has grown up children nearby said that she has always been happy to ask 
them for help but she is now reluctantly contemplating getting help with cleaning: 
“Yes, I’ll probably hire a cleaner, once a week or twice a week…When I hoover I 
hoover on my knees. I balance where my stump is and just hoover, you know what 
I mean. At some point I’ll have to stop doing that because it’s how my knee got 
damaged in the first place.” Carol 
A few were finding having help in the home from strangers very difficult. Jenny described 
her feelings about privacy and dependence: “I’ve had cleaners and I’ve found that really 
difficult. I really don’t like having people in my house. It’s all very personal – I just hate it”. 
She went on to say: “I really don’t want to be dependent on people. You know, when I 
stopped the cleaner, I felt – I know there’s a cost to it in time and the stress on my hands 
but gosh – I felt so good”.   
As the Health and Wellbeing survey results showed, a significant proportion of 
Thalidomide survivors saw giving up work or reducing their working hours as one of the 
most beneficial things they could do to preserve their function. Rick was experiencing 
back and neck problems and an assessment from his employer’s occupational health 
doctor showed that these problems were being exacerbated by office tasks such as using 
a computer and answering the phone. Rick said: “Since I gave up work, the day-to-day 
issues, a lot of them have gone away because, as I say, there was a lot of keyboard use 
and stuff like that, in an office environment”. The extract from Alex’s interview below, 
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reveals that peoples reasons for giving up work were often mixed but at the core was a 
desire to preserve their functioning: 
“It was a bit about family – I’ve got quite a young family, who actually quite like to 
do family things really – it’s quite nice.  And because I’m in a position where I can 
– my wife works and she’s got a reasonable job – so from the finance point of 
view, it was doable.  But there was also the issue of ‘It’s actually getting quite hard, 
this’ – having to carry lots of things – finding that quite hard work.  I mean, the 
employer was as..... they do their best, don’t they?  They say ‘OK, how can we fit 
this in?’  They got the Access to Work people involved, got me a motorised desk 
and this, that and the other.  But at the end of the day, you’re still having to put the 
effort in, you’re still having to do things with your feet and legs. The job I had was 
in was in Adult Care – an Adult Social Services role.  I was going out, giving 
people advice about various things.  I was seeing people with disabilities myself 
who had left it too late.  These were people who were maybe in their 60s and 70s 
[who had said] ‘Oh, I’ll do it when I retire…When I retire, I’m going to do that’.  
Something happened – their health deteriorates, a road traffic accident, or 
whatever it is, and now they can’t do it.  That was in my mind as well.  I was 
thinking, ‘Well, if I keep going like this, by the time I’m 60, I could just…I might be 
worse’.  At the time, it felt that it was actually quite a big possibility – that’s not just 
a random, nonsense type of thing people say.  It could happen.  So I made that 
decision – quit while I’m ahead.” Alex 
Several participants explained that for them, it wasn’t just the strain their actual job placed 
on them, it was everything surrounding working, from getting up and dressed, to travelling 
to work, to unsympathetic employers. Ben, who has a prosthetic leg, described how 
commuting to work by train (e.g. lifts not working, walking long distances, crowds etc.) had 
become increasingly difficult after major problems with his ‘good’ leg: “I thought to myself, 
well, I don’t want to put any more strain on my right leg, so I made the decision to give up 
on that basis because I just didn’t want to damage myself any more”. Ben’s and Alex’s 
comments suggest that some participants were not just trying to preserve function within 
the current framework of their lives, they were actually prioritizing function and in so doing 
changing aspects of their lives quite significantly.  
Conversely, a few participants were keen to continue working, albeit usually part time. 
Sometimes the motivation was financial but often it was because people enjoyed their 
work and/or valued the social contact it provided. Although some participants had bad 
experiences with employers, several said that their employer (and work colleagues) had 
made changes to their working environment so that they could continue working without 
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putting a strain on their bodies. Others were buying in more help at home or from 
workplace personal assistants so that they could keep working: “I’ve worked hard at my 
job and yes it’s a very important part of my life.  It’s financial too.  I’m a single parent with 
two children – I’ve got to work” (Penny). 
It was clear that the introduction of the Health Grant had been a factor in some 
participants deciding to give up work or reduce their working hours, in effect using their 
Health Grant to offset loss of income. As such, it gave them the choice or at least the 
perception of choice about whether to work or not.   However, the Health Grant also made 
it more possible for people to use home adaptations and equipment to help preserve their 
function. For most participants, especially those with upper limb damage, the adaptations 
to their homes that made the most difference were kitchens and bathrooms, as the 
quotations below illustrate: 
“Currently my husband is putting in a kitchen, which is a thing I’ve wanted for 
absolutely years and finally we just said that’s what we need to do for myself so 
that I can access the cupboards…It’s going to be my own space with a work 
surface at a level that I can lean on and I’m having everything made so that I don’t 
have to stretch”. Joyce 
“We decided to put in a shower – a wet room – that’s the word I’m looking for.  But 
basically, it’s a shower.... it’s a bit like when you go into a swimming pool, the 
shower rooms that you go in, and everything’s tiled, so there’s more space for me 
to move about.  I can sit on the floor.  I can wash myself as best I can.  For the 
areas where I’m not able to wash myself, my wife will come in and help out, so 
there’s room for two of us”. Alex 
Many participants were also making more minor adaptations to their homes and these 
often made a significant difference to their daily lives. The most common minor 
adaptations were things like changing taps, door handles and locks to make them easier 
to use but also fitting new windows. The quotation below vividly illustrates this point: 
“I have done another door with the automatic blipper. We live in an old house and 
all the handles are quite low and I’d been going down on my knees to try and turn 
the key. Now I’ve got this blipper…my wrist doesn’t work like your wrist. I can’t do 
Yale locks. We had the Chubb ones and I can just about do those at a push. So 
this is amazing – you just have this little blipper that you take with you. It cost a lot 
of money but I use it every day of my life”. Karen 
Alongside physical adaptations to their homes, most participants were making a range of 
small changes in their daily lives, all with the aim of making life easier and so preserving 
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function. Often they were things that anyone might do such as online supermarket 
shopping or using taxis more frequently but sometime they were more unusual e.g. 
electric curtains or bespoke pieces of equipment such as dressing stations. Participants 
also talked about changing their routines or ‘pacing’ themselves or just being more careful 
about what and when they did things. Several participants, like Tessa, explained that they 
tried to do tasks in the morning or when they had more energy: “I’m quite all right first 
thing in the morning, and I whizz through everything, but as the day goes on, I get tired 
quicker obviously, so I do try and do what I can when I can”. For others it was about 
generally slowing the pace of life or interspersing busy or working days with ‘rest’ days.  
Importantly many participants saw all these adaptations and changes as a progressive – 
something that they would continually have to revisit as their impairments shifted and they 
aged. Alison described her thoughts about this: 
“As you’re getting older, you’re thinking ‘Oh, that used to work but this doesn’t 
work anymore’.  So as time goes on you’re constantly adapting. I mean before we 
know it, the 10 years [of the Health Grant] will be up and we’ll probably be at a 
completely different stage again… it’s kind of like a rolling programme because 
something that worked 5 years ago, or 10 years ago, may need further change”. 
Alison 
Whilst preserving function was a distinct conceptual category, the approaches participants 
were using to achieve this often overlapped with efforts to maintain their independence or 
rethink what independence looked like for them at this point in their lives. Money also 
played an important part in creating choice and facilitating what people did. I discuss how 
money mattered in section 7.4.  
7.3 Rethinking Independence 
For Thalidomide survivors, like all of us, independence is a relative concept but how they 
thought about their independence was complex and nuanced.  They judged it relative to 
both their peers in the general population and in the Thalidomide community but also to 
their younger selves – perhaps something that few people in their 50’s would do. Their 
feelings about it were influenced not only by the extent to which they had used help 
throughout their lives but also by the type of help they needed and who (or what) provided 
that help. Furthermore, as they age and their impairments shift, many Thalidomide 
survivors are having to rethink what independence means for them, which often brought 
with it a sense of uncertainty about what the future might hold. However, the start point for 
them rethinking independence is slightly unusual. Thalidomide survivors have a strong 
group identity, which was revealed by participants’ use of ‘we’ and ‘us’ rather than ‘I’ when 
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talking about their attitudes towards independence, even seeing certain personally traits 
as common to the group: 
“We’re quite stubborn. I don’t think we mean to be.  But sometimes if I’m speaking 
to people and you do a sort of self-appraisal of yourself, and you think ‘yes, I am 
quite stubborn actually’.  But it’s because you want to show the world that ‘yes, I’ve 
got quite a disability, but I’m as independent as I can be’”. Alex 
For many participants, independence appeared to be intimately linked to both their 
individual identity and that of the group, and they feared that accepting more help (and so 
in their eyes becoming less independent), would somehow change who they were.   
“I think it’s something that’s just coming upon us now because I think so many of 
us have been so independent.  So you know, we met our husbands, we were 
completely independent, the same as everyone else, we’ve had our children, 
we’ve brought our children up – we’ve been very independent – and for us now to 
start finding we can’t do things, it’s changing the person we are…if you start 
becoming somebody who needs help all the time, then you’re different to who you 
have been.  Does that make sense?” Amy 
Some participants felt this group identity, perhaps reinforced by public perceptions, had a 
negative side, making it harder for people accept that they may need to change how they 
lived. As Carol put it: 
“I think people have always been made to do stuff or to feel that they should do 
certain stuff and if they don’t they’re a bit of a looser or have given up but they 
haven’t, it’s just that you have to make lifestyle choices”. Carol 
In section 7.1 Shifting Impairment I explained that participants often used their ability to 
carry out everyday activities as a measure of how their impairment had shifted. Similarly, 
in relation to independence, people compared what they could do now (unaided) with 
what they could do when they were younger. Over the years people had developed ‘work 
arounds’ to enable them to do tasks themselves but increasingly they were finding that 
these no longer worked. 
“There are certain things I can’t do now that I used to be able to do, like I used to 
be able to unload the dishwasher but I can’t do that…Lifting heavy stuff – I can’t do 
that…things like washing my hair.  I do do that but I find it a bit harder, and 
washing the top of my head a bit harder still but I find things to use to compensate 
in that respect.  It doesn’t always work very well but at least it does it”. Tessa 
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As a result many participants were making greater use of aids and equipment (e.g. wash 
and dry toilets) or were modifying aids they already had (e.g. dressing stations), and/or 
making adaptations to their homes, in particular kitchens and bathrooms. This was partly 
to preserve their function (see section 7.2 above) but also so that in their own environment 
they were as independent as possible. It was often when people were away from home 
that their independence felt most fragile. 
“It’s more when we go away or out anywhere else because I think you mould your 
own environment round yourself, don’t you?  So you can manage where you are 
but when you’re away in a different environment, then that’s a bit tricky”. Isobel 
Even in these situations people were rethinking independence and finding new strategies. 
For example, Robbie travels to London regularly and so he found a London based 
personal assistant (PA) who assists him when he is there. Simon takes a potable bidet 
with him when he travels and Martin has his trousers altered: 
“I like smart trousers and now I’ve found a guy who will elasticate them and put 
little hoops on them so that I can pull them on and off myself. It’s all right getting 
my wife to help but if I’m out at a meeting somewhere and I need the loo I’ve got to 
be able to do it myself”. Martin 
However, even with aids and adaptations, as I discussed in Preserving Function, for many 
people there was a continuing tension between doing things for themselves and knowing 
that if they did they would be in pain or excessively tired or even cause further damage i.e. 
there was a ‘physical price’ for independence. Participants talked about how gradually 
they were having to accept they needed more help. Clearly some, like Kathleen, still found 
it hard: “It was having to admit that I needed more help than I realised and I can’t do 
everything I think I can, as my daughter keeps pointing out. Just using the term ‘I can’t’ 
sticks in my throat”. Others like Karen, were more philosophical: "We’ve all gone through 
the ‘I cans’. We’ve proved it to ourselves that we can and now its hang on, what can I do 
to make life easy”. 
The majority of participants had always had some help from family members and many 
were conscious that they were needing more help. However, peoples’ perceptions of what 
this meant for their independence and what was acceptable to them varied. Most 
participants accepted help, albeit sometimes reluctantly, with practical tasks around the 
home but for some there was a sense that needing help with personal care from their 
partner marked a decline in their independence. Others struggled with the more intimate 
aspects of personal care that: 
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“I’ve had these shoulders done and now I cannot leave the house unless [wife] 
dresses me.  I mean, I really don’t like it. So she really does do quite a bit for me, 
you know.  But there are things I won’t let her do, if you see what I mean, which is 
very personal things”. Jim 
Interestingly, some participants were comfortable with help and even personal care from 
family members but clearly saw needing help from outside the family as a step change in 
their independence. Despite having help around the home from personal assistants Karen 
remarked: “it’s the personal care…but I haven’t crossed that line yet because the family 
help me personally”.  
Many Thalidomide survivors with more severe damage have had help from carers or 
personal assistants for much of their adult lives. Interestingly, the participants in this group 
actually saw PAs as a means of maintaining their independence, not reducing it. Gwen 
said: “It means that I can do things I wouldn’t be able to do without a PA, like when you’re 
away you can go out and do activities and stuff – it all helps”. However, for her and 
several other participants having a Direct Payment which gave them the freedom to 
choose their PAs, decide what hours they worked, and what they did, was crucial to their 
sense of independence. For others, accepting more help from their PAs or applying for a 
Direct Payment so that they could employ PAs, was part of the process of rethinking 
independence. For example, in the past when her PA was off sick or on holiday, Alison 
would have tried to cope on her own. Now she employs a relief PA: “Whereas at one time, 
I would have managed and just got on with it, I’m teaching myself not to do that anymore.  
So I call in this other young lady on a casual basis…I’m making myself delegate and not 
struggle”. Others had decided to apply for help from social services for the first time, in 
part to help them maintain their independence: 
“I am losing a lot of function and also the amount of effort I’m putting into doing 
basic functional tasks is having a massive impact on energy levels – I’m using up 
all my energy doing basic tasks. So yes, I’ve been referred to social work and they 
have been out an done an initial assessment and they’ve written a report for the 
Direct Payment services…So I’ll hopefully being employing somebody, hopefully in 
the next few months”. Moira 
Conversely, a few participants saw accepting help from social services as diminishing 
their independence. Carol said: “I’m not severe enough to actually apply for money for 
personal help. I suppose I could but then I’d lose part of my independence, part of who I 
am, my identity”.  
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Compared to disabled people in general, Thalidomide survivors have perhaps had more 
freedom to decide whether to seek state help to maintain their independence because 
they have resources from their Annual (compensation) Grants and more recently the 
Government Health Grant. However, as I discuss in the next section, money was 
important for much more than independence.  
7.4 Money Matters 
In Chapter 2, I describe how the legal settlement in 1974 led to the establishment of the 
Thalidomide Trust and the payment of Annual (compensation) Grants to all UK 
Thalidomide survivors. For many years these payments were not substantial. They were 
also subject to income tax, with Thalidomide survivors (and previously their families) 
having to submit receipts if they wished to claim tax relief on items that were related to 
their disability: a system they found bureaucratic and patronising. It is only in the past two 
decades that Thalidomide survivors’ financial situation has improved: in 2000 
compensation payments became tax exempt; in 2005, Diageo agreed a new multi-year 
financial settlement, which doubled beneficiaries Annual Grants; in 2010 the Government 
made a pilot Health Grant of £26 million over three years; and this was then renewed for 
ten years from 2013. These changes have not only given Thalidomide survivors much 
needed resources (in 2018 the average Annual Grant was £37,000 and the average 
Health Grant was £24,000), they have also empowered them to use those resources in 
the ways that they judge will have most benefit to them and their families. 
It is perhaps important to begin by saying that because the interviews were conducted as 
part of the Health Grant monitoring process, they specifically explored how participants 
had used their grants, the impact (if any) of the grant on their health and wellbeing, and 
whether the resources they had felt adequate in relation to their needs. Inevitably this did 
shape participants’ responses, in that they perhaps focused more on the changes brought 
about by the Health Grant, than on their financial resources generally, and so some 
caution in interpretation was needed. Nevertheless a number of clear intermediate codes 
emerged. They suggested that money mattered, not only because of what it could buy but 
also because of how it made people feel. Having money gave participants a sense of 
security, including the ability to cope with unforeseen events. It gave them choice about 
how best to maintain their independence or preserve their function, and the resources to 
do this through equipment, adaptations and support. However, the extent to which money 
made a difference was tempered by the high cost of living with disability, for many, the 
loss of income from paid work, and a sense that often participants were still having to 
make trade-offs.  
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Participants frequently prefaced their thoughts on the Health Grant and their financial 
situation by reflecting on how things had been for them and their families before the 
introduction of the grant. Jim talked about the difference it had made to him: “It’s changed 
our life so much, it’s been incredible.  It has been smashing, to tell you the truth…We 
have struggled in the past and now we don’t have to”. The quotation from Linda below 
also reveals how some participants with less severe of damage even felt ‘lucky’: 
“I feel myself really, really lucky to be honest with you, and even with the Trust 
money [Annual Grant] as well, because, as I said, I’m at the bottom end of the 
spectrum where I’ve just got no thumbs and slightly shorter arms – and I just feel 
really, really lucky because what I am getting is making my life a lot easier.  If I 
wasn’t getting that, then we would be struggling”. Linda 
A few compared their situation to other people with disabilities, who did not have the same 
support, and again stressed how ‘lucky’ they were to have the additional resources 
provided by the Health Grant: 
“To be honest, I feel incredibly lucky to have it.  It feels like an enormous gift and, 
like you say, it’s enabled me to carry on working…I think I’d really feel I was 
struggling without it.  I think that’s partly because of the job that I do.  I’ve got a 
decent wage.  I do earn a decent amount of money but the Health Grant has 
meant that splitting up from my partner hasn’t made me feel too panicky and 
powerless and out of control and that I can still keep working.  I don’t feel that it’s 
not enough but that’s partly because I work with lots of disabled people who are 
struggling and don’t get anything.  So I feel very, very lucky in many ways”. Penny 
In many respects these comparisons set the context for participants’ reflections on the 
sense of security that having money gave them. Many talked about practical and current 
concerns like having the money to pay for their vehicle or wheelchair to be repaired if they 
broke down or being able to have the heating on more during cold weather. Others spoke 
more broadly about how reassuring it was to have the certainty of the money they 
received via the Trust, enabling them to save for the future or cope with unexpected 
events or changing circumstances. As Nicola put it: “It has given me a safety net really – 
peace of mind”. Interestingly Nicola also commented that she didn’t have an employers’ 
pension and so she was now trying to save some money from her Health Grant and 
Annual Grant in anticipation of having to give up work early.  
The Health and Wellbeing survey results suggested that only a fifth of Thalidomide 
survivors have social care support funded by their Local Authority (although the proportion 
increased with the severity of impairment). For some, their Annual and Health Grants 
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meant they could choose not to seek help from social services or the benefits system. The 
reasons for this varied but appeared to be largely about bad experiences in the past and 
the dislike of the ‘bureaucracy of disability’. Penny explained that she had had some local 
authority support in the past but “found them really very difficult to deal with, very intrusive, 
unpleasant – I really didn’t have a good experience at all”. However, for participants with 
more severe damage, the prospect of being able to use their combined income from the 
Trust to help meet their care needs, if support or funding from their local authority was 
reduced, was important for their sense of security: 
“Having the grant makes you feel safe so if there was an eventuality we’d be able 
to cope with it. I’m very careful with it and you know I eek it out until the next one is 
due if I can but it is peace of mind, it helps you sleep at night. I don’t think there is 
anything more on offer from the local authority because as you know there are 
cutbacks everywhere”. Karen 
These reflections suggest that ‘security’ has a number of dimensions for Thalidomide 
survivors: the comfort of being able to afford things in the here and now; the reassurance 
of having ‘insurance’ to cover unexpected events; and the confidence that if necessary, 
the resources are there to meet changing needs. 
Several participants described how money brought wider benefits for their family, many of 
which were the same as anyone might wish for, such as family holidays or helping their 
children out financially. For some this was also around taking the load off a partner who 
provided care:  
“I have used part of my grant to buy a cleaner, a lady to clean 5 hours a week, just 
to take some of the edge off it for my wife. Otherwise it all falls to her. I think that’s 
one of the advantages of the Health Grant – it knocks on and give her a bit of 
respite. You know, she’s forever helping”. Martin 
However, many participants explained that simply having the funds to do pleasurable 
things, helped them by improving their emotional or mental wellbeing (I discuss this further 
in section 7.6) and helped their family. Tracy explained that she was unable to work and 
her husband did not have a well-paid job. Prior to the Health Grant, they had struggled 
financially, rarely being able to afford nights out or holidays, and she had experienced 
bouts of depression: 
“Up until we got the Health Grant and the extra money to do things, depression 
was a big problem as well. I can say definitely since having the Health Grant the 
depression has been the one thing that has not completely disappeared but has 
99% disappeared. The money has given me the opportunity to be able to do other 
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things and not rely on household income. To be able to go out and do various 
activities to keep me occupied and interested in living a life…a worthwhile and 
purposeful life”. Tracy 
Others also commented on how money mattered for their emotional wellbeing. Jenny 
echoed Tracy. She explained that because of her disability, simply doing routine 
household activities like shopping, cooking, cleaning and gardening took up a huge 
amount of time. Having the money to buy in help gave her time for a social life: “That extra 
money allows you the time to have a life…to have a social life, and not to feel so cut off”. 
Amy described her feelings about the Health Grant: “It’s really made us feel like we can 
use it to do things that physically help us, but also emotionally help us”. She had used 
some of her money to pay for personal care task such as cutting her toenails and doing 
her hair, that she found difficult but as she put it “make you feel better – and normal”. She 
went on to say: 
“And it’s nice that it’s something that we’ve been trusted to spend the way we feel 
that we can best spend it for our bodies because obviously we’re all really 
different. What I’d spend mine on, somebody else might not spend theirs on”.  Amy 
Interestingly, a number of participants drew a distinction between their Annual Grant and 
general household income, and the Health Grant. They clearly saw the Health Grant 
money as being specifically for their health and wellbeing and used it accordingly. For 
some there was a sense that this almost gave them permission to spend it in certain ways 
“It’s nice having it kind of separate as well because you can ‘think this is for my 
well-being so its fine to use it in this way’. It’s like a wheelchair costing £6000 or 
£7000. It’s a huge amount of money and you have to think about the other things 
this money is to be used for. I’ve spoken to other beneficiaries who’ve said ‘this is 
what this money is for. Don’t feel guilty that you’ve bought two wheelchairs….the 
money is there to make your life easier and better’.” Meg 
More broadly, having money gave people options and choices, particularly in relation to 
how best to maintain their independence or preserve their function. This affected many 
areas of life from work and health care, to home adaptations and personal care. As I 
discussed in section 7.2 Preserving Function, having money (to replace lost income) 
meant people could choose not to work, or work fewer hours or change the type of work 
they did, or even buy in help to enable them to continue working. 
Money also mattered in relation to how people looked after their health and wellbeing. The 
guidance agreed with the Departments of Health stated that the Health Grant was not to 
be used to meet needs already being met by the NHS. However, as I discuss more fully in 
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section 7.5, for many participants the NHS was not meeting their needs and so they were 
finding ways to self-manage their health problems. Often this involved buying treatments 
such as physiotherapy, osteopathy and massage privately. Even amongst those who 
needed surgical treatments, there was a strong view that having money gave them 
greater choice over when and where they had that treatment: 
“I've also got the reassurance that…in the future I'm going to need me, me left 
knee sorting and I'm going to need me right hip replaced for a third time. I can 
have it done private, I don't have to wait on the waiting list, I don't have to suffer 
pain for eighteen months to two years waiting on the waiting list, I can go for it”. 
Tom 
Simply being able to afford adaptations and equipment was very important to participants. 
As Martin put it “I do something every year that makes my life easier”. However, it was 
also about having more choice over what those adaptations and equipment were. Some 
participants explained that they could now afford ‘standard’ but better quality equipment 
(e.g. domestic appliances with buttons instead of knobs, or cars with features such as 
electronic seating adjustment), whilst others were paying for bespoke equipment. In 
addition to the obvious practical benefits, having choice could also be quite liberating: 
“I think it’s important to understand the freedom that having the knowledge that 
you can afford to spend a bit more gives you. It means you don’t have to accept 
second best and you can look with hope really. You think ‘oh I can do that’ or you 
can find someone. Given enough money you can work it out”. Amanda 
However, there was also a clear sense that people were having to make difficult decisions 
about what adaptations were most important for their independence or function, when 
they could afford to replace vehicles, wheelchairs and specialist equipment, and/or 
whether they should buy in more help. Whilst such decisions might be regarded as part of 
most peoples’ lives, they are brought into sharp focus when set in the context of the cost 
of living with disability, and especially rare impairments. Participants talked frequently 
about the additional expenses they incurred in all aspects of life. This included everyday 
expenses such as: higher shopping bills because they had to buy ready chopped 
vegetable or smaller more manageable packets; the higher cost of routine home 
maintenance (e.g. paying an electrician to change a lightbulb or a fuse); and higher 
heating bills because of needing to keep warm.  
The costs associated with home adaptation, adapted vehicles, and specialist equipment 
were even more significant. Despite the Health Grant, many participants were unable to 
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do all the things they felt were needed to preserve their function or maintain their 
independence, and like Jo, were having to phase expenditure: 
“Because it’s like, even though we’re getting the funding now, we still have to 
budget because we can’t, you know.... you’re talking about your kitchen which is 
like 40k odd or whatever and it doesn’t stop there because there’ll be appliances to 
buy and everything on top of that.  And then I need a new car.  I can’t buy that new 
car until next year now because by the time we’ve paid for what we’re doing this 
year, there’s no money left…But I’d like to do it now because my car’s 11 years old 
now”. Jo 
It was also apparent from the way participants talked about their decisions in relation to 
adaptations and equipment, that they felt their needs were continuing to change – 
equipment that helped in the past was no longer adequate or further adaptations would be 
needed. For example, some participants had used normal toilets all their lives, perhaps 
with the help of a toilet stick but were now struggling to do so without help. They were now 
installing specialist ‘wash and dry’ toilets, which cost around £3000. Other participants 
were experiencing similar changing needs in relation to wheelchairs and vehicles. For 
example Moira has always driven an adapted car but now needs one with foot steering 
rather than conventionally steering. “A new vehicle with all the adaptations I need, is 
looking like it’s going to be about £48k in total, which is actually about two years’ worth of 
my health grant”. 
It was clear that having money gave people choice and options, and this in turn gave them 
a sense of control and empowerment. Participants chose to use their resources, 
particularly the Health Grant, in very different ways but there appeared to be an 
acknowledgement within the Thalidomide community that this was as it should be, given 
the range of impairments and personal circumstances.  
7.5 Taking Control of Own Health 
A key aim of the interviews was to gather information about the types of health problems 
people were experiencing. In particular I was interested in problems which were in some 
way related to peoples’ original Thalidomide damage, and in any health care treatment or 
self-management strategies they had use to address them. However, it is important to 
understand that the context in which Thalidomide survivors made these treatment 
decisions and self-management choices was strongly influenced by their experiences of 
doctors and healthcare both as ‘Thalidomide children’ and adults (see Chapters 2 and 6).  
A broad but common theme to emerge from the interviews was a wariness or even 
distrust of health care professionals, especially doctors. For some participants this was 
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rooted in theirs, and their mothers’ experiences of doctors when they were children. Jo 
said: “I think we’ve had the medical things shoved down our throats all our lives and a lot 
of people shy away from that”. Martin was equally forthright: “I don’t do GPs! They’re all 
right if you want an antibiotic but my faith in them stops after antibiotics. I think it comes 
from my mother’s bad experience”. However, many participants had more recent 
experiences of healthcare professionals’ lack of understanding of how Thalidomide had 
affected their bodies and their failure to listen and respect what Thalidomide survivors told 
them about it. They (and their families) often had to be very assertive to stop inappropriate 
or unnecessarily invasive treatment. Beth’s experience when she broke her arm vividly 
illustrates this.  
“When originally I broke my arm, we were talking about operating.  The day I did 
break the arm…I went to the hospital, the chap said ‘We need to take blood’ and I 
said ‘You’re going to have trouble getting blood’…I had the ‘Don’t you worry 
sweetheart, we know what we’re doing’.  So I’m like ‘No – you do not know what 
you’re doing about blood’ and he never got blood.  Then they kept me sitting for – I 
went down on the Thursday and they kept me sitting until the following Monday, 
when they were going to come and do the surgery.  In the meantime, my sister 
had spoken to the [Thalidomide] Trust and they had told them under no 
circumstances to let them do the operation without an MRI scan because they 
know that the nerves do not run the same in our bodies as in others”.  Beth 
Beth went on to say that when she had a gynaecological operation a few years previously 
her consultant had really listened to her and had found a specialist maxillofacial 
anaesthetist. She explained this to the doctors treating her arm but they ignored her. She 
said: “As soon as the anaesthetist came, he took one look at me and wouldn’t do the 
surgery – and I was more than glad – and he didn’t do the surgery – and the arm’s been 
fine”. Karen also talked about having to be very assertive to stop inappropriate treatment: 
“I had a flair up with my shoulder and I ended up in A&E and they tried to give me 
gas and air to put my shoulder joint back in and I haven’t got one. They wanted to 
operate but I said no. They showed me the x-rays and said ‘there it is you’ve 
dislocated your shoulder’ and I had to get Martin involved at the [Thalidomide] 
Trust. I said look they are threatening to take my driving licence away because I 
won’t have this operation and he rang me back and said ‘Karen, you haven’t got a 
ball and socket anyway’. You learn to speak up”. Karen 
Participants gave numerous examples of similar situations and it was often these 
experiences that led to people feeling that where possible they had to take more control of 
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their own health. Alison, who is in the most severe impairment group (band 5) and uses a 
wheelchair, described this very clearly: 
“I think back in October, when I’d hurt my shoulder in the May, and I didn’t feel like 
it was getting any better, even though I’d been attending physio…they simply gave 
up on me. They didn’t know what else to do and I think by September, I thought 
enough is enough – I’ve got to take control of the situation myself. So I booked the 
holiday and found myself an osteopath…I did go back to the GP and said ‘Look, 
I’m in so much pain’ but the GP was really horrible, really horrible – very sharp, 
very unsympathetic. He didn’t seem to appreciate that having an injured shoulder 
had a massive knock-on effect to my ability. That things were difficult anyway, so 
that hurting myself made life even more difficult.  I didn’t feel he appreciated that at 
all but he was the one that gave me the Tramadol, which did help a lot with the 
pain.  So I then decided to book the holiday and just try and take control of the 
situation myself really”. Alison 
Taking control of their health meant different things to different people. For some 
participants it began with their relationship with their GP. Like Alison, a few participants 
had had bad experiences but others simply felt that their GP didn’t really understand how 
Thalidomide had affected them. Several participants described how they worked with their 
GP to improve their understanding. Some made a point of trying to see the same GP, a 
few arranged for their GP to get information from the Thalidomide Trust or even talk to the 
Medical Adviser at the Trust, and one agreed to talk to medical students in the practice.  
For those who needed conventional healthcare treatments, particularly surgery, taking 
control was more about finding the right specialist – one who had treated other 
Thalidomide survivors and had developed some knowledge of how their bodies might be 
different. The Thalidomide Trust has been working to identify specialists in different fields 
and several participants had sought their advice about who to be referred to. Some had 
paid to be seen privately because of problems getting an NHS referral. Moira decided to 
pay privately to see a hand specialist after spending months trying to get appropriate 
treatment through the NHS: 
“I think that has been much more helpful than the struggle through the NHS 
system. It can take a hell of a long time and it’s very reliant on finding an individual 
who is willing and able to help, because my experience is that some of the staff in 
NHS services are brilliant, others really couldn’t care at all or lack information or 
are scarred of treating me or just didn’t have the knowledge needed or the 
confidence to do it. It was pot luck!...I got to a general surgeon who was more 
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used to doing hip replacements. This was for my right hand and right knee. My 
right hand has a very, very unconventional structure so of course a general 
orthopaedic surgeon who mostly does hip replacements, which I don’t need – I 
don’t need a hip replacement – it was kind of inevitable that he was going to say 
‘oh well, there is nothing I can do for you, go away’ but that process I think took 18 
months. It was a huge learning point for me. I vowed that I would never get stuck 
that way again and be much more…take more charge of… or be more mindful of 
what’s going on rather than just letting myself be taken along by the system. It’s 
like throwing yourself into a river and then being surprised when you get dumped 
somewhere”. Moira 
Private healthcare, particularly for surgical procedures, also gave people choice about 
when they had their treatment. This was important for some people as they needed to 
arrange for extra help at home when they came out of hospital. However, several 
participants described very good care in the NHS. Jo initially paid privately to see a pain 
specialist but he then referred her to a pain specialist at her local hospital who had trained 
with him, and she was happy with the change: “She’s going to do exactly the same as he 
did and also it’s more convenient because we’re less than 10 miles away”.  
A number of participants faced dilemmas about when to have treatment or whether to 
proceed with treatment at all, especially where the outcome was uncertain. Often they 
were weighing up reducing pain against loss of function. Tom’s and Ann’s situations 
illustrate this. Tom, who is a foot user, was advised that he needed a knee replacement 
but he was concerned that the prosthetic knee would not function as well and so he was 
putting off the surgery: “I’m better coping and suffering with the pain at the moment, 
possibly sticking with it for another five to ten years”. Ann, who has relatively minor 
Thalidomide damage, has severe back problems. The extract from her interview not only 
illustrates the treatment dilemma she faced, it also reflects a common concern that 
doctors do not fully understand the consequences of ‘routine’ treatments for Thalidomide 
survivors: 
“The consultant wanted to fuse 5 of the vertebrae but I said ‘no, you’re not 
because I’m not like a normal person, and if you fuse all my spine…I won’t be able 
to bend.  I’ll lose my flexibility and if I lose my flexibility, I won’t be able to be 
independent.’  I’m going through all the different things to try to prevent that but I 
won’t have that operation – I won’t have it…[It’s] not guaranteed to work.  He said 
after you’ve fused the five discs, the top and the bottom ones become unstable, so 
you have to do that.  You’ve got lots of metal and you’ve lots of problems with 
infections, so at the moment I’m putting up with the pain – a lot of pain”. Ann 
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A very common aspect of taking control of health was finding ways to manage pain. 
Participants were using a range of approaches. As I discuss in section 7.2, Preserving 
Function, some participants had made lifestyle changes or used adaptations and 
equipment or bought in more help to reduce the strain on their bodies. For many these 
changes were also about managing pain or avoiding more pain in the future. The simplest 
approaches to pain management involved ‘pacing’ or avoiding certain activities. Some 
participants focused on fitness, flexibility and weight management, partly as a way of 
reducing or avoiding pain medication: 
“I don’t believe in drugs. I don’t really believe in doctors or drugs. I save them for 
when I really need them. I think pain should really be managed but not with drugs. 
I do use them very rarely but I find they upset me so I either have a treatment, you 
know physical therapy treatment or I do exercises and stuff or I rest”. Amanda 
Many participants said they tried to avoid taking pain medication or they wanted to reduce 
the amount they were currently taking. There were a variety of reasons for this: a dislike of 
all drugs; a recognition of general advice about the use of pain killers; a feeling that in the 
future they would need more pain medication so they needed to limit it now; and a dislike 
of the effect that strong pain killers had on their mood. Rowena said: “I try not to take 
painkillers, cos I don’t want to start taking them now if in the future I’m going to need them 
more”. As she mentions in the quotation above, Alison was taking prescription pain 
medication but was very concerned about over using it: “They are on prescription and 
they’re quite worrying actually because they’re very strong – Tramadol – and although I’m 
aware that they can be quite addictive, I’m trying really hard to be cautious of how I use 
them”. The effect of prescription pain medication on peoples’ mood or ability to function 
was a common concern. Robbie said: “The other thing with me is the medication 
suppresses mood” whilst Tessa explained: 
“I do take a painkiller at night and if it’s really bad, I up it but I try and keep to the 
minimum of what I do use.  There is one I use every so often if it gets really bad 
but I can’t take that if I’m driving, cos it tends to make you a bit zonk-i-fied the next 
morning, so I only take that when needs must, basically”. Tessa 
A small number of participants had sought more specialist pain treatments such as 
injections or patches but the majority had chosen to use physiotherapy and/or 
complementary therapies to help manage pain and to maintain flexibility/movement. 
Where participants were using physiotherapy, they were generally paying for this 
privately. Sometimes this was so that they could see a specialist physiotherapist (e.g. one 
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specialising in upper limbs), but it was mainly so that they could have on-going treatment 
from the same person.  
“I have been privately seeing a very experience physio and she has me on an 
exercise routine…she is fantastic. I gave her a copy of the MRI scan and said she 
thought she could help me and I see her once every 4 to 6 weeks”. Colin 
Similarly, those using osteopathy and other complementary therapies had often been 
seeing the same person for several years – they had established a relationship with them 
and felt that they had built up knowledge of their bodies. Kathleen had been seeing the 
same Osteopath for 20 years, and Alison said of her Osteopath: “I’ve built up quite a big 
trust in her – I say she’s got magic hands – and considering my disability, I think she’s 
wonderful.  She’s sort of been learning about me”. Many participants were using massage 
to manage pain and muscle tension, sometimes combining it with physiotherapy, as the 
quotation below illustrates: 
“I do receive regular sort of fortnightly massage to help keep on top of that. The 
place I go for the massage which is a sports injury clinic and if the pain isn’t sorted 
out with the massage I ask to be referred over to see one of the physios there, so 
paying privately, and that works really well because they liaise with one another”. 
Meg 
For some participants, ‘taking control’ was also about coping and coming to terms with 
comorbidity. A number of people were experiencing both secondary physical health 
problems and depression and/or anxiety and I discuss this in more depth in section 7.6 
below. A few had other health problems such as diabetes, bladder and/or bowel problems 
(e.g. irritable bowel), and more rarely, chest or heart problems. Colin described the 
difficulties he was now encountering in managing his diabetes:  
“I’ve got diabetes as well which is thalidomide related and had for 40 years but I’m 
in the danger years for related things but I don’t have those at the moment. An 
example is I can’t manage a pen – click on it and hold it at the same time. So what 
I do is use pen cartridges but I use syringes with them and I just draw up the 
insulin in the syringe with that and it works fine for me…One of the issues which I 
suspect is going to become a more significant one is that the areas of my body 
which I easily reach, my stomach area, when you have been jabbing in them for 
multiple years you can over jab in some areas and then you can reach a point 
where the insulin doesn’t get absorbed as well and I’m beginning to find that I’m 
jabbing but when I check later its almost as if I haven’t jabbed…that may be a sign 
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that I am over jabbing in certain areas and the issue that I am going to have is that 
in terms of reach I’m going to struggle to go to too many other places easily”. Colin 
Robbie has a gastric band to help him control his weight but he had started to have 
problems with a low iron count. He had the band loosened and took iron tablets but his 
weight increased and so he eventually decided to have the band tightened again. 
Robbie’s experience also highlights the place of broader lifestyle issues (in particular 
weight management) and how participants used lifestyle changes as one way to take 
more control of their health. Gwen has always struggled with her weight and since losing 
her sight has found it even harder to stay active:  
“I’ve been doing dieting on and off for years but my problem is because of my 
disability, I have to rely on people cooking for me, so it’s very hard sometimes to 
get the meals worked out for me… I wouldn’t say I’m an excessive eater. I like stuff 
but I think because as the years have gone on, I’m not able to do as much as I 
used to, I sit about much more and therefore weight just seems to pile on”. Gwen 
Simon also talked about how he had struggled with his weight and was now trying to stick 
to a very strict regime: 
“Weight management is something that’s ongoing and I’m firmly in control of and 
something I can’t afford to let go of.  I went through a substantial weight loss 
program a couple of years ago and I soon discovered that the difficulty is 
maintaining that lower level of weight and that has a knock on effect for various 
things: my general physical fitness, for reach and range of motion available, for 
various muscular skeletal pain issues.  Keeping that going is a tough one, its 
something you have to be constantly on your guard about – you can’t just lose 
your weight and then go back to the way you were. So that’s an ongoing battle, a 
battle I’m winning but one I have to be constantly aware of”. Simon 
Often people wanted to do more exercise but were put off using facilities such as public 
swimming pools or gyms because of people staring at them. However, they did find 
solutions. Beth and her sister were hiring a private pool each week, whilst others had 
bought exercise equipment they could use in their own homes. A number of participants 
had personal trainers who came to their homes. Carol said: “I’ve also got a personal 
trainer as well and we do a lot of core work and manipulation to stretch the muscles, you 
know to try and counteract the effects of using a wheelchair really”.  
In describing how participants tried to take more control of their own health, I have 
focused on physical health. However, mental wellbeing is a growing health concern within 
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the Thalidomide community, and one which participants found far harder to ‘take control’ 
of.  
7.6 Vulnerable Mental Wellbeing 
The Health and Wellbeing survey began to quantify mental wellbeing problems, with the 
results suggesting that around half of UK Thalidomide survivors have experienced low 
mood, depression and/or anxiety. However, the interviews revealed why the mental health 
of Thalidomide survivors is becoming more vulnerable. Two primary factors emerged: the 
cumulative impact of living with a rare disability, and in particular the sense of ‘being 
different’ which that engendered; and the emotional impact of further loss of function, and 
the implications this had for independence. How much these experiences affected people 
and how they made sense of them, was influenced by both individual circumstances (e.g. 
family attitudes or life events) and the wider societal context.  
Participants talked either directly or obliquely about what they saw as the cumulative 
impact of living with disability, especially rare impairments. Some people focused on the 
mental effort involved in coping with daily life, constantly having to adapt and think ahead 
or plan how to manage in different situations. The extract from Malcolm’s interview below 
is interesting not only because of his analysis of this but also because he uses ‘they’ 
rather than ‘we’, perhaps as a way of distancing himself from the experience: 
“I have had some counselling for anxiety and depression.  I think that was about 6 
or 7 years ago.  That was because I was drinking a lot previously – about 13 years 
ago, drinking – and I had to sort of come back into the human race, as I call it, and 
I found it very difficult and I was going through a very big stress-y period of my life.  
I thought it was just drinking and stuff like that but my counsellor took one look at 
me and said ‘It’s possibly related to your disability a little bit’. You’ve probably 
heard most us almost try and dismiss it as ‘This is what we’ve got – we’ve just got 
to face the fact of it’ but I think a lot of Thalidomiders don’t realise that they’ve 
been deeply affected by it, a lot more than they really realise…Now it’s starting to 
hit hard…It’s becoming a new challenge because they’re having to adapt, whereas 
when they were younger, they probably just didn’t think about it and adapted 
naturally – and obviously people who saw them thought ‘Oh, what marvelous 
children these are’ but they didn’t realise the mental strain they had to go through 
to adapt and the frustration”. Malcolm 
For many, especially those with upper limb damage and/or facial disfigurement, it was the 
psychological impact of ‘being different’ that touched their mental wellbeing. Often the 
situations they described were mundane, such as people looking at them in restaurants if 
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they needed help with cutting up their food or being stared at in the gym or swimming pool 
or just in the street. Moreover, they stressed that they had never come to terms with 
unwanted attention this brought: “People say they get used to it.  I’m not used to it and I 
never will be” (Jim). However, a number of people described more disturbing events: 
Joyce had been stopped in her home city by a small group of tourists who tried to take 
photographs of her; Colin had to seek help from the police after being targeted by vandals 
in his community; and Nicola felt her disability had been a factor in bullying at work.  
Family attitudes and childhood experiences also clearly influenced participants’ mental 
wellbeing, both positively and negatively, but the extent to which these were directly linked 
to their Thalidomide damage varied. Diane explained that her mother had her when she 
was 45 and her siblings were in their late teens. She feels that they never accepted her 
and this has had a long term emotional impact on her:  
“I mean the, you know, the fact that I've got no legs is nothing to me cos I don't 
know any different but it's them [siblings] that are the problem, and that is 
why…my biggest thing is the this psychological abuse which went on from, my 
earliest memory is from the age of five up to like last year”. Diane 
Jenny had grown up in a very sporty family where her Thalidomide damage was rarely 
discussed. She felt her mum struggled to come to terms with having a disabled child and 
carried a lot of guilt about taking Thalidomide. She explained: 
“So there was a lot going on in the family and the Thalidomide really didn’t help 
and I think that really affected me.  So I know that a lot of the counselling I’ve had 
has always come back to that sense of being a freak and not being as good as 
other people really.  Somehow, just, you have that underlying feeling that you’re 
different from other people – and actually my disabilities are not noticeable at all”. 
Jenny 
Conversely, many participants described how supportive their family had been and how 
their parents had helped them develop a resilient attitude to life. A few said that the 
improved financial situation of Thalidomide survivors had caused tensions with siblings 
but others were still close to their siblings and really valued their support.  
As I discussed in section 7.1, shifting impairment was leading to loss of function for many 
participants. This was reflected in a changing ability to carry out everyday tasks and 
activities. They often used words like “frustrated” or “irritated” to describe their feelings 
about this change but for some the impact had been more profound: 
“I didn’t think about it. I went with the flow and got on with my life and it was only 
really when my own personal health started failing and I had to sort of pull right 
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back from doing the same old things the same old way, and old coping strategies 
didn’t work anymore, that I went on to a different journey. I had to open myself out 
to what was happening to my body, all the background to the Thalidomide story, 
the injustice and allowed it all in. It’s been quite tough and I have had a period of 
being quite stuck and not necessarily being very kind to myself”. Moira 
The emotional impact of loss of function appeared to be more significant when it led to 
peoples’ lives becoming more limited or resulted in them giving up activities they enjoyed, 
and when it had a knock on consequences on their family. Joyce described how many 
everyday activities had become more difficult for her and thinking back to what she was 
able to do previously made her feel quite low: 
“It depresses you because you realise what you can’t do now. I wouldn’t go out 
shopping on my own because of the simple fact that I can’t lift and I’d be scared of 
falling because of my leg, when carrying things”. Joyce 
Amy, whose children were still relatively young, reflected on how her declining mobility 
had affected both her and her family: 
“I think sometimes I feel like I would love to go on a really, really long ramble, like I 
used to, and I can’t do that because it hurts my knees and my back too much to go 
on very uneven ground for too long and so I suppose it does stop you going on the 
sorts of activities or family holidays that you would otherwise have chosen to do.  I 
think that can be very frustrating and get you down a bit”. Amy 
However, several participants talked about finding new activities to replace the ones they 
could no longer do. Amanda explained that she didn’t feel safe in her sailing dingy 
anymore but she was determined to keep active: 
“Your world might get smaller because you’re less able but there is still a lot you 
can do with it. I’ve never been able to do team sports until recently but now I cox 
for a rowing team and I’ve won my first ever team event which I’ve done through 
making them work hard and steering the boat and thinking but I’m involved in a 
normal event and a normal rowing team. I have to keep fit and I have to keep 
skinny or they won’t want me otherwise. But there are a lot of things you can do”. 
Amanda 
Others were buying in help or making adaptations so that they keep doing valued 
activities. For example Rick had his bike adapted and Ann was hoping to keep diving by 
finding holiday companies that had equipment to help her get in and out of the water. Beth 
reflected on her situation: 
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“I still have a good life.  I go to the theatre a lot and I have to now pay for 
somebody to go with me because I sit in the wheelchair, because I can’t walk from 
the car park to the theatre, which I used to be able to do”. Beth 
Alongside the impact of current changes in peoples’ lives, several participants speculated 
about the implication of further change in their circumstances. There was a clear sense 
from some that their current way of life was fragile and this made them feel vulnerable. In 
particular they worried about losing their partner or their partner’s health declining such 
that they were no longer able to support them. Karen, whose husband had recently had a 
“cancer scare” said: “Obviously it’s brought to the fore what happens if [husband] ever 
gets sick – we have nobody. This is it – I don’t have any sisters”.  
For a few people their feelings of vulnerability were related to the wider environment. 
Jenny, who lives alone with her two dogs explained they provide company and exercise 
but also make her feel less vulnerable. Others talked about seemingly trivial but real 
concerns such as not being able to open doors in toilet cubicles or use cutlery in 
restaurants, whilst Joyce felt physically vulnerable in public places: 
“I’m scared of getting mugged. You have that fear because you’re vulnerable. I 
keep my mobile phone in the pocket of my coat or trousers or whatever and then if 
anything happened and they do take my bag, at least I’ve got my mobile phone. I 
would never use my mobile phone in the street as it would be so easy for someone 
to just snatch it and run. You know anybody can get mugged or have things taken 
but I would never walk with my purse in my hand because it would be so easy to 
take. It’s just those we things we have to think about as well”. Joyce 
It seemed that what was important was not each separate ‘vulnerability’ but the fact that 
together and over time they had a corrosive effect on peoples’ mental wellbeing. 
In section 7.3 I discuss the positive and negative aspects of the group identity of 
Thalidomide survivors for their perceptions of independence. Similarly, in relation to 
mental wellbeing it created both benefits and difficulties. Several participants said that 
their contact with other Thalidomide survivors had increased in recent years, partly 
facilitated by email and social media, but mainly because as they developed more 
physical and emotional difficulties they had felt a greater need to connect with their peers. 
Tracy said that a long period of depression had led to her seeking friendships within the 
Thalidomide community: 
“I didn’t have any peers around me that I could talk to on a regular basis. I used to 
go to the meetings, the Thalidomide Society meetings once a year but since that 
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time I’ve developed my own friendships within that circle and there are people 
there that I can ring up and we see each other”. Tracy 
Others had set-up informal local groups or connected via social media, whilst many used 
Thalidomide Trust and Thalidomide Society events as an opportunity for mutual support: 
“A lot of people get together at the NAC meeting, stay the night, because they actually 
enjoy talking to other Thalidomiders” (Carol). However, those participants who had 
become a beneficiary much later in life or who had minor damage sometimes felt they 
were ‘on the outside’.  
Although vulnerable mental wellbeing stands alone as a conceptual category, it is 
intimately intertwined with and influenced by the other categories. It is also an important 
part of the disabling experience.  Shifting impairment, coupled with loss of function and 
the need to rethink independence, did have a detrimental impact on many participants 
mental wellbeing. Conversely, having money, both for the support it could buy but also for 
the choice and security it provided, was having a positive effect on many participants’ 
mental wellbeing.  
7.7 Ageing Differently 
The preceding conceptual categories reveal that Thalidomide survivors’ experiences of 
ageing (in late middle age), are different to those of their peers in the general population, 
but perhaps similar in some respects to other people with early acquired disabilities. For 
many there was a sense that their bodies, and particularly their limbs, were ‘wearing out’. 
Most commonly participants associate this with the way they have used their bodies to 
compensate for their impairments. Rick, like many Thalidomide survivors with relatively 
limited upper limb damage, has one arm which is longer and stronger than the other. He 
explained: 
“I’m conscious that with both arms, but particularly the left one, it’s going to 
become more and more of an issue.  As I get older, I’m using my left side for 95% 
of the day, compared to the right side, it’s a lot of wear and tear on that part of my 
body.” Rick 
However, others talked about their bodies in some way becoming weaker and less 
resilient as they aged. Malcolm, who has two very short arms, talked about how the strain 
that everyday living had placed on his and other Thalidomide survivors’ limbs was now 
being exacerbated by normal ageing processes: 
“I know what it is. Its age – it’s just muscles and bones deteriorating and 
unfortunately, because of the way our arms are – the size them – they’re probably 
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equivalent to the size of maybe a 2 or 3-year-old’s and that is the strength they 
have.  If you ask a 2-year-old to take a bin bag out, they’d just look at you and say 
‘I can’t’.  I think that’s the problem. It’s that we like to think that we can do heavy 
stuff or we’ve grown up to be able to do it, and then as we’ve got older we’ve 
started to become weaker.” Malcolm 
Alongside this notion of bodies becoming weaker or ‘wearing out’, Thalidomide survivors 
had a strong perception that they are ageing prematurely. Again some people associated 
this with the way they had used their bodies, and to a lack of advice when they were 
younger, about how to preserve function. 
“I’m going to be 53 in a few months so the way I look at it, any 53 year old is going 
to start and have pains and aches. Yes our bodies are say about 20 years older 
they reckon because of what we’re doing, and maybe if they had been more 
vigilant about how we used our limbs years ago maybe we wouldn’t be having the 
problems now so much. You know I think maybe they’ve closed the stable door 
and the horse has already away. So I think there was a lack of medical advice say 
in your late teens, twenties.” Joyce 
They felt their bodies were older than their chronological age or they talked more broadly 
about ‘feeling old before their time’. Like Joyce (above) and Jenny (below) they 
acknowledge that most people would expect to slow down to some degree in their 50s, 
but they felt that for them, this change was happening more rapidly: “I know you’re slowing 
down in your 50s anyway but…I think as probably a lot of people say, you feel it’s coming 
a bit too early. I feel more than my age” Jenny. 
This sense of premature ageing had implications for both physical and emotional 
wellbeing. Ann had been a very active person all her life, taking part in sports such has 
skiing and scuba diving but recent back problems related to her Thalidomide damage had 
had a profound effect on her physically and emotionally: 
“I never even thought about it.  Never even thought about it.  I’ve been much more 
angry and frustrated over the last 2 years…it’s really curtailed what I’ve been able 
to do.  When I was younger, I was fine. I was fit, I could do everything, I didn’t 
need any help…even just thinking into the future, and thinking, well maybe in 10 
years’ time, when I’m 63, I’ll be like a bloomin’ 80-year-old and I will need help, 
and that makes me angry. You know, I want to not have it and be able to do 
everything I’ve always been able to do without any help.” Ann 
Inevitably people compared their experience of late middle age with that of their friends, 
siblings and peers of a similar age. The sense of being out of step with others at the same 
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stage in their life course seemed to prevail regardless of the severity of people 
impairments as the three short quotations below (from participants in bands 1, 3 and 5 
respectively) illustrate: 
“I’ve got 3 sisters…and they are able to do far more than I am. I think that’s the 
best comparison because obviously we were brought up in the same household, 
the same genetics, and they are much more able.” Jenny 
“I know it’s the same for everybody as you get older but usually, when you’re in 
your 50s, you can still do what you did in your 20s can’t you?” Fiona 
“I think when you get to 50, normal people tire but I find that I tire even quicker 
maybe than somebody the same age as me, just because everything’s so much 
more effort.” Gwen 
By contrast a few participants felt less out of step as they got older because their 
contemporaries were also experiencing aches and pains or finding it harder to do things 
they had done with ease when they were younger. Having felt ‘different’ for much of their 
lives this was perhaps a way for some people to normalise their experiences. 
Importantly, not only are Thalidomide survivors ageing prematurely, they also ageing 
differently. The combination of a rare condition and the fact that Thalidomide survivors are 
ageing as a cohort means that they do not have an older generation to look to and learn 
from. People often felt uncertain about whether the problems they were experiencing were 
caused by the normal process of ageing or by the long term consequences of their 
Thalidomide damage. Jo reflected on this issue: “What’s happening to your body now is it, 
because obviously now we’re all over 50, all age-related or is it because of the drug?  It’s 
a difficult one to call, isn’t it?” Others talked about ageing being layered on to their existing 
impairments. For those with less severe impairments it appeared to remind them of their 
disability: 
“Only very recently [there was] something where I thought I haven’t done as well – 
and then I thought, hang on a minute – I have got a disability and I am getting 
older...I think we’ve all got normal ageing things coming in on top of how we are 
now.” Nicola 
However, some like Simon who has severe Thalidomide damage and has used both 
equipment and personal assistance much of his life, highlighted both the practical and 
emotional implications of ageing compounding existing impairments: 
“I do worry about the aging process, I almost have to tell myself not to dwell on it. 
I’m kind of thinking ‘in our old age who is going to make the specialist walking 
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sticks’? These are all the things that older people use to maintain their mobility. 
We are going to need a whole lot of other stuff aren’t we? The average walking 
frame is not going to work for us. I think our care needs are going to increase 
exponentially. Already we know that the sum of more than one impairment is 
greater…aging is just another impairment to add on top of the other impairments 
we’ve already got – the impact will be profound and I don’t like the idea but that’s 
the reality isn’t it. I don’t want to be a very old man.” Simon 
Just as Simon’s closing comment implies, others (men in particular), expressed concerns 
about the implications of ageing with Thalidomide for both the quality and length of their 
lives. The quotations below from Rick and Martin highlight this: 
“I think we’re all conscious – well, none of us knows how long we’re going to live 
but we’re all conscious that, in terms of our own bodies, in real terms, your life is a 
bit less than the norm, I suppose.” Rick 
“I mean older people can’t do things that they used to do and I think that’s nagging 
in the back of my mind. Ok 52 and I’m thinking fast forward, 62 then what. I live in 
dread. I don’t fancy getting old at all. I think when the quality of my life’s gone I’ll 
want out.” Martin 
The perception of ageing prematurely and ageing differently left Thalidomide survivors 
feeling increasingly out of step with their peers in the general population at the same 
stage in the life course. Moreover, because they do not have an older generation to look 
to and learn from, and the long term effects of the drug are poorly understood, they are 
ageing with heightened sense of uncertainty.  
7.8 Summary 
This chapter describes the seven conceptual categories to emerge from the secondary 
grounded theory analysis of the semi-structured telephone interviews, exploring how they 
overlap and intersect. I have shown how Shifting Impairment is about both increasing 
impairment and the interconnection between original impairment, secondary conditions 
and ageing, and how it led participants to think about Preserving Function. The 
approaches they used to achieve this often involved them in Rethinking Independence. 
This process was complex and nuanced, and influenced by Thalidomide survivors’ beliefs 
and attitudes, as well as their health, social and economic circumstances. In particular, 
Money Matters, not only because of what it can buy but also because of the sense of 
security and empowerment it gave people. It also influenced the fifth conceptual category, 
Taking Control of Own Health, although this was strongly shaped by Thalidomide 
survivors’ often negative experiences of healthcare professionals over the course of their 
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lives. Vulnerable Mental Wellbeing stands alone as a conceptual category but it is 
intimately intertwined with and influenced by the other categories. It is also an important 
part of the disabling experience but one, which is sometime under explored. Together the 
conceptual categories suggest that Thalidomide survivors are Ageing Differently when 
compared to their peers in the general population, and in some respects to other people 
with early acquired disabilities.  
In the next and final chapter I discuss how the conceptual categories described in this 
chapter, together with the findings from the literature review and the health and wellbeing 
survey, led to Ageing Differently emerging as my core category, or as I have termed it, my 
‘emergent theory’.   
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Chapter 8 Discussion and Conclusion 
I began this thesis by stating that Thalidomide cannot be dismissed as a historical 
tragedy. It is a contemporary disability issue. Across the world, Thalidomide survivors and 
their families are still living with the consequences of the drug. In the UK, Thalidomide 
survivors are now approaching later life, and as they do so they are experiencing new 
Thalidomide-related health problems. My study captures their experiences at this 
particular stage in their lives, where impairment, disability and ageing are beginning to 
intersect. It also sheds light on the cumulative experience of disability over their life 
course. In particular, how the historical, social and economic context of their lives, their 
unique group identity, and their efforts to negotiate and re-negotiate their independence, 
have shaped their navigation of the life course. 
I open this discussion in section 8.1 with a brief descriptive summary of the main findings. 
I then go on to discuss my findings in more depth under three integrative explanatory 
categories: shifting impairment; preserving function/rethinking independence; and 
vulnerable mental wellbeing. Under each of these categories I bring together the findings 
from the literature review, the health and wellbeing survey and the conceptual categories 
which emerged from the secondary grounded theory analysis of the interviews. Where 
appropriate I make links to the wider literature (both empirical and theoretical) about 
ageing with early acquired disability. These integrative categories provide the framework 
or grounded theory ‘storyline’ for my emergent theory - Ageing Differently - which explores 
the extent to which Thalidomide survivors’ experiences of ageing at this point in the life 
course is different or similar to their peers in the general population and to other people 
with early acquired disabilities. This is presented in the final part of the chapter.  
I go on to consider what this study has contributed to the body of knowledge about the 
long term consequences of TE and ageing with early acquired disability more broadly, 
along with the implications of my findings for policy and practice. I discuss where further 
research is needed, both in relation to the health of Thalidomide survivors as they age and 
the growing population of people ageing with early acquired disability. Finally, I reflect on 
the strengths and limitations of the study, before presenting my overall conclusions.  
8.1 Main Findings 
The findings from this thesis clearly show that whilst TE is regarded as a non-progressive 
condition, its consequences are not static. Thalidomide survivors are now experiencing a 
range of secondary health problems which are connected to and interacting with, their 
original impairments. This is causing further loss of function, which in turn has disabling 
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consequences. The literature about the health of Thalidomide survivors as they age 
revealed that they are increasingly experiencing secondary and associated conditions, 
which are linked either directly or indirectly to their Thalidomide damage. Of course ageing 
is an inevitable process, which involves a decline in physical function over time. For 
Thalidomide survivors, and other people with early acquired disabilities, this ‘normal’ 
ageing process is layered on to their original impairments (Treischmann 1987). 
Furthermore it is often complicated by secondary conditions (e.g. osteoarthritis in the case 
of Thalidomide survivors), which are a direct result of the original impairments (Kemp and 
Mosqueda 2004). 
The literature review showed that internationally, musculoskeletal problems are the most 
commonly reported health issue. This conclusion is supported by the findings from the 
health and wellbeing survey which suggests that the majority of UK Thalidomide survivors 
were experiencing some kind of musculoskeletal problems. For many these problems 
were associated with restricted movement and further loss of function, which people 
perceived to be beyond the gradual loss of function associated with ageing.  
Shifting impairment was leading to many Thalidomide survivors needing more help in their 
daily lives, more equipment and home adaptations, and to them giving up paid work 
prematurely. These changes were in part about Thalidomide survivors trying to preserve 
their function and gain some control over what was happening to them. However, 
accepting more help or using more aids and equipment involved many Thalidomide 
survivors rethinking what independence means to them. Despite the majority having lived 
relatively independent lives, many are having to adjust to growing disability.  
For Thalidomide survivors, as for all of us, physical and mental health were intimately 
intertwined, and so loss of function and the need to rethink independence had profound 
implications for their mental wellbeing and mental health-related quality of life. In both the 
international literature and the health and wellbeing survey, common mental health 
problems were the second most frequently reported health issue. Almost half the 
Thalidomide survivors who responded to the survey reported that they were currently, or 
had recently, experienced depression and/or anxiety. The interviews revealed why the 
mental health of Thalidomide survivors was becoming more vulnerable. Two primary 
factors emerged: the cumulative impact of living with disability, particularly a rare 
disability, and the sense of ‘being different’ which that engendered; and the emotional 
impact of further loss of independence, associated with secondary health problems. How 
much these experiences affected people and how they made sense of them was 
influenced by both individual circumstances (e.g. financial resources, family attitudes or 
life events) and the wider societal context. 
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However, Thalidomide survivors (as a group) are in some respects atypical of people with 
disabilities. They have, for example, a similar level of education to their peers in the 
general population. For many, any employment disadvantages (as indicated by lower 
rates of labour market participation) are relatively recent and at least in the last decade or 
so, they have been more financially secure because of the Health Grant. My research 
suggests that having money matters, not only because of what it can buy but also 
because of the material and psychological reassurance it provides in the context of a 
somewhat uncertain future. Having money creates a sense of security, and for 
Thalidomide survivors this has a number of dimensions: the comfort of being able to afford 
things that help them in the here and now; the reassurance of having ‘insurance’ to cover 
unexpected events; and the confidence that the resources are there to meet changing 
future needs. It also creates options and choices, particularly in relation to how best to 
maintain independence. 
Nevertheless, at this relatively late stage in life Thalidomide survivors are experiencing 
greater exposure to the environmental and other disadvantages common to many 
disabled people and appear to be increasingly out of step with their peers in the general 
population at the same stage in the life course. In essence, they are ageing differently. 
8.1.1 Shifting Impairment  
Thalidomide is now known to be a very powerful human teratogen which can cause a 
wide range of birth defects. However, Dysmelia (missing, short and/or deformed limbs) 
and associated damage to joints, are the most common and characteristic features of TE. 
It is perhaps not surprising then, that in the international literature musculoskeletal 
problems were the most commonly reported health issue. This conclusion was supported 
by the findings from the health and wellbeing survey which showed that over 90% of UK 
Thalidomide survivors were experiencing some kind of musculoskeletal problem, with half 
reporting multiple problems (five or more). Back problems, ranging from degenerative 
changes in the spine to muscular pain, were the most common (72%) but a high 
proportion of Thalidomide survivors were also experiencing restricted movement, pain and 
muscle weakness/tension in their necks, shoulders, arms/hands, hips and/or knees. The 
prevalence and severity of musculoskeletal problems appeared to increase with the 
severity of impairment but this relationship was not simple or linear.  
Alongside the pain and loss of function associated with musculoskeletal problems, two 
thirds of the Thalidomide survivors in the survey said they experienced neuropathic 
symptoms and almost half reported generalised pain (which may be neuropathic in 
nature). These findings were broadly supported by the literature review. Clinically the 
causes are unclear and disputed, although most authors agree that Thalidomide survivors 
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are more vulnerable to compressive neuropathies. However, regardless of the clinical 
cause, it was clear that for some Thalidomide survivors, pain and neuropathy were having 
a significant impact on their general wellbeing and function. Changes in other areas of 
original damage, such as eye sight, hearing and internal organs, were also a concern for 
many survey respondents. However, in the literature there is very limited evidence about 
the extent and nature of these problems, and it is unclear whether this deterioration is 
Thalidomide related or due to general aging.  
All the international studies which discuss deterioration in original musculoskeletal 
impairments and secondary conditions, conclude they are caused by the way in which 
people have had to use their bodies to compensate for missing, short or damaged limbs 
and joints. Kruse et al (2013) talk about the patterns of movement people adopted at an 
early age to compensate for missing functions; Kowalski et al (2015) refer to 
‘compensatory postures’; and several authors use terms such as ‘overuse syndrome’ or 
‘symptoms of overuse’. However, none of these studies have really explored what 
Thalidomide survivors themselves perceive to be the causes of these problems or how 
they made sense of this shifting impairment. The interviews with Thalidomide survivors 
suggested that they felt there were three root causes.  
The first was deterioration of known damage (e.g. in eye sight) and/or the emergence of 
newly recognised damage (e.g. a missing kidney) or an increased understanding of the 
extent of known damage (e.g. the nature of malformed joints). The second was accidents 
and injuries where these had occurred as a result of existing impairments (e.g. falls linked 
to mobility, balance or sight problems). The third and most commonly described root 
cause was premature wear and tear caused by the ways in which people have had to use 
their bodies to compensate for their impairments, which clearly accords with the literature.  
However, people made sense of these changes in different ways and their response to 
them also varied. For those with more severe damage, there was sometimes a sense that 
the deterioration was inevitable, given the nature of their original impairments i.e. they 
attributed the decline they were experiencing to their original damage, not to the ageing 
process. Amongst participants whose original impairments were less severe, there was 
more uncertainty about what could be attributed to ‘normal’ ageing and what to their 
original impairments.  Regardless of this, deterioration in their function or mobility often 
engendered a new or heightened sense of ‘being disabled’.  Participants often talked 
about the everyday activities they could no longer manage or could only manage with aids 
or support. As such, these activities had become the barometer or benchmark by which 
they measured their shifting impairment. For some participants, the ‘unpicking’ of how 
they used their bodies was perhaps a way of understanding or even reconciling 
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themselves to shifting impairment. For others it also appeared to be about finding ways to 
take control of their health and develop strategies to reduce further loss of function.  
In many respects, Thalidomide survivors are reluctant pioneers because the long term 
consequences of their condition are emerging at the same as they experience them 
(Lowton and Higgs 2010). This is perhaps different to many other disabling conditions. 
Nevertheless, there are similarities between Thalidomide survivors’ experiences of shifting 
impairment and those of other people with early acquired ‘non-progressive’ disabling 
conditions. Molton and Yorkston (2017) note that: “…functional limitations are often not 
stable across the life span. Rather there is now mounting evidence that the cumulative 
effects of living with a disability condition for many years contribute to premature declines 
in health” (p291). They go on to suggest that this might include the early onset of 
musculoskeletal conditions, medical comorbidities and “the development of secondary 
conditions, like pain and fatigue”.  Studies into ageing with specific conditions such are 
Cerebral Palsy (Haak et al 2009), spinal cord injury (Groah et al 2012) and Spinal Bifida 
(Klingbeil et al 2004) have drawn similar conclusions. Not only are people with these types 
of disabling conditions dealing with the normal physiologic issues of aging, they are also 
coping with secondary complications of their disability, and the inter-relationship between 
the two (Klingbeil et al 2004), all of which can have a significant impact on their functional 
ability as they age. Unfortunately, as a number of commentators have observed (Iezzoni 
2014; LaPlante 2014) health care services, and rehabilitation medicine in particular, have 
tended to focus on supporting people with newly acquired disabilities, and so knowledge 
and services to support people with early acquired disabilities as they age have been slow 
to develop.  
Interestingly, a broad but common theme to emerge from my interviews was a wariness or 
even distrust of health care professionals, especially doctors. For some this was rooted in 
their experiences as children. However, many participants had more recent experiences 
of healthcare professionals’ lack of understanding of how Thalidomide had affected their 
bodies and the secondary problems they were now experiencing. This often set the 
context for how people tried to take control of their own health. The survey showed that 
many Thalidomide survivors (70% of survey respondents) are self-managing their 
musculoskeletal problems by paying privately for physiotherapy and complementary 
therapies. The interviews suggested that this was partly about being able to establish a 
relationship with the person treating them so that they understood their Thalidomide 
damage but it was also about trying to defer or finding alternatives to more invasive 
treatments, in particular joint replacement surgery. 
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Overall, 17% (60) of the Thalidomide survivors who responded to the survey had had joint 
or back surgery (in the last ten years). The rate of hip and knee surgery was far higher 
than the general population of a similar age and the rate for shoulder and elbow surgery 
also appeared to be higher, although comparative data was limited. The interviews 
revealed that Thalidomide survivors often face difficult decisions about whether (or when) 
to have surgical treatments, especially where the outcome was uncertain. In particular, 
joint replacement surgery can remove or substantially reduce pain but it can also leave 
people with restricted movement. However, as a recent study about shoulder replacement 
(Merkle et al 2016) suggests, knowledge and treatments for Thalidomide survivors are 
advancing, albeit slowly. For those who needed conventional healthcare treatments, 
particularly surgery, taking control was often about finding the right specialist – one who 
had treated other Thalidomide survivors and had developed some knowledge of how their 
bodies might be different.  
In terms of ‘lifestyle’ diseases or diseases of ageing, there is some evidence from the 
literature that Thalidomide survivors are marginally more likely to have hypertension and 
heart disease (i.e. it may be ‘associated’ with TE). The results from my survey were 
inconclusive but this may be partly because of problems with the phrasing of questions 
and the resulting difficulty in making comparisons. However, both in the literature and in 
my own work the issue of risk factors for lifestyle diseases emerges. Thalidomide 
survivors often experience problems with weight management and for some there are 
physical, social and practical barriers to taking regular exercise. Moreover, obtaining 
accurate measurements for two of the most commonly used indicators of risk factors for 
lifestyle diseases – blood pressure and body mass index – is difficult when people have 
missing or short limbs. Again there are parallels with people with disabilities more 
generally. An American study (Altman and Bernstein 2008) drawing on the National 
Health Interview Survey found that people with disabilities had higher rates of risk factors 
(i.e. obesity, smoking and physical inactivity) for lifestyle diseases than their peers. 
Moreover, some authors (Iezzoni 2011) have speculated that health care professionals 
may be less likely to address risky health behaviours in people with disabilities. There is 
also a small but growing body of literature which contends that commonly used models of 
successful ageing have been developed with little consideration of early acquired disability 
(LaPlante 2014; Molton and Yorston 2017). As a consequence, insufficient attention has 
been paid to health promotion and prevention for this group of people, and more 
appropriate indicators and goals for healthy living are needed. I return to the issue of 
successful ageing in 8.1.4. 
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What was clear from both the survey and the interviews is that multimorbidity (including 
lifestyle diseases and mental as well a physical health) is a growing issue for Thalidomide 
survivors, with almost half of the survey respondents reporting between four and nine 
separate health problems. None of the studies in the literature review (and few in the 
wider literature about ageing with disability) explicitly discuss multimorbidity but some 
record the number of chronic health conditions participants reported or talk more generally 
about an the number of diagnosed medical condition. Whilst multimorbidity is increasing in 
the UK population as a whole (Barnett et al 2012), my findings suggest that a higher 
proportion of Thalidomide survivors are experiencing multimorbidity than would be 
expected at this point in their life course, when compared to their peers who do not have 
impairments with disabling consequences.  
Conceptually, shifting impairment was not just about increased impairment, it was about 
the somewhat unpredictable interconnection between original impairment, secondary 
conditions and ageing, and as such it carried with it inherent uncertainly about the 
disabling consequences. Although we have no comparative data from when Thalidomide 
survivors were young or middle aged adults, my contention is that the shifting nature of 
their impairments is one of the main factors contributing to their poor physical health-
related quality of life, as indicated by the SF12 results. They perceive that their ‘health’ in 
its very broadest sense (i.e. as reflected in the SF12 component scores of physical 
functioning, role limitation, pain and general health) is declining and they are increasingly 
experiencing the disabling consequences of this decline, such as having to give up paid 
work and finding it harder to maintain independent mobility. Shifting impairment was 
therefore intertwined with efforts to preserve function, and for some, the necessity to 
rethink or renegotiate independence.  
8.1.2 Preserving Function/Rethinking Independence 
Coping with the loss of function associated with shifting impairment involved both physical 
and psychological adjustments. Over the course of their lives Thalidomide survivors have 
developed ‘work arounds’ to enable them to do tasks themselves but increasingly they 
were finding that these no longer worked. Within the literature, a few studies discuss 
Thalidomide survivors’ efforts to preserve function and maintain their independence, by 
making greater use of aids, equipment, adaptations and/or personal assistance. The 
health and wellbeing survey and interviews confirmed this. For example, the survey found 
that whilst only a minority of Thalidomide survivors were receiving local authority funded 
social care, almost two thirds of survey respondents were buying support privately (e.g. 
help in the home). The interview findings suggested that this had increased significantly 
following the introduction of the Health Grant. The survey also showed that many 
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participants were making other changes in their lives such as giving up paid work or 
reducing the hours they worked.  
For many participants, these practical changes were driven by a desire to reduce strain on 
their bodies, and so avoid or reduce pain and preserve the function they still had. As such 
they were implicitly assessing the likely risks to their independence and making an active 
choice to try and protect it. There are links here to the wider literature about disability and 
rehabilitation. In the past decade or so, this philosophy of “conserve it and preserve it” has 
also appeared in the literature about ageing with early acquired disability. Kemp and 
Mosqueda (2004) suggest that after the Second World War, the emphasis in rehabilitation 
was on maximising function. This philosophy prevailed when Thalidomide survivors were 
children and young adults. However, there is now recognition that it can cause problems 
for people ageing with disability, in particular premature degeneration in limbs and joints. 
Indeed some interview participants reflected that when they were younger they had been 
given little or no advice about preserving function and were now dealing with the 
consequences. In that sense Thalidomide survivors face similar issues to other people 
ageing with disability but, as I discuss below, they are also dis-similar in terms of group 
identity and public perceptions.  
My findings suggest that decisions about how much and what type of help and support to 
accept were influenced by peoples’ idea of independence (and the resources available to 
them). We know from previous research that independence is a contested concept 
(Barnes 2006; Rabiee 2013). In her longitudinal study with disabled adults and older 
people about choice and control, Rabiee (2013) found that it: “is not a fixed and ‘given’ 
concept, but is highly relative, conditional and multidimensional”. Thalidomide survivors’ 
perceptions of independence often appeared to be shaped by the extent to which they 
had used help throughout their lives. Those who had always had personal assistance 
and/or relied on aids and adaptations, saw independence as less about being self-reliant 
and performing tasks without assistance, and more about being able to make decisions 
about one’s life and having control over the help provided (Oliver 1989). Conversely those 
who had largely lived their lives without assistance or equipment or with minimal help from 
family, associated reduced self-reliance with reduced independence. For these 
participants, the process of ‘rethinking independence’ had more in common with people 
who acquire a disability condition later in life (Groomes and Leahy 2002; Uppal 2006). 
More generally what emerged was a sense of how much Thalidomide survivors valued 
their independence, which was perhaps because many had struggled to achieve and 
maintain it throughout their lives.  
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For many participants there was a continuing tension between doing things for themselves 
and knowing that if they did they would be in pain or excessively tired or even cause 
further damage i.e. there was a ‘physical price’ for independence when seen as self-
reliance. There was also a temporal element. Some participants saw accepting more help 
and a modest reduction in some dimensions of independence now as a way to preserve 
function and so maintain their overall independence in the longer term. Importantly many 
Thalidomide survivors viewed the changes in how they lived as progressive – something 
that they would continually have to revisit as their impairments shifted and they aged. 
Trieschmann (1987) described this as an adaptive model of ageing with disability in which 
peoples’ health and functional skills evolve over the life course. However, LaPlante (2014) 
suggests that this is a “balancing act… [that] becomes more tenuous with age” (pS46), 
and which is neither predictable nor orderly. Certainly for Thalidomide survivors there was 
an awareness that their independence was both hard won and precarious. Their sense of 
vulnerability mediated their current experience of ageing, while also creating uncertainty 
about the future. I discuss this further in 8.1.4.  
Thalidomide survivors are unusual in that they are a clearly identifiable group who are 
ageing together. In relation to preserving function and perceptions of independence, the 
strong group identity within the Thalidomide community (reinforced by media coverage 
and public perceptions) has brought benefits but also created problems. It often motivated 
Thalidomide survivors to maximise their independence and lead active lives but, as I 
describe in 8.1.1 and 8.1.3, it has also contributed to secondary health problems, and 
difficulties adjusting to the need for assistance. It has also influenced how Thalidomide 
survivors judged their independence. Interestingly very few participants compared 
themselves to other people with disabilities.  
My observation is that Thalidomide survivors with more severe damage often have strong 
connections with the Thalidomide community, e.g. through involvement with the 
Thalidomide Society and Thalidomide Trust or attending the same residential school, and 
so for them the natural comparison is with other Thalidomide survivors. Conversely, 
Thalidomide survivors with less severe damage often had less involvement with the 
Thalidomide community: some had only been recognised as a Thalidomide survivor later 
in life; others described themselves as ‘the lucky ones’ and they perceived that they 
weren’t like Thalidomide survivors with severe damage; and a few implied that they had 
not wanted their lives to be defined by Thalidomide and so had purposefully had little 
contact with the Thalidomide community. Furthermore, for much of their lives many of 
these Thalidomide survivors had not thought of themselves as ‘being disabled’, and so 
were more likely to compare themselves to their peers in the general population. This 
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echoes thinking in the field of disability studies about narratively constructed self-identity. 
Carol Thomas (2007), drawing on the work of Margaret Somers explains that this: 
Suggests that people with life-long or acquired impairments make sense of their 
experiences and who they are by continually weaving stories about themselves 
that draw upon the public and cultural narratives they are exposed to about ‘people 
like them/us (negative and positive). Individual’s social circumstances (familial, 
educational, socio-economic and so forth) differentially expose them to these 
public and cultural narratives….this perspective can explain why many disabled 
people do not or will not identify as ‘disabled’. (p80) 
Importantly, participants also judged their independence relative to their younger selves. 
Whist many people in their 50’s might reflect on how easily or quickly they could do 
something compared to when they were younger, few would conceptualise this in terms of 
their independence or expect to make fundamental changes in how they live their daily 
lives. They are perhaps forced to look back because they do not have an older generation 
to compare themselves to. 
The interviews suggested that decisions about the use of aids, equipment, adaptations, 
personal assistance and lifestyle changes, and associated perceptions of independence 
were also influenced by the financial resources people had access to. Having money gave 
them choice (or at least perceived choice) about the best way to preserve their function 
and maintain the aspects of independence that mattered to them. This in turn gave them a 
sense of control and empowerment. In relation to financial resources Thalidomide 
survivors are again unusual. Since the up-lift in the Annual (compensation) Grants and the 
introduction of the Health Grant, they are financially more secure than many disabled 
people. The sense of control this gave them was akin to that found in the research into 
disabled peoples’ experiences of Direct Payments, (Priestley et al 2007; Glasby 2005) 
and confirms the link between independence, choice and control (Rabiee’s 2013). 
8.1.3 Vulnerable Mental Wellbeing 
In both the international literature and the health and wellbeing survey, mental health 
problems emerged as the second most common health problem amongst Thalidomide 
survivors. Although estimates vary, based on the nature of the studies and the measures 
used, the evidence from Germany, Japan and Brazil suggests that between 40% and 50% 
of Thalidomide survivors are currently or have recently experienced mental health 
problems, a level far higher (the studies suggest) than found in the general population of a 
similar age in those countries. Depression was the most frequently reported mental health 
problem, which unlike in the general population, appeared to affect men and women 
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equally. The health and wellbeing survey found a very similar picture with half the 
respondents reporting recent or current experience of depression and/or anxiety. The 
survey results for the SWEMWBS also suggest that a far higher proportion of Thalidomide 
survivor (especially those who report being unable to work) have poor mental wellbeing, 
compared to their peers in the general population. There are no studies of the mental 
health of Thalidomide survivors in early adulthood or middle age and so it is hard to know 
whether their mental health has always been vulnerable, or has become so as they grow 
older. My observation is that there has always been vulnerability but as they age they are 
being exposed to a greater range of risk factors (i.e. increasing impairment, secondary 
health problems, changing social roles such as giving up paid work, and a sense that their 
independence is precarious), which for some have implications for mental wellbeing. 
The relationship between physical disability and depression is complex and our 
understanding of this relationship in working-age adults remains limited (Turner and Noh 
1988; Karahalios et al. 2019). In particular few studies have examined functional 
impairment (as measured by Activities of Daily Living/Instrumental Activities of Daily Living 
(ADL/IADL) and prevalence of depression. A UK study by Meltzer et al (2012) found a 
higher prevalence of depression and mixed depression/anxiety amongst people with 
disabilities compared to people who do not have impairments with disabling 
consequences, a finding supported by a more recent study of middle-aged and older 
Chinese adults (He et al 2019). However, Meltzer et al (2012) describe two other findings 
that are potentially highly relevant to Thalidomide survivors. The authors found that the 
number of ADL/IADL limitations people experience had an incremental effect on the 
likelihood of depression: “each additional limitation appears to add to the psychological 
burden on the individual in an almost linear fashion” (p108). Furthermore, whilst physical 
health problems were also associated with depression, disability seemed to be more 
strongly related to feelings of depression.  
In the international literature, restricted physical function (especially decline in physical 
function) was one of the factors highlighted as contributing to higher levels of common 
mental health problems amongst Thalidomide survivors. Social isolation, pain, 
unemployment, and the need for care and personal assistance were also highlighted, 
although clearly these factors are likely to be linked to and influenced by physical function. 
In my research, loss of function, especially where it led to wider changes in peoples’ lives 
such as giving up work or valued activities, or the need for personal assistance, also 
emerged as an important factor in Thalidomide survivors’ mental wellbeing becoming 
more vulnerable. The results of the SF-12 Health Survey cast further light on this. Overall 
the mental health-related quality of life of Thalidomide survivors was only marginally 
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poorer than their peers in the general population. However, the results also showed that 
the less severe a respondents’ Thalidomide damage, the poorer their mental health-
related quality of life was likely to be. This suggest that it is not restricted physical function 
per se but rather the decline in physical function that was significant, especially where this 
results in ADL/IADL limitations.  
However, my research also revealed another important influence on mental wellbeing 
which is rarely touched on in the international literature: the cumulative impact of living 
with disability (Karahalios et al 2019), and especially with rare impairments such as limb 
difference and facial disfigurement. Some participants described the mental effort involved 
in coping with daily life, constantly having to adapt and think ahead or plan how to 
manage in different situations. Those with upper limb damage and/or facial disfigurement, 
particularly highlighted the psychological impact of ‘being different’ and the unwanted 
attention that this sometimes brought. How these factors affected people and how they 
made sense of them, was influenced by both individual circumstances and characteristics 
(e.g. family attitudes, life events, personality traits) and the wider societal context (such as 
access to care and support, social networks, and financial resources). To understand this 
in more depth it is helpful to look again at the wider literature about ageing with disability.  
Kemp and Mosqueda (2004) make the point that although rates of depression are higher 
amongst people with disabilities, depression does not appear to be caused by disability. 
Furthermore, they contend that there is very little connection between severity of 
impairment and rates of depression. They suggest that the reason for this conundrum: 
“appears to relate to stress and the way people differ in their ability to cope with stressful 
circumstances such as having a disability” (p57). To explain this they draw on the theory 
of stress and coping developed by Lazarus and Folkman (1984). The theory states that 
there are five factors which influence how much stress a person will experience in 
response to life challenges: 1) life events (or stressors) – number of life events, changes, 
or loses, in particular negative ones; 2) appraisal – the way the person views the events 
and their perception of the potential threat; 3) social support – how much people feel 
supported and understood by others when coping with life events; 4) coping method – the 
type of coping strategies the person uses to deal with events both emotionally and 
practically; and 5) personality – the persons long standing personality traits. The authors 
argue that people with disabilities are likely to experience more negative life events 
throughout their lives (e.g. discrimination, health problems, financial pressures) and that 
these increase with age. It is this that accounts for the higher rates of depression amongst 
disabled people. They go on to suggest that the differences in the rate of depression 
within groups of disabled people is determined by the other four factors (appraisal, social 
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support, coping method and personality) but that there is no evidence these factors should 
be significantly different in people with disabilities. They do not discuss the role of financial 
resources but it might be reasonable to assume that having financial resources influences 
the extent to which they see life events as a threat because people can use these 
resources to ‘buffer’ themselves. They may also facilitate better social support because 
people can afford to be more socially active.  
Furthermore, the conclusion which Kemp and Mosqueda (2004) reached, fails to take 
account of a number of important factors. Individuals do cope differently with stressful 
events but this coping occurs in a social context and is conditions by what people have to 
cope with. People with disabilities often experience a wider range of negative life events 
or stressors (Groomes and Leahey 2002), and these stressors tend to be more complex. 
In addition, as Iwasaki and Mactavish (2005) point out, “the stress they experience also 
tends to be chronic and magnified by factors related to their disability” (p194). This 
certainly accords with the experiences of the Thalidomide survivors. Iwasaki and 
Mactavish (2005) group the causes of stress for disabled people into two ‘theme clusters’:  
“Individual and systemic/environmental. The individual theme cluster contains four 
specific categories of stress: (a) disability (i.e., added demands in daily living and 
the complications of disability and aging), (b) health, (c) interpersonal 
relationships, and (d) the inability to meet expectations. The 
systemic/environmental cluster also incorporates four sources of stress: (a) 
exclusionary social systems and structures, (b) physical accessibility, (c) 
employment accessibility, and (d) economic marginality”. (p199)  
A number of these themes resonate with my findings and in particular the cumulative 
impact on mental wellbeing of a lifetime of disability. The participants in Iwasaki and 
Mactavish (2005) study highlighted the added demands that disability places on daily 
living, in particular “the extra energy, effort, time, and care required to fulfil daily 
responsibilities” (p199). My research suggests that this issue may be amplified for 
Thalidomide survivors with severe upper limb damage. Living with missing or short arms 
presents obvious practical challenges to daily living but these are often exacerbated by a 
wider systemic/environmental failure to understand and accommodate these rare 
impairments. For Thalidomide survivors the demands of living with their original 
impairments were being complicated by secondary health problems, decline in function 
and the associated impact on independence. Furthermore, fears that these problems 
would increase in the future led to some participants to feel their current way of life was 
fragile, which in turn had a corrosive effective on their mental wellbeing. Similarly, Iwasaki 
and Mactavish (2005) found that “the stress evoking implications of disability were 
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compounded with age related health problems, life changes and reduced independence” 
(p200). The authors also discuss the effect of social systems and structures which leads 
to disabled people feeling excluded. They note that feelings of exclusion were often 
associated with negative attitudes and behaviours toward disabled people. Thalidomide 
survivors, especially those with rare and visible impairments, report similar feelings of 
exclusion and ‘difference’.  
Finally, a number of studies (Moll and Cott 2013; Kemp and Mosqueda 2004; Iwasaki and 
Mactavish 2005) clearly show that the assumption that people with early acquired 
disabilities are somehow better able to cope with the secondary health problems and 
decline in function associated with ageing, is questionable. Kemp and Mosqueda (2004) 
observe that people with early acquired disabilities may have had long periods where their 
physical function was stable, during which they were able to maximise their independence 
and quality of life. The experience of age-related changes, especially where these occur 
earlier than for people without disabling conditions, and are life limiting, can have a very 
significant impact on mental wellbeing. Furthermore, these changes “may signify that the 
disability has finally ‘won’” (p61). In many respects the experiences of Thalidomide 
survivors mirror these observations. However, my research suggests that the impact of 
these changes may be felt more keenly by those people with less severe impairment, who 
have needed little or no assistance for most of their lives. Importantly, for some of this 
group their perspective was less that ‘the disability has won’ and more that they are ‘now 
disabled’. 
8.1.4 Emergent Theory - Ageing Differently  
My research has focused on Thalidomide survivors at a particular stage in their lives, 
where disability and ageing are beginning to intersect. The findings clearly show that 
physically Thalidomide survivors are ageing differently to their peers in the general 
population but they also reveal how their experience of ageing is both different and similar 
to other people with early acquired disabilities. Importantly, my emergent theory considers 
how what is happening to Thalidomide survivors now needs to be seen in the particular 
historical, social and economic context of their lives and how, throughout their lives, they 
have had to continually negotiate and re-negotiate their independence. I begin by briefly 
considering the notion of ‘normal’ ageing and how normative assumptions about ageing 
may not ‘fit’ for people with early acquired disability. I then describe how a life course 
perspective might inform our understanding of Thalidomide survivors’ particular 
experience of ageing with disability.  
‘Normal biological’ ageing involves a range of predictable age related changes. It does not 
include changes that cause disease, although some health conditions may become more 
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common with age (e.g. a slower gait is a normal age related change but osteoarthritis is 
not) (Kemp and Mosqueda 2004). Psychological changes are also a normal part of ageing 
but again these need to be distinguished from mental health conditions which are more 
common in later life (e.g. changes in a person’s in motivation and emotions are normal but 
depression is not). Similarly peoples’ social roles and relationships will change as they 
move through phases of their life course, but these are often influenced by social and 
cultural norms (Balcombe and Sinclair 2001). All of these dimensions bring with them 
assumptions about what constitutes ‘normal’ ageing (e.g. level of health, mental 
functioning and social roles) at certain chronological ages or phases in the life course. For 
Thalidomide survivors and people with early acquired disability in general, these 
normative assumptions may be incorrect and even problematic.  Indeed, Lowton et al 
(2017) suggest that the existence of these new ageing populations, ‘challenge an 
understanding of the normal within discourses of ageing’ (p9).  
A life course perspective encourages us to think about how disability may have affected a 
person throughout their life, not just how it is affecting them in middle and later life 
(Jeppsson Grassman et al 2012). It also reminds us that aspects of identity, like age and 
disability, overlap and intersect throughout the life course (Naidoo et al 2012). Traditional 
approaches to the life course are underpinned by the idea of a ‘normal’ life course, in 
which people move through a series of stages linked to chronological and biological 
ageing (Priestley 2003). However, many people with early acquired disabilities will have 
lived atypical lives where, for example impairment and age related changes may be 
overlapping sooner than expected, potentially leading to increased disability. Their 
experience of ageing needs to be seen in the light of this. Furthermore, the historical era 
and social context in which people live plays a role in shaping their life course (Elder et al 
2003). This is particularly significant in relation to Thalidomide survivors because they are 
a generational cohort who, broadly speaking, have been exposed to the same social 
influences.  
Thalidomide survivors’ experiences of shifting impairment reinforce the point that whilst 
many disabling conditions are regarded as static, peoples function does change over their 
lives (Molton and Yorkston 2017). Concepts such as ‘biographical disruption’ (Bury 1982) 
developed in the field of sociology of chronic illness and disability, tend to take a short 
term perspective that does not capture the experience of disability over the life course 
(Jeppsson Grassman et al 2012). Certainly, Thalidomide survivors perceived that a 
lifetime of living with disability is leading to their bodies ‘wearing out’ or becoming less 
resilient. They have a sense of being older than their chronological age and often 
described themselves as being out of step (in terms of overall health) with their peers. My 
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research confirms that, as a group, their health and function is poorer than their peers in 
the general population: they are increasingly experiencing secondary conditions which are 
linked to and being layered on to their original Thalidomide damage; many are dealing 
with other health problems commonly associated with ageing; and multi-morbidity is a 
growing concern, all of which impacts on their experience of disability.  
The rate at which the changes associated with normal ageing take place will vary from 
person to person, whether disabled or non-disabled, and is affected by a range of 
influences (e.g. genetics, lifestyle, environmental exposures, socio-economic status). Pre-
existing disability creates a further complication (Trieschmann 1987). Most people reach 
their peak physical/functional capacity in their twenties, after which it slowly decreases. 
This decrease does not in itself cause illness but as Kemp and Mosqueda (2004) explain, 
it does reduce the “buffer zone” or physiologic reserve that enables our bodies to deal with 
or recover from stressors. People with early acquired disabilities are often unable to reach 
the same peak capacity in one or more body system (e.g. the peak bone density and peak 
lung capacity of a person who has never been able to walk is likely to be lower than 
someone who has always been able to walk). This means that whilst their physiologic 
reserve may decrease at the same rate as their peers who do not have impairments with 
disabling consequences, they are starting from a lower point i.e. they have a narrower 
buffer zone. As a result they may experience changes associated with ‘normal’ ageing at 
an earlier age, although for them this is the norm. 
As such, the Thalidomide survivors’ perception that they are ageing prematurely (in 
relation to the normative assumptions in our society), suggests that their experiences are 
similar to other people ageing with early acquired disability. However, there are interesting 
differences too. Thalidomide survivors in the UK are the first (and only) generation of 
people living with TE, and so they do not have an older generation to look to and learn 
from. Furthermore, despite recent advances in research, we still know relatively little about 
the long term effects of the drug. For these reasons it can be particularly hard for 
Thalidomide survivors to distinguish between ‘normal’ age-related change and secondary 
conditions linked to their Thalidomide damage. This also creates uncertainty about the 
future. This sense of uncertainly is not unique to Thalidomide survivors. As they approach 
later life, many disabled people have concerns about the future (e.g. about further loss of 
function, the need for assistance, changing family circumstances etc.) but these are 
exacerbated by lack of knowledge about the long term consequences of TE.  
The integrative category ‘Preserving Function/Rethinking Independence’ highlights the 
acute awareness that many Thalidomide survivors have of their bodies, and how they are 
changing. They recognised that their function was declining, or might do so in the future, 
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and many were taking steps to preserve their function. In part this was about retaining 
control over what was happening to their bodies, which sometimes involved rethinking 
long held notions of independence. They also saw this as an on-going process, something 
that they would continuously need to revisit as they grew older. These findings echo those 
of the Swedish Disability, Life Course and Ageing study (Jeppsson Grassman et al 2012), 
one of the few studies to examine what it means to live a long life with disability. The 
authors conclude that: autonomy is a process and not a state. It, too, must be created and 
recreated frequently over time (p107).  
However, here again the experience of Thalidomide survivors is slightly different. In the 
last two decades there has been a significant improvement in their financial situation, with 
the up-lift in their annual compensation payments and the introduction of the Government 
Health Grant. Unlike many people with early acquired disabilities, they do have resources 
which they can use to help them preserve their function and re-negotiate their 
independence. Moreover, they have the freedom to use these resources in the way that 
makes most sense to them, whether that is changes to their home, changes in lifestyle 
(e.g. giving up paid work) or changes in the nature and type of assistance they used. To 
some degree these resources also buffer them from some of the uncertainties of ageing 
with disability described above. They not only enable them to pay for things here and now, 
they also provided a form of ‘insurance’ which could help them cope with as yet 
unspecified future needs.  In this sense Thalidomide survivors are ageing differently in 
relation to negotiating independence. As disability and ageing begin to intersect, the 
independence they have established over the course of their lives is increasingly 
threatened, both now and in the future, and they are using their resources to reduce the 
associated uncertainty and risk. 
Despite the benefits brought by this relative financial security, my research shows that 
depression and anxiety was far more prevalent amongst Thalidomide survivors than the 
general population of a similar age, and people with physical disabilities in general. In 
8.1.3 I suggest that one reason for this is the decline in physical function and increase in 
secondary health problems that many Thalidomide survivors are experiencing. It might be 
assumed that over their lifetime, people with early acquired disabilities get used to living 
with disability and are in some way better able to cope with further loss of function and 
additional health problems but the experience of Thalidomide survivors and others shows 
this is not the case (Jeppsson Grassman et al 2012; He et al 2019). I would also argue 
that, whilst not unique to Thalidomide survivors, the cumulative impact of living with rare 
impairments such as limb difference and facial disfigurement has been particularly 
corrosive to their mental wellbeing. However, my observation is that this is less about the 
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ageing per se and more about exposure to negative social attitudes over nearly six 
decades.  
In these final paragraphs I consider how Thalidomide survivors might be regarded as 
ageing differently not just as they approach later life but also when we look at the full arc 
of their lives. In particular I examine how their experiences reflect prevailing social and 
institutional attitudes to disability at different periods in their lives but also how they 
themselves have contributed to the change in some of these attitudes. Throughout the 
Thalidomide survivors’ childhood and early adulthood, biomedical definitions of disability 
prevailed. It might even be said that Thalidomide survivors were ‘victims’ of this view of 
disability, which saw disability as primarily an individual ‘problem’ (Rembis et al 2018). It 
brought with it a desire to, where possible, ‘correct’ impairments. As I briefly describe in 
Chapter 2, as children many Thalidomide Survivors underwent multiple surgical 
procedures. Whilst some of these were necessary and beneficial (e.g. creating a thumb 
from a finger so that those born without thumbs had the ability to grip), others were 
cosmetic and detrimental (e.g. amputating malformed digits that were thought to be of no 
use). Some were also expected to use prosthetic limbs which were often uncomfortable 
and even dangerous (e.g. causing falls and injuries). These childhood experiences have 
left many Thalidomide survivors with a distrust of doctors and a reluctance to seek and 
accept medical advice and treatment. 
In some ways the often atypical experiences of Thalidomide survivors serve to highlight 
the kinds of social and structural barriers to participation that all disabled people faced at 
that time. Perhaps partly because of the visibility of the ‘Thalidomide children’ and partly 
as a result of the tenacity of their parents, Thalidomide survivors as a group achieved 
similar educational attainment to their peers in the general population but this was not the 
case for most disabled people in the 1960s and 1970s. Indeed, those Thalidomide 
survivors who lacked family support often had difficult childhoods and inadequate 
education. As Thalidomide survivors reached adulthood, disability activists and academics 
were challenging bio-medical definition of disability and developing the ideas that would 
eventually underpin social models of disability. Thalidomide survivors were part of this 
wider dynamic, and their efforts to negotiate their independence as young adults helped to 
put some of this thinking into practice. For example when Thalidomide survivors reached 
their late teens and wanted to be able to drive, there was no nationwide system for 
obtaining adapted cars, especially not cars that a person with limb difference could drive. 
The Motability adapted car scheme was developed in large part in response to their desire 
for independent mobility.  
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In this way, in the public discourse, Thalidomide survivors began to move from being seen 
as passive tragic victims to heroic pioneers. However, it was in their 40s and 50’s that 
Thalidomide survivors, as a group, with a collective shared experience, became truly 
active politically, in particular campaigning for reparation from the British Government for 
their failure to properly regulate the drug in the late 1950s and early 1960s. This led, in 
2010, to the creation of the Health Grant, which whilst clearly being seen by many as 
social justice, was also an implicit acknowledgement that Thalidomide survivors needed 
substantially more resources if they were to have a good quality of life as they grew older 
i.e. if they were to flourish not just ‘get by’. Furthermore, Thalidomide survivors are able to 
use their Health Grants in whatever way they feel will be most beneficial to their health. In 
effect, for this small group of high profile disabled people, the Government has conceded 
that disabled people need adequate resources and the freedom to use them if they are to 
age successfully, a philosophy that has not been evident in wider policy towards disabled 
people in the last decade of austerity. This final observation brings us full circle and once 
again highlights to contemporary relevance of the Thalidomide ‘tragedy’. 
8.2 Contribution of the Study to Existing Knowledge 
This study makes three important contributions. First, it extends and deepens our 
understanding of the health and independence of Thalidomide survivors as they approach 
later life.  Second, it adds to the body of knowledge about ageing with early acquired 
disability. Third, it provides further examples of two underused research approaches; the 
use of grounded theory in the context of mixed methods research; and a grounded theory 
analysis of secondary data. I discuss each of these contributions in more detail below.  
The literature about ageing with TE is still relatively limited, despite an increase in 
research over the last decade. Much of this recent research focuses on the clinical 
aspects of ageing with TE, although a few studies have looked more broadly at aspects of 
health and independence. Mine is the first study to examine the experience of ageing with 
TE in depth, and to consider how this experience is different from or similar to 
Thalidomide survivors’ peers with and without disabling conditions. It has also 
documented how the health and impairment of UK Thalidomide survivors is changing, and 
revealed how they are renegotiating their independence in the light of these changes. It 
shows the important role that financial compensation plays in these negotiations, but also 
how the strong group identity of Thalidomide survivors can both assist this process (e.g. 
through sharing information and peer support), and hinder it because people may be 
reluctant to acknowledge that they need assistance if this implies that they are not ‘coping’ 
as well as other members of the group. The insights gained have important implications 
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for the provision of healthcare and social support for Thalidomide survivors, particularly 
since health and social care agencies often struggle to offer such support. 
The combination of impairments (particularly limb difference) caused by Thalidomide is 
rare, and the historical and social context of Thalidomide survivors lives is unique. 
Nevertheless, by focusing on such an identifiable group who are ageing together, and 
comparing their experiences to other people with early acquired disability, my study 
contributes to our overall understanding of ageing with disability. Specifically, it adds to 
our knowledge about two issues, the cumulative impact of disability over the life course, 
and the place of the ‘impaired body’ in peoples’ experiences of ageing with disability. 
Relatively few authors have used a life course perspective to understand the nature of 
ageing with disability but those that have (Priestley 2003; Naidoo et al 2012; Jeppsson 
Grassman et al 2012) have made a valuable contribution. In particular they highlight ‘the 
centrality of temporality’ (Jeppsson Grassman et al 2012, p107): the experience of 
growing older having already lived a long life with disability; the interaction between the 
historical time in which a person has lived their life and biographical time; the importance 
of seeing the maintenance of independence and autonomy as a process, which has to be 
revisited over time; and the implications of uncertainty about the future. My findings 
reinforce these themes and strengthen the case for more work of this kind.  
Over the past five decades the lives of UK Thalidomide survivors have been documented 
in the media. Their ‘impaired bodies’ have been photographed and filmed and, in the 
medical press, X-rayed in order to illustrate the consequences of TE. Thalidomide 
survivors themselves have also made explicit use of images of their bodies in their 
campaign for compensation from Chemie Grünenthal. Given this coverage, it is perhaps 
not surprising that Thalidomide survivors are very aware of their ‘impaired bodies’, how 
they are changing as they age, and what they might need to do to preserve them. 
Jeppsson Grassman et al (2012) also found that their participants used awareness of their 
bodies as a strategy for retaining control of their everyday lives. These practical realities 
reflect a much bigger theoretical debate within disability studies and medical sociology 
about the place of the body, and the extent to which disability is caused by impairment 
and social exclusion or social disadvantage (Thomas 2004). I believe that my findings 
support Carol Thomas’s argument for a sociology of disability that recognises both 
disablism and the impairment effects that arise from the lived experience of the impaired 
body (Thomas 2012).  
Finally, my study provides new examples of two underused research approaches: the use 
grounded theory within mixed methods research and grounded theory analysis of 
secondary data. A systematic review of the application of MM-GT (Guetterman et al 2017) 
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in health sciences, social sciences and education, noted that despite the widespread use 
of both mixed methods research and grounded theory, combining the two is relatively 
new. The review identified just 61 articles that claimed to use both qualitative and 
quantitative empirical data (regardless of whether they were described as ‘mixed methods’ 
studies), and to use grounded theory (at least for the qualitative strand of the study). It 
found that researchers claiming to use grounded theory in mixed methods research rarely 
drew upon all or even most of the six grounded theory features identified by the authors 
(see Chapter 3, section 3.7.1). Whilst my decision to adopt a MM-GT approach emerged 
from a heuristic process, I believe my research represents an interesting and clearly 
documented example of a MM-GT study. Undertaking grounded theory analysis of 
secondary data is even less common. My attempt to find examples which I could draw on 
yielded only one paper (Whiteside et al 2012), although Birks and Mills (2015) do discuss 
this topic in their excellent practical guide to grounded theory. For me, the grounded 
theory secondary analysis of the interviews was a particularly valuable element of my 
study. It added significantly to the richness of my findings, because it helped me to look 
deeper in to the data to understand how people experienced and made sense of their 
health problems, and how these problems affected them physically, mentally and 
practically. It also facilitated my reflexivity as a researcher. The line by line coding pushed 
me to look at the data with fresh eyes and, in doing so, examine my preconceived ideas 
about how Thalidomide survivors were responding to changing health. This may be a 
valuable reflection for other researchers contemplating secondary analyses of their own 
data.  
8.3 Strengths and Limitations of the Study 
The study has a number of important strengths but also several limitations. Importantly, I 
had worked with people in the Thalidomide community for a number of years prior to 
starting my doctoral studies. I had come to know some individuals well and developed an 
understanding and empathy for the challenges many of them were facing. As such there 
was a risk of overfamiliarity and the possibility that I might find it difficult to question or 
shed preconceived ideas. Certainly I felt this was the case when I came to undertake the 
secondary analysis but as I note in 8.2 above, the line by line coding did push me to re-
examine my assumptions. More generally, the overall structure of the study, sound 
methods and regular supervision in which I could discuss my thinking, enabled me to 
avoid this pitfall.  
Looking at the study overall, the interconnection between my doctoral research and the 
Thalidomide Trust Health Grant Monitoring project helped to strengthen the study in two 
important respects: it ensured that all the main stages of data collection were strongly 
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informed by Thalidomide survivors; and it facilitated a very good response to the survey. 
The two methods of data collection and the overall timetable for conducting the data 
collection were determined by the Health Grant Monitoring project but in fact this 
encouraged me to think creatively about the sequencing of my research and how to make 
best use of my data. It also led me to adopt a MM-GT approach, which worked well as it: 
provided a coherent and practical ‘structure’ for the study; enabled me to use the most 
appropriate methods for addressing my research questions; facilitated integration of the 
different stages; and created greater explanatory potential. 
Looking more closely at the different elements of the study, the choice of a scoping review 
(rather than a systematic review) felt appropriate to needs of the study. I did conduct it in a 
‘systematic’ manner e.g. using a systematic approach to searches and so I am confident 
that I captured all the key literature about TE. The Grounded Theory approach to 
analysis/synthesis enabled me to generate themes relevant to the objectives of the study, 
and helped me develop my understanding of Grounded Theory methods at an early stage 
in my doctoral studies. The results of the scoping literature review have now been 
published in the Disability and Health Journal (see Appendix 10). 
The qualitative study had a number of limitations, partly reflecting the need to balance 
feasibility with desirability. Recruitment for the study was led by the Trust and was a 
relatively informal process when compared to the approach a University would take. 
Specifically, participants were self-selected and so may not be fully representative of UK 
Thalidomide community as a whole. The group comprised of significantly more women 
than men, whereas the Thalidomide community is split equally. It is possible that people 
who felt more comfortable with research and/or had a higher level of education were more 
likely to volunteers to take part. Conversely, those less engaged with the Thalidomide 
community or those with low mood or depression might have been less likely to volunteer. 
Broadly, the severity of participants’ impairments (as indicated by the Trust’s impairment 
bands) was similar to that of all UK Thalidomide survivors but those with severe hearing 
impairment were under-represented and so my findings may not fully reflect their 
experiences. Having to structure the topic guide for the interviews around the issues the 
Trust wanted to explore created a tension, but the interviews nevertheless yielded a great 
deal of rich data. Using both initial content analysis and then secondary analysis of 
interview data meant that I was able to draw a great deal from it without placing a further 
burden on Thalidomide survivors, an important consideration given the concerns within 
the Thalidomide community about research. There was a danger of duplication/overlap or 
insufficient distinction between the two phases of analysis but the use of Grounded 
Theory for secondary analysis prevented this.  
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The Health and Wellbeing Survey worked particularly well. Offering Thalidomide survivors 
the option to complete the questionnaire online, by post, and over the telephone was well 
received and this together with the reminder and more informal encouragement from Trust 
staff and volunteers, produced a very good response rate (75%). Furthermore, the survey 
respondents were highly representative of all UK Thalidomide survivors in terms of 
gender, UK country of residence, and the nature/severity of their impairments. However, 
there were some issues with the phrasing of health questions and consequent difficulties 
with comparisons with general population. I also felt that the data generated by a few of 
the questions was not robust and so decided not to use it in my thesis. The statistical 
analysis was also relatively limited because my original plan had been to just use 
descriptive statistics. It was only after I had completed the initial analysis that I realised the 
quantity and quality of the data would allow for further statistical analysis. I did undertake 
additional analysis, particularly in relation to the results for health-related quality of life, but 
inevitably the data would allow for even more analysis. The main results from the survey 
have now been published in PLOS One (see Appendix 10). 
It might be assumed that because Thalidomide survivors are such a unique group, the 
findings from this study may have limited transferability to other groups. However, as the 
study progressed it became apparent to me that there was much to learn from comparing 
their experiences to other people with early acquired disabilities. I believe that my 
emergent theory, Ageing Differently has the potential for wider application. This accords 
with grounded theory tradition. Birks and Mills (2015) explain that whilst early writers saw 
the emergent theory (or core category) as reflecting a basic social process, later writers 
have taken a more flexible approach. Charmaz (2014) focuses on ‘usefulness’, suggesting 
that: the categories within the emergent theory should suggest some generic processes; 
that the analysis could be applied in other settings; and that the emergent theory can be 
understood and applied in the real world. I begin to demonstrate these points in the next 
two sections.  
8.4 Implications for Policy and Practice 
My research provides further evidence that the health needs of Thalidomide survivors are 
often more complex than those of their peers in the general population. Knowledge of 
secondary conditions is increasing but the long term consequences of TE remain 
uncertain. It is vital therefore, that they have access to health and social care 
professionals who understand their original impairments and secondary conditions 
associated with TE, and the implications of age related conditions. In the UK the 
Thalidomide Trust has been working to identify doctors in key specialties, notably different 
branches of orthopaedic surgery (i.e. hip, shoulder, and arm/wrist), cardiology, and 
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neurology who have developed experience in diagnosing and treating Thalidomide 
survivors. Similar initiatives are going on in Germany, Japan, Sweden and Australia, and 
efforts are increasing to share specialist knowledge internationally. It is essential that 
these initiatives continue. However, it is also important that other non-specialist healthcare 
practitioners (e.g. GPs, physiotherapists, practice nurses and advanced practitioners) 
have some understanding of their needs or at least recognise their own lack of 
knowledge. They should work with the Thalidomide survivor they are treating to improve 
their understanding and get access to good advice and information. The Thalidomide 
Trust has recently produced information about key practical topics such as measuring 
blood pressure and taking blood samples from people with short or missing arms, and the 
potential musculoskeletal differences physiotherapists should be aware of when treating 
Thalidomide survivors. 
The Thalidomide Trust is a unique organisation, which has both the remit and the 
resources to support its beneficiaries in this way. Many people with early acquired 
disability, including those with rare impairments, do not have this type of support. Whilst it 
would be unreasonable to expect all healthcare practitioners to have an in-depth 
knowledge of early acquired disability and ageing with disability, the NHS should ensure 
that there is greater awareness. Thalidomide survivors often describe how, across their 
life course they have had negative experiences of healthcare including: inappropriate or 
inadequate treatment; negative even discriminatory attitudes; a failure to comprehend the 
implications of impairments for treatment and recovery; an inability to distinguish between 
their disabling condition and conditions common in ageing; and importantly, a lack of 
understanding of the mental health consequences of lifelong disability. For some this has 
led to a general distrust of healthcare practitioners. Other groups with early acquired 
disabilities report similar experiences (Iezzoni 2011; Molton and Yorkston 2017). The 
number of people ageing with disability in population is growing and so healthcare 
practitioners will increasingly encounter them in their everyday practice. They should have 
the knowledge to support them appropriately.  
More specifically, healthcare services need to recognise that whilst many disabling 
conditions are regarded as static, peoples function does change over their lives. For this 
reason, habilitation (i.e. attaining, keeping or improving skills and abilities) and 
rehabilitation (i.e. regaining skills or abilities that have been lost) should be seen as 
something that disabled people may need throughout their lives. This is particularly 
important for people ageing with disability, where a seemingly modest loss of function can 
have major consequences for a person’s independence. However, there are conflicting 
views, especially about rehabilitation within disability studies with some seeing it as 
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emphasising ‘normalisation’, whilst others suggest that where disabled people themselves 
are actively involved in decisions about their rehabilitation, it can mitigate impairment 
(Shakespeare et al 2018). Perhaps the key is for healthcare practitioners to see 
rehabilitation as supporting disabled people to manage their bodies as they age, and as 
such a collaborative approach is essential. Healthcare practitioners also need to 
understand the implications for mental health, of loss of function and decline in physical 
health. They should not assume that people with early acquired disabilities get used to 
living with disability and are in some way better able to cope with additional health 
problems. Nor should they assume that depression is an inevitable consequence of 
disability (as I discuss in 8.1.3). It can be prevented and when it does occur it should be 
treated.  
In recent years the concept of ‘successful’ or ‘healthy’ ageing has received increasing 
attention. Although there are social and psychological models of successful ageing, the 
medical model (i.e. that chronic illness and disability can be delayed or prevented so that 
people live more of their lives in a healthy state) predominates (Bowling and Dieppe 
2005), especially in public discourse. Molton and Yorkston (2017) point out that this 
emphasis on preventing or delaying disability “embodies ableism” and implies that 
“individuals ageing with disabling conditions cannot age successfully” (p291). As the 
experiences of Thalidomide survivors and other people with early acquired disability show, 
this perspective fails to recognise the strategies that people use to preserve their function 
and age healthily on their own terms and not in accordance with an ideal and imagined 
norm. However, the experiences of Thalidomide survivors as a group also reveal the vital 
importance of financial resources in enabling people to adopt such strategies. The 
introduction of the Health Grant increased Thalidomide survivor annual ‘income’ from the 
Trust by about 75%. This gave them greater choice about how to preserve their function 
and renegotiate their independence as they age. It also enabled many of them to 
overcome some of the barriers that disabled people face, and so lead fuller lives i.e. to 
‘flourish’ with disability (Berghs et al 2019). In essence, flourishing with disability is about 
respecting individual experience while challenging the context in which disability is 
generated. However, in later life it is also about challenging normative assumptions about 
successful ageing and recognising that people find fulfilment in different ways (Jeppsson 
Grassman et al 2012). This has important implications for the relevance to disabled 
people of current public health messages about healthy ageing, and for the level of 
disability benefits. 
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8.5 Further Research 
A number of possible avenues for further research have emerged from my study. Some 
topics are specifically concerned with the health of Thalidomide survivors, whilst others 
are broader questions related to ageing with disability. I discuss these further below and 
link them where appropriate.  
In relation to the specific health problems of Thalidomide survivors, some work is already 
taking place in the UK, Germany and Japan to identify the most effective interventions, 
particularly surgical interventions, for treating the musculoskeletal problems Thalidomide 
survivors are experiencing. However, there would be value in developing greater 
understanding of the non-invasive treatments and self-management strategies 
Thalidomide survivors use to manage pain and preserve their function. Not only would this 
benefit Thalidomide survivors, it may also help younger people with limb difference to 
‘conserve it and preserve it’. 
Many Thalidomide survivors report neuropathic pain and symptoms of neuropathy (e.g. 
pins and needles, numbness). Current research evidence suggest that for some people 
this may be caused by compressive neuropathy (e.g. carpal tunnel syndrome) but so 
many Thalidomide survivors describe these symptoms that it seems possible that they are 
related to the long term effects of the drug. Certainly developmental biologists researching 
the action of the drug believe this could be the case19. Research that sheds light on the 
possible causes of these symptoms (which can be debilitating), would assist clinicians in 
identifying appropriate treatments. 
My research also suggests that multimorbidity is an increasing concern for Thalidomide 
survivors and as people with disabilities live longer, it will become an increasingly 
common issue in the population as a whole. Research is needed to understand how 
people with early acquired disabilities experience multimorbidity, and whether any 
adjustments are needed in the approach to their care and treatment. 
There has been a good deal of research in recent years into the link between long term 
health conditions and depression and between ageing and depression but research into 
the relationship between ageing with early acquired disabilities and depression remains 
sparse, despite the prevalence of the condition. This gap in our knowledge needs to be 
addressed so that people are able to get timely diagnosis and treatment. However, we 
also need to develop a better understanding of the mental health consequences of living a 
long life with disability so that disabled people can be supported to maintain their mental 
                                               
19 Personal correspondence with Prof Neil Vargesson, University of Aberdeen.  
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wellbeing, and the societal conditions which have a detrimental influence on their mental 
health can hopefully be addressed. 
Finally, to my knowledge there have been no longitudinal cohort studies in the UK which 
have focused on people ageing with early acquired disabilities, especially those moving 
from late middle age to older age. Such a study could be used to explore a number of 
topics but here I highlight three which I feel are particularly important in terms of improving 
the health and quality of life of disabled people: 
 Their experience of shifting impairment and changing health, and in particular how 
they respond, physically, emotionally and practically, to the onset of secondary 
conditions and/or conditions associated with ageing, after having navigated their life 
course with their primary disability condition 
 Their access to health services that are able to meet their needs. There is a danger 
that disability services used to dealing with younger adults are not geared up to 
support people ageing with disabilities, whilst services for older adults may struggle to 
understand the impact of living a long life with disability. We need to understand what 
service models work best and what features of services people value most 
 Their understanding of what it means to ‘age healthily’ with an early acquired disability 
and whether it is possible to develop a model of successful ageing with disability that 
can be used to inform public health messages. 
8.6 Impact and Dissemination 
At various points during my doctoral research I have taken opportunities to disseminate 
my findings. The results of the scoping review and the Health and Wellbeing survey have 
both been published in peer reviewed journals. In 2016 I organised two events. The first 
was the UK premiere of 50 Years of Shame, a film about the situation of Thalidomide 
Survivors in Spain. The screening was held at the University of York, and was followed by 
a panel discussion involving the film’s director, two Thalidomide survivors (one from Spain 
and one from the UK) and myself. The event was jointly funded by the Department of 
Health Sciences and the Centre for Global Health Histories at the University of York. The 
second was an interdisciplinary ‘Legacy of Thalidomide’ meeting, supported by the 
Wellcome Trust funded Centre for Chronic Diseases and Disorders, at the University of 
York. A report from the meeting was published in Birth Defects Research.  
I made oral presentations at the first and second International Thalidomide Embryopathy 
Symposiums held in Tokyo, Japan in 2015 and 2019. In 2019 I also made a written 
submission to the Australia Senate Community Affairs Reference Committee inquiry into 
support for Australian Thalidomide survivors. I was subsequently invited to give oral 
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evidence (by teleconference) to the hearing held in Sidney. My evidence was quoted 
extensively in the interim report from the inquiry and as a result I was asked by the Royal 
Australasian College of Physicians to write (jointly with two colleagues) a continuing 
Professional Development module about Thalidomide. These and other dissemination and 
impact activities are summarised in Appendix 14. 
8.7 Conclusion 
The aim of this study was to explore the changing nature and perceptions of health and 
independence amongst UK Thalidomide survivors, at a stage in their lives where disability 
and ageing are beginning to intersect. The study contributes to our understanding of the 
interaction between original impairment, secondary health problems and the ageing 
process. Importantly, given the biomedical in focus of much of the existing literature, it 
gives Thalidomide survivors a voice and an opportunity to articulate how this interaction is 
affecting their daily lives. My hope is that this knowledge will inform how healthcare 
professionals, and health and care services, treat and support Thalidomide survivors and 
other people ageing with early acquired disabilities.   
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Appendix 1 Initial Consent Form 
 
Monitoring the 10 Year Health Grant 
 
Consent Form 
 
Thank you for offering to be part of the Health Grant monitoring Study Group. 
Please complete this consent form and return it to Firefly Research. 
Please tick the boxes. YES  NO 
I agree to take part in the Health Grant monitoring project    
    
I agree to be interviewed once a year    
    
I agree that you can record the interview    
    
I understand that the information I give in my interview will 
be treated in confidence 
 
 
 
    
I agree to the Thalidomide Trust giving Firefly Research 
information about my impairment (6ivb) band and the value 
of my Annual Grant and Health Grant 
 
 
 
    
I understand that no other information about me will be 
given to Firefly Research by the Thalidomide Trust 
 
 
 
 
Signature:  Date:  
Name:  
Address:  
Tel. No.  
Email:  
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Appendix 2 Revised Consent Form for Interviews 
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Appendix 3 Ethical Approval Letter and Response 
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Appendix 4 Substantial Amendment and Letter of Approval 
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Appendix 5 Health and Wellbeing Survey 
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Appendix 6 Interview Invitation Letter 
 
 
 
Date  
Address 
 
 
 
 
 
  
 
Dear  
Monitoring the 10 Year Health Grant – Can You Help? 
I hope all is well with you. I am writing to you, as someone who kindly helped us 
with the evaluation of the three year Health Grant, to ask if you would like to be 
involved in the monitoring of the new 10 year Health Grant. Although there is no 
requirement to evaluate the new Health Grant the Thalidomide Trust and the NAC 
felt it would be valuable to put in place some ‘light touch’ monitoring to: 
 
 Be able to present a case to the UK Departments of Health for the Health 
Grant to be renewed in 10 years-time   
 Support negotiations with Diageo 
 
The Thalidomide Trust Scientific Committee has asked Firefly Research to 
undertake the monitoring of the Health Grant over the next eight years. There will 
be two parts to the monitoring: 
 
 A survey of the health-related quality of life of all beneficiaries in years 1, 3 and 
8 of the Health Grant (i.e. 2013, 2015 and 2020). 
 Annual interviews with a ‘case study’ group of around 25 beneficiaries 
 
In late November/early December this year we will be sending out (via the Trust) a 
short questionnaire which will ask people about their health needs and health-
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related quality of life. All beneficiaries will have the opportunity to take part in the 
survey.  
However, we are also looking for around 25 beneficiaries (our ‘case study’ group) 
who would be willing to get more involved by being interviewed once each year. 
As someone who contributed to all three years of the Health Grant evaluation, we 
wondered if you might be willing to continue working with us on the monitoring 
project. 
As before, the interviews can either be done by telephone or face to face and will 
take about an hour. They will probably take place in December and January. This 
time we won’t be asking people to give us a full breakdown of their Health Grant 
expenditure but we would like to talk to people about broadly how they used their 
Health Grants, and the extent to which the Grant is enabling them to meet their 
health-related needs. 
If you take part in the study group, it would be helpful if you would allow us to have 
access to some very limited information held by the Thalidomide Trust about you, 
notably the severity of your impairment (6ivb band), and the levels of both your 
Annual Grant and Health Grant. No other information will be given to us by the 
Trust.  
All the information you provide for the monitoring project will be treated in 
confidence and will only be seen by the Firefly team. We will not give any 
individual information to the Trust without the person’s consent, and the reports we 
prepare for the Trust will not name or identify any individual beneficiaries. 
If you would like to be part of the study group, it would be really helpful if you could 
complete the enclosed consent form and return it to me in the Freepost envelope 
provided. If you would prefer to have a chat before deciding whether to get 
involved, please do give me a call, or email and we can arrange a time to talk. 
Many thanks for taking the time to read this letter. 
With best wishes 
 
Liz Newbronner 
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Appendix 7 Interview Topic Guide 
 
Long-Term Monitoring of the 10 Year Health Grant to                        
Thalidomide-impaired People 
Topic Guide for 2014 Study Group Interviews (Final) 
 
Introductory Notes 
 Explain the overall purpose and structure of the Health Grant Monitoring study 
 Clarify that this is the first of three annual interviews 
 Note that at the start I will collect some background information designed to 
help me understand their situation but explain that providing this information is 
optional 
 Explain that the interview is likely to last approximately one hour and check that 
this is ok 
 Reassure the interviewee that everything they say will be treated in confidence 
and explain that a) their interviews notes will only be seen by me; b) no 
information about individual beneficiaries will be passed to the Trust and; c) if I 
use personal stories in reports I will use pseudonyms and will ask their 
permission 
 Explain that the Trust has given me permission to use material from the Health 
Grant Monitoring study for my doctoral research. Note that I am now seeking 
verbal consent from each participant for me to their interview transcript in my 
research. Explain that they are free to decline and this will not affect their 
involvement in the Health Grant Monitoring study 
 Check circumstances (below) 
 
Background Information 
 
 Background Information 
Home Circumstances  
 
Employment 
Situation 
 
 
Impairment Band  
Level of Annual Grant  Level of Health Grant  
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Current or Recent Health Problems 
 
1. What health problems (if any) have you experienced over the past few years 
that you believe are related to the Thalidomide damage you experienced? 
 
Explore: description of the nature/impact of the problem/s; how long have they 
have been experiencing the problem/s; whether the problem is static or 
deteriorating 
 
2. How have these health problems affected you? 
 
Explore: Physical and emotionally affects as well as practical affects (e.g. 
lifestyle/quality of life; impact on family; impact on employment) 
 
3. Have you sought and/or had any treatment for the health problems you are 
experiencing or support to deal with the effects of them?  
 
If yes, explore: where this help has come from i.e. NHS; social services; 
Thalidomide Trust; paid for privately; other sources? How confident they felt in the 
advice/treatment given (specialist centre option)? What difference this 
treatment/help has made?  
 
If no, explore: reasons why? Whether they have had problems getting 
(appropriate) treatment? Willingness to travel to a specialist centre if available? 
What are their main current unmet health needs/outstanding problems? 
 
Social Care Support 
 
4. Do you have any social care support?  
Explore: any problems with access to and/or level and appropriateness of social 
care/support 
 
Use of Health Grant 
 
5. How have you used your (2013/14) Health Grant? 
 
Explore: Main types/areas of expenditure and ask for very approximate break-
down, if appropriate/possible 
 
6.  What were the main reasons for using your health grant in these ways?  
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7. Has the level of health grant you received this year been adequate in terms of 
meeting your main health or health-related needs? 
 
Explore: any trade offs/compromises made and any unmet needs 
 
8. Do you think that the things (e.g. home adaptations, equipment, treatments) 
you have been able to fund through the Health Grant or the way you have used 
it (e.g. to replace lost income) have had any impact on your health and 
wellbeing? 
 
If yes, explore in what ways (e.g. changes in a specific health problem; lifestyle 
change so less stress)? Any wider impact on partners/family? 
 
If no, explore why not? 
 
The Future 
 
9. Looking ahead, what do you think your biggest health-related needs are likely 
to be over the next 5 to 10 years? 
 
10. Do you have any plans/ideas for how you might use your Health Grant to help 
you deal with these longer term health or health-related needs?  
Other information/concerns/questions? 
Closing Notes 
 Thank the Beneficiary for taking part in the interview 
 Ask if they have any questions 
 Explain what will happen next, timetable for the report etc. 
 Remind them of where they can contact me if, at a later point there is anything 
they want to add or any questions they want to ask 
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Appendix 8 Survey Information Sheet 
 
 
The Thalidomide Trust 
 
Health and Wellbeing Survey 2015 
Dear Beneficiary 
Many thanks for taking the time to complete this health and wellbeing questionnaire. Your 
contribution is really important as the findings from the survey will help guide the Trust’s 
work over the next few years. They will also be used in negotiations with Diageo and to 
help the Trust make the case for continued funding of the Health Grant. 
The survey is completely confidential. Your answers will only be seen by the team at 
Firefly Research and the report from the survey will not include any names or details 
which would enable individual beneficiaries to be identified.  
The questionnaire should take about 20 minutes to complete. Most of the questions are 
either tick boxes or yes/no responses but there are a few places where you can add more 
information if you would like to. The questionnaire has 10 sections: 
 About You 
 Family and Housing 
 Work and Pensions 
 Original Thalidomide Impairments 
 Mobility and Equipment 
 Health Problems 
 Use of health Services 
 Social Care Support 
 Mental Wellbeing 
 Health-related Quality of Life 
 
If you would like more information about the Health and Wellbeing Survey or would like 
help completing the questionnaire, please contact Liz Newbronner on 01751 798927 or 
email liz@firefly-research.co.uk  
The survey can also be completed online by going to 
 http://surveys.firefly-research.co.uk/s/HWSurvey15/  
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Appendix 9 Survey Cover Letter from Thalidomide Trust 
 
Dear [name of beneficiary] 
We are writing to ask you to fill in the attached Health and Wellbeing Survey 2015.  We 
are asking all beneficiaries to complete this survey.  We would like to get as full a picture 
as we can of all beneficiaries’ current situations and the challenges you are currently 
facing and think you’ll have to deal with over the next few years.  This information will be 
very important because: 
 It will help the Trust develop its services so we can provide you with the information, 
help and support you will need 
 It will enable us to demonstrate to the Departments of Health the sort of health-related 
issues that you are facing and help us to secure further funding when the current 
Health Grant comes to an end. 
 It will also be extremely useful in our forthcoming negotiations with Diageo about 
future funding  
The survey should only take 20 minutes to fill in.   You can also fill in part of it, save your 
answers and come back to complete it later.  Most of the questions can be answered very 
quickly (yes/no; tick boxes).  There are a few places where you can add more information 
if you would like.  
The Thalidomide Trust has commissioned the Health and Wellbeing Survey from Firefly 
Research. Your answers will go direct to Firefly Research and will be kept completely 
securely – and no individual responses will be shared with the Trust.  The Survey 
does ask for your name and it would be enormously helpful if you could provide this as it 
will help us to identify trends (for example if certain health problems are more common 
amongst beneficiaries with particular patterns of thalidomide damage or if worries about 
the future are different for males and females) and enable us to get in touch with you to 
ask further questions on specific issues that emerge. It also means that we can check who 
has/has not replied and save bothering you with further reminders.   Of course, if you don’t 
wish to include your name, you can still complete the questionnaire anonymously and it 
will provide us with really helpful information. 
For the last survey that Firefly carried out in 2013, on how you were using the Health 
Grant, over half (59%) of you responded.  We’d like to do even better this time!   So 
please do take a few minutes to fill in the survey.   
If you’d prefer to complete the survey online, please go to: http://surveys.firefly-
research.co.uk/s/HWSurvey15/.  If you’d find it easier to answer the survey questions over 
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the phone, please  contact Liz Newbronner at Firefly Research on 01751 798927 or email 
her at liz@firefly-research.co.uk, and she will be happy to go through the survey with you.  
If you have any queries or concerns about the survey or how the information will be used, 
please don’t hesitate to contact Liz or Michelle-Jane at the Trust on 01480 474074.  
Thank you in advance for your help – and best wishes 
Deborah Jack, Director                         
Simone Illger, Chair of NAC Health & Wellbeing Committee  
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Appendix 10 Published Papers 
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Appendix 11 Study Selection Form 
Study Eligibility Form 
Date Completed:  
Study Title:  
Authors:  
Year of Publication:  
Language/Country:  
1. Is the study population Thalidomide-affected people born in the late 1950/early 
1960’s? 
Yes Unclear No 
2. Does the study report on the health and/or impairment of Thalidomide-affected 
people? 
Yes Unclear No 
3. Does the study report on the quality of life of Thalidomide-affected people? 
Yes Unclear No 
4. Does the study focus on the health/quality of life of Thalidomide-affected people as 
adults and/or as they age? 
Yes Unclear No 
Study Design: 
Additional Information: 
Final Decision: 
Include Unclear Background No 
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Appendix 12 Example of Completed Data Extraction Form  
 
Data extraction 
field 
Information extracted 
Citation Jankelowitz, S. K., et al. (2013). Late-onset neurological symptoms 
in thalidomide-exposed subjects: A study of an Australasian cohort. 
European Journal of Neurology 20(3): 509-514. 
Country Australia & NZ 
Aims of study Over the past few years reports of increasing disability in 
thalidomide-affected subjects. These complaints provoked concern 
about a late degenerative disorder, raising parallels with ‘post-polio’ 
Syndrome. 
More recently, thalidomide and its analogue, lenalidomide, have 
regained acceptance as therapeutic agents in the treatment for 
multiple myeloma. The main complications of treatment in this 
setting are venous thrombosis for both drugs and peripheral 
neuropathy for thalidomide. 
In view of the peripheral neuropathy described in multiple myeloma 
patients treated with thalidomide, as well the sensory neuropathy 
that occurred in adults who used thalidomide as a sedative in the 
1950s, we reviewed 16 thalidomide-deformed subjects presenting 
with new neurological complaints in their fifth decade. We wished to 
determine whether there was ongoing nerve damage/loss in this 
population as a ‘late effect’ of thalidomide exposure or whether the 
effects were due to exacerbation of the normal ageing process as a 
result of lack of the normal ‘redundancy’ within the nervous system. 
Ethics – how 
ethical issues 
were addressed 
Informed consent was obtained from all subjects, and the study was 
approved by the Human Ethics Committee of the Sydney Southwest 
Area Health Service (now Sydney Local Health District). 
Study setting Hospital based examination  
Theoretical 
background of 
study 
 
Sampling 
approach 
16 of the 45 Thalidomiders in Australia/NZ presenting with new 
neurological symptoms who were able to give informed consent and 
able to participate when neurological team were available. 
Participants 
characteristics 
Of the 16 thalidomide-deformed subjects, 11 reported numbness or 
tingling in the upper limbs. Five of the 11 also reported sensory 
symptoms, with or without pain, in the lower limbs. The other five 
subjects reported cranial nerve problems. Upper limb symptoms 
were generally worse at night or with driving and were more 
prominent in the dominant limb. In four subjects, the sensory 
symptoms spread into the arm. A further five subjects reported 
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longstanding numbness and weakness of the face, with or without 
hearing loss and eye movement abnormalities. This ranged from 
mild unilateral weakness to complete absence of facial muscle 
movement. 
Study design 
(data collection 
& analysis) 
A detailed medical history was taken with particular reference to 
symptoms referable to the nervous system; a clinical neurological 
examination was tailored to the symptoms; neurophysiological 
testing was guided by the examination. “Despite the heterogeneity 
of malformations, studies were performed on the assumption that 
nerves would be in a comparable anatomical site as in normal 
subjects”. 
Findings Adult-onset neurological symptoms in subjects exposed to 
thalidomide in utero appear to be due largely to compressive 
neuropathies or secondary to musculoskeletal deformity. In the 
present cohort, there was no evidence clinically or neuro-
physiologically of late-onset generalized neuropathy. Compressive 
neuropathies were more common in the more disabled subjects, for 
example those who had no functioning lower limbs and were in 
wheelchairs.  
The chance of developing median nerve compression at the wrist is 
probably greater in thalidomide-affected subjects because the 
musculoskeletal deformities may lead to further narrowing of the 
carpal tunnel, and there is overuse of the hand to compensate for 
other limb deformities. 
Lower limb musculoskeletal symptoms were also present, being 
more prominent in the subjects with the greatest disability, and 
these were thought clinically to be due to the postural abnormality 
imposed by their disability. Given awareness of the long-term 
adverse consequences of the functional compensation for the 
thalidomide induced deformity, these effects could be anticipated 
and probably limited by physical therapies, such as the appropriate 
use of preventive measures, orthotics and technical aids. 
The present clinical study provides no reasons to implicate ongoing 
neuronal loss or late reactivated neural degeneration in adult 
thalidomide survivors who develop new neurological symptoms, and 
no evidence of a generalized peripheral neuropathy. Rather, the 
development of new symptoms in subjects can be explained by (i) 
compressive neuropathies, due to, for example, median nerve 
compression at the wrist, and (ii) compensatory postures employed 
to perform tasks of daily living. The former is likely a reflection of the 
overuse and abnormal postures required to accommodate the 
disability, poor mobility arising from the limb deformities and 
narrowing of the carpal tunnel by musculoskeletal defects. 
Quality of the 
study 
High quality; very relevant to thesis; provides comparison with UK 
neuropathy study (as yet unpublished). 
 
Completed: 25/5/15  
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Appendix 13 Interview Participants – Pseudonyms and 
Background Information 
 
Participant 
Number 
Pseudonym Band Male/ 
Female 
Employment Status Home 
Circumstances 
101 Simon B5 M Working part-time – 
health/personal 
reasons  
Lives alone 
102 Jenny B1 F Working part-time – 
health reasons  
Lives alone 
104 Carol B4 F Not working – 
personal reasons 
Lives alone 
105 Moira B3 F Not working – unable 
to work 
Lives with partner 
106 Nicola B2 F Working part-time – 
health reasons 
Lives with partner 
107 Joyce B2 F Working part-time – 
health reasons 
Lives with partner 
108 Martin B3 M Working full-time Lives with partner 
109 Rowena B1 F Working part-time – 
health reasons 
Lives with partner 
112 Jim B2 M Not working – unable 
to work 
Lives with partner 
113 Gwen B5 F Not working – unable 
to work 
Lives with children 
114 Isobel B3 F Working part-time – 
health reasons 
Lives with partner 
115 Amy B2 F Not working – health/ 
personal reasons 
Lives with partner 
117 Gary B3 M Not working – unable 
to work 
Lives with partner 
118 Kathleen B3 F Not working – health/ 
personal reasons 
Lives with children 
119 Alison B5 F Not working – unable 
to work 
Lives with children 
120 Tracy B3 F Not working – health/ 
personal reasons 
Lives with partner 
121 Rick B1 M Not working – health/ 
personal reasons 
Lives alone 
124 Fiona B3 F Not working – unable 
to work 
Lives with partner 
125 Alan B5 M Not working – unable 
to work 
Lives with partner 
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126 Jo B4 F Not working – unable 
to work 
Lives with partner 
127 Beth B4 F Not working – unable 
to work 
Lives alone 
128 Meg B4 F Not working – health/ 
personal reasons 
Lives with partner 
129 Amanda B3 F Working part-time – 
health/personal 
reasons 
Lives with partner 
130 Ann B1 F Working full-time Lives alone 
131 Ben B3 M Not working – health/ 
personal reasons 
Lives with partner 
134 Linda B1 F Working part-time – 
health/personal 
reasons 
Lives with partner 
136 Penny B2 F Working part-time – 
health/personal 
reasons 
Lives with children 
140 Tom B5 M Not working – unable 
to work 
Lives with partner 
141 Alex B3 M Not working – health/ 
personal reasons 
Lives with partner 
142 Robbie B4 M Not working – unable 
to work 
Lives with partner 
143 Karen B5 F Not working – unable 
to work 
Lives with partner 
144 Colin B2 M Working part-time – 
health/personal 
reasons 
Lives alone 
145 Diane B3 F Not working – health/ 
personal reasons 
Lives with partner 
147 Maria B4 F Not working – unable 
to work 
Lives with partner 
148 Malcolm B4 M Not working – 
personal reasons 
Lives with children 
149 Tessa B5 F Not working – unable 
to work 
Lives with partner 
151 June B5 F Not Working – 
unable to work 
Lives with partner 
153 Helen B3 F Not working – unable 
to work 
Lives with partner 
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Appendix 14 Dissemination and Impact 
 
Published Papers 
The health and quality of life of Thalidomide survivors as they age - Evidence from a UK 
survey. Newbronner, Elizabeth; Glendinning, Caroline; Atkin, Karl; Wadman, Ruth. 
In: PLoS ONE, Vol. 14, No. 1, e0210222, 16.01.2019. 
 
The Changing Health of Thalidomide Survivors as they Age: A scoping review. 
Newbronner, Elizabeth Vivien; Atkin, Karl Michael. 
In: Disability and Health Journal, 28.10.2017. 
 
‘The legacy of thalidomide’ - A multidisciplinary meeting held at the University of York, UK, 
on September 30, 2016. Newbronner, Elizabeth; Vargesson, Neil; Atkin, Karl. 
In: Birth Defects Research Part A: Clinical and Molecular Teratology, Vol. 109, No. 4, 
01.03.2017, p. 296-299.  
 
Oral presentations 
First International Thalidomide Embryopathy Symposium – November 2016, Tokyo, Japan 
Presentation Title: UK Health and Wellbeing Survey 2015 – Initial Results 
 
Second International Thalidomide Embryopathy Symposium – July 2019, Tokyo, Japan  
Presentation Title:  Growing older with TE – research and support in the UK 
 
Thalidomide Society Annual Conference, April 2019 
Presentation Title: Adapting not Surrendering 
 
Poster Presentations  
First International Thalidomide Embryopathy Symposium – November 2016, Tokyo, 
Japan.  
NIHR Doctoral Training Camp – July 2018, Ashridge College, Berkshire, UK. 
 
Other Activities and Events 
Film Premiere 
I organised the UK premiere of 50 Years of Shame, a film about the situation of 
Thalidomide Survivors in Spain. The screening was held at the University of York on 21st 
April 2016, and was followed by a panel discussion involving the film’s director, two 
Thalidomide survivors (one from Spain and one from the UK) and myself. The event was 
jointly funded by the Department of Health Sciences and the Centre for Global Health 
Histories at the University of York.  
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Legacy of Thalidomide Meeting 
The meeting was held at the University of York in September 2016, and is one of just a 
few interdisciplinary gatherings to explore the broader legacy of Thalidomide. It brought 
together Thalidomide survivors, historians, scientists, clinicians and social scientists to 
explore what lessons can be learnt from the history and use of the drug, its impact today, 
and how this knowledge can benefit Thalidomide survivors and others with rare 
impairments. The meeting was supported by the Wellcome Trust funded Centre for 
Chronic Diseases and Disorders, at the University of York. A report from the meeting was 
published in Birth Defects Research (see Appendix 10) 
 
Thalidomide Symposium - Hamburg 
In October 2017 I attended a Thalidomide Symposium - Mobility Maintenance of People 
with Thalidomide Embryopathy – Prevention, Pain Therapy and Alternative Therapeutic 
Procedures, which was held in Hamburg, Germany.  
 
Australian Senate Thalidomide Inquiry 
In 2018/19 the Australia Senate Community Affairs Reference Committee held an inquiry 
in to support for Australian Thalidomide survivors. I made a written submission to the 
inquiry and was subsequently invited to give oral evidence (by teleconference) to the 
hearing held in Sidney on the 30th January 2019. My evidence was quoted extensively in 
the interim report from the inquiry which was published in February 2019. The report listed 
eight recommendations, one of which was that “the Royal Australian College of General 
Practitioners, the Royal Australasian College of Physicians and the Australian College of 
Rural and Remote Medicine take steps to raise awareness of thalidomide and thalidomide 
injuries, including by incorporating a module on thalidomide injuries in their next round of 
Continuing Professional Development”. I was invited to write the CPD module, along with 
Prof Neil Vargesson from Aberdeen University and Dr Dee Morrison from the Thalidomide 
Trust. The module is due to be available in spring 2020.  
 
Public Lecture 
In 2019 the National Science Museum undertook a major refurbishment of its medicines 
galleries. One of the galleries has a display about Thalidomide and Selina Hurley, the 
Curator of Medicine, approach me for my thoughts on how the drug might be represented. 
She then kindly agreed to give a public lecture at the University of York, about the new 
galleries, using Thalidomide as a case study. The lecture took place on the 28th January 
2020 and was jointly organised by myself and colleagues in the History Department.  
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